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Chronic Hepatitis C Virus (HCV) infection is prevalent in approximately 3.2 million people in 
the United States.  Understanding mechanisms of HCV treatment response and conditions seen 
in people with HCV such as steatosis and Insulin Resistance (IR) are important to preventing 
excess morbidity and mortality and improving HCV treatment outcomes.  Host genetic factors 
may be important with respect to these issues.    
The purpose of this research was to investigate host genetic relationships with 28 day 
viral decline after treatment initiation, steatosis and insulin resistance and to examine these 
associations separately in African Americans and Caucasian Americans infected with HCV 
genotype-1.   
Data from the Study of Viral Resistance of Antiviral Therapy of Chronic Hepatitis C 
(Virahep-C) were used.  Virahep-C was designed to understand the mechanisms of resistance to 
antiviral therapy for chronic HCV genotype-1 patients.  The studies reported in this dissertation 
included up to 194 Caucasian Americans (CA) and 180 African Americans (AA) who agreed to 
participate in the Virahep-C genetics ancillary study.   
In longitudinal analyses of 28 day treatment induced viral decline, polymorphisms in 
Myxovirus resistance 2 (MX2), Oligoadenylate synthetase-like (OASL), Signal transducer and 
activator of transcription 1 and 2 (STAT1 and STAT2) were significantly associated with viral 
 iv 
decline.  Additionally, significant Protein Kinase (PKR) haplotype associations with viral 
decline were observed among AAs.  
In cross-sectional analyses, significant associations between selected genetic variants and 
either steatosis or IR were observed in Interleukin-10 (IL10), Leptin Receptor (LEPR), 
Interleukin-6 (IL6) and Transforming Growth Factor Beta 1 (TGF-β1) for both conditions.  
Statistically significant interactions were observed between IL10, LEPR and TGF-β1 
polymorphisms and HOMA2-IR scores when examining steatosis. 
Statistically significant associations were observed for Adiponectin Receptor 1 
(ADIPOR1) polymorphisms and 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (HMGCS2) 
polymorphisms and steatosis or IR.   
Overall, these findings suggest that host genetic factors are associated with treatment 
induced 28 day viral decline, steatosis and IR.  Understanding the biological mechanisms that 
contribute to these findings has significant public health implications because it could help 
establish new therapies and interventions to prevent HCV related morbidity and mortality.  
Results may also contribute to understanding the mechanisms of treatment response, steatosis 
and IR. 
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1.0  DISSERTATION OVERVIEW AND OBJECTIVES 
The Hepatitis C Virus (HCV) is involved in the development of liver disease, liver damage and 
chronic HCV infection.(Choo, 1989)  Hepatitis C virus is a major public health concern and the 
leading cause of chronic liver disease in the United States (US).(Strader, 2002)  
Viral factors, host genetic factors and environmental factors are thought to influence the 
progression of HCV, development of virus related complications and treatment response.(Seeff, 
2002)  Viral and host factors have been carefully examined in the literature, but studies that 
examine host genetic associations with treatment outcomes and complications of HCV infection 
are still being studied and verified.   
Viral dynamics are the examination of viral level change during the early course of 
treatment and have been used to study the efficacy of various treatment regimens.(Herrmann, 
2003; Neumann, 2000; Neumann, 1998; Perelson, 2005; Zeuzem, 2001)  Rapid virologic 
response or very early virologic response, which can be examined using viral dynamics models 
in the first 28 days of therapy, can be used as a prognostic factor for long-term treatment 
outcomes.(Neumann, 2000; Neumann, 1998)   No studies have been found that examined the 
association between the polymorphisms of interferon stimulated genes (ISGs) examined in this 
dissertation and differences in viral level in the first 28 days of treatment.  ISGs are important in 
immune response because they induce antiviral actions and activate mechanisms to enhance 
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immune response and understanding their mechanisms of action in HCV treatment could lead to 
the development of more effective therapy.  
Steatosis and Insulin Resistance (IR) are two metabolic complications that can occur in 
people with or without HCV infection.  The presence of steatosis or IR are thought to negatively 
impact the ability to achieve sustained virologic response (SVR).(Guidi, 2005; Jian Wu, 2006; 
Patton, 2004; Romero-Gomez, 2006; Romero-Gomez, 2005; Soresi, 2006; Westin, 2007)  No 
studies were identified that tested the association between the genetic variants utilized in this 
dissertation and the pathogenesis of steatosis or IR in HCV infection.  
Racial differences exist in the occurrence of chronic HCV infection, in treatment 
outcomes and development of conditions associated with infection.  In the US, the prevalence of 
chronic HCV is higher among African Americans compared to Caucasian 
Americans.(Armstrong, 2006)  HCV genotype-1, -2 and -3 are commonly identified in US HCV 
patients and genotype-1 infection is more common in African Americans.(Alter, 1999; Strader, 
2004)  Individuals with HCV genotype-1 infection are less likely to have long-term treatment 
response compared  to those with other than genotype-1 infection.(Conjeevaram, 2006; MW 
Fried, 2002; Manns, 2001)  Studies also suggest that African Americans with HCV genotype-1 
have lower response rates to therapy compared to Caucasian Americans with the same 
genotype.(Conjeevaram, 2006; Hepburn, 2004; Jeffers, 2004; Kinzie, 2001; Muir, 2004; Strader, 
2004)  Further, racial differences also exist in the development of complications from HCV 
infection.  African Americans have a lower prevalence of steatosis and higher occurrence of IR 
compared to Caucasian Americans who have higher prevalence of steatosis and are less likely to 
have IR.(Browning, 2004; Conjeevaram, 2007; Heathcote, 2002; Petit, 2001; Romero-Gomez, 
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2005)  HCV research has attempted to explain racial differences and testing genetic associations 
may provide an additional link to understanding these differences.   
An initial objective of this dissertation was to examine the host genetic relationships with 
differences in 28 day treatment induced viral decline and the occurrence of both steatosis and 
insulin resistance.  Further objectives were to determine if associations were present in both 
Caucasian Americans and African Americans and if the associations remained after adjustment 
for potential confounding factors.  Specifically, the following research questions were addressed 
in a series of three research articles:   
1. Are selected interferon stimulated genes associated with differences in viral levels over 
the first 28 days of treatment?   
a. Do viral levels significantly differ by genotypes of interferon stimulated gene 
polymorphisms?   
b. Are the same genetic variants associated with 28 day viral decline in both African 
Americans and Caucasian Americans? 
2. Are selected genes associated with steatosis or insulin resistance in African Americans 
and Caucasian Americans?   
a. Are polymorphisms for the selected genes associated with steatosis and IR? 
b. Are these associations present in both African Americans and Caucasian 
Americans? 
3. Are adiponectin receptor 1 (ADIPOR1) and 3-hydroxy-3-methylglutaryl-CoA Synthase 2 
(HMGCS2) polymorphisms associated with steatosis and insulin resistance among 
African Americans and Caucasian Americans with HCV genotype-1?  
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a. Are tag selected genetic variants in ADIPOR1 and HMGCS2 associated with 
steatosis and IR? 
b. Are these associations present in both African Americans and Caucasian 
Americans? 
These research questions were investigated in The Study of Viral Resistance to Antiviral 
Therapy of Chronic Hepatitis C (Virahep-C), a multi-center treatment study that recruited 
African Americans and Caucasian Americans with chronic HCV genotype-1 with no prior 
history of treatment between July 2002 and December 2003.(Conjeevaram, 2006) 
 
 
 23 
2.0     BACKGROUND 
2.1 HEPATITIS C VIRUS 
The Hepatitis C Virus (HCV) was identified in 1989 and is a causative agent for liver disease, 
liver damage or chronic HCV infection.(Choo, 1989)  HCV infection occurs primarily through 
contact with blood, blood-derived products, organ donation, perinatal transmission, or body 
fluids such as vaginal fluids or semen.(Major, 1997; Van Leeuwen, 1996, 2005)  HCV is a 
member of the Flaviviridae virus family and has the ability to change and 
mutate.(Bartenschlager, 2000; Major, 1997; Reed, 2000; Van Leeuwen, 1996, 2005)  HCV 
exhibits genotypes and within each genotype there are multiple subtypes.(Major, 1997; 
Robertson, 1998)   
2.1.1 Epidemiology of the Hepatitis C Virus 
Hepatitis C virus is a major public health concern.  It is the leading cause of chronic liver disease 
and is the most common chronic, blood-borne infection in the United States (US).(Alter, 1999; 
Strader, 2002).  It is estimated that 4.1 million people in the US have antibodies to HCV (anti-
HCV), and of those, 3.2 million have chronic HCV infection identified as the presence of HCV 
RNA.(Armstrong, 2006)  Approximately 3% of the world population is estimated to be infected 
with chronic HCV.(Alberti, 1999)  Risk factors for HCV include exposure to blood or blood 
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products, blood transfusion before 1992, intravenous drug use, many sexual partners, tattoos, and 
body piercings.(Alter, 1999; Armstrong, 2006; Van Leeuwen, 1996, 2005)  In the US, the 
prevalence of chronic HCV infection is higher among African Americans (3.0%) compared to 
Caucasian Americans (1.5%) and higher among men (2.1%) compared to women 
(1.1%).(Armstrong, 2006)  In the US, there are three common genotypes of HCV:  genotype-1 is 
prevalent in 75% of cases, genotype-2 in 15% of cases, and genotype-3 in 7% of cases.(Alter, 
1999)   Ninety-one percent of chronic HCV infection in African Americans is genotype-1 
compared to 67% of infection in Caucasian Americans.(Strader, 2004)   
HCV infection during the first six months is referred to as acute infection.   
Approximately 20-30% of persons infected with HCV clear the virus naturally during the acute 
phase.  Failure of the immune system to naturally clear the virus results in chronic HCV and 
occurs in 54-86% of those exposed.(Seeff, 2002)  HCV genotypes and subtypes may contribute 
to the transition from the acute phase of infection to chronic illness.(Farci, 2000)  Chronic HCV 
can be mild or asymptomatic, but an estimated 20-40% of infections can cause severe morbidity 
and mortality from liver diseases or disease progression resulting from viral 
complications.(Reddy, 1999; Seeff, 2002)  A systematic review of histological activity studies 
with follow-up ranging from 4-12 years found that cirrhosis developed in 27% of cases and of 
those 5% died of liver disease.(Pagliaro, 1999)  Without treatment, 20-30% of those exposed to 
HCV may progress to cirrhosis on average in 20 years after infection.("National Institutes of 
Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 
10-12, 2002)," 2002) 
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2.2 DIAGNOSIS OF CHRONIC HEPATITIS C VIRUS 
Diagnosis of HCV for an individual may be initiated with the identification of elevated liver 
enzymes in routine blood tests, blood donor tests or through accidental screening such as medical 
examinations for health insurance or employment.  Assays to detect and quantify the virus can be 
used to monitor disease progression, liver damage and patient health.(Pawlotsky, 1998, 2002)   
2.2.1 Detection of Antibodies for Hepatitis C Virus 
Antibodies for HCV (Anti-HCV) are markers of HCV exposure and infection.  However, the 
presence of anti-HCV is not a sign of active infection, but that an individual was exposed to the 
virus and either resolved the infection naturally or developed chronic infection.(Pawlotsky, 
2003)  Anti-HCV is identified using enzyme immunoassays (EIA), with specificity greater than 
99%, where serum or plasma antibodies or viral antigens are captured on microtiter plate wells 
using antigen or specific antibodies.(Pawlotsky, 2002)   
2.2.2 Detection of Hepatitis C Virus RNA 
HCV RNA is considered to be a direct marker of HCV replication and chronic 
infection.(Pawlotsky, 2003)  Chronic infection is characterized by a gradual decline in HCV 
RNA levels that eventually stabilize and remain in a steady state between virus production and 
elimination.(Pawlotsky, 2002)  HCV RNA concentration can be measured by amplifying viral 
genome copies enabling quantification of the amount of viral genomes in the sample.(Pawlotsky, 
2002)  The international unit (IU), a universal standard unit of measurement for HCV RNA, was 
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established by the World Health Organization (WHO) to adjust for variability among 
assays.(Pawlotsky, 2000; Saldanha, 1999)  Quantitative assays using polymerase chain reaction 
(PCR) to quantify HCV RNA viral levels have a specificity of 98-99% with a lower limit of 
detection of approximately 600 IU/mL.(Pawlotsky, 2002)  Qualitative HCV RNA assays based 
on target amplification using PCR extract, amplify and read viral levels and have a lower HCV 
RNA detection limit of 50 IU/mL.(Pawlotsky, 2002)  Qualitative tests are generally used to 
evaluate sustained virologic response to antiviral therapy.       
2.2.3  Identification of HCV Genotype and Subtype 
HCV genotype and subtype can also be assessed in infected patients.  HCV has 6 genotypes 
numbered 1-6 which are further subdivided into subtypes denoted with lower case 
letters.(Simmonds, 1999)  Phylogenetic analysis, testing for type-specific antibodies or direct 
sequencing of the NS5B or E1 region of the virus are used to determine HCV genotype and 
subtype.(Pawlotsky, 2002; Simmonds, 1999) 
2.3 TREATING CHRONIC HEPATITIS C 
Treatment for patients with chronic HCV has evolved since the discovery of the virus.  
Treatment is recommended for all chronic HCV patients.(Fontaine, 2001)  The ultimate goal of 
therapy is to achieve a sustained virologic response (SVR) defined as undetectable levels of 
HCV RNA in the blood 24 weeks after therapy ends.(Lindsay, 2002)   
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The first treatment for HCV, interferon (IFN) alpha-2b monotherapy, was developed 
before the virus was identified and named.(Hoofnagle, 1986)  SVR rates were about 10-20% 
with a high rate of relapse.(Carithers, 1997)  Adding the nucleoside analog ribavirin to IFN 
monotherapy doubled the SVR rates in treatment naïve patients.(McHutchison, 1998; Poynard, 
1998)  To improve outcomes, pegylated interferon was examined in patient therapy.  Pegylated 
interferon is a chemically inactive polyethylene glycol (PEG) molecule that attaches to IFN-α2a 
or IFN-α2b to slow the absorption rate of the interferons allowing them to remain in the body 
longer.(Shiffman, 2001)   
The currently recommended treatment for chronic HCV infection is the combination of 
pegylated IFN-α2a or IFN-α2b weekly and weight-based dosing of ribavirin daily 
(pegINFα/RBV) for 24 to 48 weeks.(Lindsay, 2002)  Interferon treatment is thought to work by 
stimulating the host’s immune system and activating interferon stimulating genes 
(ISGs).(Zeuzem, 1996)  Ribavirin is believed to inhibit viral infection of susceptible cells.(Lau, 
2002)       
2.4 OUTCOMES OF HEPATITIS C TREATMENT 
2.4.1  Factors Associated with Sustained Virologic Response 
SVR occurs in 54-56% of individuals treated for HCV infection.(MW Fried, 2002; Manns, 2001)   
Host and viral factors that have been associated with treatment response include viral levels at 
the onset of treatment, HCV genotype, race, gender, age, obesity, steatosis and fibrosis.(Gao, 
2004; Lau, 1993; McHutchison, 1998; Zeuzem, 2004; Zeuzem, 2000)    Higher baseline viral 
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levels were associated with lower risk of achieving SVR in HCV-genotype-1 
patients.(Conjeevaram, 2006)  In two studies, fewer patients (42-46%) with HCV genotype-1 
infection achieved SVR compared to 76-82% of patients with HCV genotype-2 or -3.(MW Fried, 
2002; Manns, 2001)   
Several studies have shown that African Americans have lower response rates to therapy 
compared to Caucasian Americans.(Conjeevaram, 2006; Hepburn, 2004; Jeffers, 2004; Kinzie, 
2001; McHutchison, 2000; Muir, 2004; Strader, 2004)  Two studies have shown that  men have a 
significantly lower risk of achieving SVR compared to women with the same 
genotype.(Conjeevaram, 2006; Hayashi, 1998) Younger age was associated with better response 
to HCV treatment in several studies.(Bruno, 2004; Hayashi, 1998; Martinot-Peignoux, 1995; 
McHutchison, 2000; Muir, 2004)   
Fat mass and hepatic steatosis were associated with poor response to pegIFNα treatment 
in three studies.(Bressler, 2003; Charlton, 2006; Poynard, 2003)  Studies suggested that high fat 
mass and hepatic steatosis decreased pegIFNα bioavailability, impaired immune response to 
HCV and increased fibrosis progression reducing treatment response.(Bressler, 2003; Charlton, 
2006; Conjeevaram, 2006)  The presence of fibrosis was also associated with treatment non-
response.(Myers, 2003)                    
2.4.2  Rapid Virologic Response in the Prediction of Sustained Virologic Response 
Assessing virologic response very early during the course of treatment to predict SVR could be 
useful in HCV treatment research.  The ability to accurately detect SVR at four weeks of 
treatment could identify SVR non-responders.  Rapid virologic response (RVR) has been defined 
as at least a 2 log10 IU/mL drop in viral level in the first four weeks of treatment.(Moucari, 2007)   
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One study of patients treated with standard IFN three times weekly found that 30% of 
individuals who achieved a SVR had at least a 3 log10 decrease in viral level from baseline to 
week 4 of treatment.(Zeuzem, 1998)  Another study that compared different treatment regimens 
in HCV genotype-1 through -6 patients found that all patients, regardless of regimen or 
genotype, with an HCV RNA level greater than 450,000 IU/mL (5.65 log10 IU/mL) at week 4 
were non-responders at the end of treatment.(Berg, 2003)  However, using a four week cutoff of 
450,000 IU/mL (5.65 log10 IU/mL) only identified 15% of treatment responders.(Berg, 2003)  
Another study among mostly HCV genotype-1 patients receiving pegIFNα2b plus ribavirin 
found that 27 of 45 patients achieved at least a RVR.(Moucari, 2007)  Of those, 14 patients 
achieved a SVR resulting in a positive predictive value of 52%.(Moucari, 2007)  Of the 18 
patients who did not achieve a RVR, 17 did not achieve a SVR resulting in a negative predictive 
value of 94%.(Moucari, 2007)  Due to the relationship of very early viral response to ultimate 
SVR, identifying factors, including genetic variants, associated with viral decline in the first 28 
days may help to understand the mechanisms of treatment response and contribute to 
improvements in treatment options and ultimately treatment response.   
2.5 HEPATITIS C VIRAL DYNAMICS 
Viral dynamics are the time course of treatment induced changes in HCV viral levels.  HCV viral 
levels remain stable in chronic HCV infection with only minor changes in untreated patients 
representing a dynamic equilibrium between viral production and viral clearance.(Nguyen, 1996)   
Treatment with interferon changes the balance leading to a multi-phasic decline of HCV 
RNA.(Neumann, 2000; Neumann, 1998) 
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Viral dynamics models were developed to describe the decay of HCV RNA induced by 
interferon therapy.(Bekkering, 1997; Neumann, 2000; Neumann, 1998; Nowak, 1996; Perelson, 
1996; Powers, 2003; Ribeiro, 2003; Zeuzem, 1996)  Obtaining these models requires collecting 
frequent viral level measurements after the initiation of therapy.(Herrmann, 2003; Neumann, 
2000; Neumann, 1998; Powers, 2003; Ribeiro, 2003; Zeuzem, 2001; Zeuzem, 1996)  Dynamics 
models are thought to be useful in evaluating the antiviral effectiveness of therapy, estimating 
the rate of virion clearance, and approximating the rate of the clearance of HCV infected 
cells.(Perelson, 2005)         
Early viral dynamics research by Neumann et al. described a bi-phasic decline in viral 
level with interferon monotherapy.(Neumann, 1998)  The first phase of decline was rapid, dose 
dependent, and occurred within the first 24-48 hours of therapy.(Neumann, 1998)  The first 
phase of viral decline reflected clearance of free virions through the effect of IFN on the innate 
immune response and the blockage of viral production by IFN causing the rapid decline in viral 
level.(Layden-Almer, 2003; Neumann, 2000; Neumann, 1998; Zeuzem, 2001)  The second phase 
24-48 hours after initiation of treatment through day 14 was observed to be slower, highly 
variable and dependent on the effectiveness of IFNα in blocking viral production and causing the 
loss of infected cells.(Layden-Almer, 2003; Neumann, 2000; Neumann, 1998; Zeuzem, 2001)  
Early viral dynamics models provided information about the virus and how IFN therapy works.          
Viral dynamics models have also examined patients treated with pegIFNα2a 
monotherapy and showed a bi-phasic decline consisting of a rapid first phase decline within the 
first 48 hours followed by a second slower phase decline observed through day 28 of 
treatment.(Zeuzem, 2001)  Viral dynamics models in patients treated with pegIFNα2a and 
ribavirin showed three phases of viral decline.(Herrmann, 2003)  In the tri-phasic model, phase 
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one occurred within the first 24-48 hours after treatment initiation and was characterized by the 
clearance of free virus.(Herrmann, 2003)  The second phase from treatment day 2 to day 6 was 
distinguished by the exponential decay of productively infected cells.(Herrmann, 2003)  The 
third phase from day 7 to day 28 of treatment was a more rapid viral decay from delayed 
treatment induced infected cell loss.(Dahari, 2007; Herrmann, 2003)     
Viral dynamics are believed to be a prognostic factor in the early course of treatment to 
identify response to therapy at the end of treatment.(Neumann, 2000; Neumann, 1998)  In the tri-
phasic model, a more rapid third phase decay was strongly associated with SVR.(Herrmann, 
2003)  Viral dynamics may also be an important factor in determining why some individuals 
respond to treatment and others do not.(Layden-Almer, 2003)  For example, very early viral 
decline may vary by race.(Layden-Almer, 2003)  Provided that viral clearance is occurring, a 
small initial decrease in HCV RNA level over the first 24 hours may indicate that peg-IFNα is 
not effective in blocking viral production and a slow or absent second phase might indicate the 
inability of the host to clear infected cells.(Layden-Almer, 2003)  Caucasian Americans have a 
higher phase one viral decline and a higher rate of infected cells loss (98%) compared to African 
Americans (89%).(Layden-Almer, 2003)  Fewer African Americans experience a phase two viral 
decline compared to Caucasian Americans.(Layden-Almer, 2003)  These results suggest that the 
first phase viral decline has a significant influence on the second phase viral decline and 
ultimately treatment response.(Jessner, 2001; Layden, 2002) 
Viral dynamics models could be used to optimize therapy for patients with reduced 
response rates such as African Americans or HCV genotype-1 patients.  Models can be used to 
monitor individual response early during treatment and to adjust regimens as necessary.  These 
models may also be important in evaluating the antiviral efficacy of new therapies.  
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Understanding how host immune response, host genetic factors or combination therapy influence 
viral dynamics may guide the development of novel HCV treatments and provide insight into 
more effective treatment regimens or drug dosage. 
2.6 INTERFERON STIMULATED GENES AND HCV TREATMENT RESPONSE 
Clinical implications are not always immediately recognized with one genetic association study, 
but genetic epidemiology is useful in translational medicine.  An underlying assumption of 
genetic epidemiology is that understanding human disease through basic science will ultimately 
help lead to clinical improvements by recognizing risk groups that should be treated differently, 
by identifying novel molecular treatment targets and by generating hypotheses about why and 
how therapies work differently in different populations.   
The interferon system is a vital component of the innate immune response to infectious 
agents.  Interferon stimulated genes (ISGs) induce proteins with antiviral actions and activate 
mechanisms that enhance immune response.  HCV is thought to have developed mechanisms to 
circumvent the host immune response by inhibiting the functions of several ISGs.  Viral proteins 
may block the production or reduce the effectiveness of ISG proteins which normally have 
antiviral actions to enhance immune response to infection.(MacQuillan, 2003)  Since ISGs are 
important in immune response, studies have examined the role of host genetics in the response to 
interferon therapy, although most studies have focused on SVR as the primary 
outcome.(Hijikata, 2001; Hijikata, 2000; Knapp, 2003; H Saito, 2002; T Saito, 2004; Suzuki, 
2004; Tena-Tomas, 2007; Thursz, 1997; Wietzke-Braun, 2006)   
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2.6.1 Myxovirus Resistance Genes 
The myxovirus resistance 1 (MX1 or MXA) protein was observed to influence IFN-induced 
antiviral activities of host cells against infectious viruses.(Jakschies, 1994; Pavlovic, 1990; 
Roers, 1994; Zhao, 1996)   In a study of Western Australian patients,  MX1 mRNA expression 
has been found to be up-regulated in chronic HCV infection, but intrahepatic MX1 expression 
did not correlate with baseline HCV viral levels though strong baseline MX1 expression in 
hepatocytes were associated with HCV treatment non-response.(MacQuillan, 2003)  In HCV 
patients treated with interferon monotherapy, MX1 mRNA levels increased after initiation of 
therapy and declined after completion of treatment.(Fernandez, 1999)  For HCV treatment naïve 
patients treated with pegIFNα2b/RBV, MX1 expression was lower in people who had SVR than 
in those who did not respond.(Giannelli, 2004)  In spite of these conflicting results, the MX1 
protein may be involved in HCV treatment response.  Further, MX1 could be examined at a 
genetic level because the gene may affect antiviral actions of host cells in response to viral 
infection.  
Studies have examined associations between MX1 single nucleotide polymorphisms 
(SNPs) and HCV treatment outcomes.  Statistically significant associations between the MX1 
SNP at position -88G/T with respect to the transcription initiation site and HCV treatment 
response have been reported.(Hijikata, 2001; Hijikata, 2000; Knapp, 2003; Suzuki, 2004)  In two 
studies of interferon monotherapy, the MX1 -88 GT and TT genotypes were significantly 
associated with SVR such that carriage of the T allele was associated with SVR.(Knapp, 2003; 
Suzuki, 2004)  Two separate studies in Japanese populations confirmed the association between 
the MX1 -88 GT and TT genotypes and SVR.(Hijikata, 2001; Hijikata, 2000)  These studies 
indicate that MX1 variants may be important to understanding HCV treatment response. A 
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different study examined the MX1 -88G/T polymorphism, but found no statistically significant 
association with initial treatment response defined undetectable HCV RNA at four months into 
treatment.(Wietzke-Braun, 2006)  Though results of these studies are conflicting, they use 
different methodologies making the association between MX1 polymorphisms and HCV 
treatment response uncertain.  Thus, further research could contribute to a greater understanding 
of the importance of this gene in HCV treatment response.   
Myxovirus resistance 2 (MX2) functions by encoding a protein that has nuclear and 
cytoplasmic forms.(Rebhan, 2007) The MX2 gene function with respect to HCV treatment 
response is unknown.  Testing genetic variant associations with MX1 and MX2 may contribute to 
understanding the association of these genes with HCV treatment response.  
2.6.2 2’-5’ Oligoadenylate Synthetase (OAS) Gene System 
The 2’-5’ oligoadenylate synthetase (OAS) gene system contains ISGs that function by degrading 
cellular and viral RNA thereby inhibiting viral replication.(Hovanessian, 1977; Zhou, 1993)   
The HCV core protein disrupts normal immune response and studies have suggested that 2’-5’ 
OAS levels before and during IFN treatment are influenced by the virus core 
protein.(Murashima, 2000; Naganuma, 2000)  Increased 2’-5’ OAS expression was associated 
with the effectiveness of pegIFNα2b/RBV in HCV RNA clearance.(Kim, 2006)    
2’-5’ oligoadenylate synthetase 1 (OAS1), an interferon stimulated gene, may influence 
immune response by breaking down viral and cellular RNA.(Castelli, 1998; Pestka, 1987)  
Knapp et al. observed a statistically significant association between OAS1 rs2660 and  
spontaneous clearance of HCV, but not with response to interferon therapy.(Knapp, 2003)  
Despite the lack of a significant association with SVR, since OAS1 covers a 12.97 kilobase (kb) 
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region on the chromosome with several polymorphisms, additional variants along this gene could 
be examined to identify associations with HCV treatment response.   
2’-5’ oligoadenylate synthetase 2 (OAS2) and 2’-5’ oligoadenylate synthetase 3 (OAS3) 
are thought to function by encoding an enzyme that activates the degradation of viral and cellular 
RNA.(Hovanessian, 1991)  2’-5’ oligoadenylate synthetase like (OASL) has the ability to bind to 
double stranded RNA and DNA.(Hovanessian, 1991)  The genes in the OAS gene system may be 
important to understanding immune response and genetic variant associations in these genes may 
contribute to understanding the mechanisms of HCV treatment response.  
2.6.3 Protein Kinase 
Studies testing the association between Protein Kinase (PKR) expression and HCV treatment 
response have been conducted.  The HCV core protein is thought to inhibit innate PKR function 
and allowing virus transmission to uninfected cells.(Pflugheber, 2002)  In one study, PKR 
expression was found to be enhanced within a few hours of pegIFNα treatment and facilitated the 
clearance of HCV infected cells.(Clemens, 1997)  Other studies have suggested that PKR protein 
expression was not predictive of SVR.(Giannelli, 2004; MacQuillan, 2002)  Although these 
results are conflicting, PKR appears to be implicated in HCV treatment response.  Further, PKR 
could be examined at a genetic level because it may be involved in reducing transmission of 
HCV to uninfected cells. (Clemens, 1997; Pawlotsky, 1998) 
Studies have also tested PKR polymorphism associations with HCV treatment response.  
Two different studies were unable to identify a statistically significant association between PKR 
polymorphisms -168 and -180 and HCV treatment response (SVR).(Clemens, 1997; Knapp, 
2003)  Although these studies did not identify a significant association with treatment response, 
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PKR is thought to function by shutting down protein synthesis following viral infection of a cell 
and limiting the transmission of the virus to uninfected cells.(Clemens, 1997; Pawlotsky, 1998)  
Further, PKR is a large gene that contains many polymorphisms and examining associations 
between additional genetic variants may be important to understanding if this gene is associated 
with HCV treatment response.   
2.6.4 Interferon Regulatory Factor Family 
Interferon regulatory factor 1 (IRF1) is an activator of interferon alpha and beta transcription 
and may be involved in immune response.(Rebhan, 2007)  The activation of IRF1 through a PKR 
dependent pathway was observed to impact virus replication directly or through stimulation of 
the adaptive immune response which may be blocked by the HCV core protein.(Pflugheber, 
2002; T Taniguchi, 1997)  One study examined the relationship between IRF1 rs2549009 and 
initial virologic response in 147 Caucasian HCV patients and did not find a statistically 
significant association.(Wietzke-Braun, 2006)  Although this study did not find a statistically 
significant association with one genetic variant, IRF1 spans about 7.7 kb and additional variants 
in this gene may be associated with HCV treatment response.  Interferon regulatory factor 7 
(IRF7) may also play a role in transcriptional activation of virus-inducible cellular genes and 
response to viral infection, but its genetic association with HCV treatment response is 
unknown.(Rebhan, 2007)    
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2.6.5 Interferon Alpha Receptor Genes 
Interferon alpha receptor subunit 1 (IFNAR1) and interferon alpha receptor subunit 2 (IFNAR2) 
genes were observed to initiate antiviral activity and higher levels of both proteins were observed 
in HCV treatment responders compared to HCV treatment non-responders.(Gao, 2004)  Two 
polymorphisms in IFNAR1 were examined in relation to SVR among 103 Brazilian HCV 
patients treated with conventional IFNα administered three times weekly or pegIFNα 
administered once weekly with ribavirin.(Tena-Tomas, 2007)  This study did not identify a 
statistically significant association between genotypes of IFNAR1 L168V (rs2257167) or 
G17470C and SVR.(Tena-Tomas, 2007)  In spite of these non-significant associations with SVR, 
these genes were observed to initiate antiviral response (Gao, 2004) and examining additional 
genetic variants may explain their relationship to HCV treatment response.  Further, the 
association between 28 day viral decline and IFNAR1 or IFNAR2 is not known.           
2.6.6 Signal Transducer and Activator of Transcription Genes 
Expression of HCV core proteins is thought to inhibit the interferon induced signal transduction 
of the Jak-STAT pathway.(Blindenbacher, 2003; Heim, 1999)  Over expression of Signal 
Transducer and Activator of Transcription 1 (STAT1) is able to control HCV viral 
production.(Lin, 2005)  However, since the HCV core protein can block STAT1 protein 
production, STAT1 may not be able to enhance immune response.(Larrea, 2006; Lin, 2005)  In 
response to interferons, the Signal Transducer and Activator of Transcription 2 (STAT2) protein 
is thought to act with the STAT1 protein and the IFN regulatory factor family to initiate the 
immune response to infectious agents.(Rebhan, 2007)  An unpublished study in HCV genotype-1 
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infected patients observed a statistically significant association between STAT2 rs2066811 and 
SVR.(Su, 2008)  These studies indicate the importance of STAT1 and STAT2 in immune and 
HCV treatment response, but the association between these genes and 28 day viral decline is 
unknown. 
2.6.7 Ubiquitin-Like Modifier Genes 
ISG15 ubiquitin-like modifier (ISG15/G1P2) functions by encoding a protein that targets 
interferon stimulation.(Rebhan, 2007)  ISG15/G1P2 has displayed antiviral activity in response 
to viral infections.(Rebhan, 2007)  G1P3/IFI6 was one of the first interferon induced genes 
identified and expression was up-regulated in HCV infection and may stimulate interferon 
activity.(Bieche, 2005)  Another ISG, interferon induced protein 35 (IFI35) was found to be up-
regulated by the presence of IFNα in human liver cells.(Yan, 2004)  These genes have functions 
related to immune response and may be important in understanding mechanisms of HCV 
treatment response.     
2.6.8 Importance of Genetic Associations with HCV Treatment Response 
The studies describing associations between ISGs and HCV treatment SVR indicate that ISGs 
are important to understanding the mechanisms of SVR, but do not tell us if ISG polymorphisms 
are important to 28 day viral decline or if ISG polymorphisms are similarly associated with SVR 
in African Americans and Caucasian Americans.  Identifying genetic variant associations with 
28 day viral decline in HCV treatment may contribute to understanding factors associated with 
SVR or biological reasons for treatment non-response.  Also, identifying associations in African 
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Americans, an under-represented population in HCV treatment literature, could contribute to 
understanding racial differences in treatment response.  Identifying genetic variant associations 
with 28 day viral decline may help to understand the early mechanisms of immune response and 
treatment effectiveness.  These findings could be utilized in the development of new therapies 
that target those ISGs that stimulate immune response in the early course of treatment to 
ultimately improve long-term outcomes. 
Previous research describing the relationship between ISGs and HCV treatment response 
has focused on the expression of the ISGs or examined genetic variant associations with 
SVR.(Clemens, 1997; Fernandez, 1999; Giannelli, 2004; Hijikata, 2001; Hijikata, 2000; Knapp, 
2003; MacQuillan, 2002; Murashima, 2000; Naganuma, 2000; Su, 2008; Suzuki, 2004; Tena-
Tomas, 2007) No studies were found that examined associations between the ISG 
polymorphisms described in this dissertation and viral decline in the first 28 days of treatment. 
Examining 28 day viral decline is beneficial because it may be possible to draw long-
term conclusions in the short time frame where outside influences such as side effects or dose 
reductions may not occur as often as in the full time course of treatment.  Understanding host 
genetic factors that influence viral decline in the first 28 days of therapy may identify the 
underlying biological mechanisms responsible for differences in treatment response.       
Examining racial differences in the first 28 days of HCV treatment may be useful in 
achieving better long-term outcomes in African Americans who do not typically respond.  
Identifying ISG polymorphisms that are associated with greater viral decline in different race 
groups may be useful in understanding if different factors influence treatment response in the 
race groups.  If different host genetic variants are associated with treatment response in different 
race groups, then future treatments could even be customized based on host genetics.   
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Finally, this improved understanding of biological mechanisms may be an important 
factor not only in improving the HCV treatment outcomes, but also in reducing co-morbidities 
related to HCV infection.  For example, HCV viral clearance has been associated with restoring 
insulin function and ultimately reducing the occurrence of type 2 diabetes.(Kawaguchi, 2007; 
Konrad, 2000; Tanaka, 1997)     
2.7 CHRONIC HEPATITIS C DISEASE PROGRESSION 
Some individuals have rapidly progressing disease which may lead to severe morbidity and 
mortality due to liver damage while other individuals infected with HCV do not have rapid 
disease progression and may not experience symptoms.  It is not fully understood why some 
individuals with chronic HCV experience non-progressive disease versus progressive disease.  
Inflammation and fibrosis are common conditions used to assess disease progression.  HCV 
infection can lead to fibrosis, cirrhosis, steatosis or liver cancer.  Liver inflammation is 
characterized the presence of inflammatory cells in the liver resulting from damage to 
hepatocytes.(Markiewski, 2006; Nathan, 2002)  Inflammation can result in changes in liver 
structure, slowed blood circulation, death of liver cells or scar tissue formation.(Nathan, 2002)  
Fibrosis is tissue scarring caused by the healing process from liver injury.  Cirrhosis occurs when 
normal, healthy tissue is replaced with scar tissue, blocking the flow of blood through the liver 
and preventing proper function.  Steatosis is the accumulation of fat in liver cells.   
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2.7.1 Factors Associated with HCV Disease Progression 
The relationship between viral factors and disease progression is still being examined.  Most of 
the literature does not support an association between viral level or genotype and disease 
progression (Fanning, 1999; Lau, 1993; Poynard, 2001) although one study has suggested that 
progression was faster in genotype-1b infection compared to genotype-2.(Kobayashi, 1996)  
Host related factors associated with disease progression include age, race, obesity, sex and 
alcohol consumption.(Alter, 1999; Benhamou, 1999; Deuffic, 1999; Hickman, 2002; Lesens, 
1999; Poynard, 2001; Ragni, 2001; Reddy, 1999; Wiley, 2002)  Younger age at infection and 
female gender were associated with slower disease progression compared to older age at 
infection and male gender, respectively.(Deuffic, 1999; Poynard, 2001)  African Americans have 
slower progression to cirrhosis compared to Caucasian Americans even though African 
Americans also have higher rates of chronic HCV infection and lower rates of treatment 
response.(Reddy, 1999; Wiley, 2002)  Further, alcohol consumption was observed to increase the 
rate of HCV disease progression in several studies.(Corrao, 1998; Frieden, 1999; Noda, 1996; 
Ostapowicz, 1998; Pessione, 1998; Peters, 2002; Wiley, 1998)   Studying host genetic factors 
associated with HCV related conditions could contribute to better understanding of the 
differences in progression and may lead to methods of prevention.   
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2.8 MEASURING DISEASE PROGRESSION  
2.8.1 Liver Enzyme Measures 
Liver enzyme measures can be used to measure HCV disease progression and the extent of 
damage to the liver.  Liver enzyme tests including alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) may initially identify a problem because elevated levels could indicate 
liver damage.        
2.8.2 Liver Biopsy and Scoring Systems for Histological Activity 
Liver damage or disease progression can be measured by examining liver biopsies.  Biopsies are 
read by a pathologist to determine the extent of liver inflammation, fat cells in the liver and 
fibrosis.  Inflammation and fibrosis can be measured using scoring techniques that were 
developed to clinically classify the grade and stage of the hepatic process from liver histology.   
2.8.2.1 Liver Biopsy Scoring Systems 
The first scoring system for liver damage examined in liver biopsies was the Histological 
Activity Index (HAI).(Knodell, 1981)  The HAI grades the amount of inflammation in the liver 
with scores ranging from 0-18 and fibrosis scores from 0-4.(Desmet, 1994; Di Bisceglie, 1995; 
Knodell, 1981)  The original Knodell HAI scoring system was criticized because it was based on 
a small number of samples and did not validate the reproducibility of the scoring 
system.(Desmet, 2003; Hubscher, 1998)  The Knodell’s HAI scoring system has some additional 
limitations including the use of a non-continuous scale, combined inflammatory activity and 
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fibrosis scores, and piecemeal necrosis included with bridging necrosis.(Desmet, 2003; 
Hubscher, 1998) 
The Scheuer System was developed to address some of the concerns with the original 
HAI score.  It scores necroinflammatory activity in chronic hepatitis by classifying grade, lobular 
activity and stage of chronic HCV.(Scheuer, 1991)  The Scheuer System has advantages over the 
HAI system because it uses a continuous scale of measurement, inflammatory activity is 
considered separately from fibrosis and bridging necrosis is measured with lobular activity 
instead of piecemeal necrosis.(Scheuer, 2002)  A disadvantage to this system is the narrow range 
of scores with limited applicability to clinical practice.(Hubscher, 1998) 
The Modified HAI Scoring System was developed to further address concerns with the 
HAI score.(Ishak, 1995)  The maximum inflammation score is 18 and fibrosis is measured with a 
6 point scale.(Ishak, 1995)  The modified HAI scoring system has good inter- and intra-observer 
reliability and necroinflammatory changes are assessed separately from assessment of fibrosis 
stage.(Hubscher, 1998; Rozario, 2003) 
Another system to quantify histologic activity is the Metavir Scoring System.  This 
system examines necrosis and lobular necrosis to score histological activity and scores fibrosis in 
5 levels.(Bedossa, 1994; Bedossa, 1996)  The Metavir Scoring System has good inter- and intra-
observer reliability.(Bedossa, 1994)      
2.9 STEATOSIS AND HEPATITIS C VIRUS INFECTION 
Nonalcoholic fatty liver disease (NAFLD) may range from steatosis, or the occurrence of fat 
cells in the liver, to nonalcoholic steatohepatitis (NASH), a liver disease characterized by both 
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inflammation and the accumulation of fat in the liver.(Ruhl, 2004; Teli, 1995)   Steatosis is 
prevalent in as few as 30% to as many as 84% of chronic HCV patients.(Adinolfi, 2001; Asselah, 
2006; Castera, 2003; Conjeevaram, 2006; Conjeevaram, 2007; Czaja, 1998; Hourigan, 1999; 
Hui, 2002; Monto, 2002; Patton, 2004; Poynard, 2003; Rubbia-Brandt, 2004; Rubbia-Brandt, 
2001; Serfaty, 2001; Westin, 2002)        
2.9.1 Diagnosis of Steatosis 
Steatosis is most commonly diagnosed by reading a liver biopsy and calculating the percentage 
of fat in the liver cells.(Brunt, 1999)  Liver biopsy is the gold standard for diagnosing and 
quantifying steatosis, but is an invasive procedure associated with health complications, 
sampling error and inter-observer variability.(Regev, 2002)  Other methods to measure steatosis 
among HCV patients have been developed that are less invasive such as transabdominal 
ultrasound or Doppler technology which examines the right hepatic vein.(Celle, 1988; Dietrich, 
2002; Dietrich, 1998; Oguzkurt, 2005)  Focal hypoechoic areas (FHA) within the liver hilum and 
hepatic vein flow (HVF) pattern were correlated with liver biopsy findings for steatosis.(Hirche, 
2007)   
2.9.2 Epidemiology of Steatosis among HCV Patients 
Steatosis is thought to occur more frequently in patients with chronic HCV compared to the 
general population.(Asselah, 2006; Browning, 2004)  Studies have suggested that African 
Americans have a lower prevalence of steatosis compared to Caucasian Americans with chronic 
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HCV infection.(Browning, 2004; Conjeevaram, 2007)  Understanding host genetic associations 
with steatosis may help to explain the observed racial differences. 
Steatosis among people with HCV genotype-1 infection has been associated with host 
factors such as BMI, alcohol consumption, age, gender, race, hepatic inflammation, 
hyperlipidaemia, triglyceride levels, cholesterol, ALT levels, AST levels, fibrosis scores and 
insulin resistance (Adinolfi, 2001; Asselah, 2006; Castera, 2003; Conjeevaram, 2007; Czaja, 
1998; Fabris, 2004; Hourigan, 1999; Leandro, 2006; Monto, 2002; Poynard, 2003; Rubbia-
Brandt, 2001; Rubbia-Brandt, 2000; Ruhl, 2004; Serfaty, 2001; Serfaty, 2002; Solis-Herruzo, 
2005; Younossi, 2004)  Moderate alcohol consumption was observed to increase the amount of 
steatosis.(Hezode, 2003)  Evidence from a few studies suggests that higher body mass index 
(BMI) is associated with steatosis in HCV genotype-1 infection.(Asselah, 2006; Hwang, 2001; 
Matos, 2006; Ruhl, 2004; Solis-Herruzo, 2005; Younossi, 2004)  In general African Americans 
have a lower prevalence of steatosis, but have higher BMI, compared to Caucasian 
Americans.(Browning, 2004)  Men are more likely to develop steatosis compared to women and 
the sex difference may be associated with greater alcohol intake in men or hormonal 
differences.(Browning, 2004)  Higher age was also associated with development and progression 
of steatosis.(Fabris, 2004)  Host genetic associations may contribute to a greater understanding 
of the differences in the occurrence of steatosis.   
Steatosis can also affect HCV treatment outcomes and can have an impact on disease 
progression and fibrosis.(Adinolfi, 2001; Castera, 2003; Hourigan, 1999; Serfaty, 2002; Westin, 
2002)  HCV genotype-1 patients with steatosis achieved SVR less frequently (29-46%) 
compared to those without steatosis (62-65%).(Jian Wu, 2006; Soresi, 2006; Westin, 2007) 
Steatosis and the steatosis grade were found to be predictive of the severity and progression of 
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fibrosis which could lead to cirrhosis.(Adinolfi, 2001; Castera, 2003; Fartoux, 2005; Hourigan, 
1999; Leandro, 2006; Serfaty, 2002; Westin, 2002)   
2.10 INSULIN RESISTANCE AND HEPATITIS C VIRUS INFECTION 
Insulin Resistance (IR) is a condition in which typical amounts of insulin are insufficient to use 
blood glucose for energy and metabolism, particularly in fat, muscle and liver cells.(Rao, 2001; 
Romero-Gomez, 2006)  Insulin resistance may be a common pathogenic event linking obesity, 
type 2 diabetes mellitus, hypertension, and lower high density lipoprotein levels with fatty liver 
disease.(Meigs, 2000)  Studies have suggested that IR is common and can occur early in the 
course of HCV infection.(Fartoux, 2005; Puri, 2006)  Patients with chronic HCV infection were 
observed to have higher HOMA-IR index scores, a measure of IR, compared to healthy 
controls.(Hui, 2003)  Studies have also suggested that HCV RNA clearance with antiviral 
therapy may result in the restoration of insulin sensitivity and insulin action.(Konrad, 2000; 
Tanaka, 1997)      
2.10.1 Diagnosis of Insulin Resistance 
Insulin resistance can be quantified and measured using fasting insulin and glucose 
levels.(Pacini, 2003)  Several validated methods exist to measure and quantify IR including the 
Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR) which is calculated as 
HOMA-IR = [fasting glucose (millimoles per liter) x fasting insulin (milliunits per 
liter)]/22.5.(Matthews, 1985)  However, the HOMA-IR underestimates insulin sensitivity and 
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overestimates β-cell function (insulin secretion).(Wallace, 2004)  More recently, a model to 
obtain more accurate measures of insulin resistance, the Homeostasis Model Assessment Insulin 
Resistance Index Version 2.2 (HOMA2-IR) was released and the computer based model was 
made available in 2004.(Levy, 1998; Wallace, 2004)  The HOMA-IR and HOMA2-IR scores 
have been validated against the hyperinsulinemic euglycemic clamp, the gold standard.(Wallace, 
2004)  HOMA-IR has been used in studies with various values used to indicate insulin resistance 
(e.g. 1.5 or 2.0).(Bonora, 1998; Conjeevaram, 2007; Hedblad, 2000; Matsumoto, 1997; Nakai, 
2002; A Taniguchi, 2000) 
2.10.2 Epidemiology of Insulin Resistance in Hepatitis C Virus Infection 
Risk factors associated with IR among HCV patients include African American race, obesity, 
cirrhosis, age, fibrosis, and gender.(Heathcote, 2002; Petit, 2001; Romero-Gomez, 2005) African 
Americans had higher odds of IR than Caucasian Americans in one study.(Shaheen, 2007)  
Obese individuals had higher HOMA-IR scores compared to non-obese controls.(Puri, 2006)  
Viral genotype appeared to influence the occurrence of IR such that genotype-3 infected patients 
had lower HOMA-IR scores compared to people with other genotypes after adjusting for BMI 
and other confounders.(Hui, 2002)  Studying host genetics may also contribute to explaining 
differences in the occurrence of IR. 
Other factors related to higher HOMA-IR scores in HCV patients include fibrosis, 
steatosis, portal inflammation and diabetes.(D'souza, 2005; Fartoux, 2005; Hui, 2003; Knobler, 
2000; Lonardo, 2004; Mason, 1999; Petit, 2001; Puri, 2006; Shintani, 2004; Sud, 2004)  The 
prevalence of type 2 diabetes was higher in HCV infected patients (14.5%) compared to the 
general population (7.8%).(Zein, 2005)  Given the high prevalence and the worldwide 
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distribution of HCV infection, the association between HCV infection and the occurrence of type 
2 diabetes may have an important impact on public health and understanding the mechanisms 
may be important to reducing additional complications from type 2 diabetes in chronic HCV 
patients.(Knobler, 2000) 
The presence of IR before therapy was found to negatively impact the ability to achieve 
an SVR in HCV genotype-1 infection.(Romero-Gomez, 2006; Romero-Gomez, 2005)  
Maintaining viral clearance for six months after treatment was associated with improved 
HOMA-IR scores and insulin function.(Kawaguchi, 2007; Konrad, 2000; Tanaka, 1997)  
Improvement in HOMA-IR scores among HCV genotype-1 and genotype-2 patients was only 
observed among individuals achieving SVR.(Kawaguchi, 2007)  Understanding factors 
associated with IR in HCV infection may reduce the occurrence of related conditions such as 
type 2 diabetes and improving SVR.(Romero-Gomez, 2005)    
2.11 GENETIC ASSOCIATIONS WITH STEATOSIS AND INSULIN RESISTANCE 
Understanding the biological mechanisms of steatosis and IR in HCV infection may be useful in 
developing prevention and treatment methods that reduce the occurrence of these conditions, 
decrease the likelihood of other HCV co-morbidities (such as cirrhosis or type 2 diabetes) and 
ultimately improve treatment outcomes.  Expression or polymorphism associations for genes 
with functions related to fat metabolism, lipid metabolism, diabetes and obesity have been 
studied with steatosis and insulin resistance. (Cardellini, 2005; Kubaszek, 2003; Kubaszek, 2003; 
Qi, 2006; Sartipy, 2003; Scarpelli, 2006; Simeoni, 2004; Testa, 2006; Y Yang, 2003)  For the 
genes examined in this dissertation, only one published study was found that examined genetic 
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associations with steatosis or IR in HCV infection.(Sanchez-Munoz, 2004)  Only one study was 
found to examine genetic variants with steatosis and IR among African American 
children.(Crimmins, 2007)     
2.11.1 Adiponectin Receptor 
The adipocyte, an endocrine cell that releases free-fatty acids and secreting factors called 
adipokines such as TNF-α, interleukins, leptin, resistin and adiponectin, is considered to be 
important in the occurrence of steatosis and insulin resistance in obese patients.(Whitehead, 
2006)  Plasma adiponectin levels were decreased in one study of obese participants (Arita, 1999)  
and subsequent studies found that low adiponectin levels were associated with IR and 
steatosis.(Chandran, 2003; Jonsson, 2005; Stefan, 2002)        
Adiponectin Receptor 1 (ADIPOR1) is a gene that encodes adiponectin which is mainly 
expressed in skeletal muscle.(Rebhan, 2007)  Statistically significant associations were identified 
in studies between ADIPOR1 polymorphisms and IR or steatosis.(Collins, 2007; Crimmins, 
2007; Siitonen, 2006; Stefan, 2005)  Among European decent participants, the rs6666089-A 
allele and the -C allele of the -1927 polymorphism were associated with insulin resistance and 
high liver fat.(Stefan, 2005)   A study of British participants confirmed the association between 
ADIPOR1 rs6666089-A allele and IR.(Collins, 2007)  In a study of healthy African American 
children aged 10-19,  the rs1342387-A allele was associated with decreased HOMA-IR scores in 
a non-obese subset, but no association was observed for rs6666089.(Crimmins, 2007)   A study 
examining ADIPOR1 polymorphisms among a population of Old Order Amish confirmed the 
association between the rs1342387-A allele and lower HOMA-IR scores.(Damcott, 2005)  These 
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studies indicate that ADIPOR1 is associated with steatosis and IR, but these associations have 
not been studied in HCV infection.    
2.11.2 Tumor Necrosis Factor System 
Chronic HCV is thought to activate and up-regulate the tumor necrosis factor (TNF) 
system.(Itoh, 1999; Nelson, 1997)  TNF-α is a pro-inflammatory cytokine secreted by 
endothelial, smooth muscle cells, macrophages and adipose cells that play a critical role in viral 
induced liver damage and may participate in the pathobiology of IR.(Hotamisligil, 1999; Puri, 
2006)  TNF-α was observed to block the action of insulin by inhibiting the insulin receptor 
tyrosine kinase activity.(Feinstein, 1993)  Increased TNF-α levels in the liver were observed in 
people infected with HCV.(Gershon, 2000; Kallinowski, 1998; Nelson, 1997; Petit, 2001; 
Valenti, 2005)  Other studies also found that increased TNF-α levels were associated with the 
occurrence of IR (Halse, 2001; Maeno, 2003; Mishima, 2001; Moller, 2000; Valenti, 2005) or 
the degree of steatosis.(Gochee, 2003; Sougleri, 2001; Valenti, 2005)  These studies indicate that 
TNF-α expression is associated with the occurrence of steatosis and IR. 
One study examined TNF-α polymorphism associations with steatosis in HCV infection.  
This study found no statistically significant association between TNF-α -238 or -308 in 133 
chronic HCV patients with no history of treatment.(Sanchez-Munoz, 2004)  Despite these 
negative results, TNF-α is involved in inflammatory response and TNF-α protein expression may 
be related to steatosis or IR.  Examining genetic associations may identify functional TNF-α 
polymorphisms that could contribute to understanding the occurrence of steatosis and IR in HCV 
infection.           
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2.11.3 Interleukin Genes 
Interleukin 6 (IL6) is a proinflammatory cytokine secreted by immune cells, adipose tissue and 
muscles that accelerates the inflammatory process.(Fried, 1998; Mohamed-Ali, 1997)  Studies 
have suggested that increased IL6 levels were associated with insulin resistance and type 2 
diabetes.(Cardellini, 2005; Danielsson, 2005; Deepa, 2006; Hamid, 2005; Hermann, 2005; Illig, 
2004; Kubaszek, 2003; Mohlig, 2004; Qi, 2006; Testa, 2006; Tsiavou, 2004; Vozarova, 2003; X 
Yang, 2005)  These results indicate that the IL6 protein may be important in the development of 
IR.   
IL6 genetic studies have examined the association between the promoter polymorphism (-
174 G>C) and IR or type 2 diabetes.(Cardellini, 2005; Fernandez-Real, 2000; Hamid, 2005; 
Kubaszek, 2003; Qi, 2006; Testa, 2006; X Yang, 2005) Five of these studies identified a 
statistically significant association between the IL6 -174 GG genotype and IR in European, 
healthy or diabetic patients.(Cardellini, 2005; Fernandez-Real, 2000; Hamid, 2005; Testa, 2006; 
X Yang, 2005)  Other studies were unable to identify a statistically significant association 
between the IL6 -174 variant and type 2 diabetes.(Kubaszek, 2003; Qi, 2006)  Although some of 
these results are negative, IL6 is thought to accelerate inflammatory response which may be 
important in the occurrence of both steatosis and IR.  This gene spans approximately 5 kb and 
studying additional variants may contribute to understanding these conditions in HCV infection.         
Interleukin 10 (IL10) is an anti-inflammatory cytokine produced by T cells, B cells, 
monocytes and macrophages and contributes to immune response.(Fiorentino, 1991; O'garra, 
1990)  Low IL10 levels were associated with the metabolic syndrome, which is also related to IR 
and steatosis.(Esposito, 2003)  In two studies, a positive correlation between IL10 levels and 
higher insulin sensitivity was observed.(Bluher, 2005; Straczkowski, 2005)  IL10 promoter 
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polymorphisms (-1082G/A, -819C/T and -592C/A) were also examined with IR in Caucasian 
Italian diabetic and non-diabetic patients.(Scarpelli, 2006) The A allele of the -592C/A IL10 
polymorphism was associated with higher HOMA-IR scores compared to the C allele in non-
diabetic patients.(Scarpelli, 2006)  These results indicate that this IL10 polymorphism is 
associated with IR in non-diabetic patients.  Examining associations between steatosis or IR and 
the -592 polymorphism and other IL10 polymorphisms among individuals with chronic HCV 
may contribute to the understanding of these conditions in HCV infection.  
2.11.4 Monocyte Chemoattractant Protein Genes 
Monocyte chemoattractant protein-1 (MCP1/CCL2) is a member of the chemokine family 
produced by macrophages and endothelial cells and contributes to inflammatory action.(Rebhan, 
2007; Rollins, 1996)  Subjects with steatosis or IR had increased MCP1/CCL2 levels compared 
to healthy controls.(Deepa, 2006; Haukeland, 2006)  In German subjects, there was a statistically 
significant association between G allele carriers of MCP1/CCL2 -2518A>G and decreased 
prevalence of IR and type 2 diabetes.(Simeoni, 2004)  MCP1/CCL2 -2518 G allele carriers also 
had lower plasma MCP1/CCL2 levels.(Simeoni, 2004)  These studies indicate that this gene may 
be important to understanding the biological mechanisms of IR.  Monocyte chemoattractant 
protein-2 (MCP1/CCL8) may play a role in host inflammatory response, but its relationship to 
steatosis and IR is unknown.(Rebhan, 2007) 
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2.11.5 3-hydroxy-3-methylglutaryl-CoA Synthase 2 
3-hydroxy-3-methylglutaryl-CoA Synthase 2 (HMGCS2) encodes an enzyme that condenses 
acetyl-CoA in the HMG-CoA pathway of fatty acid metabolism or ketogenesis.(Rebhan, 2007)  
The up-regulation of HMGCS2 is thought to be involved in the pathogenesis of steatosis.(Sanyal, 
2001)  People with steatosis and with insulin resistance were observed to have higher HMGCS2 
expression compared to people with steatosis and without IR.(Chitturi, 2004; Sanyal, 2001; 
Younossi, 2005; Younossi, 2004)  These results indicate that HMGCS2 expression may be 
important in understanding steatosis and IR, but genetic associations between these conditions 
and HMGCS2 has not been examined. 
2.11.6 Transforming Growth Factor Beta 
Another gene thought to influence steatosis and insulin resistance is Transforming growth factor-
β-1 (TGF-β1).(Kharbanda, 2004; Park, 2005)  TGF-β1 is a cytokine over-expressed with liver 
injury.(Kharbanda, 2004)  One study of TGF-β1 polymorphisms in Swedish non-diabetic 
patients found that those with the Leu10 polymorphism heterozygote genotype had significantly 
higher HOMA-IR scores compared to homozygote carriers.(Rosmond, 2003)  Although this 
study was completed in a healthy population, a statistically significant association was observed 
between a TGF-β1 polymorphism and IR and this could be studied in other populations that 
experience IR.  Infection with HCV could contribute to the occurrence of IR and examining 
genetic associations with IR in this gene may explain the mechanism of occurrence of IR in HCV 
infection.   
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2.11.7 Leptin Receptor 
The leptin receptor (LEPR) is a member of the cytokine receptor family and is involved in fat 
metabolism.  Leptin, a protein secreted by LEPR and produced by inflammatory regulatory cells, 
may participate in the inflammatory process.(Sanna, 2003)  Under normal circumstances, leptin 
reduces fat accumulation in the liver, but with the presence of IR, leptin does not reduce liver fat 
and steatosis develops.(Medina, 2004)  High leptin levels inhibited actions of insulin and 
increased insulin resistance in one study.(Marchesini, 2005)  One study examined LEPR genetic 
variant associations with IR in healthy Caucasian subjects and found a statistically significant 
association between the R allele of -223Q>R and the occurrence of insulin resistance.(Chiu, 
2004)  Although these studies were completed in healthy or diabetic patients, significant 
associations between LEPR and steatosis or IR were observed.  LEPR may be involved in 
inflammatory response which also may be important to the occurrence of these conditions in 
HCV infection.  Thus, examining genetic associations between LEPR polymorphisms and 
steatosis or IR may be important to understanding these conditions in HCV infection. 
2.11.8 Cytochrome P-450 2E1 
Cytochrome P-450 2E1 (CYP2E1) is a source of oxidative stress and possibly involved in the 
pathogenesis of steatosis.(Weltman, 1998)  CYP2E1 is up-regulated in patients with 
steatohepatitis specifically in obese and diabetic patients.(Chalasani, 2003; Dong, 1988; Favreau, 
1987; Weltman, 1998)  A strong correlation between HOMA-IR levels and hepatic CYP2E1 
activity was found in one study.(Chalasani, 2003)  CYP2E1 polymorphism associations with 
steatosis or IR have not been published. 
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2.11.9 Importance of Genetic Associations with Steatosis and Insulin Resistance 
Most of the previous research on host genetic relationships with steatosis and insulin resistance 
focused on gene expression or function.(Bluher, 2005; Chandran, 2003; Gochee, 2003; Halse, 
2001; Itoh, 1999; Maeno, 2003; Moller, 2000; Nelson, 1997; Younossi, 2005)  Some candidate 
gene associations with steatosis or insulin resistance were observed in obese or diabetic 
patients.(Cardellini, 2005; Collins, 2007; Crimmins, 2007; Qi, 2006; Scarpelli, 2006; Simeoni, 
2004; Stefan, 2005; Testa, 2006; X Yang, 2005)  None of these studies examined host genetic 
associations between the genetic variants in this dissertation and these conditions in HCV 
infection.  HCV may influence the activity of these genes and may be associated with the 
development of insulin resistance and steatosis.  African American adults were not examined in 
studies of host genetic variants with steatosis or IR that were selected for this 
dissertation.(Cardellini, 2005; Collins, 2007; Crimmins, 2007; Qi, 2006; Scarpelli, 2006; 
Simeoni, 2004; Stefan, 2005; Testa, 2006; X Yang, 2005)  Examination of steatosis and IR in 
African Americans may help to understand racial differences in the occurrence of these 
conditions in HCV infection.  Moreover, understanding the mechanisms of steatosis and IR by 
examining host genetic factors among HCV infected patients may reduce the occurrence of other 
co-morbidities that may develop such as type 2 diabetes or cirrhosis.        
2.12 SPECIFIC AIMS 
This dissertation examined host genetic relationships between interferon stimulated genetic 
variants and 28 day viral decline among a sample of African American and Caucasian American 
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HCV genotype-1 infected patients.  Further, this dissertation examined associations between host 
genetic variants and steatosis and insulin resistance among African American and Caucasian 
American HCV genotype 1 patients.   
The aims of Research Article 1 were to identify associations between interferon 
stimulated gene (ISG) polymorphisms and 28 day viral decline from treatment.     
The aims of Research Article 2 were to test for an association between selected genes and 
both steatosis and insulin resistance in a sample of African Americans and Caucasian Americans 
infected with HCV genotype-1.      
The aims of Research Article 3 were to test the association between adiponectin receptor 
1 (ADIPOR1) and 3-hydroxy-3-methylglutaryl-CoA Synthase 2 (HMGCS2) polymorphisms and 
the occurrences of steatosis and insulin resistance in African Americans and Caucasian 
Americans infected with HCV genotype-1.  Grant funding from the Epidemiology Department in 
the Graduate School of Public Health, Epidemiology Small Grants Program was used to partially 
pay for tag selection and genotyping polymorphisms in the ADIPOR1 and HMGCS2 genes 
reported in Research Article 3.      
2.13 THE STUDY OF VIRAL RESISTANCE TO ANTIVIRAL THERAPY OF 
CHRONIC HEPATITIS C (VIRAHEP-C) 
Data were obtained from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis 
C (Virahep-C).  “The Virahep-C Study was designed to assess the rates of response to 
peginterferon combination therapy for chronic HCV genotype-1 among African Americans and 
Caucasian Americans and to evaluate clinical, immunologic, virologic and host genetic reasons 
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for treatment non-response.”(Conjeevaram, 2006)  The Virahep-C Study recruited HCV 
genotype-1 patients 18-70 years of age who were not previously treated.(Conjeevaram, 2006)  
Patients were recruited from 8 US clinical centers between 2002 and 2003.(Conjeevaram, 2006)   
Study inclusion criteria included the presence of HCV RNA, compensated liver disease, 
histologic evidence of chronic HCV infection on a liver biopsy and self designation of African 
American or Caucasian American race.(Conjeevaram, 2006)  Study patients provided written 
informed consent before participation. 
There were 401 patients (205 CA and 196 AA) enrolled in the study.(Conjeevaram, 
2006)  Patients were treated for up to 48 weeks with peginterferon α-2a with a dosage of 180μg 
weekly and ribavirin with a dosage of 1000 or 1200 mg per day based on body 
weight.(Conjeevaram, 2006)  Virologic response to treatment was assessed using the Roche 
HCV Amplicor version 2 assay (Roche Diagnostic Systems, Somerville, N.J.) at week 24 of 
treatment and those with positive HCV RNA were considered non-responders and HCV therapy 
was stopped.(Conjeevaram, 2006)  Responders continued treatment for another 24 weeks and 
SVR was assessed at 24 weeks after treatment completion.(Conjeevaram, 2006)   
Results from the Virahep-C study provided information about SVR and factors associated 
with achieving SVR.  SVR was achieved in 28% of African Americans compared to 52% of 
Caucasian Americans.(Conjeevaram, 2006)  Factors associated with achieving an SVR include 
Caucasian American race, female sex, lower baseline HCV RNA levels, lower Ishak fibrosis 
scores, and greater amounts of maximum peginterferon taken.(Conjeevaram, 2006) 
Viral decline in the first 28 days of treatment was also examined in the Virahep-C study 
and two phases of HCV RNA decline were observed.(Hoofnagle, 2008)  The first phase occurred 
from treatment initiation to day 7 and the second phase began at day 7 and lasted through day 28.  
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The median decline in HCV RNA during the first 28 days was 1.81 log10 IU/mL.(Hoofnagle, 
2008)  The median decline was higher in Caucasian Americans (2.07 log10 IU/mL) compared to 
African Americans (1.72 log10 IU/mL).(Hoofnagle, 2008)  Factors associated with a greater 28 
day viral decline included age, body weight, HOMA-IR score, HCV RNA levels and pre-
treatment fibrosis score.(Hoofnagle, 2008)   Viral decline was examined in association with 
SVR.  Patients with less than a 1 log10 IU/mL decline in HCV RNA at 28 days had only a 5% 
chance of achieving an SVR.(Hoofnagle, 2008)  Ninety-three percent of patients with more than 
a 4 log10 IU/mL drop in HCV RNA levels in the first 28 days became HCV RNA negative by the 
end of treatment and 85% achieved SVR.(Hoofnagle, 2008)  Virahep-C results indicate that viral 
decline in the first 28 days was predictive of SVR therefore understanding what factors are 
associated with very early viral decline may be important in predicting and achieving SVR. 
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3.1 ABSTRACT 
Early and rapid viral decline during the first 28 days of treatment for chronic hepatitis C virus 
(HCV) with pegylated interferon and ribavirin therapy may be an important predictor of 
achieving a sustained virologic response (SVR).  Interferon stimulated genes (ISGs) play an 
important role in the antiviral response to HCV.  This study examines whether genetic variants in 
ISGs are associated with the 28 day viral decline.   
The association between genotypes of ISG polymorphisms and the dynamics of viral 
decline among 180 African American (AA) and 194 Caucasian American (CA) patients with 
genotype-1 HCV infection treated with pegylated interferon alpha-2a and ribavirin during the 
first 28 days of treatment was tested using linear mixed models.  Viral levels were obtained prior 
to treatment and at days 1, 2, 7, 14 and 28.  Analyses were conducted separately for CAs and 
AAs.   
Sixteen ISGs were examined in this study and statistically significant (p<0.05) 
associations with viral decline were observed for polymorphisms in MX2, OASL, STAT1 and 
STAT2.  Similar viral decline patterns by the same ISG polymorphism genotype were observed 
in both race groups for IFNAR1, IRF1, MX1, OAS3 and PKR, but were not statistically 
significant.   
Genetic variants in some ISGs were associated with 28 day viral decline, but many of the 
associations differed by race.  These results indicate that some ISG polymorphisms may be 
important in understanding 28 day viral decline and improving long-term treatment outcomes.  
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Further studies should be conducted to confirm these results and examine additional 
polymorphisms in these genes to determine the importance of the gene on 28 day viral decline.  
3.2 INTRODUCTION 
Infection with the hepatitis C virus (HCV) may lead to adverse outcomes such as cirrhosis of the 
liver or hepatocellular carcinoma.(Seeff, 2002)  Treating patients who have chronic HCV 
infection with pegylated interferon alpha-2a (pegIFNα) plus ribavirin results in sustained 
virologic response (SVR), defined as the absence of detectable HCV RNA in the serum at 24 
weeks after the end of treatment,(Lindsay, 2002) in only 54-56% of those treated 
overall.(Conjeevaram, 2006; Fried, 2002; Manns, 2001; Marcellin, 1997; McHutchison, 1999; 
Poynard, 1996)  Among patients infected with genotype-1 virus, lower rates of response (42-
46%) have been reported compared to patients with non genotype-1 virus (76-82%).(Fried, 2002; 
Lindsay, 2002; Manns, 2001; Martinot-Peignoux, 1995; McHutchison, 1998; Poynard, 1998; 
Zeuzem, 2000)  Racial differences have also been observed with African American patients 
experiencing lower SVR when treated with combination therapy compared to Caucasian 
American patients infected with the same viral genotype.(Conjeevaram, 2006; Fried, 2002; 
Kinzie, 2001; Layden-Almer, 2003; Manns, 2001; J. G. McHutchison, 2000; Reddy, 1999; 
Zeuzem, 2004; Zeuzem, 2000)  In particular, African American genotype-1 patients had lower 
SVR (19%-32%) compared to Caucasian American genotype-1 patients (50-52%).(Conjeevaram, 
2006; Jeffers, 2004; Muir, 2004)  
Viral dynamics are the time course of treatment induced changes in serum HCV RNA 
levels.  Mathematical modeling of early viral decline during the first 28 days of treatment 
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suggest that viral levels decline in a bi- or tri-phasic pattern(Bergmann, 2001; Herrmann, 2003; 
Neumann, 2000; Neumann, 1998) and that the dynamics of the decline may predict 
SVR.(Conjeevaram, 2006; Neumann, 2000; Neumann, 1998)   
Interferon stimulated genes (ISGs) play an important role in the innate immune response 
against HCV.(Itsui, 2006; Macquillan, 2003)  Given the importance of ISGs in immune 
response, studies have examined the potential role of host genetic diversity in the response to 
interferon, although most studies have focused on SVR as the primary outcome.(Hijikata, 2001; 
Hijikata, 2000; Knapp, 2003; H Saito, 2002; T Saito, 2004; Suzuki, 2004; Tena-Tomas, 2007; 
Thursz, 1997; Wietzke-Braun, 2006) This study utilizes frequent viral level measurements 
obtained in the initial 28 days of therapy for HCV in a single treatment cohort and examines the 
association of single nucleotide polymorphisms (SNPs) in selected ISGs including ISG15 
ubiquitin-like modifier (G1P2), Interferon alpha-inducible protein 6 (G1P3), Interferon-induced 
protein 35 (IFI35), Interferon-alpha receptor 1 (IFNAR1), Interferon-alpha receptor 2 
(IFNAR2), Interferon-regulatory factor 1 (IRF1), Interferon-regulatory factor 7 (IRF7), 
Myxovirus resistance 1 (MX1), Myxovirus resistance 2 (MX2), Oligoadenylate synthetase 1 
(OAS1), Oligoadenylate synthetase 2 (OAS2), Oligoadenylate synthetase 3 (OAS3), 
Oligoadenylate synthetase-like (OASL), Protein Kinase (PKR), Signal transducer and activator 
of transcription 1 (STAT1), and Signal transducer and activator of transcription 2 (STAT2) with 
the dynamics of the 28 day early viral decline. 
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3.3 MATERIALS AND METHODS 
3.3.1  Study Population 
Data were from the Study of Viral Resistance of Antiviral Therapy of Chronic Hepatitis C 
(Virahep-C) which was designed to assess treatment response to combination therapy among 
African- and Caucasian-Americans.(Conjeevaram, 2006)  Further, Virahep-C aimed to examine 
host genetic reasons for treatment non-response in previously untreated HCV genotype-1 
patients.(Conjeevaram, 2006)  Briefly, 401 HCV patients consented and were treated with 
pegylated interferon α-2a and ribavirin.(Conjeevaram, 2006)  Of those, 374 (194 CA and 180 
AA) provided additional consent for the genetics studies.(Yee, 2007) 
3.3.2 Single Nucleotide Polymorphism (SNP) Selection and Genotyping  
Interferon stimulated genes were genotyped as part of the genetics component of the Virahep-C 
study.  Two different approaches were utilized for selecting SNPs and genotyping for the 
polymorphisms targeted in this study.  These approaches were based on publically available 
genetic information and genotyping technology at the time that each component was completed.   
The first method for selection was used to identify SNPs for the candidate genes MX1, 
IRF1 and PKR and details of this process have been described elsewhere.(Yee, 2007)  Briefly, 
SNPs were selected by examining the haplotype blocks for each race and selecting 
polymorphisms from the International HapMap Project (Phase I) and National Center for 
Biotechnology Information (NCBI) databases.(Yee, 2007)  SNPs with a minor allele frequency  
of at least 10% in a reference population were selected to cover the entire gene at 2-3 kb intervals 
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for small genes and 5-9 kb intervals for larger genes.(Yee, 2007)  An allelic discrimination assay 
was used to genotype haplotype-tagging genetic variants in MX1, IRF1 and PKR and was 
performed using the ABI 7000 Sequence Detection System with TaqMan technology (Applied 
Biosystems Inc., Foster City, CA).(Yee, 2007)   
SNPs for G1P2, G1P3, IFI35, IFNAR1, IFNAR2, IRF7, MX2, OAS1, OAS2, OAS3, 
OASL, STAT1, and STAT2 were selected using a two stage approach.  For each of these genes, 
SNPs with a minor allele frequency of at least 5% in a reference population were selected from 
the International HapMap Project (Phase I) approximately every 3-5 kb to cover the entire 
gene.(Su, 2008)  The Illumina BeadArray System (Illumina, San Diego, CA) was used for 
genotyping the selected SNPs in stage 1.(Su, 2008)  The SNPs selected in the first stage were 
tested for an association with SVR.  If a significant association was observed, additional SNPs 
were selected for that gene during the second stage of SNP selection.(Su, 2008)  The second 
stage included a comprehensive database scan for possible functional SNPs in potential 
transcription factor binding sites, intron regions, exon regions, intron-exon borders or potential 
splice sites.(Su, 2008)  Additional SNPs selected in stage 2 were genotyped using ABI 
TaqMan® technology (Applied Biosystems, Foster City, CA).  Further details of the two stage 
SNP selection method and laboratory methods have been reported elsewhere.(Su, 2008)  
3.3.3 Analysis of Genetic Data 
Statistical procedures to examine the genetic data used the SAS® 9.1.3 Genetics Component 
(SAS Institute Inc., Cary, NC, 2002-2003).  Genotype frequencies and Hardy Weinberg 
Equilibrium (HWE) chi square tests were calculated by race for each SNP studied.  Minor allele 
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frequencies (MAF) were examined by race and SNPs with a MAF less than 5% in the study 
sample were not analyzed.   
Haplotypes were estimated for ISGs separately by race using the EM 
algorithm.(Excoffier, 1995)  SNPs were excluded from haplotype analyses if they violated 
assumptions of HWE (Kirk, 2002; Yang, 2003) (rs455055, rs1476415, rs2248420, rs17000900, 
rs2660, rs2285934, rs6489865, rs1981557, rs6489879 and rs2107418), were monomorphic 
(rs1141746, rs1316896, rs12298890, rs12315068, rs28360476, rs3861793, rs7969180, 
rs2066816 and rs2228259) or had minor allele frequencies less than 5% (rs2831495 and 
rs2307478).  Following these exclusions, 84 of 107 SNPs initially identified were used in 
haplotype estimation. The probability of being a true haplotype had to be at least 0.7 to be 
retained and used in further analyses.  Haploview software version 4.0 was used to calculate the 
amount of variation accounted for in the gene (r2) by the tagged SNPs separately by 
race.(Barrett, 2005)  The variation accounted for by selected SNPs refers to a measure of the 
percent of variation captured and reflecting SNPs cataloged in the International HapMap Project, 
Phase II.  This analysis was done to evaluate how well the SNP selection methods utilized for 
this study captured the common genetic variation compared to the more recently available 
HapMap Phase II data.  
3.3.4 Evaluation of Population Structure 
Based on previous evaluation of population structure in the Virahep-C cohort, a strong 
association was observed between self-reported race and estimated individual admixture.(Yee, 
2007)  For this reason, this study utilized self-reported race to stratify the analyses.   
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3.3.5 Viral Level Measures in the First 28 Days of Treatment 
The primary goal was to determine if viral levels differed over the first 28 days of treatment by 
the genotypes of ISG polymorphisms.  Data were stratified by race to examine differences in 
viral level by ISG polymorphism genotypes.  Viral levels were obtained prior to treatment at 
baseline and at days 1, 2, 7, 14 and 28 after initiation of treatment using the Roche HCV 
Amplicor version 2 assay (Roche Diagnostic Systems, Somerville, N.J.).  Since the assay had a 
lower limit of detection of 600 International Units (IU)/mL, viral level measures after baseline 
that were below the detectable level were imputed using a uniform distribution.  The time on 
treatment variable was expressed in days and treated as a discrete variable.   
3.3.6 Potential Confounders and Model Building 
Risk factors considered to be associated with 28 day viral decline included age, gender, weight, 
Ishak fibrosis score, alanine aminotransferase (ALT), aspartate aminotransferase (AST), amount 
of medication taken, source of infection, number of years since HCV infection, viral subtype and 
time on treatment, and were used to build models to determine if viral levels differed over the 
first 28 days of treatment by genotypes of the ISG polymorphisms.  Age was centered by 
subtracting the mean age for the population (47.8) from each patient’s age.  Backwards 
elimination was used to remove variables that did not contribute, as defined below, to the model.  
The first elimination removed variables with a p-value greater than 0.25, the second elimination 
excluded variables with a p-value greater than 0.15 and the final elimination removed variables 
with a p-value greater than 0.05.  The final models included each individual genetic variant, time 
on treatment, age and the interaction between time on treatment and the genetic variant.     
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3.3.7 Data Categorization 
For each SNP, indicator variables were created for the genotypes to test for genotype 
associations with viral decline in the first 28 days of therapy.  An a priori decision was made that 
if the less common homozygote genotype had a minor allele frequency of less than 5% it was 
combined with the heterozygote genotype to test for a difference.  Haplotypes were categorized 
as carrier (at least one copy) or non-carriers (no copies).  For regression analyses, haplotypes 
with a frequency less than 5% in one race group were not analyzed in that race group.  
3.3.8 Statistical Methods 
Linear mixed models were used to determine if viral levels differed significantly over the first 28 
days of treatment for each ISG polymorphism.  A random intercept model was used to account 
for inter-patient variability by allowing the intercept to vary for all study patients.  The variables 
age (centered), SNP genotype, time on treatment, and SNP genotype by time on treatment 
interaction were included in the final model as fixed effects.  Statistical significance was set at 
α=0.05.  Pictorial depictions of viral level over the first 28 days of treatment were completed by 
graphing the predicted mean viral level at each time point for a representative individual for each 
ISG polymorphism genotype or ISG haplotype separately by race.  Statistically significant 
associations were retested excluding 12 individuals of Hispanic ancestry to determine if these 
individuals influenced the association with the outcome.  SAS® version 9.1.3 (SAS Institute Inc., 
Cary, NC, 2002-2003) was used to analyze the data.  
Several methods were initially utilized to examine 28 day viral decline in the early stages 
of this project.  One method examined a three level categorical variable based on the absolute 
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difference in viral decline from baseline to day 28.(Taylor, 2007)  Poor responders (N=149) were 
defined by a 0 to 1.4 log drop in viral level, intermediate responders (N=108) were defined by a 
1.4 to 3.5 log drop in viral level, and marked responders (N=103) were defined by a > 3.5 log 
drop in viral level.(Taylor, 2007)  In the categorical analyses, the relative risk of achieving a 
marked response was examined for genotypes of each ISG SNP.  The categorical outcome only 
allowed comparisons between baseline and day 28 viral levels and the viral level measurements 
in between were not considered.  Also, in the categorical analyses the intermediate group was 
removed excluding 108 participants and reducing the ability to detect associations.  A second 
method examined viral decline in each of two phases (Phase I: Day 0 – Day 7 and Phase II: Day 
7- Day 28) with the ISG polymorphisms using linear mixed models.  When the Phase I and 
Phase II overall F tests from the linear mixed models were compared to the results from the full 
28 day viral decline models, the results were similar.  These results are not included in this 
manuscript because the pattern of decline over the first 28 days may be more useful in 
understanding the association between ISG polymorphisms and early viral dynamics.  Thus, the 
full 28 day viral decline models are presented to represent the whole picture of viral decline 
including the multiple viral level measurements at time points between baseline and day 28.   
3.4 RESULTS 
3.4.1 Sample Characteristics 
Table 3-1 describes the baseline characteristics.  The average viral levels at baseline, day 1, 2, 7, 
14 and 28 are also presented in Table 3-1.  African Americans and Caucasian Americans did not 
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differ significantly with respect to gender, source of infection, duration of infection or Ishak 
fibrosis score.  African Americans were significantly older, weighed more and had higher ALT 
and AST levels than Caucasian Americans.  Baseline viral levels did not differ significantly by 
race, but starting on treatment day 2 through day 28 Caucasian Americans had significantly 
lower viral levels compared to African Americans.   
3.4.2 Interferon Stimulated Genetic Polymorphisms 
Table 3-2 presents the genotype frequencies for the SNPs examined in this study.  The average 
genotype call rate, defined as the percentage of individuals where a genotype could be 
determined compared to the total number of individuals where genotyping was attempted, was 
99% in Caucasian Americans and 98% in African Americans.  Overall, the SNP selection 
method for MX1, IRF1 and PKR accounted for 39% (20-94%) of the variation in African 
Americans and 56% (33-88%) of the variation in Caucasian Americans and the two stage SNP 
selection method accounted for 29% (11-100%) of the variation in African Americans and 54% 
(23-100%) of the variation in Caucasian Americans.   
3.4.3 Interferon Stimulated Gene Haplotypes 
There was at least a 0.7 probability of being a true haplotype for 371 of 374 patients for G1P2, 
IFI35, IFNAR1, IRF7, OAS1 and STAT2.  Haplotypes were estimated in 340, 363, 334, 345, 360, 
365, 356 and 347 individuals for IFNAR2, IRF1, MX1, OAS2, OAS3, OASL, PKR and STAT1, 
respectively.  Haplotypes were not estimated for G1P3 because there was only one polymorphic 
SNP or MX2 because there was not enough correlation between the selected SNPs.  Table 3-3 
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presents the common haplotypes for the ISGs that were present in at least 5% of African 
Americans or Caucasian Americans.  Individual haplotypes were tested for 14 ISGs to see if 
there was a difference in viral levels over the first 28 days of treatment by presence or absence of 
the haplotype using the linear mixed models.  For most of the ISGs, the haplotype results did not 
provide further information about differences in viral level for ISG polymorphisms in the gene in 
addition to what was observed in the individual SNP association tests.  
3.4.4 Interferon Stimulated Gene Associations with 28 Day Viral Decline in Virahep-C 
Analyses were completed for all ISGs, however only the associations with a p-value less than 
0.10 are reported in this manuscript.  Results of all tests are included in the supplement to this 
manuscript (Appendix A).  The exclusion of the 12 self-identified Hispanics did not result in any 
differences and these individuals were retained in the analyses.  The direction of the predicted 
mean viral levels at different time points during the first 28 days differed by race for several of 
the SNPs and haplotypes examined.  Estimates for the difference in viral level over the first 28 
days are shown in Table 3-4 for SNPs and in Table 3-5 for haplotypes.   
Three MX2 SNPs were significantly associated with differences in viral decline over the 
first 28 days of treatment.  Associations with genotypes in Mx2 rs443099 were observed in both 
African Americans and Caucasian Americans (Figures 1A and 1B).  Different genotypes for Mx2 
rs443099 were associated with viral decline over the first 28 days in the two race groups.  
African Americans with the TT genotype demonstrated lower HCV RNA levels throughout the 
28 days, but in Caucasian Americans it was not always clear which genotype showed the greater 
decline.  Statistically significant differences in viral decline were also observed for MX2 
rs369908 genotypes in Caucasian Americans and MX2 rs464090 genotypes in African 
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Americans.  The pattern of decline and the genotype associated with greater 28 day viral decline 
differed in the two race groups.  Although individual MX2 haplotypes could not be estimated for 
study participants, haplotype frequencies for different outcome groups categorized in previous 
Virahep-C studies (Taylor, 2007) showed no additional statistically significant associations that 
were not identified through the SNP association tests.    
Greater viral decline was observed among Caucasian Americans with OASL rs1169279-
GG genotype compared to those with either the AA or AG genotypes (Table 4).  Among African 
Americans, the pattern of viral decline for OASL rs1169279 was not statistically significant and 
showed that those with the AA or AG genotype had a greater decline compared to those with the 
GG genotype.  Statistically significant differences in viral level over the first 28 days of 
treatment were observed in STAT1 and STAT2 SNPs (Table 4).  For each of the SNPs, the 
genotypes that were associated with greater viral decline over 28 days differed by race.  
Although not statistically significant, there was a similar pattern of viral decline for both 
race groups with the CC or CG genotype of OAS3 rs1981557 showing a more rapid decline 
compared to those with the GG genotype (Figures 2A and 2B).  A similar, but not statistically 
significant pattern of viral decline was observed among Caucasian Americans and African 
Americans and IFNAR1 rs1041868 (p=0.47, p= 0.07, respectively).  Individuals with the AA or 
AG genotype for IFNAR1 rs1041868 had a greater viral decline over the first 28 days compared 
to those with the GG genotype (Figures 3A and 3B).  
A similar pattern of decline was observed with the absence of the IRF1 ATCCATCC 
haplotype among both race groups, but the difference in the viral decline was not statistically 
significant.  Individuals with no copies of the IRF1 ATCCATCC haplotype had a greater viral 
decline compared to those with one or more copies of the haplotype (Figures 4A and 4B).   Two 
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PKR haplotypes had statistically significant differences in viral levels over the first 28 days.  The 
presence of either haplotype (AAT or CAC) was associated with greater decline among African 
Americans (Table 5).   
3.5 DISCUSSION 
This study investigated differences in viral level over the first 28 days of treatment by 
polymorphisms of ISGs among Caucasian Americans and African Americans.  Statistically 
significant differences in viral decline were observed for MX2, OASL, STAT1 and STAT2 SNPs 
and PKR haplotypes.     
This study found statistically significant differences in 28 day viral decline with ISG 
polymorphism genotypes, but the pattern of viral decline differed by race.  One explanation may 
be that the associated SNPs were not directly affecting viral decline, but rather were in linkage 
disequilibrium or correlated with functional polymorphisms.  If this were the case, the different 
patterns of results may be explained by different linkage disequilibrium patterns in the 
populations and the different population histories of African Americans and Caucasian 
Americans.  For example, an associated SNP could be ‘tagging’ a causal genetic variant in one 
population that is not even present in the other population.  Alternatively, if the functional 
genetic variants are newer or more recent in the population history and the associated genetic 
variants are old, the associations may differ in race groups because of differences in migration 
out of Africa.  This study also identified some differences in 28 day viral decline that were not 
statistically significant, but showed a similar pattern of decline by the ISG polymorphism 
genotypes in both race groups.  Since the viral decline pattern was similar in both race groups 
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and people with the same polymorphism genotype showed the faster decline, it seems plausible 
that these genetic variants may be associated with early viral decline.  Below is a summary of 
results for MX2 and OASL. 
Statistically significant differences in 28 day viral decline induced by treatment were 
found for MX2 rs443099 genotypes for both Caucasian Americans and African Americans.  
Differences in viral decline were also observed for MX2 rs369908 genotypes in Caucasian 
Americans and MX2 rs464090 genotypes in African Americans.  These findings may indicate a 
true causal relationship with 28 day viral decline or may be the result of linkage disequilibrium 
with one or more nearby causal polymorphisms.  MX2 rs443099 has no known function, 
rs369908 is predicted to be an intronic enhancer and rs464090 has no known function reported 
from the Fast SNP website.(Yuan, 2006)  An intronic enhancer could change the way the protein 
is produced (Yuan, 2006) and may influence that association between the polymorphism and 
viral decline. 
Individual haplotypes for MX2 could not be estimated in this study because there was not 
enough correlation between the selected genetic variants.  The MX2 selected SNPs accounted for 
15% of the genetic variation in African Americans and 34% in Caucasian Americans.  Thus, 
further exploration of this gene by selecting more SNPs may be useful in understanding the 
importance of MX2 in 28 day viral decline and identifying other genetic variants that could be 
associated with viral decline.         
Statistically significant differences in 28 day viral decline were observed for genotypes of 
two OASL SNPs, but these differences were not consistent across race.  Caucasian Americans 
possessing the OASL rs1169279-GG genotype or OASL rs3213545-CT or -TT genotype had 
greater viral decline in the first 28 days compared to the other genotypes for these variants.  No 
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statistically significant differences were observed in African Americans.  Since the observed 
SNPs were associated with different decline patterns by race, it is possible that the true causal 
polymorphism is nearby the associated polymorphisms on the gene.  OASL rs1169279 is located 
in the 5’ upstream region of the gene and is predicted to be a promoter polymorphism, which 
may regulate gene expression.(Yuan, 2006)  OASL rs3213545 is located in the coding region of 
the gene and predicted to be involved in splicing regulation.(Yuan, 2006)  Alternative splicing 
allows a gene to express different combination of exons which encode gene products such as 
proteins with diverse functions.(Mercatante, 2000)  Additional studies to determine the proteins 
encoded by these polymorphisms and understanding the function of the polymorphism may help 
to determine how these polymorphisms influence viral decline.  Due to the percentage of genetic 
variation accounted for by the selected OASL SNPs in African Americans (40%) and Caucasian 
Americans (52%), haplotypes were examined.  No statistically significant OASL haplotype 
associations with 28 day viral decline were observed.  Since there was unaccounted variation in 
OASL, it was not possible to provide a whole picture of the gene association. As a result, it is 
possible that the true causal variant was not captured by the selected polymorphisms or may be 
close to associated polymorphisms.   
Previous work on ISGs in the Virahep-C cohort identified an association between three 
alleles in different OASL SNPs and SVR.(Su, 2008)  The study by Su et al. identified positive 
and similar associations by race in OASL genetic variants (rs1169279-A allele, rs3213545-T 
allele and rs2859398-C allele) with SVR.  The current study found statistically significant 
differences in 28 day viral decline for individuals with the rs1169279-GG and rs3213545-CT or 
–TT genotypes implying greater viral decline in Caucasian Americans compared to the other 
genotypes.  However, these differences were neither significant nor consistent with the findings 
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in African Americans.  Results of the two studies were likely different because the outcomes in 
the two studies were different.  The Su et al. study examined the association between selected 
ISGs and SVR and the current study examined associations between ISG polymorphisms and 28 
day viral decline.   The different results might indicate that some ISGs may take more than 28 
days to be effective in enhancing immune response.  Thus over the full course of treatment (24-
48 weeks), some ISGs may be more important in activating immune response and achieving 
SVR as well as important to 28 day viral decline.     
Although the Virahep-C study allowed for the examination of viral dynamics in the first 
28 days with a reasonable sample size, the study was not adequately powered to test genetic 
associations.  Despite the relatively small sample size, statistically significant associations were 
observed between ISG polymorphisms and 28 day viral decline.  On the other hand, this study 
did not adjust for multiple comparisons since it was an exploratory examination of the 
association between ISG polymorphisms and 28 day viral decline.  Thus, the results of this study 
should be validated with an additional sample of HCV infected patients to confirm the findings.  
Another limitation of this study was the selection of SNPs for these genes.  At the time the 
selection of SNPs was completed, HapMap Phase I was the main source of reference population 
data and was not able to identify SNPs to account for more of the common genetic variation 
observed in different race groups.  The second phase of HapMap has the ability to better capture 
the common variation in the genes.  Since much of the variation was not accounted for using the 
selected SNPs, it is difficult to understand the overall association of many of the genes examined 
in this study. 
In conclusion, this study identified some differences in 28 day viral decline in ISG 
polymorphisms.  Several of the associations showed varying patterns of decline by the SNP 
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genotype when comparing the race groups.  Reasons for HCV treatment response may be 
complex and influenced by host genetic, environmental and viral factors.  Treatment response is 
likely to be associated with several genes and the association may vary over the time course of 
treatment.  Additional studies could be completed to confirm the results of the current study in 
other HCV populations, examine additional genes related to immune response, or select more 
polymorphisms in the ISGs with observed associations with 28 day viral decline.  Based on these 
results, it is difficult to positively conclude whether or not ISGs are important to early viral 
dynamics for HCV.     
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Table 3-1: Baseline Demographic and Viral Characteristics for Study Participants by Race (N = 
374) 
 
 African Americans Caucasian American P-Value 
Characteristic (N=180) (N=194) 
Gender, n (%)    
Men 118 (65.6) 126 (65.9)  
Women 62 (34.4) 68 (35.1) 0.90* 
0.03† Age (years), mean (SD) 48.7 (7.1) 47.0 (8.6) 
0.001† Weight (kg), mean (SD) 91.0 (19.2) 83.9 (17.3) 
Duration of HCV Infection (yrs)‡,  mean 
(SD) 
   
24.4 (9.4) 25.5 (10.0) 0.27† 
Baseline ALT Levels†, mean (SD) <0.0001† 71.3 (45.8) 107.9 (91.9) 
Baseline AST Levels†, mean (SD) 0.06† 60.4 (42.1) 73.7 (60.5) 
Ishak Fibrosis Score†, mean (SD) 0.56† 2.2 (1.4) 2.3 (1.6) 
HCV RNA Level, (log10IU/ml), mean 
(SD) 
   
0.13† Baseline 6.2 (0.7) 6.3 (0.8) 
0.07† Day 1 5.8 (0.8) 5.6 (1.2) 
0.02† Day 2 5.6 (1.0) 5.3 (1.2) 
<0.0001† Day 7 5.7 (1.1) 5.2 (1.4) 
<0.0001† Day 14 5.3 (1.3) 4.6 (1.7) 
<0.0001† Day 28 4.6 (1.6) 3.5 (2.0) 
† Wilcoxon Two Sample Test 
* Chi-square test 
‡  Estimated duration of HCV infection was obtained for 148 Caucasian Americans and 134 African 
Americans 
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Table 3-2:  Genotype Frequencies for Single Nucleotide Polymorphisms in African Americans and 
Caucasian Americans  
 
 
Single Nucleotide 
Polymorphisms 
African 
Americans 
N = 180 
 
Genotype 
Call Rate 
 
 
HWE* 
Caucasian 
Americans 
N = 194 
 
Genotype 
Call Rate 
 
 
HWE* 
IFNAR1 rs1041868       
AA 8 (0.05)   4 (0.02)   
AG 65 (0.36)   55 (0.29)   
GG 106 (0.59) 0.99 0.62 134 (0.69) 0.99 0.55 
IRF1 rs839       
AA 48 (0.27)   24 (0.12)   
AG 81 (0.45)   92 (0.48)   
GG 50 (0.28) 0.99 0.20 77 (0.40) 0.99 0.67 
IRF1 rs2070726       
GG 50 (0.28)   79 (0.41)   
GT 82 (0.46)   86 (0.45)   
TT 48 (0.27) 1.0 0.23 28 (0.15) 0.99 0.56 
Mx1 rs462903       
AA 131 (0.73)   65 (0.34)   
AG 46 (0.26)   92 (0.47)   
GG 53 (0.29) 1.0 0.65 37 (0.19) 1.0 0.66 
Mx2 rs443099       
GG 116 (0.64)   28 (0.15)   
GT 57 (0.32)   94 (0.49)   
TT 7 (0.04)  1.0 0.99 71 (0.37) 0.99 0.73 
Mx2 rs369908       
AA 9 (0.05)   128 (0.66)   
AG 68 (0.38)   55 (0.29)   
GG 102 (0.57) 0.99 0.59 10 (0.05) 0.99 0.21 
Mx2 rs464090        
CC 57 (0.32)   130 (0.67)   
CT 89 (0.49)   54 (0.28)   
TT 34 (0.19) 1.0 0.94 9 (0.05) 0.99 0.55 
Oas1 rs3741981       
CC 92 (0.51)   29 (0.15)   
CT 81 (0.45)   98 (0.51)   
TT 7 (0.04) 1.0 0.03 65 (0.34) 0.99 0.42 
Oas3 rs1981557       
CC 4 (0.02)   15 (0.08)   
CG 17 (0.10)   98 (0.51)   
GG 157 (0.88) 0.99 0.73 80 (0.42) 0.99 0.04 
Oas3 rs6489879       
AA 161 (0.89)   80 (0.42)   
AG 19 (0.11)   99 (0.51)   
GG 0 (0) 1.00 1.0 14 (0.07) 0.99 0.03 
Oas3 rs2107418       
GG 39 (0.22)   33 (0.17)   
GT 71 (0.39)   106 (0.55)   
TT 70 (0.39) 1.0 0.01 54 (0.28) 0.99 0.12 
OASL rs1169279       
AA 20 (0.11)   29 (0.15)   
AG 80 (0.44)   82 (0.43)   
GG 80 (0.44) 1.0 1.0 82 (0.83) 0.99 0.26 
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OASL rs3213545       
CC 125 (0.69)   95 (0.50)   
CT 52 (0.29)   74 (0.39)   
TT 3 (0.02) 1.0 0.56 23 (0.12) 0.99 0.15 
PKR rs2307479       
AA 142 (0.79)   185 (0.95)   
AC 33 (0.18)   9 (0.05)    
CC 4 (0.02) 0.99 0.26 0 (0) 1.0 1.0 
STAT1  rs2066797       
AA 123 (0.68)   168 (0.88)   
AG 51 (0.28)   23 (0.12)   
GG 6 (0.03) 1.0 0.78 1 (0.01) 0.99 0.83 
STAT1  rs1467199       
CC 84 (0.47)   124 (0.64)   
CG 78 (0.43)   61 (0.32)   
GG 18 (0.10) 1.0 0.99 8 (0.04) 0.99 0.89 
STAT2  rs2066811       
AA 125 (0.69)   192 (0.99)   
AG 49 (0.27)   1 (0.01)   
GG 6 (0.03) 1.0 0.66 0 (0) 0.99 1.0 
* P-value from test of Hardy Weinberg Equilibrium 
 
Table 3-3:  Haplotype Frequencies for Interferon Stimulated Genes (ISGs) in African Americans and Caucasian Americans  
  African Americans Caucasian Americans 
Haplotype SNPs* N = 180 N = 194 
    
IFNAR2 
* SNPs are listed in order that they appear in the haplotype and along the chromosome 
 
rs9636866, rs2300370, rs4986956, rs2252650,   
rs2834165, rs2834166, rs2250226,  rs2834167 
TGTTGAAA  0.17 0.25 
IRF1  rs839, rs2070726, rs2070723, rs2070721,    
rs2549009,  rs2549006, rs2549003, rs736801 
ATCCATCC  0.38 0.35 
OAS2 rs2010604, rs2072138, rs1293762, rs1293739   
GGAA  0.03 0.07 
OASL rs1169279, rs7134141, rs2259697, rs12819210,   
rs7969180,  rs2260399,  rs10849829,  rs3213546,  
rs3213545,  rs10849832,  rs10849833,  rs2859394,  
rs2589398,  rs7134069 
AGTCGTAGTTGTCA  0.13 0.27 
PKR rs2307479, rs2287350, rs2254958   
AAT  0.05 0.04 
CAC  0.09 0.02 
STAT1 rs2066797, rs3088307, rs1400657,  rs1914408,    
rs2280234,  rs12693950,  rs2066802,  rs1467199 
ACAGCATC  0.11 0.44 
STAT2 rs2066808, rs2068807, rs2066811, rs2228259, 
rs2066816, rs2066819  
  
CGGGAC  0.16 0.01 
TGAGGT  0.42 0.91 
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Table 3-4:  Multivariable Model Estimating Change in Viral Level by Interferon Stimulated Gene Single Nucleotide Polymorphisms 
During the First 28 Days of Treatment by Race* 
 
 African Americans (N = 180) 
Estimated Change in Viral Level by Treatment Day* 
 Caucasian Americans (N = 194) 
Estimated Change in Viral Level by Treatment Day* 
 
Genetic Marker N 0** 1 2 7 14 28 p- ue p- ueval N 0** 1 2 7 14 28 val
                 
IFNAR1 rs1041868                 
AA/AG  6. 0  6. 7 73 2       59 3       
GG 106 6.23 0. 1 0. 9 0. 6 0. 1 0. 8 0. 7 0. 3 0. 7 0. 7 0. 6 -0 4 0. 7 0 0 0 3 1 0 134 6.18 0 1 1 0 .1 4
IRF1 rs839                 
AA 4  8 5. 1 3       25 6. 5 4       
AG 81 5.19 0. 04 -0 8 -0 2 -0 7 -0 1 -0 1 -0 3 -0 9 -0 3 0. 3 0 .1 .1 .2 .2  92 6.39 .0 .1 .1 .3 0  
GG 50 6.15 0.003 -0.13 0.10 -0.03 0.01 0. 5 0. 9 5 77 6.19 -0.19 -0.26 -0.20 -0.46 0.14 0
IRF1 rs2070726                 
GG 5  0 6. 5 1       79 6. 0 2       
GT 82 6.24 0. 3 -0 5 -0 1 -0 3 -0 1 0. 9 0. 3 0. 3 0. 4 -0 7 00 .0 .2 .2 .2  86 6.39 1 1 0 1 .0  
TT 48 6.24 -0.01 0.13 -0.14 0.002 -0.03 0. 5 0. 8 5 28 6.45 0.12 0.18 0.14 0.36 -0.25 0
Mx1 rs462903                 
AA 1 1 3 6. 5 2       65 6. 6 2       
AG/ -0 1 -0 6 0. 5 -0 2 -0 1 0. 2 0. 9 0. 5 0. 5 0. 1 0. 3 0. 7 GG 49 6.13 .0 .0 0 .1 .2 4 129 6.35 1 2 4 4 1 0
Mx2 rs443099                 
GG 1 6 1 6.24       28 6. 3 3       
GT 57 6.18 0. 0 -0 1 -0 4 -0 7 0. 4 0. 0 0. 5 -0 3 -0 0 -0 9 1 .0 .0 .0 0  94 6.35 3 4 .0 .1 .2  
TT 7 6.02 -0.76 -0.83 -0.62 -0.91 -0.99 0. 4 0. 3 0 71 6.27 0.17 0.38 -0.10 -0.10 0.04 0
Mx2 rs369908                 
AA 9 6. 8 1       1 8 2 6. 5 3       
AG 68 6.19 0. 7 0. 8 0. 4 0. 1 0. 5 -0 0 -0 4 -0 0 -0 1 -0 7 7 8 6 6 5  55 6.25 .3 .4 .5 .6 .9  
GG 102 6.23 0.69 0.83 0.56 0.54 0.36 0. 6 0. 3 0 10 6.32 0.18 0.10 -0.11 -0.40 0.10 00
Mx2 rs464090                 
CC 5  7 6. 5 2       1 0 3 6. 8 3       
CT/TT 123 6.20 0. 6 0. 3 0. 3 0. 7 0. 9 0. 5 -0 0 -0 1 -0 3 -0 9 -0 3 0. 4 1 2 0 1 2 04 63 6.18 .2 .3 .4 .5 .6 1
OAS1 rs3741981                 
CC 9  2 6. 0 2       29 6. 2 5       
CT 81 6.26 0. 6 0. 5 0. 1 0. 0 0. 3 0. 3 0. 6 0. 2 0. 0 0. 9 0 0 0 2 0  98 6.17 0 1 1 2 3  
TT 7 5.90 -0.36 -0.66 -0.32 -  0 8 0 5 0.003 0.12 .0 65 6.43 0.24 0.26 0.48 0.62 0.67 .3
OAS3 rs1981557                 
CC/CG           21 6.20  113 6.25  
GG 1  6. 2 -0 4 -0.001 0. 1 0. 7 0 7 8  6. 1 0. 2 0. 6 0. 9 0. 1 0. 6 0 9 57 2 .0 1 -0.01 1 .6 0 4 2 1 3 5 4 .0
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OAS3 rs6489879                 
AA 16 6. 0  6. 1 1 2       80 4       
AG/GG 19 6. 4 0. 1 0. 7 0. 7 0. 9 0. 7 0. 5 1 3 6. 5 -0 2 -0 6 -0 9 -0 1 -0 6 0. 9  3 1 0 0 1 0 8 1 2 .2 .1 .3 .5 .4 0
OAS3 rs2107418                 
GG 39 6.27       33 6.37       
GT 71 6.14 -0.05 0.10 -0.08 -0.07 -0.18  106 6.24 0.10 0.28 0.23 0.67 0.77  
TT 70 6. 6 2 -0.09 -0.08 0. 50  0.  0.  0.  0.  0.  0.07 -0.02 0. 7 9 54 6. 44 20 32 35 49 36 0. 6 0
OASL rs1169279                 
AA/AG 100 6.20       111 6.34       
GG 80 6.23 0.07 0.16 0.12 0.05 0.15 0.58 82 6.28 -0.08 -0.11 -0.26 -0.19 0.24 0.007 
OASL rs3213545                 
CC 125 6.20       95 6.28       
CT/TT 55 6.24 -0.05 -0.10 -0.12 0.05 0.01 0.63 97 6.35 -0.01 0.08 0.18 0.05 -0.33 0.02 
PKR rs2307479                 
AA 142 6.20       185 6.30       
AC/CC 37 6.25 -0.22 -0.34 -0.32 -0.57 -0.57 0.045 9 6.64 0.10 0.06 -0.16 -0.20 0.06 0.90 
STAT1 rs2066797                 
AA 123 6.25       168 6.31       
AG/GG 57 6.14 -0.08 -0.12 -0.10 -0.10 0.02 0.78 24 6.32 0.22 0.20 0.44 0.42 -0.11 0.04 
STAT1 rs1467199                 
CC 84 6.18       124 6.37       
CG/GG 96 6.24 -0.17 -0.12 0.09 0.03 -0.15 0.02 69 6.21 -0.12 -0.26 -0.17 -0.25 -0.10 0.43 
STAT2 rs2066811                 
AA 125 .21 9 6        1  2        
AG/GG 55 6.23 0.21 0.21 0.01 0.01 0.23 0.02 1 †       
                 
*   Model adjusted fo  ge varia  and int raction ween t me and etic v ant 
**  Reflects the A l
   Minor allele  than  
r age, time,
V
netic nt e bet i gen ari  
mean HC
 frequency le
 RN
ss
evels 
 5% in one † race group 
Only the results for the genotype variable are presented 
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**  Reflects th N  
† Haplotype fr s an  a p tio
‡ No variation in the haplot pe  
p-v e
Table 3-5: Multivariable Model Estimating Change in Viral Level for Interferon Stimulated Gene Haplotypes During the First 28 Days of 
Treatment by Race* 
*   Mo usted for age, tim
R
 genet variant d inte ion b een ti and ge tic va t 
e mean HC
equency le
V 
s th
A levels
5% in opula n 
y
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p-value Baseline Day 1 Day 2 Day 7 Day 14 Day 28 p-value Baseline Day 1 Day 2 Day 7 Day 14 Day 28 
GT  - 0.30 0.93 0.77 0.67 0.82 GT  - 0.34 0.12 0.72 0.75 0.91 
  TT - 0.001 0.01 0.09 0.03 0.03 TT - 0.08 0.05 0.92 0.73 0.38 
Caucasian Americans 
Mx2 rs443099: p = 0.91 
Mx2 rs443099*time: p = 0.03 
African Americans 
Mx2 rs443099: p = 0.07 
Mx2 rs443099*time: p = 0.04
 
Figure 3-1a and 3-1b:  Predicted Viral Decline for Mx2 rs443099 During the First 28 Days of HCV Treatment for African Americans (N=180) 
and Caucasian Americans (N=193) 
Depictions of viral level over the first 28 days of treatment were completed by graphing the predicted viral levels at each time point for representative 
individuals at each level of the genetic variant  
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Figures 3-2a and 3-2b:  Predicted Viral Decline for OAS3 rs1981557 During the First 28 Days of HCV Treatment for African Americans 
(N=178) and Caucasian Americans (N=193)  
Depictions of viral level over the first 28 days of treatment were completed by graphing the predicted viral levels at each time point for representative 
individuals at each level of the genetic variant  
 
p-value Baseline Day 1 Day 2 Day 7 Day 14 Day 28 
GG - 0.06 0.31 0.03 0.02 0.04 GG - 0.76 0.99 0.61 0.97 0.54 
Caucasian Americans 
OAS3 rs1981557: p = 0.01 
OAS3 rs1981557*time: p = 0.09 
African Americans 
OAS3 rs1981557: p = 0.82 
OAS3 rs1981557*time:  p = 0.66 
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Figures 3-3a and 3-3b:  Predicted Viral Decline for IFNAR1 rs1041868 During the First 28 Days of HCV Treatment Among African 
Americans (N=179) and Caucasian Americans (N=193) 
Depictions of viral level over the first 28 days of treatment were completed by graphing the predicted viral levels at each time point for representative 
individuals at each level of the genetic variant  
p-value Baseline Day 1 Day 2 Day 7 Day 14 Day 28 p-value Baseline Day 1 Day 2 Day 7 Day 14 Day 28 
GG - 0.94 0.46 0.67 0.06 0.32 GG - 0.83 0.33 0.39 0.78 0.55 
Caucasian Americans 
IFNAR1 rs1041868: p = 0.22 
IFNAR1 rs1041868*time: p = 0.47 
African Americans 
IFNAR1 rs1041868: p = 0.39 
IFNAR1 rs1041868*time: p = 0.07
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Figure 3-4a and 3-4b:  Predicted Viral Decline for IRF1 ATCCATCC During the First 28 Days of HCV Treatment Among African Americans 
(N=175) and Caucasian Americans (N=188) 
Depictions of viral level over the first 28 days of treatment were completed by graphing the predicted viral levels at each time point for representative 
individuals at each level of the genetic variant  
 
 
 
 
p-value Baseline Day 1 Day 2 Day 7 Day 14 Day 28 
≥ 1 Copy - 0.17 0.33 0.70 0.30 0.69 
Caucasian Americans 
IRF1 ATCCATCC:  p = 0.08 
IRF1 ATCCATCC*time: p = 0.07 
Day 28 p-value Baseline Day 1 Day 2 Day 7 Day 14 
≥ 1 Copy - 0.84 0.46 0.99 0.90 0.81 
African Americans 
IRF1 ATCCATCC:  p = 0.51 
IRF1 ATCCATCC*time: p = 0.84 
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4.1 ABSTRACT 
Hepatic steatosis is the accumulation of fat in the liver and is prevalent in 30-84% of chronic 
hepatitis C virus (HCV) patients.  Insulin resistance (IR) is the condition for which normal 
amounts of insulin do not produce a typical response from cells.  Both are common in HCV 
infection and are thought to be biologically related.   
This study tested genetic variant associations with steatosis and IR among 167 African 
Americans (AA) and 184 Caucasian Americans (CA) infected with HCV genotype-1.  Steatosis 
was defined as having at least 5% of fat in cells on liver biopsy.  The Homeostasis Model 
Assessment (HOMA) Version 2.2 was used to quantify IR and the presence of IR was 
categorized as a score greater than 2. Associations between genetic variants and the occurrence 
of steatosis or IR were investigated using logistic regression models separately by race. 
Statistically significant associations (p<0.05) were observed for polymorphisms in 
Interleukin-10 (IL10), Leptin Receptor (LEPR), Interleukin-6 (IL6) and Transforming Growth 
Factor Beta 1 (TGF-β1) for both outcomes.  Some significant interactions were observed 
between IL10, LEPR and TGF-β1 polymorphisms and HOMA2-IR scores when examining 
steatosis. The interaction of HOMA2-IR and IL10 was consistent in both races whereas for 
LEPR and TGF-β1 the interactions were statistically significant in only one of the racial groups.  
When examining IR, there were no significant interactions observed between the SNPs and 
steatosis.  Both AAs and CAs possessing the GG genotype for TGF-β1 rs2278422 had 
significantly lower odds of IR compared to those with the CC or CG genotypes.   
If IR is along the causal pathway for steatosis, these results could imply that some IL10, 
LEPR and TGF-β1 polymorphisms may modify an association between steatosis and IR.  
Understanding genetic associations with these conditions and further learning the function of the 
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associated polymorphisms may help to explain the mechanisms of steatosis and IR in HCV 
infection.     
4.2 INTRODUCTION 
Hepatic steatosis is characterized by the accumulation of fat in the liver and diagnosis is 
generally made by examining a biopsy to calculate the percentage of fat in liver cells.(Teli, 1995)  
The prevalence of steatosis has been reported to be as low as 30% and as high as 84% among 
chronic hepatitis C virus (HCV) patients.(Adinolfi, 2001; Asselah, 2006; Castera, 2003; 
Conjeevaram, 2006; Conjeevaram, 2007; Czaja, 1998; Hourigan, 1999; Hui, 2002; Monto, 2002; 
Patton, 2004; Poynard, 2003; Rubbia-Brandt, 2004; Rubbia-Brandt, 2001; Serfaty, 2001; Westin, 
2002)  Steatosis occurs less frequently in the general population (31%).(Browning, 2004)  The 
mechanisms of hepatic steatosis are thought to be multifactorial and the presence of insulin 
resistance may be associated with its development.(Adinolfi, 2001; Castera, 2003; Hourigan, 
1999; Rubbia-Brandt, 2000; Serfaty, 2001; Serfaty, 2002)   
Factors previously identified to be associated with steatosis in HCV infection were 
alcohol consumption, higher body mass index (BMI), older age, male gender, Caucasian 
American race, presence of hepatic inflammation, hyperlipidaemia, increased triglyceride levels, 
higher cholesterol levels, increased alanine aminotransferase (ALT) levels, increased aspartate 
aminotransferase (AST) levels, higher fibrosis scores and the presence of insulin 
resistance.(Asselah, 2006; Browning, 2004; Conjeevaram, 2007; Fabris, 2004; Leandro, 2006; 
Matos, 2006; Ruhl, 2004; Solis-Herruzo, 2005; Younossi, 2004)  African Americans have a 
lower prevalence of steatosis despite having a higher BMI.(Browning, 2004; Ruhl, 2004)  The 
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presence of steatosis was found to be associated with fibrosis progression in HCV 
patients.(Adinolfi, 2001; Castera, 2003; Hourigan, 1999; Serfaty, 2002; Westin, 2002)  Steatosis 
may also adversely influence HCV sustained virologic response (SVR).(Fabris, 2005; Guidi, 
2005; Jian Wu, 2006; Patton, 2004; Soresi, 2006; Westin, 2007)  HCV genotype-1 patients with 
steatosis achieved SVR less frequently (29-46%) compared to those without steatosis (62-
65%).(Jian Wu, 2006; Soresi, 2006; Westin, 2007)    
Insulin resistance (IR) is a condition in which normal amounts of insulin are insufficient 
to produce a typical response from cells, especially fat, muscle and liver cells.(Rao, 2001; 
Romero-Gomez, 2006)  IR is often measured and quantified by the Homeostasis Model 
Assessment of Insulin Resistance Index (HOMA-IR).(Matthews, 1985)  IR can occur early in the 
course of HCV infection.(Petit, 2001)  Patients with chronic HCV infection were observed in one 
study to have higher HOMA-IR scores compared to healthy controls.(Hui, 2003)  Risk factors 
for IR among people with chronic HCV infection include older age, African American race, 
obesity, cirrhosis, and fibrosis.(Heathcote, 2002; Petit, 2001; Romero-Gomez, 2005)   Presence 
of IR may negatively impact the function of interferon therapy and the ability to achieve SVR in 
HCV patients, especially those infected with genotype-1.(Romero-Gomez, 2006; Romero-
Gomez, 2005)          
Genes with functions related to fat metabolism or lipid metabolism were examined for 
associations with steatosis or IR in primarily diabetic, obese or healthy subjects.(Cardellini, 
2005; Kubaszek, 2003; Kubaszek, 2003; Qi, 2006; Sartipy, 2003; Scarpelli, 2006; Simeoni, 
2004; Testa, 2006; Y Yang, 2003)  In patients with chronic HCV infection, increased expression 
of tumor necrosis factor alpha in the liver was associated with IR (Gershon, 2000; Halse, 2001; 
Kallinowski, 1998; Maeno, 2003; Mishima, 2001; Moller, 2000; Nelson, 1997; Petit, 2001; 
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Valenti, 2005) or steatosis.(Gochee, 2003; Sougleri, 2001; Valenti, 2005)   Previous observations 
found that higher Interleukin 6 and Monocyte chemoattractant protein-1 expression was 
associated with IR in HCV infection.(Cardellini, 2005; Danielsson, 2005; Deepa, 2006; Hamid, 
2005; Hermann, 2005; Illig, 2004; Kanda, 2006; Kubaszek, 2003; Mohlig, 2004; Qi, 2006; Testa, 
2006; Tsiavou, 2004; Vozarova, 2003; X Yang, 2005)  In studies of steatosis, transforming 
growth factor-β1 was over expressed with fatty liver (Kharbanda, 2004) and increased 
Interleukin 10 production was associated with less steatosis.(Den Boer, 2006)  Cytochrome P-
450 2E1 activity was found to be positively correlated with HOMA-IR levels.(Chalasani, 2003)  
These studies indicate the importance of these genes in the occurrence of steatosis or IR, but 
little is known about the associations with polymorphisms in these genes and these conditions in 
HCV infection.  Understanding these genetic associations with steatosis and IR may help to 
understand the mechanisms of these conditions in HCV infection and reduce additional 
morbidity and mortality. 
This study hypothesized that genetic variants in Collagen, Type 1, Alpha 1 (COL1A1), 
Cytochrome P450 2E1 (CYP2E1), Interleukin 6 (IL6), Interleukin 10 (IL10), Interleukin 1 
Receptor Type 1 (IL1R1), Leptin Receptor (LEPR), Chemokine (C-C motif) ligand 2 
(MCP1/CCL2), Chemokine (C-C motif) ligand 8 (MCP2/CCL8), Tumor Necrosis Factor-Alpha 
(TNF-α) and Transforming Growth Factor Beta 1 (TGF-β1) are associated with steatosis or 
insulin resistance in a sample of African Americans and Caucasian Americans infected with 
HCV genotype-1. 
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4.3 MATERIALS AND METHODS 
4.3.1 Study Population and Clinical Data 
Data were from the Study of Viral Resistance of Antiviral Therapy of Chronic Hepatitis C 
(Virahep-C), a multicenter study supported by the National Institutes of Health (NIH).  Virahep-
C study design and primary outcomes have been described elsewhere.(Conjeevaram, 2006)  
Briefly, there were 401 HCV treatment naïve patients who were enrolled in the study among 
whom 374 (194 Caucasian and 180 African Americans) agreed to participate in the genetics 
studies and included in the present analyses.   
4.3.2 Measurement of Steatosis and Insulin Resistance 
Per protocol, patients without cirrhosis were to obtain a liver biopsy within 18 months of study 
enrollment.(Conjeevaram, 2007; Yee, 2007)  Liver biopsies were scored by a single pathologist, 
who was masked with respect to patient outcome and clinical status.  Biopsies were assessed for 
the severity of chronic HCV by grading inflammation and staging of fibrosis using the modified 
histologic activity index (HAI) scoring system.(Ishak, 1995)  Steatosis was scored on a scale of 0 
to 4 according to the percentage of cells with fat where: 0 = none, 0.5 = <5%, 1 = 5-<25%, 2 = 
25-<50%, 3 = 50-<75%, 4 = ≥75%.(Conjeevaram, 2007)  For this study, IR was quantified by 
using the Homeostasis Model Assessment-Insulin Resistance (HOMA2-IR) Calculator Version 
2.2 based on the mathematical model released in 2004 and downloaded from 
http://www.dtu.ox.ac.uk/.(Levy, 1998; Wallace, 2004)  The HOMA2-IR model estimates insulin 
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sensitivity using fasting glucose and insulin levels and is calibrated with current insulin 
assays.(Levy, 1998; Wallace, 2004)        
4.3.3 Single Nucleotide Polymorphism (SNP) Selection and Genotyping 
Prior to this study, Virahep-C supported the selection and genotyping of single nucleotide 
polymorphisms as part of a study of host genetics.  The genes examined for this manuscript were 
chosen from a list of genes already genotyped as part of the previous study.  The list included 
genes that have been associated with steatosis or IR in diabetic, obese or healthy populations in 
the literature.  Two different approaches were utilized in the selection of SNPs and genotyping 
and were based on publically available genetic information and genotyping technology at the 
time that each component was completed.   
One selection method identified SNPs for the candidate genes IL6, IL10, TGF-β1 and 
TNF-α and details of this process have been described elsewhere.(Yee, 2007)  Briefly, SNPs 
were selected by examining the haplotype blocks for each race and identifying polymorphisms 
from the International HapMap Project (Phase I) and National Center for Biotechnology 
Information (NCBI) databases.(Yee, 2007)  SNPs with a minor allele frequency of at least 10% 
in a reference population were selected to cover the entire gene at 2-3 kb intervals for small 
genes and 5-9 kb intervals for larger genes.(Yee, 2007)  An allelic discrimination assay 
employing the ABI 7000 Sequence Detection System with TaqMan technology (Applied 
Biosystems Inc., Foster City, CA) was used to genotype the haplotype-tagging SNPs.(Yee, 2007)   
The second method for SNP selection and genotyping was utilized for COL1A1, 
CYP2E1, IL1R1, LEPR, MCP1/CCL8 and MCP2/CCL8.  For each of these genes, SNPs with a 
minor allele frequency of at least 5% in a reference population were selected from the 
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International HapMap Project (Phase I) approximately every 3-5 kb to cover the entire gene.(Su, 
2008)  SNPs identified were genotyped using Illumina BeadArray technology (Illumina, San 
Diego, CA).(Su, 2008)  Further detail of the SNP selection and laboratory methods have been 
reported elsewhere.(Su, 2008)  
4.3.4 Variable Categorization 
Steatosis was categorized into a dichotomous variable using data from the liver biopsies with 
steatosis (steatosis score greater than 0) versus no steatosis.  In general, a HOMA-IR score of at 
least 1.5 is thought to indicate decreased insulin sensitivity.(Conjeevaram, 2007)  For this study, 
IR was defined as HOMA2-IR score of at least 2.0 based on a previous study of the Virahep-C 
cohort.(Conjeevaram, 2007)  For each SNP, indicator variables were created for the genotypes to 
test for genotype associations with steatosis or IR.  An a priori decision was made that if the less 
common homozygote genotype had a minor allele frequency of less than 5% it was combined 
with the heterozygote genotype.  Haplotypes were categorized as having at least one copy of the 
haplotype or having no copies. 
4.3.5 Risk Factor Variables and Model Building 
Ishak fibrosis score, weekly alcohol consumption, age, BMI, log10 of baseline viral level, 
inflammation score, ALT levels, AST levels, cholesterol levels and triglyceride level were 
continuous factors centered at their mean values and examined in the model building for steatosis 
and IR.  Diabetes status and HCV subtype were categorical factors examined in the model 
building for the outcomes.  Self-reported race was used in this study since it was previously 
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reported that the individual admixture in the Virahep-C study strongly agreed with self-reported 
race.(Yee, 2007)  Steatosis was assessed as a risk factor for IR and IR was assessed as a risk 
factor using the continuous HOMA2-IR scores when examining steatosis.  HOMA2-IR scores 
were transformed using the natural log and were centered at the mean.      
4.3.6 Genetic Analytical Methods 
Genotype and allele frequencies as well as Hardy Weinberg Equilibrium (HWE) chi square tests 
were calculated by race for each SNP.  A genotype call rate, defined as the percentage of 
individuals where a genotype could be determined compared to the total number of individuals 
where genotyping was attempted, was calculated for each race group.  Minor allele frequencies 
(MAF) were examined by race and SNPs with a MAF less than 5% were not analyzed.  
Haplotypes were estimated using the EM algorithm for all genes separately by race.(Excoffier, 
1995)  SNPs that violated HWE assumptions or were monomorphic or had an allele frequency 
less than 5% were excluded from haplotype estimation.(Kirk, 2002)  Estimated haplotypes for 
individuals with at least a 0.7 probability of being the true haplotype were retained and used in 
subsequent analyses.  If estimated haplotypes had a probability less than 0.7, no haplotypes were 
assigned to the study patient.  Haplotypes with a frequency of at least 5% in either Caucasian 
Americans or African Americans were investigated in analyses.  SAS® Genetics Version 9.1.3 
was used to conduct SNP and haplotype analyses (SAS Institute Inc., Cary, NC, 2002-2003).  
The Tagger Program in the Haploview Software Suite version 4.0 was used to calculate the 
amount of variation accounted for in the gene (r2) by the tagged SNPs separately by 
race.(Barrett, 2005)  This analysis was done to evaluate how well the SNP selection methods 
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utilized for this study captured the common genetic variation compared to the more recently 
available HapMap Phase II data. 
4.3.7 Statistical Analyses 
Twelve individuals identified as Hispanics and 11 individuals using exogenous insulin were 
removed from analyses resulting in a sample size of 351.  Demographic characteristics and risk 
factors for steatosis and insulin resistance were assessed by race using appropriate association 
tests.  SNP association tests were completed with steatosis and insulin resistance separately by 
race using the genotype case control chi square test (results in Appendix B).(Nielsen, 1999)  A 
haplotype trait chi square test was performed to identify an association between any possible 
haplotype for a gene and steatosis or IR (results in Appendix B).(Zhao, 2000)   
Odds ratios were used to quantify the association between steatosis or IR and the SNPs or 
haplotypes.  Adjusted models were built using backwards elimination that included possible 
confounding variables and removing those that did not significantly contribute to the prediction 
of the outcome.  The backwards elimination method first removed variables with p-values 
greater than 0.25.  The second elimination removed variables with p-values greater than 0.15 and 
the final elimination removed those variables with a p-value greater than 0.05.  To avoid 
problems with multicollinearity with significantly correlated variables, only one variable was 
used in the model building and was chosen because there was more support in the literature for 
an association.  For example, steatosis was significantly correlated with ALT levels and steatosis 
was used because the literature commonly describes associations between steatosis and IR.  
Steatosis was retained in the model predicting IR because steatosis and IR are thought to be 
biologically related and it is unclear if steatosis contributes to the occurrence of IR or vice versa.  
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All possible interaction terms between the main effects variables remaining in the model after the 
three elimination steps were tested to determine their contribution to the prediction of the 
outcome.  A significant log likelihood ratio test (p<0.05) was used to determine if an interaction 
term significantly contributed to the prediction of the outcome.     
After the final model was determined for each outcome, an interaction between the 
natural log transformed HOMA2-IR scores (when predicting steatosis) or steatosis (when 
predicting IR) and the genetic variant was tested separately in African- and Caucasian-
Americans.  The log likelihood ratio test was used to determine the significance of the 
interaction.  For log likelihood ratio tests with p-values greater than 0.05, the interaction was not 
included in the model.  If the log likelihood was significant, then the model included the 
interaction to predict the outcome. Odds ratio (OR) estimates and 95% Confidence Intervals (CI) 
were estimated for each genetic variant in both unadjusted (results in Appendix B) and adjusted 
models separately by race.  An alpha level of 0.05 was used to determine statistical significance.  
The SAS®/STAT software system version 9.1.3 was used to complete analyses (SAS Institute 
Inc., Cary, NC, 2002-2003). 
4.4 RESULTS 
4.4.1 Population Characteristics 
Comparisons of demographic characteristics by race are shown in Table 4-1.  African Americans 
and Caucasian Americans did not significantly differ by gender, age, hepatic inflammation score, 
baseline viral level, Ishak fibrosis score, steatosis, AST levels, cholesterol levels, triglyceride 
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levels or weekly alcohol consumption.  African Americans had significantly higher HOMA2-IR 
scores, ALT levels and BMI compared to Caucasian Americans.  There were 53 individuals who 
had missing data for HOMA2-IR because their insulin and glucose levels were not fasting or 
were not available. 
4.4.2 SNP Genotyping and Estimation of Haplotypes 
Genotype frequencies, call rate and p-values from HWE tests are shown in Table 4-2.  Haplotype 
estimation used 45 of 52 genotyped SNPs because four SNPs violated assumptions of HWE 
(rs1880242, rs1805096, rs1892534 and rs2229094), two were monomorphic (rs3917257 and 
rs3917879) and one had an allele frequency less then 5% in either race group (rs3917275).  
Haplotype estimation with a 0.7 probability of being a true haplotype occurred in four of the 
genes (IL10, TNF-α, MCP1/CCL2 and MCP2/CCL8) with 350 of a possible 351 haplotypes 
estimated.  Haplotypes were estimated in 344, 339, 336, 325, 313 and 293 individuals for LEPR, 
TGF-β1, IL1R1, IL6, CYP2E1 and COL1A1, respectively.  Results of haplotype estimation are in 
Appendix B.  The selected SNPs for IL6, IL10, TGF-β1 and TNF-α accounted for 38% (11-85%) 
of the common variation of the gene in African Americans and 47% (7-81%) in Caucasian 
Americans.  The selected SNPs for COL1A1, CYP2E1, IL1R1, LEPR, MCP1 and MCP2 
accounted for 19% (0-40%) of the common genetic variation in African Americans and 39% (16-
83%) in Caucasian Americans.  Common genetic variation tables for each gene are found in 
Appendix B.   
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4.4.3 Associations with Steatosis 
The final model used to estimate the odds of steatosis was adjusted for Ishak fibrosis score, 
weekly alcohol consumption, baseline viral level, natural log transformed HOMA2-IR scores 
and body mass index.  Results from the adjusted models for IL6, IL10, LEPR and TGF-β1 
polymorphisms are reported in Table 4-3.  CYP2E1, IL1R1, MCP2/CCL8 and TNF-α SNPs were 
not statistically significantly associated with steatosis.   Haplotype analysis for the association 
with steatosis yielded similar results to individual SNP analyses and were not reported in this 
manuscript.  
Among Caucasian Americans possessing the COL1A1 rs2586494-CC genotype, the odds 
of steatosis for a one unit increase in HOMA2-IR score (OR=2.3: 95% CI=1.1-5.0) were 
significantly lower than the odds for a one unit increase in HOMA2-IR score for those with the 
AA or AC genotype (OR=19.5: 95% CI=2.3-164.5).  The odds of steatosis were significantly 
higher for a one unit higher HOMA2-IR score among African Americans with the MCP1/CCL2 
rs2857657-CG/GG genotypes (OR=24.8: 95% CI=1.2-500.2) compared to those with the CC 
genotype and a one unit higher HOMA2-IR score (OR=1.7: 95% CI=0.95-3.16).  Results for 
SNPs not presented in Table 4-3 are available in Appendix B.  
Caucasian Americans possessing the IL6 rs2069845-AG or GG genotype had 
significantly higher odds of steatosis (OR=2.5: 95% CI=1.1-6.0) compared to those with the AA 
genotype (Table 4-3).  No significant associations were observed for this polymorphism in 
African Americans and the direction of the odds ratio was different.  The odds of steatosis 
among African Americans with the TGF-β1 rs2278422-GG genotype were 4.4 times the odds of 
steatosis among African Americans with the CC or CG genotype.  No significant associations 
were observed in Caucasian Americans for this polymorphism, but the direction of the odds ratio 
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was the same (Table 4-3).   Higher odds of steatosis were observed for a one unit higher 
HOMA2-IR score for African Americans possessing the TGF-β1 rs2241716-GG genotype 
(OR=3.3: 95% CI=1.6-6.9) compared to the odds for a one unit higher HOMA2-IR score among 
those with the AA or AG genotype (OR=0.7: 95% CI=0.2-1.9) 
Statistically significant interactions between IL10 SNPs and HOMA2-IR scores were 
observed in the prediction of steatosis.  The odds of steatosis for a one unit higher HOMA2-IR 
score for Caucasian Americans possessing the IL10 rs3024496-CT (OR=7.7: 95% CI=2.3-25.4) 
or TT (OR=9.3: 95% CI=1.5-59.2) genotype were significantly higher than the odds for a one 
unit higher HOMA2-IR score for those with the CC genotype (OR=1.5: 95% CI=0.5-4.2)   In 
African Americans, the odds of steatosis for the IL10 rs3024496-CT genotype with a one unit 
higher HOMA2-IR score were higher (OR=3.4: 95% CI=1.3-8.8) compared to those with the CC 
genotype (OR=0.3: 95% CI=0.1-1.3). Table 4-4 shows the IL10 rs3024496 genotype frequencies 
for those with and without steatosis and those with or without IR and may be useful for 
understanding the observed interaction. There were higher percentages of individuals with the 
CT (90%) and TT (85%) genotypes with higher HOMA2-IR scores who had steatosis compared 
to individuals with the CT (60%) and TT (67%) genotypes and lower HOMA2-IR scores.  
Figures 4-1A and 4-1B graphically depict the interaction between the IL10 rs3024496 genotypes 
and HOMA2-IR scores in the prediction of steatosis through different slopes for the log odds of 
steatosis for the polymorphism genotypes.  For African Americans, the graph shows that the 
IL10 rs3024496-CT and TT genotypes have similar increasing log odds of steatosis and the CC 
genotype has a very different and decreasing slope for the log odds of steatosis as HOMA2-IR 
score increases.  In Caucasian Americans, the IL10 rs3024496-CT and TT genotypes have 
similar increasing log odds of steatosis and the CC genotype has slower increasing log odds of 
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steatosis as the HOMA2-IR score increases.  Individuals who possess the IL10 rs3024496 
associated genotypes and have higher HOMA2-IR scores also have higher odds of steatosis 
compared to those with lower HOMA2-IR scores.   
Statistically significant associations were observed between LEPR SNPs and steatosis 
(Table 4-3).  African Americans with the LEPR rs1137100-AG or GG genotype had 0.3 (95% 
CI=0.1-0.6) times lower odds of steatosis compared to those with the AA genotype.  The 
observed association in Caucasian Americans was not statistically significant, but the direction 
of the odds ratio was the same.   African Americans possessing the LEPR rs1892534-AG 
genotype had triple the odds of having steatosis compared to those with the AA genotype (Table 
4-3).  Statistically significant interactions were observed between HOMA2-IR scores and two 
LEPR polymorphisms in Caucasian Americans.  For a one unit increase in HOMA2-IR score 
among Caucasian Americans, the odds of steatosis for LEPR rs1892534 AG genotype were 29.6 
(95% CI=4.3-205.2) times greater compared to those with the AA genotype (OR=1.2: 95% 
CI=0.4-3.90).  The odds of steatosis for a one unit higher HOMA2-IR score among Caucasian 
Americans possessing the LEPR rs1805096-CT genotype were significantly higher (OR=26.2: 
95% CI=3.8-180.4) than the odds for a one unit higher HOMA2-IR score among those with the 
CC genotype (OR=2.0: 95% CI=0.8-5.4).  Table 4-5 shows the LEPR rs1805096 genotype 
frequencies for both race groups by steatosis and IR.  In Caucasian Americans, There is a higher 
percentage of steatosis among those with the heterozygote genotype and higher HOMA2-IR 
scores (100%) compared to those with the same genotype and lower HOMA2-IR scores (56%).  
Figure 4-2A depicts the log odds of steatosis by HOMA2-IR scores in African Americans. This 
graph shows similar log odds of steatosis for the LEPR rs1805096 genotypes and the interaction 
was not observed to be statistically significant (p=0.13).  Figure 4-2B graphically describes the 
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statistically significant interaction between the LEPR rs1805096 genotypes and HOMA2-IR 
scores in the prediction of steatosis in Caucasian Americans by showing three very different log 
odds of steatosis slopes for the genotypes.   
4.4.4 Associations with Insulin Resistance 
Models predicting the odds of IR were adjusted for Ishak fibrosis score, BMI, age, steatosis and 
triglyceride levels.  Results of the adjusted main effects models are presented in Table 4-6.  No 
statistically significant SNP associations with IR were observed in either race group for 
COL1A1, CYP2E1, IL1R1, MCP1/CCL2, MCP2/CCL8 or TNF-α.  Additional SNP results not 
described in Table 4-6 are in presented in Appendix B.  Haplotype analysis for the association 
with insulin resistance yielded similar results as those from individual SNP analyses and were 
not presented in this manuscript.  Haplotype results are available in Appendix B.  No significant 
interactions between the genetic variants and steatosis contributed to the prediction of IR. 
Statistically significant associations were observed between IL6, IL10, LEPR and TGF-β1 
polymorphisms and insulin resistance in either race group.  African Americans with the IL10 
rs3024496-CT genotype (OR=0.3: 95% CI=0.1-0.8) or the rs1800900-TT genotype (OR=0.4: 
95% CI=0.2-0.9) had lower odds of IR compared to the rs3024496-CC genotype or the 
rs1800900-AA or AT genotype.  No statistically significant associations for these SNPs were 
observed in Caucasian Americans, but the odds ratios were in the same direction.  Caucasian 
Americans with the IL6 rs1880242-TT genotype had 0.3 times lower odds of IR compared to 
Caucasian Americans with the GG or GT genotype.  For TGF-β1 rs2278422, African Americans 
with the GG genotype had 0.2 times lower odds of IR (95% CI=0.2-0.9) and Caucasian 
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Americans with the GG genotype had 0.4 time lower odds of IR (95% CI=0.1-0.9) compared to 
those with either the CC or CG genotype.    
4.5 DISCUSSION 
This study investigated host genetic associations with steatosis and IR for African American and 
Caucasian American patients with HCV genotype-1 infection.  Statistically significant 
associations with steatosis or IR were identified in IL6, IL10, LEPR or TGF-β1 in both race 
groups.   
This study stratified all data by race for the purpose of detecting gene associations with 
steatosis and IR.  The decision to complete the analyses separately by race was based on an a 
priori genetic expectation of different effects of SNPs in different ethnic groups.  Even if the 
same gene is affecting the outcome in Caucasian Americans and African Americans, there is an 
expectation that different SNPs within a gene for each race will show an association because of 
different population histories.  Some associations identified in this study were only statistically 
significant in one race group or the direction of the association was different by race.  One 
explanation may be that the associated genetic variants were not directly affecting the conditions, 
but rather were in linkage disequilibrium with functional genetic variants.  If this were the case, 
the different patterns of results may be explained by different linkage disequilibrium patterns in 
the populations and the different population histories of African Americans and Caucasian 
Americans.  For example, an associated SNP could be ‘tagging’ a causal genetic variant in one 
population that is not even present in the other population.  Alternatively, if the functional 
genetic variants are newer or more recent in the population history and the associated genetic 
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variants are old, the associations may differ in race groups because of differences in migration 
out of Africa.  
The findings from this study imply that some genetic variants may moderate or influence 
the association between steatosis and IR.  For example, the association between steatosis and IR 
may be affected by IL10 rs3024496.  Those with higher HOMA2-IR scores who possess the CT 
or TT genotype were more likely to also have steatosis compared to those with the CC genotype 
and higher HOMA2-IR scores.  IL10 rs3024496 is located in the 3’ untranslated region of the 
gene and is predicted to have no known function.(Yuan, 2006) Determining the function of 
associated genetic variant may provide more information about how this genetic variant 
influences steatosis or IR.   
For the LEPR gene, there were main effects associations of SNPs with steatosis or IR.  
The LEPR rs1137100-AG or GG genotype was associated with lower odds of steatosis.  Two 
statistically significant interactions were also observed between LEPR SNPs and HOMA2-IR 
scores in the prediction of steatosis in Caucasian Americans.  Based on findings from the 
models, it seems plausible that the association between the LEPR polymorphisms and steatosis 
could be moderated by higher HOMA2-IR scores.  The interactions between LEPR rs1805096-
CT and rs1892534-AG and HOMA2-IR scores could have been the result of influential points 
because there were no individuals who carried the heterozygote genotypes in the no steatosis and 
higher HOMA2-IR score group.  LEPR rs1137100 or rs1805096 are located in the coding region 
and contribute to splicing regulation.(Yuan, 2006)  LEPR rs1892534 is located in the 3’ 
downstream untranslated region with no known function.(Yuan, 2006)  The genetic variants with 
predicted functions related to splicing regulation may allow the gene to express different exons 
which encode gene products such as proteins.(Mercatante, 2000) Further, understanding the 
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function of the associated genetic variants may explain how these genetic variants are related to 
the occurrence of steatosis or IR in HCV infection. 
There were statistically significant associations between TGF-β1 SNPs and steatosis or 
IR.  Possession of the TGF-β1 rs2278422-GG genotype indicated lower odds of IR for both race 
groups compared to the CC or CG genotype.  One significant interaction was observed in 
African Americans between TGF-β1 rs2241716-GG genotype and higher HOMA2-IR scores 
such that higher odds of steatosis were observed than expected for the main effects of HOMA2-
IR scores and the genotype alone.  TGF-β1 rs2241716 is located in the intron region and 
predicted to be an intronic enhancer which could change how the encoded protein is 
produced.(Yuan, 2006)  This change in the production of the protein may influence the 
occurrence of these conditions.     
Three previous studies described associations between the IL6 rs1800795-G allele and 
the occurrence of IR in Caucasian European decent, healthy or diabetic populations.(Cardellini, 
2005; Testa, 2006; X Yang, 2005)  The current study did not identify a statistically significant 
association between this polymorphism and the occurrence of IR.  Furthermore, in the current 
study the direction of the association contradicted the previous work.  The observed differences 
could be related to different phenotype measures, statistical methods and different populations. 
The previous studies examined Caucasian individuals who were healthy or diabetic compared to 
the current student that examined both Caucasian Americans and African Americans infected 
with HCV genotype-1.  HCV infection may contribute to the occurrence of IR and the 
mechanisms for the development of IR may be different in populations with and without HCV.  
The three previous studies used HOMA-IR to quantify IR compared to HOMA2-IR used in the 
current study and HOMA2-IR is a more accurate estimate of IR.(Wallace, 2004)  
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A different study found an association between the MCP1/CCL2 rs1024611-A allele and 
the occurrence of IR among 2798 Caucasians in a CVD risk cohort.(Simeoni, 2004)  In the 
current study, no statistically significant association was observed in 156 Caucasian Americans.  
The difference in the findings could be due to different sample sizes, phenotype measures and 
cohorts.  The previous study utilized HOMA-IR and treated IR as a continuous outcome and the 
current study used HOMA2-IR and created a categorical variable for IR.  Another difference is 
that the previous study examined IR in a cohort of CVD risk patients compared to HCV 
genotype-1 infected patients and HCV may contribute to the occurrence of IR.     
A limitation of this study was that the Virahep-C cohort was small and had limited power 
to detect host genetic associations.  However, even with the small sample size this study was able 
to detect statistically significant associations between genetic variants and steatosis or IR.  The 
results of this study are also limited by the inability to validate the findings because a similar 
sample of HCV infected patients with the conditions of interest was not available.  It is important 
to validate these findings because no adjustment for multiple comparisons was made.  Another 
limitation was the different methods utilized for selecting genetic variants.  At the time the 
selection of SNPs was completed, HapMap Phase I was the main source of reference population 
data and was not able to identify SNPs to account for more of the common genetic variation 
observed in different race groups.  Thus, the amount of common variation characterized by the 
tag-SNPs selected is not as high as those expected by the second phase of HapMap which has the 
ability to better capture the common variation in the genes.  Since much of the variation was not 
accounted for using the selected SNPs in some of the genes, it is difficult to understand the 
overall gene association with these conditions.  However, the single SNP results still provide 
useful information about genetic variant associations with the conditions in HCV infection. 
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Nevertheless, the results of this study are an important contribution to the literature by 
identifying genetic variants associated with steatosis and insulin resistance among Caucasian 
American and African American patients infected with HCV genotype-1.  The findings from this 
study should be validated by additional studies to confirm the findings.  A next step in research 
could be to examine genetic variants that are in high linkage disequilibrium or close to the 
associated genetic variants to identify the true causal genetic variant.  In addition, further 
research is needed to understand the functional purpose of the associated genetic variants to 
better understand how they influence the occurrence of steatosis and IR.  In particular, it may be 
important to complete functional studies for the associated genetic variants that currently have no 
known function.  These studies would further contribute to understanding how these genetic 
variants affect steatosis and IR.   
To make conclusions about gene associations with steatosis and IR, additional SNPs from 
the examined genes could be selected and genotyped to account for more of the common 
variation and possibly identify additional associations.  The genetic variants examined in this 
study should be investigated in other studies with a larger cohort of HCV patients or other patient 
populations with steatosis or IR to possibly identify associations not observed in this study.     
In conclusion, this study identified host genetic associations with steatosis or insulin 
resistance in African Americans and Caucasian Americans with HCV genotype-1.  Significant 
associations between IL6, IL10, LEPR or TGF-β1 and steatosis or IR were identified and the 
relationship between IR and steatosis may be moderated by genetic variants such as SNPs in the 
IL10 gene.      
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Table 4-1:  Demographic Characteristics by Race 
 
 African American Caucasian American  
Characteristics N = 167 N = 184 p-value 
    
 N (%) N (%)  
Gender    
Male 107 (64.1) 118 (64.1)  
0.99‡ Female 60 (35.9) 66 (35.9) 
Portal Inflammation Score (HAI)    
Mild 27 (16.2) 30 (16.3)  
Moderate 108 (64.7) 101 (54.9)  
0.09‡ Severe 32 (19.2) 53 (28.8) 
Steatosis    
No Steatosis 64 (38.3) 63 (34.2)  
0.43‡ Steatosis Present 103 (61.7) 121 (65.8) 
Insulin Resistance    
HOMA2 < 2 83 (58.5) 104 (66.7)  
0.14‡ HOMA2 ≥ 2 59 (41.6) 52 (33.3) 
    
 Mean (SD) Mean (SD)  
Homeostasis Model Assessment 2   
(ln HOMA2-IR) 
   
0.006† 0.6 (0.7) 0.4 (0.7)  
<0.0001† Alanine Aminotransferase (ALT) 70.6 (45.8) 108.0 (91.5) 
0.06† Aspartate Aminotransferase (AST) 60.0 (43.2) 73.0 (58.7) 
0.13† Age (years) 48.7 (6.9) 47.3 (8.4) 
<0.0001† Body Mass Index (BMI) 30.8 (6.4) 28.2 (5.2) 
0.08† Baseline Viral Level (log10 IU/mL) 6.2 (0.6) 6.3 (0.8) 
0.21† Total Inflammation (HAI) 10.0 (3.2) 10.4 (3.5) 
0.14† Triglycerides (mg/dL) 132.4 (100.0) 114.9 (68.4) 
0.67† Cholesterol (mg/dL) 177.7 (36.7) 179.2 (35.5) 
0.33† Ishak Fibrosis Score 2.1 (1.4) 2.3 (1.5) 
0.99† Alcohol Consumption (Week) 3.6 (10.8) 2.3 (6.2) 
    
† Chi-square test 
‡  Wilcoxon Two Sample Test 
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Table 4-2:  Frequencies of Genotypes for Single Nucleotide Polymorphisms among African 
Americans and Caucasian Americans 
 
 African Americans 
N = 167 
Caucasian Americans 
N = 184 
Single Nucleotide 
Polymorphism 
Genotype 
Frequency 
Call 
Rate 
 
HWE* 
Genotype 
Frequency 
Call 
Rate 
 
HWE* 
IL6 rs1880242       
GG 4 (0.02)   34 (0.19)   
GT 48 (0.29)   106 (0.58)   
TT 115 (0.69) 1.0 1.0 43 (0.24) 0.99 0.03 
IL6 rs2056576       
CC 54 (0.32)   69 (0.38)   
CT 79 (0.48)   94 (0.51)   
TT 33 (0.20) 0.99 0.67 20 (0.11) 0.99 0.15 
IL6 rs2069827       
GG 158 (0.96)   152 (0.83)   
GT 7 (0.04)   30 (0.16)   
TT 0 (0) 0.99 1.0 1 (0.01) 0.99 1.0 
IL6 rs1800797       
AA 0 (0)   23 (0.12)   
AG 22 (0.13)   92 (0.50)   
GG 144 (0.87) 0.99 1.0 69 (0.38) 1.0 0.37 
IL6 rs1800795       
CC 0 (0)   27 (0.15)   
CG 23 (0.14)   91 (0.49)   
GG 143 (0.86) 0.99 1.0 66 (0.36) 1.0 0.63 
IL6 rs2069830       
CC 133 (0.81)   182 (0.99)   
CT 30 (0.18)   1 (0.01)   
TT 2 (0.01) 0.99 0.69 0 (0) 0.99 1.0 
IL6 rs2069837       
AA 132 (0.80)   159 (0.86)   
AG 34 (0.20)   25 (0.14)   
GG 0 (0) 0.99 0.20 0 (0) 1.0 1.0 
IL6 rs1554606       
GG 79 (0.48)   60 (0.33)   
GT 71 (0.43)   95 (0.52)   
TT 16 (0.10) 0.99 0.99 29 (0.15) 1.0 0.40 
IL6 rs2069845       
AA 75 (0.45)   60 (0.33)   
AG 75 (0.45)   95 (0.52)   
GG 17 (0.10) 1.0 0.78 28 (0.15) 0.99 0.34 
IL10 rs11119474       
AA 0 (0)   0 (0)   
AG 2 (0.01)   27 (0.15)   
GG 175 (0.99) 1.0 1.0 156 (0.85) 0.99 0.61 
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Table 4-2 (Continued)       
IL10 rs3024505       
CC 148 (0.89)   138 (0.76)   
CT 19 (0.11)   40 (0.22)   
TT 0 (0) 1.0 1.0 4 (0.02) 0.99 0.54 
IL10 rs3024498       
AA 128 (0.77)   96 (0.53)   
AG 39 (0.23)   67 (0.37)   
GG 0 (0) 1.0 0.13 20 (0.11) 0.99 0.12 
IL10 rs3024496       
CC 28 (0.17)   50 (0.27)   
CT 82 (0.49)   86 (0.47)   
TT 57 (0.34) 1.0 0.87 48 (0.26) 1.0 0.38 
IL10 rs1554286       
CC 61 (0.37)   132 (0.72)   
CT 79 (0.47)   50 (0.27)   
TT 27 (0.16) 1.0  0.87 3 (0.02) 1.0 0.76 
IL10 rs2222202       
CC 84 (0.50)   48 (0.26)   
CT 68 (0.41)   86 (0.47)   
TT 15 (0.09) 1.0 0.82 50 (0.27) 1.0 0.38 
IL10 rs1800890       
AA 10 (0.06)   29 (0.16)   
AT 60 (0.36)   87 (0.47)   
TT 97 (0.59) 1.0 0.86 67 (0.37) 0.99 0.93 
LEPR rs6673324       
AA 42 (0.25)   51 (0.28)   
AG 87 (0.52)   90 (0.50)   
GG 37 (0.22) 0.99 0.53 41 (0.22) 0.99 0.91 
LEPR rs1137100       
AA 112 (0.67)   100 (0.55)   
AG 49 (0.29)   69 (0.68)   
GG 6 (0.04) 1.0 0.82 14 (0.08) 0.99 0.66 
LEPR rs1343982       
AA 16 (0.10)   16 (0.09)   
AG 75 (0.45)   69 (0.38)   
GG 76 (0.45) 1.0 0.69 99 (0.54) 0.99 0.45 
LEPR rs1137101       
AA 42 (0.25)   53 (0.29)   
AG 73 (0.44)   91 (0.50)   
GG 52 (0.31) 1.0 0.11 39 (0.21) 0.99 0.99 
LEPR rs2376018       
AA 115 (0.69)   124 (0.68)   
AG 49 (0.29)   54 (0.29)   
GG 3 (0.02) 1.0 0.58 5 (0.03) 0.99 0.76 
LEPR rs1805096       
CC 52 (0.31)   74 (0.41)   
CT 83 (0.50)   70 (0.38)   
TT 32 (0.19) 1.0 0.91 38 (0.21) 0.99 0.01 
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Table 4-2 (Continued)       
LEPR rs1892534       
AA 33 (0.20)   40 (0.22)   
AG 83 (0.50)   69 (0.38)   
GG 51 (0.31) 1.0 0.94 74 (0.40) 0.99 0.003 
TGF-Β1 rs2278422       
CC 14 (0.08)   29 (0.16)   
CG 71 (0.43)   101 (0.55)   
GG 82 (0.49) 1.0 0.80 54 (0.29) 1.0 0.11 
TGF-Β1 rs2241716       
AA 0 (0)   0 (0)   
AG 16 (0.10)   0 (0)   
GG 151 (0.90) 1.0 1.0 183 (1.0) 0.99 - 
TGF-Β1 rs1800471       
CC 0 (0)   1 (0.01)   
CG 23 (0.14)   17 (0.09)   
GG 144 (0.86) 1.0 1.0 165 (0.90) 0.99 0.38 
       
* P-value from test of Hardy Weinberg Equilibrium
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Table 4-3: Adjusted Odds Ratios for Steatosis for Single Nucleotide Polymorphisms among African Americans and Caucasian Americans 
 
 African Americans* 
N = 167 
Caucasian Americans* 
N = 184 
  SNP Main Effects HOMA2-IR  SNP Main Effects HOMA2-IR 
Single Nucleotide 
Polymorphism 
 
N 
Odds Ratio      
(95% Confidence 
Interval) 
p-
value
Odds Ratio      
(95% Confidence 
Interval) 
p-
value
 
N 
Odds Ratio   
(95% Confidence 
Interval) 
p-
value
Odds Ratio 
(95% Confidence 
Interval) 
p-
value
IL6 rs1880242           
GG/GT 5   2 1.00    140 1.00    
TT 115 1.28 ( 2.89)  0.76 ( 2.06)  0.57- 0.55 ‡  43 0.29- 0.61 ‡  
IL6 rs2056576           
CC 54 1.00    69 1.00    
CT 1.08 (0 2.52)   0.57 (0 1.42)  79 .47- 0.85 ‡  94 .23- 0.23 ‡  
TT 33 1.10 ( 1.34)  0.91 ( 3.65)  0.38- 0.86 ‡  20 0.23- 0.90 ‡  
IL6 rs2069827           
GG 158 1.00    152 1.00    
GT/TT 7 †  †  31 1.47 (0.50-4.30) 0.49 ‡  
IL6 rs1800797           
AA/AG 22 1.00    115 1.00    
GG 1  2.06 (0 -6.98)  44 .61 0.25 ‡  69 0.45 (0.19-1.05) 0.07 ‡  
IL6 rs1800795           
CC/CG 23 1.00    118 1.00    
GG 143 1.78 (0.55-5.73) 0.34 ‡  66 0.47 (0.20-1.10) 0.08 ‡  
IL6 rs2069830           
CC 133    1.00    182 1.00    
CT/TT 32 0.87 2.27)  (0.33- 0.77 ‡  1 †  ‡  
IL6 rs2069837           
AA 132 1.00    159 1.00    
AG/GG 0.81 (0 2.04)   0.82 (0 2.91)  34 .32- 0.65 ‡  25 .23- 0.76 ‡  
IL6 rs1554606           
GG 79 1.00    60 1.00    
GT/TT 87 0.88 (0.41-1.91) 0.75 ‡  124 2.24 (0 -5.30)  .94 0.07 ‡  
IL6 rs2069845           
AA 75 1.00    60 1.00    
AG/GG 92 0.86 ( 1.86)  2.52 ( 6.00)  0.40- 0.70 ‡  123 1.06- 0.04 ‡  
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IL10 rs11119474           
AA/AG 2 1.00    27 1.00    
GG 165 †  ‡  156 1.46 (0.48-4.48) 0.51 ‡  
IL10 rs3024505           
CC 148 1.00    138 1.00    
CT/TT 19 0.36 (0.11-1.23) 0.10 ‡  44 0.50 (0.21-1.22) 0.13 ‡  
IL10 rs3024498           
AA 128    7.53 (2 24.26) 0.001 1.00    96 1.00  .34-
AG/GG  0.56 (0 1.37)   0.85 (0 2.16)  1.62 (0 3.87)  39 .23- 0.20 ‡  87 .34- 0.74 .68- 0.28
IL10 rs3024496           
CC 28 1.00  0.27 (0 -1.31) 0.10 1.46 (0 -4.15)  .05 50 1.00  .52 0.47
CT 82 2.02 (0 6.36)  3.39 (1 8.78)  7.66 (2 25.42) 0.001 .64- 0.23 .31- 0.01 86 3.27 (1.06-10.09) 0.04 .31-
TT 3.98 (1 13.77)  2.24 (0 6.28)   1.69 (0 5.92)  9.30 (1 59.53)  57 .15- 0.03 .80- 0.13 48 .48- 0.41 .45- 0.02
IL10 rs1554286           
CC 61 1.00    131 1.00  2.15 (1 4.60)  .00- 0.05
CT/TT 106 1.41 (0.64-3.14) 0.40 ‡  52 3.01 (0.87-10.40) 0.08 15.30 (2 -88.51) 0.002 .64
IL10 rs2222202           
CC 84 1.00  3.02 (1 7.73) 0.02 .18- 48 1.00  9.30 (1.45-59.53) 0.02 
CT 68 0.55 ( 1.29)  3.21 (1 8.85)  1.94 ( 7.56)  0.23- 0.17 .16- 0.03 86 0.50- 0.34 7.66 (2.31-25.42) 0.001 
TT 15 0.85 (0.07-10.00) 0.90 0.02 (0 -3.14)  .01 0.12 50 0.59 (0.17-2.07) 0.41 1.46 (0.52-4.15) 0.47 
IL10 rs1800890           
AA/AT 70 1.00    116 1.00    
TT 97 1.60 (0.73-3.48) 0.24 ‡  67 1.00 (0.41-2.43) 0.99 ‡  
LEPR rs6673324           
AA 42 1.00    51 1.00    
AG 87 2.43 ( 6.05) 7 1.64 ( 4.62)  0.97- 0.05 ‡  90 0.58- 0.35 ‡  
GG 37 1.82 (0.57-5.79) 0.31 ‡  41 1.18 (0.34-4.06) 0.79 ‡  
LEPR rs1137100            
AA 112    1.00    100 1.00    
AG 0.25 ( 0.58) 1 0.90 ( 2.05)  /GG 55 0.11- 0.00 ‡  83 0.40- 0.81 ‡  
LEPR rs1343982           
AA/AG 91 1.00    85 1.00    
GG 76 1.66 (0.77-3.58) 0.19 ‡  98 1.11 (0.49-2.53) 0.75 ‡  
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LEPR rs1137101           
AA 42 1.00    53 1.00    
AG 73 0.92 (0.35-2.42) 0.86 ‡  91 1.58 (0.58-4.30) 0.37 ‡  
GG 52 0.67 (0.24-1.86) 0.44 ‡  39 0.31 (0.09-1.10) 0.07 ‡  
LEPR rs2376018           
AA 115 1.00    124 1.00    
AG/GG 52 1.38 (0.61-3.12) 0.45 ‡  59 2.09 (0.84-5.22) 0.11 ‡  
LEPR rs1805096           
CC 52 1.00    74 1.00  2.01 (0 5.40)  .75- 0.17
CT 83 2.11 (0.87-5.13) 0.10 ‡  70 4.36 (1.21-15.73) 0.03 29.60 (4 -205.2) 0.001 .27
TT 32 0.63 (0.21-1.90) 0.42 ‡  38 2.36 (0.76-7.33) 0.14 1.01 (0 3.32)  .31- 0.98
LEPR rs1892534           
AA 33    1.20 (0 3.90)  1.00    40 1.00  .37- 0.76
AG  2.98 (1 8.33)   1.79 (0 7.16)  26.22 (3.81-180.4) 0.001 83 .07- 0.04 ‡  69 .45- 0.41
GG  1.55 (0 4.62)   0.44 (0 1.34)  1.97 (0 5.25)  51 .52- 0.43 ‡  74 .15- 0.15 .74- 0.18
TGF-Β1 rs2278422           
CC/CG 85 1.00    130 1.00    
GG 82 4.42 (1.84-10.65) 0.001 ‡  54 1.50 (0.62-3.60) 0.37 ‡  
TGF-Β1 rs2241716           
AA/AG 16 1.00  0.65 (0 1.94)  .22- 0.44 0 1.00    
GG 151 1.48 4.62) 0.50 3.34 (1 6.91) 0.001 † (0.47- .61- 183 †   
TGF-Β1 rs1800471           
CC/CG 2  3 1.00    18 1.00    
GG 144 0.57 ( 1.76)  1.61 ( 6.95)  0.18- 0.33 ‡  165 0.37- 0.52 ‡  
* Model adjusted for the g tic Is rosis score, centered weekly a ol e H
centered body ma 10 l levels and interaction between th
significant) 
 effects e genetic variant, centered Ishak fibrosis score, c ntered weekl  alc
body mass index and centered log10 ba line  levels w ported bec use t es
A2-IR sc s were not s nifi at 0.
† Minor allele frequency
§ Homozygote geno bin pe to es ate associ
ene
ss index, centered log
 variant, centered 
 baseline vir
hak fib
a
lcoh  consumption, cent
e genetic variant and ln HOMA2-IR score (where 
red ln OM e, A2-IR scor
‡ Odds ratios from t
centered log ln HOMA2-IR score, cent
he main mod l adjusting fe o thr e y ohol consumption, 
ered se viral ere re a he log likelihood t t 
for the interaction between the genetic variant and ln HOM
ion 
ore ig cant an alpha level of 05.    
 less then 5% in one populat
type com ed with heterozygote genoty tim ations
Table 4-4: Raw Data Comparing Steatosis and Insulin Resistance and the Frequency of Il10 
rs3024496 variant genotypes 
 
 can Americans Caucasian Americans Afri
 No sis Steatosis ≥ 5% No Steatosis Steatosis ≥ 5%  Steato
 
HOMA2-IR 
< 2 
 
CC:   6 
CT: 25 
TT:   9 
 
CC:   3 (33.3) 
CT: 23 (47.9) 
TT: 17 (65.4) 
 
CC:  12 
CT:  21 
TT:   8 
 
CC:  15 (55.7) 
CT:  32 (60.4) 
TT:  16 (66.7) 
 
 
 
HOMA2-IR 
≥ 2
 
  
CC:   4 (36.4) 
CT: 18 (81.8) 
TT: 22 (84.6) 
 
CC:  6 
CT:  2  
TT:  2 
 
CC:  11 (64.7) 
CT:  20 (90.1) 
TT:  11 (84.7) 
 
CC:  7 
CT:  4 
TT:  4  
 
 
 
Table 4-5:  Fr n f LEPR rs1805096 Genotypes for African Americans and Caucasian 
Americans by Steatosis and Insulin Resistance 
 
n Americans Caucasian Americans 
eque cies o
 Africa
 No  teatosis ≥ 5% No Steatosis Steatosis ≥ 5% Steatosis S
 
HOMA2-IR 
< 2 
 
C
C
T
  
CC:  18 
CT:  19 
TT:   4 
 
CC:  22 (55.0)  
CT:  24 (55.8) 
TT:  16 (80.0) 
 
C:  12 
T:  18 
T:  10 
 CC:  12 (50.0) 
CT:  27 (60.0) 
TT:   4 (28.6) 
 
 
≥ 2 
 
  
CC:  7 
CT:  0 
TT:  3 
 
CC:  15 (68.2) 
CT:  15 (100.0) 
TT:  11 (78.6) 
 
CC:  7 
CT:  4 
TT:  4 
HOMA2-IR CC:  13 (65.0) 
CT:  19 (82.6) 
TT:  12 (75.0) 
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Table 4-6:  Adjusted Odds Ratios for Insulin Resistance in African Americans and Caucasian 
Americans 
 
 A s* frican Americans* 
N = 142 
Caucasian American
N = 156 
 
Single Nucleotide 
Polymor
 
 
N 
Odds Confidenc
In
p-  
N 
Odds 
io 
Confidence 
 
p-
value 
 95%    95% 
e 
phism Ratio terval value Rat Interval 
IL6 rs1880242          
GG/GT 45  119 0   1.00  1.0  
TT 97 1.06 0.47-2.39 0.89 36 0.29 0.10-0.80 0.02  
IL6 rs205      6576    
CC 47 58 0  1.00    1.0  
CT 65 0.2 80 2 0.62 0.48 0-1.14 0.10  21. 0.57-2.61 
TT 30 0.1 17 5 0.21 0.51 7-1.47 0.21 0.3 0.07-1.81 
IL6 rs2069827         
GG 134 1.00   130 1.00   
GT/TT 6 5.19 0.65-41.52 0.12 25 0.62 0.20-1.91 0.41 
I      L6 rs1800797    
AA/AG 19 1.00   99 1.00   
GG 122 0 0.30 57  0.20 .55 0.18-1.69 0.60 0.28-1.32
IL6 rs1800795         
CC/CG 20 1.00   99 1.00   
GG 121 0. 57 8 0.19 0.62 29-1.36 0.23  0.4 0.16-1.44 
IL6 rs2069830          
CC 113  155 0   1.00  1.0  
CT/TT 27 0.23-1  0  0.61 .65 0.33 †  
IL6 rs206      9837    
AA/AG 112  135 0   1.00  1.0  
GG 29 0. 21 4 0.03 2.07 81-5.28 0.13  0.2 0.06-0.88 
IL6 rs1554606         
GG 66 1.00   52 1.00   
GT/TT 75 1.45 0.69-3.15 0.35 104 1.71 0.76-3.85 0.20 
IL6 rs2069845         
AA 63 1.00   52 1.00   
AG/GG 79 1.59 0.73-3.48 0.24 103 1.70 0.75-3.85 0.20 
IL10 rs11119474         
AA/AG 2 1.00   23 1.00   
GG 140 †   132 1.00 0.33-2.94 0.98 
IL10 rs3024505         
CC 126 1.00   113 1.00   
CT/TT 16 0.86 0.25-2.97 0.81 41 1.16 0.49-2.73 0.73 
IL10 rs3024498         
AA 112 1.00   79 1.00   
AG/GG 30 1.71 0.68-4.33 0.26 76 1.77 0.85-3.70 0.13 
IL10 rs3024496         
CC 20 1.00   44 1.00   
CT 70 0.26 0.08-0.82 0.03 75 0.52 0.22-1.23 0.14 
TT 52 0.41 0.12-1.41 0.16 37 0.47 0.17-1.33 0.16 
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Table 4-6 (Continued)       
I 6         L10 rs155428
CC 49  109  1.00  1.00  
CT/TT 93 0.19 46 0.09 0.59 -1.31 0.26 0.48 -1.11 0.20
IL10 rs2222202         
CC 74 37 1.00   1.00   
CT 57 0.69 0.30-1.57 0.38 75 1.10 0.43-2.84 0.85 
TT 1  1  1 5.07 .10- 3.452 0.04 44 2.11 0.75- .94 5 0.16 
IL10 rs1800890         
AA/AT 55 1.00   1  02 1.00   
TT 8  7 0.39 0.18-0.88 0.02 53 0.65 0.29-1.43 0.28 
LEPR rs6673324         
AA 33 1.00   41 1.00   
AG 81 0.97 0.39-2.37 0.94 76 0.33 0.14-0.79 0.01 
GG 2  8 0.66 0.20-2.12 0.48 37 0.75 0.28-2.00 0.56 
LEPR rs1137100          
AA 9  3 1.00   88 1.00   
AG/GG 4  9 1.77 0.78-4.03 0.17 67 1.44 0.69-2.98 0.33 
LEPR rs1343982          
AA/AG 79 1.00   69 1.00   
GG 6  3 0.95 0.44-2.05 0.90 86 0.75 0.36-1.55 0.44 
LEPR rs1137101         
AA 36 1.00   49 1.00   
AG 6  2 1.60 0.60-4.22 0.35 73 0.86 0.36-2.06 0.74 
GG 44 1.77 0.63-4.95 .  0.80-6.32 0.12 0 28 33 2.25 
LEPR rs2376018          
AA 9  8 1.00   104 1.00   
AG/GG 44 1.16 0.52-2.61 .  0.25-1.30 0.18 0 72 51 0.57 
LEPR rs1805096         
CC 4  4 1.00   62 1.00   
CT 68 0.65 0.27-1.60 .  0.23-1.28 0.16 0 35 58 0.54 
TT 30 1.88 0.65-5.44 0.24 34 1.05 0.41-2.74 0.91 
LEPR rs1892534         
AA 31 1.00   36 1.00   
AG 68 0.38 0.14-1.02 0.06 57 0.57 0.22-1.50 0.25 
GG 4  3 0.62 0.22-1.78 0.38 62 1.00 0.39-2.57 0.99 
TGF-Β1 rs2278422         
CC/CG 76 1.00   111 1.00   
GG 6  6 0.38 0.17-0.89 0.03 45 0.35 0.14-0.87 0.02 
TGF-Β1 rs2241716          
AA/AG 16 1.00   0 1.00   
GG 126 1.32 0.41-4.29 0.64 155 †   
TGF-Β1 rs1800471         
CC/CG 16 1.00   16 1.00   
GG 126 1.68 0.56-5.00 0.35 139 0.77 0.25-2.39 0.65 
* Model adjusted for the genetic variant, centered Ishak fibrosis score, centered body mass in
centered age and centered triglyceride levels 
† Model could not be estimated because mino qu  5% r the 
‡ Homozygote geno  c ined  het no o e ate as ion 
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Figure 4-2A:  Comparison of Log Odds of Steatosis vs. Natural Log Transformed HOMA2-IR 
Scores for LEPR rs1805096 in African Americans 
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Figure 4-2B:  Comparison of Log Odds of Steatosis vs. Natural Log Transformed HOMA2-IR 
Scores for LEPR rs1805096 in Caucasian Americans 
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5.1 ABSTRACT  
Steatosis is fat deposition in liver cells and is prevalent in 30-84% of chronic hepatitis C virus 
(HCV) patients. Insulin resis (IR
 
b
ong 
163 African Americans (AA) and 179 Caucasian Americans (CA) infected with HCV genotype-
1.  Steatosis was defined as having at least 5% of fat in cells on liver biopsy.  The Homeostasis 
Model Assessment (HOMA) Version 2.2 was used to quantify IR and IR was categorized as 
being present with a value of at least 2.  Associations between ADIPOR1 and HMGCS2 
polymorphisms and steatosis or IR were investigated separately by race using logistic regression 
models. 
Statistically significant associations (p<0.05) were observed between ADIPOR1 
rs6666089 and rs1539355 and steatosis in Caucasian Americans.  HMGCS2 rs12123085 was 
significantly associated with steatosis and IR.  Statistically significant interactions between 
ADIPOR1 rs6666089-AG and rs1539355-AG genotypes and higher HOMA2-IR scores were 
observed in Caucasian Americans when examining steatosis and indicated higher odds of 
steatosis compared to what would be expected from the main effects of the genotypes and the 
HOMA2-IR scores. 
ADIPOR1 and HMGCS2 may be important to understanding the occurrence of steatosis 
and IR in African Americans and Caucasian Americans with HCV genotype-1 infection.  Results 
indicate that some ADIPOR1 polymorphisms may modify an association between IR and 
steatosis.  The function of these genetic variants is still being studied and identifying the function 
tance ) occurs when normal amounts of insulin do not produce a 
typical response from cells.  Both are common in HCV infection and are thought to be
iologically related.   
This study examined associations between host genetic variants, steatosis and IR am
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may contribute to understanding th ech tosis and IR in HCV genotype-1 
infection.    
Steatos
teatosis are thought to be multifactorial and the presence of insulin resistance may be 
associa
ST) levels, higher fibrosis scores and the presence of insulin 
resistan
e m anisms of stea
5.2 INTRODUCTION 
is is characterized by the accumulation of fat in the liver and diagnosis is made by 
calculating the percentage of fat in liver cells by examining liver biopsy.(Teli, 1995)  Steatosis is 
prevalent in as few as 30%, or as many as 84%, of patients with chronic hepatitis C virus (HCV) 
infection.(Adinolfi, 2001; Asselah, 2006; Castera, 2003; Conjeevaram, 2006; Conjeevaram, 
2007; Czaja, 1998; Hourigan, 1999; Hui, 2002; Monto, 2002; Patton, 2004; Poynard, 2003; 
Rubbia-Brandt, 2004; Rubbia-Brandt, 2001; Serfaty, 2001; Westin, 2002)  The mechanisms of 
hepatic s
ted with the development of steatosis.(Adinolfi, 2001; Castera, 2003; Hourigan, 1999; 
Rubbia-Brandt, 2000; Serfaty, 2001; Serfaty, 2002)   
Factors previously identified to be associated with steatosis in HCV genotype-1 patients 
include alcohol consumption, higher body mass index (BMI), older age, male gender, Caucasian 
American race, presence of hepatic inflammation, hyperlipidaemia, increased triglyceride levels, 
higher cholesterol levels, increased alanine aminotransferase (ALT) levels, increased aspartate 
aminotransferase (A
ce.(Asselah, 2006; Browning, 2004; Conjeevaram, 2007; Fabris, 2004; Leandro, 2006; 
Matos, 2006; Ruhl, 2004; Solis-Herruzo, 2005; Younossi, 2004)   African Americans have a 
lower prevalence of steatosis than Caucasian Americans despite having a generally higher BMI, 
which is also associated with steatosis.(Browning, 2004; Ruhl, 2004)  The presence of steatosis 
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may influence other HCV conditions or outcomes of treatment.  Steatosis was previously 
identified as being associated with progression of fibrosis in HCV patients.(Adinolfi, 2001; 
Castera, 2003; Hourigan, 1999; Serfaty, 2002; Westin, 2002)  The presence of steatosis may also 
negatively impact sustained virologic response (SVR).(Fabris, 2005; Guidi, 2005; Jian Wu, 
2006; Patton, 2004; Soresi, 2006; tin pe-1 patients achieved SVR less 
frequently (29-46%) if steatosis was present compared to those without steatosis (62-65%).(Jian 
Wu, 2006; Soresi, 2006; Westin, 2007) 
Insulin resistance (IR) is a condition in which normal amounts of insulin are insufficient 
to stimulate cells to use blood glucose for energy and metabolism, specifically fat, muscle and 
liver cells.(Rao, 2001; Romero-Gomez, 2006)  The Homeostasis Model Assessment of Insulin 
Resistance Index (HOMA-IR) can be used to quantify IR.(Matthews, 1985)  IR has been shown 
to occur early in the HCV infection.(Petit, 2001)  Additionally, patients with chronic HCV 
infection were observed in one study to have higher HOMA-IR scores compared to healthy 
controls.(Hui, 2003)  Studies have also shown that IR was predictive of fibrosis progression 
(D'souza, 2005; Fartoux, 2005; Hui, 2003; Lonardo, 2004; Muzzi, 2005; Sud, 2004) and hepatic 
inflammation in patients with chronic HCV.(Chitturi, 2002)  Presence of IR may reduce the 
function of interferon therapy and the ability to achieve SVR in HCV patients especially those 
through treatment has been shown to improve insulin sensitivity.(Kawaguchi, 2007)  Risk factors 
associated with IR include African American race, obesity, older age, fibrosis and 
cirrhosis.(Heathcote, 2002; Petit, 2001; Romero-Gomez, 2005)    
The roles of ADIPOR1 and HMGCS2 polymorphisms have not been examined with 
 Wes , 2007)  HCV genoty
infected with genotype-1.(Romero-Gomez, 2006; Romero-Gomez, 2005)  Clearance of HCV 
regard to steatosis or IR in HCV infection.  Most studies have examined Adiponectin Receptor 1 
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(ADIPOR1) and 3-hydroxy-3-methylglutaryl-CoA Synthase 2 (HMGCS2) expression or 
polymorphism associations with steatosis or IR in healthy, diabetic or obese patients (Crimmins, 
2007; Sanyal, 2001; Siitonen, 2006; Stefan, 2005; Stefan, 2002; Younossi, 2005; Younossi, 
2004) and only one study included African Americans.(Crimmins, 2007)   ADIPOR1 encodes 
adiponectin and low levels were associated with higher HOMA-IR scores in two 
studies.(Chandran, 2003; Weyer, 2001)  Jonsson et al. found that adiponectin levels varied by 
HCV genotype and low adiponectin levels were associated with steatosis.(Jonsson, 2005)  These 
results 
ssion compared to those with 
steatosi
indicate that ADIPOR1 may influence the occurrence of steatosis or IR.  Other studies 
have also examined ADIPOR1 polymorphism associations with IR or steatosis.(Siitonen, 2006; 
Stefan, 2005)  In a sample of people of European decent, the ADIPOR1 rs6666089-A allele was 
associated with higher HOMA-IR scores and a greater percent of fatty liver.(Stefan, 2005)  
Crimmins, et al. observed a statistically significant association between the ADIPOR1 
rs1342387-A allele and lower HOMA-IR scores in a non-lean subset of African American 
children.(Crimmins, 2007)  These results indicate that ADIPOR1 polymorphisms may be 
important in understanding the mechanisms of steatosis or IR, but no studies have examined 
these associations in HCV infection. 
3-hydroxy-3-methylglutaryl-CoA Synthase 2 (HMGCS2) is a rate-limiting enzyme of the 
HMG-CoA pathway of fatty acid metabolism or ketogenesis.  Younossi, et al. concluded that 
insulin may influence the expression of HMGCS2 suggesting that insulin resistance may 
participate in the regulation of ketogenesis pathway.(Younossi, 2005)  Other studies indicated 
that people with steatosis and IR have higher HMGCS2 expre
s and without IR.(Sanyal, 2001; Younossi, 2005; Younossi, 2004)  Few studies have 
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examined the role of HMGCS2 in the occurrence of steatosis or IR and no studies tested the 
association between HMGCS2 polymorphisms and these conditions. 
HCV infection may contribute to occurrence or severity of steatosis or IR and genetic 
associations may contribute to understanding the occurrence these conditions.  This study aims to 
test associations of ADIPOR1 and HMGCS2 polymorphisms with steatosis and with insulin 
resistance in a sample of African Americans and Caucasian Americans infected with HCV 
genotype-1.   
5.3 MATERIALS AND METHODS 
 5.3.1 Study Population and Clinical Data 
Data were from the Study of Viral Resistance of Antiviral Therapy of Chronic Hepatitis C 
(Virahep-C).  The Virahep-C study design and primary outcomes have been described 
elsewhere.(Conjeevaram, 2006)  Briefly, there were 401 people enrolled with chronic untreated 
HCV genotype-1 infection.  Of those, 374 (194 CA and 180 AA) provided consent for a genetics 
ancillary study and 365 had DNA available for genotyping.  Twelve self-identified Hispanics and 
11 individuals taking exogenous insulin were excluded from the analysis.  Therefore, 342 
individuals were included in the analyses.     
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5.3.2 Measurement of Steatosis and Insulin Resistance 
Patient
ified histologic activity index (HAI) scoring system.(Ishak, 1995)  Steatosis was 
also scored on a scale of 0 to 4 according to the percentage of cells with fat where: 0 = none, 0.5 
= <5%, 1 = 5-<25%, 2 = 25-<50%, 3 = 50-<75%, 4 = ≥75%.(Conjeevaram, 2007)  For this 
study, IR was quantified b ng  2.2 released in 2004 and 
downloaded from http://www.dtu.ox.ac.uk/.(Levy, 1998; Wallace, 2004)  The HOMA2-IR 
entage of a normal reference population and is 
calibrated to current insulin assays.(Levy, 1998; Wallace, 2004)   
; Younossi, 2005; Younossi, 2004)  SNPs were 
selected using the International HapMap Project Phase II (www.hapmap.org).  SNP selection for 
the Virahep-C Caucasian American sample was based on data from a sample of Utah residents 
with ancestry from northern and western Europe, Centre d'Etude du Polymorphisme Humain 
(CEPH).  To select tag SNPs for the African American sample, a pooled sample was created by 
s without cirrhosis were scheduled to have a liver biopsy within 18 months of study 
enrollment.(Conjeevaram, 2007; Yee, 2007)  Liver biopsies were scored by a single pathologist, 
who was unaware of patient outcome and clinical status.(Conjeevaram, 2007; Yee, 2007)   
Biopsies were assessed for the severity of HCV by grading inflammation and staging fibrosis 
using the mod
y usi  the HOMA-IR Calculator Version
model estimates insulin sensitivity as a perc
5.3.3 Single Nucleotide Polymorphism (SNP) Selection and Genotyping 
ADIPOR1 and HMGCS2 were selected as candidate genes for steatosis and IR based on literature 
describing expression or genetic variant associations with steatosis and insulin resistance in 
mainly obese, diabetic or healthy populations.(Crimmins, 2007; Jonsson, 2005; Sanyal, 2001; 
Siitonen, 2006; Stefan, 2005; Stefan, 2002
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combi ing data from the CEPH population and a sample ofn  Yoruba Africans in Ibadan, Nigeria 
(YRI) to simulate an African American population.  Tag SNPs were selected using HClust 
the common variation in each 
gene.  
e Graduate School 
of Public Health, University of Pittsburgh.  To complete the SNP genotyping, TaqMan® 
methodology (Applied Biosystems, Foster City, CA) was used with the 7900HT Real-time PCR 
were used.  Of the 365 samples, 96-99% had genotypes assigned to the SNPs.  Quality control 
measures were conducted to ensure that the lab techniques used for genotyping resulted in 
correct data.  Replication genotyping of a select number of samples was completed for each SNP 
and the successful replication rate varied from 98-100%.  Negative controls consisting of 
(http://www.wpic.pitt.edu/WPICCompGen/hclust.htm), a pairwise tagging program, with an r2 
value that would account for 80% of the common variation in the gene in both race 
groups.(Rinaldo, 2005; Roeder, 2005)  The region of the gene that was tagged included the 
transcript plus 2 kilobases (kb) upstream and 2kb downstream.  Polymorphisms were selected if 
the minor allele frequency was greater than 10% in both the CEPH and pooled population.  An 
optimization technique to select a SNP for genotyping was utilized if two suggested SNPs were 
perfectly correlated in the CEPH population.  The correlated SNPs were compared to the 
selected tag SNPs for the pooled African Americans.  If one of the correlated SNPs was selected 
to be tagged in the pooled African American sample that SNP was used in the Caucasian 
American tag selection.  Using this linkage disequilibrium tag SNP selection method, 12 SNPs 
per gene were identified in an effort to represent at least 80% of 
SNPs were genotyped by the Molecular Epidemiology Core Lab at th
Instrument.  Genotype calls were made by two independent callers and only concordant calls 
TaqMan reaction and no DNA material were also genotyped. 
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5.3.4 Variable Categorization 
Steatosis was categorized into a dichotomous variable with the presence of steatosis (fat score 
greater than 0) versus no steatosis (fat score equal to 0), HOMA2-IR scores were categorized 
into the presence of IR (HOMA2-IR at least 2) versus no IR (HOMA2-IR less than 2) for 
analyses.  In general, a HOMA-IR score of at least 1.5 is thought to indicate decreased insulin 
sensitivity.(Conjeevaram, 2007)  For this study, IR was defined as HOMA2-IR score of at least 
2.0 based on a previous study of the Virahep-C cohort.(Conjeevaram, 2007)  For each SNP, 
indicator variables were created for the genotypes to test for genotype associations with steatosis 
or IR.  An a priori decision was made that if the less common homozygote genotype had a minor 
allele frequency of less than 5% it was combined with the heterozygote genotype.  Haplotypes 
were categorized as either having at least one copy of the haplotype or no copies.    
5.3.5 Risk Factor Variables and Model Building 
ALT levels, AST levels, cholesterol levels and triglyceride levels were continuous factors 
centered at their mean values and examined as risk factors for steatosis and IR.  Diabetes status 
and HCV subtype were categorical risk factors examined in this study.  Self-reported race was 
used since previous reports from the Virahep-C study found that the individual admixture 
strongly agreed with self-reported race.(Yee, 2007)  Steatosis was assessed as a risk factor for IR 
and continuous HOMA2-IR scores were assessed as a risk factor for steatosis.  HOMA2-IR 
scores were transformed using the natural log and centered at the mean. 
Ishak fibrosis score, weekly alcohol consumption, age, BMI, baseline viral level, HAI score, 
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5.3.6 Genetic Analytical Methods 
otypes had a 
probability less than 0.7, no haplotypes were assigned to the study patient.  Common haplotypes 
n Americans or African Americans were 
investigated for an association with steatosis or IR.  SAS® Genetics Version 9.1.3 was used to 
Genotype and allele frequencies as well as Hardy Weinberg Equilibrium (HWE) chi square tests 
were calculated by race for each SNP.  The genotype call rate, defined as the percentage of 
individuals where a genotype could be determined compared to the total number of individuals 
where genotyping was attempted, was calculated for each race group.  Minor allele frequencies 
(MAF) were examined by race and SNPs with a MAF less than 5% were not analyzed.  
Haplotypes were estimated using the EM algorithm for ADIPOR1 and HMGCS2 separately by 
race.(Excoffier, 1995)  Twenty-three of the 24 SNPs were used to estimate haplotypes.  
RS667246 did not conform to the expectations of HWE and was excluded from haplotype 
estimation.(Kirk, 2002; Yang, 2003)  Estimated haplotypes with a probability of at least 0.7 of 
being the true haplotype were retained and used in analyses.  If estimated hapl
with a frequency of at least 5% in either Caucasia
conduct analyses (SAS Institute Inc., Cary, NC, 2002-2003).  The Tagger Program in the 
Haploview Software Suite version 4.0 was used to calculate the amount of common variation 
accounted for in the gene (r2) by the tagged SNPs separately by race.(Barrett, 2005)  This 
analysis was done to evaluate how well the SNP selection methods captured the common genetic 
variation in the genes. 
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5.3.7 Statistical Analyses 
Demographic characteristics and risk factors for steatosis and IR were assessed by race using 
appropriate association tests.  Genotype association chi square tests and haplotype trait chi 
square tests were completed to test for an association with steatosis or IR (Appendix C).(Nielsen, 
1999; Zhao, 2000)   
Odds ratios were used to quantify the association between steatosis or IR and the genetic 
variants.  Adjusted models were built using backwards elimination that included possible 
confounding variables and removing those that did not significantly contribute to the prediction 
of the outcome.  The elimination method first removed variables with p-values greater than 0.25.  
The second elimination removed variables with p-values greater than 0.15 and the final 
elimination removed those with a p-value greater than 0.05. To avoid problems with 
multicollinearity with significantly correlated variables, only one of the related variables was 
used in the model building and was chosen because there was more support in the literature for 
an association.  For example, steatosis was significantly correlated with ALT levels and steatosis 
was used because the literature commonly describes associations between steatosis and IR.  
Steatosis was retained in the model predicting IR because steatosis and IR are thought to be 
biologically related and it is unclear if steatosis contributes to the occurrence of IR or vice versa.  
All possible interaction terms between the main effects variables remaining in the model after the 
three elimination steps were tested to determine their contribution to the prediction of the 
outcome.  A significant log likelihood ratio test (p<0.05) was used to determine if an interaction 
term significantly contributed to the prediction of the outcome.   
In the prediction of steatosis, an interaction between the natural log transformed 
HOMA2-IR scores and each genetic variant was tested separately by race.  In the prediction of 
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IR, an interaction between steatosis and each genetic variant was tested separately.  The log 
likelihood ratio test was used to determine the significance of these interactions.  For log 
ce of the analytic tests.  The SAS/STAT® software 
system
Comparisons of demographic characteristics by race are shown in Table 5-1.  African American 
and Caucasian American patients did not differ significantly by gender, age, baseline viral levels, 
hepatic inflammation score, Ishak fibrosis score, steatosis, insulin resistance, cholesterol levels, 
BMI, ALT levels and AST levels compared to Caucasian Americans.  HOMA2-IR scores were 
missing for 52 (25 African Americans; 27 Caucasian Americans) study participants because their 
insulin or glucose levels were not fasting or not available.  
likelihood ratio tests with p-values greater than 0.05, the interaction was not included in the 
model.  Odds ratio (OR) estimates and 95% Confidence Intervals (CI) were estimated for each 
genetic variant in both unadjusted (Appendix C) and adjusted models.  An alpha level of 0.05 
was used to determine statistical significan
 version 9.1.3 was used for all analyses (SAS Institute Inc., Cary, NC, 2002-2003). 
5.4 RESULTS 
5.4.1 Population Characteristics 
triglyceride levels, or weekly alcohol consumption.  African Americans had significantly higher 
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5.4.2 SNP Genotyping and Estimation of Haplotypes 
The genotype call rate ranged from 95-99% in African Americans and 97-100% in Caucasian 
Americans.  Table 5-2 presents SNP genotype frequencies, call rate and the p-value from the 
HWE tests.  Overall, the SNPs selected for ADIPOR1 and HMGCS2 accounted for 71% (82% 
and 64%) of the variation in African Americans and 96% (100% and 93%) of the variation in 
Caucasian Americans.  Haplotypes were estimated with a 0.7 probability of being true haplotype 
in 154 of 163 African Americans and 172 of 179 Caucasian Americans for ADIPOR1 and 154 of 
163 African Americans and 178 of 179 Caucasian Americans for HMGCS2.  Common 
haplotypes are presented in Appendix C
02-0.90) had statistically significant 
lower odds of steatosis compared to those with the AA genotype.  Statistically significant 
interactions were also observed between these SNPs and HOMA2-IR scores in the prediction of 
steatosis.  The odds of steatosis for a one unit higher HOMA2-IR score for Caucasian Americans 
with the ADIPOR1 rs1539355-AG genotype (OR=16.4: 95% CI=2.4-110.8) were significantly 
. 
5.4.3 Associations with Steatosis 
The final model for steatosis was adjusted for Ishak fibrosis score, weekly alcohol consumption, 
baseline viral level, natural log transformed HOMA2-IR scores, and BMI.  The interaction term 
between the HOMA2-IR scores and the genetic variant was statistically significant for ADIPOR1 
rs1539355 and rs6666089.  Results from these models are reported in Table 5-3.  
Statistically significant associations were observed between two ADIPOR1 SNPs and 
steatosis.  Caucasian Americans with the GG genotypes for ADIPOR1 rs1539355 (OR=0.13:  
95% CI=0.02-0.75) or rs6666089 (OR=0.13: 95% CI=0.
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higher than the odds for a one unit higher HOMA2-IR score for those with the AA genotype 
(OR=1.6: 95% CI=0.6-4.1).  Table 5-4 shows the ADIPOR1 rs1539355 genotype frequencies for 
otypes.  The different slopes for the three genotypes 
indicate the interaction.  A statistically significant interaction between ADIPOR1 rs6666089 and 
ed in Caucasian Americans.  For a one unit increase in 
HOMA2-IR scores, Caucasian Americans with the AG genotype had 41.6 (95% CI=2.8-611.8) 
times the odds of steatosis compared to those with the AA genotype (OR=1.92: 95% CI=0.71-
5.21).   
ADIPOR1 polymorphisms were not significantly associated with steatosis in African 
Americans and the interaction between the HOMA2-IR scores and ADIPOR1 rs1539355 did not 
contribute to the prediction of steatosis (p=0.31). 
interaction.  The percentage of individuals with IR and with steatosis were similar for the 
ADIPOR1 rs1539355 genotypes (AA: 71%, AG: 82%, GG: 79%) and also similar for those with 
steatosis and without IR (AA: 52%, AG: 51%, GG: 50%).  Figure 5-1B is a graphic depiction of 
the log odds of steatosis by the natural log transformed HOMA2-IR scores for ADIPOR1 
those with and without steatosis and with and without IR and may be useful for understanding 
the observed interaction.  The percentage of Caucasian Americans with the rs1539355-AG 
genotype with IR and with steatosis (90%) was higher than the percentage without IR and with 
steatosis (60%).  Figure 5-1A graphically shows the interaction between the genotypes of 
ADIPOR1 rs1539355 and HOMA2-IR scores in the prediction of steatosis for Caucasian 
Americans.  The graph shows the steepest increasing slope for the log odds of steatosis was 
among those with the AG genotype and the different slower increasing slopes for log odds of 
steatosis were observed for the other gen
HOMA2-IR scores was also observ
 Table 5-4 helps to explain the non-significant 
rs1539355 genotypes.  The log odds of steatosis for the genotypes were similar showing that as 
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the HOMA2-IR score increased the log odds of steatosis also increased consistently for each 
genotype.  ADIPOR1 haplotypes were analyzed, but did not provide additional information about 
the ADIPOR1 association with steatosis that was not observed in single SNP associations.   
A statistically significant association was observed between one HMGCS2 polymorphism 
and steatosis, but only in African Americans.  African Americans possessing either the HMGCS2 
rs12123085 AG or GG genotype had 3.1 (95% CI=1.1-8.6) times the odds of steatosis compared 
to those with the AA genotype.  HMGCS2 haplotypes were analyzed, but the haplotypes did not 
provide further information about the possible association between steatosis and HMGCS2 that 
was not observed with single SNP associations.     
5.4.4 Associations with Insulin Resistance 
The final model for the prediction of IR was adjusted for age, body mass index, steatosis, Ishak 
fibrosis score and triglyceride levels.  Adjusted odds ratios are shown in Table 5-5.   No 
significant associations were observed between ADIPOR1 polymorphisms and IR for African 
Americans or Caucasian Americans.  In Caucasian Americans, one HMGCS2 polymorphism was 
significantly associated with IR.  Caucasian Americans possessing either the HMGCS2 
rs12123085 AG or GG genotype had significantly lower odds of IR (OR=0.3: 95% CI=0.1-0.9) 
compared to those with the AA genotype.  No statistically significant associations between 
HMGCS2 polymorphisms and IR were observed in African Americans.  No statistically 
significant interactions were observed between the genetic variant and steatosis in the prediction 
of IR. 
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5.5 DISCUSSION 
This study investigated associations between genetic markers in ADIPOR1 and HMGCS2 with 
steatosi
n of steatosis.  These results imply that the 
association between steatosis and IR may be moderated by some ADIPOR1 polymorphisms.  
OR1 rs1539355-AG or rs6666089-AG genotype 
and higher HOMA2-IR scores had significantly higher odds of steatosis compared to what would 
The HMGCS2 rs12123085 AG or GG genotypes were significantly associated with lower 
odds of IR compared to those with the AA genotype in Caucasian Americans.  No statistically 
significant association was observed between this genetic variant and IR in African Americans, 
s and with insulin resistance among African American and Caucasian American patients 
infected with HCV genotype-1.  Statistically significant associations for ADIPOR1 rs1539355, 
rs6666089 and HMGCS2 rs12123085 with steatosis were observed.  HMGCS2 rs12123085 was 
also significantly associated with IR.    
Statistically significant interactions between ADIPOR1 polymorphisms and natural log 
HOMA2-IR scores were observed in the predictio
More specifically, people with either the ADIP
be expected from the main effects of the genotype and HOMA2-IR scores alone.  Understanding 
the function of associated polymorphisms may indicate how the polymorphism influences 
steatosis or IR.  ADIPOR1 rs1539355 is located in the intron region and is predicted to be an 
intronic enhancer which could change the way that the protein encoded by this genetic variant is 
produced.(Yuan, 2006)  ADIPOR1 rs6666089 is located in the 5’ upstream region of the gene 
and is predicted to be a promoter which could regulate gene expression.(Yuan, 2006)  These two 
polymorphisms may influence expression of the gene or the production of the protein and these 
two activities could be related to the mechanisms for steatosis and IR in HCV genotype-1 
infection.       
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but the direction of the odds ratio w rs12123085 is located in the intron 
region and was predicted to be an intronic enhancer.(Yuan, 2006)  As an intronic enhancer, this 
 the DIPOR1 rs6666089-A allele IR.(Stefan, 2005)  In 
the pre
 measure of IR compared to the previous study which used HOMA-IR.(Wallace, 
2004)  
as the same.  HMGCS2 
genetic variant may contribute to the occurrence of IR by changing how the protein encoded for 
this genetic variant is produced (Yuan, 2006).     
A few previous studies described associations between the same ADIPOR1 
polymorphisms in the current study and IR.(Crimmins, 2007; Stefan, 2005)  Specifically, one 
study described an association between A
sent study, no statistically significant association between ADIPOR1 rs6666089 and IR 
was observed.  The contradictory findings may be due to differences in sample size, study 
population studied or measurement of IR.  The current study included a smaller sample size of 
Caucasian Americans (n=152) compared to the Stefan et al. study which included approximately 
500 Caucasian individuals of European descent.(Stefan, 2005)  With regards to study population, 
participants in the previous study were healthy (Stefan, 2005) compared to the present study 
which included HCV infected patients.  IR is a common condition in HCV infection and it is 
possible that the virus may contribute to the occurrence of this condition.  Therefore, this study 
described associations in HCV infection adding to the understanding of IR in HCV infection, 
specifically genotype-1.  Exclusion criteria also varied between the studies such that the Stefan et 
al. study excluded individuals with diabetes or those individuals taking medications that impair 
glucose levels. (Stefan, 2005)  In comparison, the current study only excluded patients taking 
exogenous insulin.  Further, the current study utilized HOMA2-IR to quantify IR which is a 
more accurate
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Another study examined the association between ADIPOR1 polymorphisms and IR in a 
non-lean group of African American children and found a statistically significant association 
between rs1342387-A allele and lower risk of IR.(Crimmins, 2007)  No statistically significant 
association was observed between this ADIPOR1 polymorphism and IR in the current study.  
The co
n may be that the associated SNPs were not directly affecting steatosis or IR, but 
rather were in linkage disequilibrium or correlated with functional genetic variants. If this were 
ntradictory findings may be attributed to differences in sample size, populations examined 
and phenotype measures.  Crimmins et al. examined a sample of African American children aged 
10-19 with no chronic illnesses (n=483) (Crimmins, 2007) whereas the current study included 
only adults infected with HCV (n=142).  Since IR commonly occurs in HCV infected patients, it 
is possible that virus infection may contribute to the occurrence of this condition.  Additionally, 
the inconsistent results could be related to different quantification methods of IR.  The previous 
study also used continuous HOMA-IR scores in the analyses (Crimmins, 2007) and the current 
study used the HOMA2-IR score as a categorical outcome.  The use of HOMA2-IR provides a 
more accurate measure of insulin sensitivity because it is consistent with current insulin assays 
compared to HOMA-IR which is calibrated to older insulin assays.(Wallace, 2004) 
This study stratified all data by race for the purpose of detecting gene associations with 
steatosis and IR.  The decision to complete the analyses separately by race was based on an a 
priori genetic expectation of different effects of SNPs in different race groups.  Even if the same 
gene is affecting the outcome in Caucasian Americans and African Americans, there is an 
expectation that different SNPs within a gene for each race will show an association because of 
different population histories.  Some associations identified in this study were only statistically 
significant in one race group or the direction of the association was different by race.  One 
explanatio
151 
the cas
e first to look 
specific
e, the different patterns of results may be explained by different linkage disequilibrium 
patterns in the populations and the different population histories of African Americans and 
Caucasian Americans.  For example, an associated SNP could be ‘tagging’ a causal genetic 
variant in one population that is not even present in the other population.  Alternatively, if the 
functional genetic variants are newer or more recent in the population history and the associated 
genetic variants are old, the associations may differ in race groups because of differences in 
migration out of Africa. 
One limitation of this study was that the Virahep-C study had a relatively small sample 
size to test genetic associations with steatosis and IR.  However, even with the small sample size 
this study was able to detect statistically significant associations between genetic variants and 
steatosis or IR.  Another limitation of this study was the inability to confirm the study findings 
with a validation sample.  A similar sample of HCV infected patients was not available to repeat 
and confirm the observed associations.  These findings should also be validated since no 
adjustment for multiple comparisons was made.   Although this study was one of th
ally at African Americans, it was only able to account for 64% of the common variation 
in HMGCS2.  This study did not have adequate funding to select and genotype enough SNPs to 
capture more of the common variation in this gene for African Americans, who are more 
genetically diverse than Caucasian Americans.(Costas, 2005)  Despite these limitations, the 
results contribute to the literature by identifying ADIPOR1 and HMGCS2 polymorphism 
associations with steatosis and insulin resistance in HCV genotype-1 infection which has not 
been previously reported.   
The findings in this study indicate directions for future research.  Since no similar sample 
was available to validate these results and there was no adjustment for multiple comparisons, 
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replication of this study is necessary to support the findings.  Further, since this study accounted 
for only 64% of the HMGCS2 common variation in African Americans additional SNPs in this 
gene should be selected for a more in depth examination of associations with these conditions in 
that race group.  Additional research could also try to understand the function of the associated 
SNPs and how they contribute to the occurrence of steatosis and insulin resistance in African- 
and Caucasian-Americans with HCV genotype-1 infection.  Studies could also examine 
associations between these genetic variants and steatosis and IR in other samples of HCV 
patients or other risk populations which were unavailable at the time of this study to determine if 
the genetic associations are specific these conditions in HCV infection or if the genetic variants 
are associated with the conditions regardless of infectious status.  Although, it may be difficult to 
examine steatosis in other populations because liver biopsy is an invasive procedure and would 
be unethical in healthy populations, ultrasound technology is currently being validated and could 
be used in future research.   
In conclusion, ADIPOR1 and HMGCS2 SNP associations were observed with steatosis or 
IR and may be important in understanding the mechanisms of steatosis and IR.  Based on the 
results, some ADIPOR1 SNPs may modify an association between steatosis and IR and may 
contribute to understanding the biological pathway of these outcomes.  
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Table 5-1:  Demographic Characteristics of the Virahep-C Sample 
eristics 
 
Charact African American Caucasian American  
N = 163 N = 179 p-value 
    
 N (%) N (%)  
Gender    
Male 103 (63.2) 115 (64.2)  
Female 60 (36.8) 60 (36.8) 0.84† 
Portal Inflammation Score (HAI)    
Mild 27 (16.6) 30 (16.8)  
Moderate 104 (63.8) 98 (54.8)  
Severe 32 (19.6) 51 (28.5) 0.14† 
Steatosis    
No Steatosis 63 (38.7) 60 (33.5)  
Steatosis Present 100 (61.4) 119 (66.5) 0.32† 
Insulin Resistance    
HOMA2-IR < 2 82 (59.4) 102 (67.1)  
HOMA2-IR ≥ 2 56 (40.6) 50 (32.9) 0.18† 
    
 Mean (SD) Mean (SD)  
Homeostasis Model Assessment 2   
(ln HOMA2-IR) 
 
0.6 (0.7) 
 
0.4 (0.8) 
 
0.007‡ 
Alanine aminotransferase (ALT) 70.3 (45.9) 108.7 (92.2) <0.0001‡ 
Aspartate aminotransferase (AST) 59.7 (42.1) 73.7 (59.3) 0.05‡ 
Age (years) 48.8 (6.9) 47.1 (8.4) 0.08‡ 
Body Mass Index (BMI) 30.8 (6.4) 28.1 (5.2) <0.0001‡ 
Baseline Viral Level (log10 IU/mL) 6.3 (0.6) 6.3 (0.8) 0.10‡ 
Total Inflammation (HAI) 10.0 (3.2) 10.4 (3.5) 0.23‡ 
Triglycerides (mg/dL) 131.1 (100.0) 114.6 (69.0) 0.17‡ 
Cholesterol (mg/dL) 177.6 (37.1) 179.5 (5.3) 0.55‡ 
Ishak Fibrosis Score 2.2 (1.4) 2.3 (1.5) 0.38‡ 
Alcohol Consumption (Week) 3.6 (10.9) 2.4 (6.3) 0.81‡ 
    
† Chi-square test 
‡  Wilcoxon Two Sample Test 
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Table 5-2:  Frequencies of Genotypes for Single Nucleotide Polymorphisms among African 
mericans and Caucasian Americans 
 African s 
N = 163 
ucasian Am
N = 179 
A
 
American Ca ericans 
Single Nucleotide 
phism 
Genotype 
Frequency Call Rate 
 
HWE* 
Genotype 
Frequency Call Rate 
 
HWE* 
  
Polymor
ADIPOR1 rs10753929       
CC 1     01 (0.63)  145 (0.83) 
CT 53 (0.34)   29 (0.17)   
TT 5 0.49 0.97 0.61 (0.03) 0.98 0 (0) 
ADIPOR1 rs10920531       
AA 3     7 (0.23)  62 (0.35) 
AC 77 (0.48)   95 (0.54)   
CC  0.72 0.99 0.07  45 (0.28) 0.98 20 (0.11) 
ADIPOR1 rs1204586    2    
CC 128 (0.80)   92 (0.52)   
CT 30 (0.19)     73 (0.41) 
TT 1 (0.01) 0.98 1.00 0.98 0.49 11 (0.06) 
ADIPOR1 rs12733285       
CC 105 (0.68)     84 (0.48) 
CT 41 (0.27)   71 (0.41)   
TT 9 (0.06) 0.08 0.98 0.40 0.95 20 (0.11)  
ADIPOR1 rs1342387       
AA 40 (0.25)     36 (0.21) 
AG 75 (0.47)     81 (0.46) 
GG 44 (0.28) 0.48 0.9  0.98 59 (0.34) 9 0.40
ADIPOR1 rs1539355       
AA 45 (0.29)     80 (0.46) 
AG 77 (0.49)     76 (0.44) 
GG 35 (0.22) 0.85 0.97 0.87 0.96 17 (0.10) 
ADIPOR1 rs16850799       
AA 140 (0.87)  1    00 (0.57) 
AG 21 (0.13)   69 (0.39)   
GG 0 (0) 0.99 1.00 8 (0.05) 0.99 0.36 
ADIPOR1 rs2275736       
AA 12 (0.08)   0 (0)   
AT 44 (0.28)   6 (0.04)   
TT 104 (0.65) 0.98 0.03 171 (0.97) 0.99 1.00 
ADIPOR1 rs4336908       
AA 142 (0.87)   106 (0.60)   
AG 20 (0.12)   66 (0.37)   
GG 1 (0.01) 1.0 0.75 5 (0.03) 0.99 0.16 
ADIPOR1 rs6666089       
AA 124 (0.77)   85 (0.48)   
AG 34 (0.21)   73 (0.42)   
GG 4 (0.02) 0.99 0.32 18 (0.10) 0.98 0.69 
ADIPOR1 rs7514221       
CC 54 (0.33)   64 (0.36)   
CT 81 (0.50)   82 (0.46)   
TT 27 (0.17) 0.99 0.72 33 (0.18) 1.00 0.46 
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ADIPOR1 rs7539542       
CC 27 (0.17)   75 (0.42)   
CG 74 (0.46  89 (0.  )  50)  
GG 59 (0.37) 0.65 13 (0.07) 0.05 0.99 0.99 
HMGCS2 rs12123085       
AA 125 (0.77)   140 (0.78)   
AG 34 (0.21)   37 (0.21)   
GG 3 (0.02) 0.99 0.73 1.00 1.00 2 (0.01) 
HMGCS2 rs12563433       
CC 1  71 ) 15 (0.72)    (0.40   
CT 43 (0.27) 85 (0.48)     
TT 2 (0.01) 0.98 0.56 0.99 0.56 21 (0.12) 
HMGCS2 rs1441008       
CC 1 (0.01)   18 (0.10)   
CT 26 (0.16) 77 (0.44)     
TT 133 (0.83) 0.98 1.00 0.99 0.99 82 (0.46) 
HMGCS2 rs1441010       
AA 35 (0.22)   65 (0.37)   
AG 78 (0.49) 82 (0.46)     
GG 47 (0.29) 0.98 0.81 0.99 0.63 30 (0.17) 
HMGCS2 rs2241868       
CC 1  35 (0.85)   150 (0.85)   
CT 22 (0.14) 27 (0.15)     
TT 1 (0.01) 0.97 1.00 0.99 0.60 0 (0) 
HMGCS2 rs3790693       
AA 8 (0.05)   25 (0.14)   
AT 58 (0.36) 80 (0.45)     
TT 94 (0.59) 0.98 0.81 0.99 0.72 71 (0.41) 
HMGCS2 rs4659233       
AA 5 (0.03)   2 (0.01)   
AT 43 (0.28) 39 (0.22)     
TT 108 (0.69) 0.96 0.78 0.97 1.00 133 (0.76) 
HMGCS2 rs536662       
AA 70 )  (0.43   42 (0.24)   
AG 69 (0.43) 86 (0.48)     
GG 22 (0.14) 0.99 0.45 50 ) 0.99 0.83  (0.28
HMGCS2 rs619167       
AA 80 (0.50)   42 (0.24)   
AG 66 (0.41) 87 (0.49)     
GG 14 (0.09) 0.98 0.94 0.99 0.67 48 (0.27) 
HMGCS2 rs649733       
AA 95 (0.59)   95 (0.54)   
AG 58 (0.36) 68 (0.31)     
GG 7 (0.04) 0.98 0.62 0.99 0.71 14 (0.08) 
HMGCS2 rs667226       
CC 1  34 (0.85)   118 (0.67)   
CT 23 (0.15) 55 (0.31)     
TT 1 (0.01) 0.97 1.00 0.98 0.31 3 (0.02) 
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HMGCS2 rs667246       
CC 69 (0.44)   95 (0.54)   
CT 65 (0.41)   57 (0.32)   
TT 23 (0.15) 0.96 0.24 25 (0.14) 0.99 0.002 
 
* P-value from test of Hardy Weinberg Equilibrium
Table 5-3: Adjusted Odds Ratios for Steatosis for Single Nucleotide Polymorphisms among African Americans and Cauc n Amer
 
 African Americans* 
N = 163 
Caucasian Ameri
N = 179 
asia
cans* 
icans  
  SNP Main Effects HOMA2-IR  SNP Main Effects OMA2H -IR 
 
Genetic variant 
 
N 
Odds Ratio     
(95% Confidence 
Interval) 
p-
value
Odds Ratio     
(95% Confidence 
Interval) 
p-
value
 
N 
Odds Ratio     
(95% Confidence 
Interval) 
p-
value
Odds tio     (9
Confidence 
rval) 
p-
alue 
 Ra
Inte
5% 
v
ADIPOR1 rs10753929           
CC 101 1.00    145 1.00    
CT/TT 59 0.71 (0.32-1.59) 0.41 ‡  29 0.45 (0.16-1.28) 0.13  ‡ 
ADIPOR1 rs10920531           
AA 37 1.00    62 1.00    
AC 77 0.67 (0.24-1.88) 0.44 ‡  95 2.03 (0.80-5.16) 0.14  ‡ 
CC 45 0.50 (0.16-1.58) 0.24 ‡  20 2.83 (0.59-13.62) 0.20  ‡ 
ADIPOR1 rs12045862           
CC 128 1.00    92 1.00    
CT/TT 31 2.51 (0.92-6.83) 0.07 ‡  84 1.16 (0.50-2.70) 0.73  ‡ 
ADIPOR1 rs12733285           
CC 105 1.00    84 1.00    
CT 41 0.86 (0.34-2.17) 0.75 ‡  71 2.19 (0.87-5.52) 0.10 ‡  
TT 9 1.69 (0.32-8.98) 0.54 ‡  20 3.26 (0.70-15.38) 0.14 ‡  
ADIPOR1 rs1342387           
AA 40 1.00    36 1.00    
AG 75 1.78 (0.66-4.81) 0.25 ‡  81 0.63 (0.20-2.03) 0.44 ‡  
GG 44 1.63 (0.55-4.80) 0.37 ‡  59 0.37 (0.11-1.28) 0.12 ‡  
ADIPOR1 rs1539355           
AA 45 1.00    80 1.00  1.55 (  0.38 0.58-4.12)
AG 77 1.05 (0.42-2.62) 0.91 ‡  76 1.42 (0.44-4.65) 0.56 16.37 (2 0) 0.004 .42-110.7
GG 35 1.01 (0.35-2.92) 0.98 ‡  17 0.13 (0.02-0.75) 0.02 3.44 (0  0.21 .50-23.58)
ADIPOR1 rs16850799           
AA 140 1.00    100 1.00    
AG/GG 21 1.26 (0.41-3.91) 0.69 ‡  77 1.34 (0.57-3.14) 0.50  ‡ 
ADIPOR1 rs2275736           
AA/AT 56 1.00    6 1.00    
TT 104 0.84 (0.38-1.89) 0.68 ‡  171 2.10 (0.14-31.90) 0.59 ‡  
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A  DIPOR1 rs4336908          
AA 142 1.00   106 1.00       
AG/GG 21 1.49 (0.49-4.56) ‡  71 1.33 (0.55-3.21) ‡  0.49 0.52 
ADIPOR1 rs6666089           
AA 1 4   2 1.00    85 1.00  1.92 (0.71-5.21) 0.20
AG or AG/GG 0.70 67) 0.47 42) 38 (0.30-1. 0.43 ‡  73 (0.16-1. 0.18 41.45 (2.81-611.81) 0.01 
GG §  18 0 ) 0.04 0.6 9) 0.73 §   .13 (0.02-0.90 4 (0.05-8.2
ADIPOR1 rs7514221           
CC     54 1.00    64 1.00    
CT 81 1.39 ( 3.27)  1.48 ( 3.71)  0.59- 0.45 ‡  82 0.59- 0.41 ‡  
TT 0.61 (0.19-1.93) 0.40 ‡  33 2.03 (0.58-7.11) 0.27 ‡  27 
ADIPOR1 rs7539542           
CC     27 1.00    75 1.00    
CG 74 1.07 ( 3.33)  2.34 ( 5.81)  0.35- 0.90 ‡  89 0.95- 0.07 ‡  
GG 59 1.26 (0.39-4.03) 0.70 ‡  13 3.72 (0.52-26.78) 0.19 ‡  
HMGCS2 rs12123085           
AA   1 0  125 1.00    4 1.00    
AG 3.13 ( 8.63)  0.71 ( 2.02)  /GG 37 1.14- 0.03 ‡  39 0.25- 0.52 ‡  
HMGCS2 rs12563433           
CC 115 1.00    71 1.00    
CT §  1.00 (0 2.42)  ‡ §    85 .41- 0.99  
CT/TT or 0.71 ( 1.73)  1.55 ( 7.28)   TT 45 0.29- 0.45 ‡  21 0.33- 0.58 ‡  
HMGCS2 rs1441008           
CC/CT 27 1.00    95 1.00    
TT 133 1.87 (0.69-5.10) 0.22 ‡  82 0.55 (0.22-1.38) 0.21 ‡  
HMGCS2 rs1441010           
AA 25 1.00    65 1.00    
AG 78 0.55 (0.20-1.49) 0.24 ‡  82 0.50 (0.19-1.35) 0.17 ‡  
GG 47 1.02 (0.34-3.10) 0.97 ‡  30 0.38 (0.10-1.47) 0.16 ‡  
HMGCS2 rs2241868           
CC 135 1.00    150 1.00    
CT/TT 23 1.73 (0.60-5.00) 0.31 ‡  27 0.75 (0.23-2.42) 0.63 ‡  
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HMGCS2 rs3790693           
AA or AA/AT 66 1.00    25 1.00    
AT § §    80 0.60 (0.15-2.45) 0.47 ‡  
TT 94 0.60 (0.27-1.35) 0.22 ‡  72 0.82 (0.19-3.61) 0.79 ‡  
HMGCS2 rs4659233           
AA/AT    48 1.00    41 1.00    
TT 108 0.54 (0 1.32)   2.05 (0 5.61)  .23- 0.18 ‡  133 .75- 0.16 ‡  
HMGCS2 rs536662           
AA 70 1.00    42 1.00    
AG 69 0.46 (0.20-1.08) 0.08 ‡  87 0.93 (0.33-2.61) 0.88 ‡  
GG 22 0.63 (0.19-2.10) 0.45 ‡  48 3.09 (0 11.50) .83- 0.09 ‡  
HMGCS2 rs619167           
AA 80 1.00    42 1.00    
AG 66 0.51 (0.22-1.17) 0.11 ‡  86 0.89 (0.31-2.49) 0.82 ‡  
GG 14 0.36 (0. 9-1.46) 0 0.15 ‡  50 3.10 (0.84-11.51) 0.09 ‡  
HMGCS2 rs649733           
AA 95 1.00    95 1.00    
AG/GG 65 1.10 (0.50-2.42) 0.80 ‡  82 0.58 (0.24-1.40) 0.23 ‡  
HMGCS2 rs667226           
CC  134 1.00    118 1.00    
CT/TT 24 0.35 ( 1.16)  1.68 ( 4.21)  0.11- 0.09 ‡  58 0.67- 0.27 ‡  
HMGCS2 rs667246           
CC 69 1.00    95 1.00    
CT 65 0.46 (0.20-1.08) 0.08 ‡  57 0.93 (0.33-2.61) 0.88 ‡  
TT 23 0.63 ( 2.10)  3.10 ( 1.50)  0.19- 0.45 ‡  25 0.83-1 0.09 ‡  
           
* Model adju tic Is rosis score, centered weekly a ol ter HOMA2
nte line viral level and interaction between 
‡ Odds ratios from ffects m l adjusting for the genetic variant, centered Ishak fibrosis score, c ntered weekly alcohol con umption, 
centered ln HOMA2-IR sc , centered dy mass index and centered log of baseli e vir ve ca e log likelihood test for 
re ere not sign icant n .   
bined with heterozy pe to es mate associ
sted for the g
ndex
ene
, e
 variant, centered 
red log of base
hak fib lcoh consumption, cen
the genetic variant and ln HOMA2-IR scor
ed ln -IR score, 
centered body mass i
significant) 
c e (where 
 the main e ode e s
ore bo n al le l were reported be use th
the interaction between the genetic variant and ln HOMA2-IR sco
ess then 5% in one populat
s w if  at a alpha level of 0.05  
† Minor allele frequ
§ Homozygote g
ency l ion 
enotype com gote genoty ti ation
Table 5-4: Raw Data Comparing Steatosis and Insulin Resistance and the Frequency of ADIPOR1 
rs1539355 variant genotypes 
 
 African Americans Caucasian Americans 
 No Steatosis Steatosis ≥ 5  % No Steatosis Steatosis ≥ 5%
 
HOMA2-IR  
< 2 
 
 
AA:  11 
AG:  19 
GG:   9 
 
AA:  12 (52.2) 
AG:  20 (51.3) 
:   9 .0 
 
AA:  13 
AG:  18 
:   6
 
AA:  32 (71.1) 
AG:  27 (60.0) 
GG  (50 GG   GG:   3 (33.3) 
 
HOMA2-IR 
 2 
 
AA:  5 
AG:  4 
GG:  3 
AA:  12 (70.6) 
:  18 .8) 
:  11 .6) 
AA:  5 
:  2 
:  2 
AA:  17 (77.3) 
G: (90.0) 
    
≥ AG
GG
 (81
 (78
AG
GG
A
GG:   4 (66.7) 
 18 
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Table 5-5:  Adjusted Odds Ratios for Insulin Resistance in African Americans and Caucasian 
Americans 
 
 African Americans* 
N = 138 
Caucasian Americans* 
N = 152 
 
Single Nucleo
Polymorphis
 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
p-
value
 
 
N 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
p-
value
 
 
N 
tide 
m 
ADIPOR1 rs1 9        075392   
CC  1.00   121 1.00    86
CT/TT 50 0.88 0.40-1.97 0.76 27 0.84 0.30-2.34 0.74 
ADIPOR s1 1        1 r 092053   
AA 30 1.00   54 1.00   
AC 1.08 0.39-2.98 0.88 82 1.08 0.47-2.48 0.85  68 
CC 0.41 0.13-1.30 0.13 14 1.46 0.37-5.67 0.59  37 
AD 1 2        IPOR1 rs 204586   
CC 107 1.00   80 1.00   
CT/TT 28 0.72 0.27-1.93 0.52 70 1.29 0.60-2.77 0.51 
ADIPOR1 rs1 5        273328   
CC 91 1.00   73 1.00   
CT 33 1.12 0.45-2.80 0.81 59 0.97 0.43-2.20 0.95 
TT 7 1.73 0.30-9.91 0.54 16 1.22 0.36-4.17 0.75 
ADIPOR1 rs1        342387   
AA    31 1.00    32 1.00
AG  0.31-2.10 0.66 68 0.86 0.32-2.33 0.76  64 0.81
GG  0.27-2.23 0.64 50 1.03 0.36-2.89 0.96  39 0.78
ADIP s1        OR1 r 539355   
AA    67 1.00    40 1.00
AG  0.35-2.17 0.78 65 0.80 0.36-1.77 0.58  61 0.88
GG  0.29-2.63 0.81 15 1.26 0.32-4.97 0.75  32 0.88
ADIPOR1 rs1 9       685079    
AA    87 1.00    118 1.00
AG/GG  0.14-1.50 0.20 63 1.03 0.48-2.21 0.94  19 0.46
ADIPOR1 rs2        275736   
AA/AT 46 1.00   6 1.00   
TT 90 2.06 0.88-4.84 0.10 144 0.10 0.01-1.10 0.06 
AD 4        IPOR1 rs 336908   
AA    92 1.00    119 1.00
AG/GG  0.34-2.97 0.99 58 0.92 0.42-2.01 0.83  19 1.00
ADIP 6        OR1 rs 666089   
AA    71 1.00    103 1.00
AG o G  0.60-3.35 0.43 62 0.62 0.27-1.41 0.26 r AG/G  35 1.41
GG   16 1.06 0.27-4.06 0.94  ‡  
AD 7        IPOR1 rs 514221   
CC    55 1.00    47 1.00
CT 67 1.12 0.47-2.68 0.80 69 0.96 0.42-2.20 0.93 
TT 23 2.18 0.71-6.74 0.18 28 0.79 0.27-2.34 0.68 
ADIPOR1 rs7       539542   
CC 22 1.00   67 1.00   
CG 64 0.90 0.30-2.74 0.85 73 1.14 0.52-2.50 0.75 
GG 50 0.47 0.15-1.52 0.21 10 1.54 0.35-6.83 0.57 
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HMGCS2 rs12123085         
AA 106 1.00   121 1.00   
AG/GG 31 0.86 31 2 0.04 0.92 0.37-2.27  0.31 0.10-0.9
HMGCS2 rs12563433         
CC 101 00   55 1.00 1.   
CT ‡ 86 0.71    75 0. 0.37-1.97 
CT/TT or TT 35 0  42 0.14  1.98 .43-2.71 0.87 20 2. 0.75-7.83 
HMGCS2 rs1441008         
CC/CT  24 0  1.00   79 1.0  
TT 112 0.41-3  71   1.17 .39 0.77  0.81 0.37-1.73 0.58
HMGCS    2 rs1441010      
AA 32 5 .00  1.00   9 1  
AG 64 0  6 .74 0.47 2.03 .71-5.80 0.19 9 0 0.32-1.68 
GG 40 1.69 0.55-5.14 0.36 22 0.97 0.32-2.96 0.96 
HMGCS2 rs2241868         
CC 112 1.00   128 1.00   
CT/TT 22 0.57 0.19-1.67 0.30 22 0.95 0.33-2.78 0.93 
HMGCS2 rs3790693         
AA or AA/AT 55 1.00   17 1.00   
AT ‡    70 0.89 0.25-3.11 0.85 
TT 80 0.75 0.34-1.68 0.49 63 1.35 0.39-4.63 0.64 
HMGCS2 rs4659233         
AA/AT 39 1.00   34 1.00   
TT 93 0.57 0.24-1.36 0.20 114 1.92 0.72-5.10 0.19 
HMGCS2 rs536662         
AA 62 1.00   32 1.00   
AG 54 0.67 0.28-1.60 0.37 73 1.40 0.52-3.78 0.51 
GG 20 0.98 0.30-3.19 0.98 45 1.20 0.41-3.54 0.74 
HMGCS2 rs619167         
AA 71 1.00   32 1.00   
AG 53 0.57 0.24-1.35 0.20 72 1.37 0.50-3.74 0.54 
GG 12 1.04 0.26-4.09 0.96 47 1.21 0.41-3.53 0.73 
HMGCS2 rs649733         
AA 83 1.00   83 1.00   
AG/GG 53 1.06 0.49-2.33 0.88 67 1.52 0.70-3.31 0.29 
HMGCS2 rs667226         
CC 117 1.00   99 1.00   
CT/TT 18 0.35 0.09-1.45 0.15 50 0.87 0.39-1.94 0.73 
HMGCS2 rs667246         
CC 60 1.00   83 1.00   
CT 55 1.17 0.51-2.69 0.72 49 1.44 0.62-3.35 0.40 
TT 18 1.22 0.36-4.10 0.75 18 1.90 0.58-6.28 0.29 
         
* Model adjusted for the genetic variant, centered Ishak fibrosis score, centered body mass index, 
steatosis, centered age and centered triglyceride levels 
‡ Homozygote genotype combined with heterozygote genotype to estimate association 
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6 GEN RAL DIS USS  
d xa  host ge etic relatio ship ith decline in the first 28 
days of treatment, steatosis, and insul ce using a ple atie d 
hepatitis C virus (HCV) genotype-1.  To address these objectives, data were obtained from The 
tance to An iral Therapy of Chronic Hepatitis C (Virahep-C), a study that 
recruited nearly equal numbe rica d C asi erican patients 
- d ior histo  of treatm
sis ded.(Conjeevaram 06  Vi p-C, ts w
treated for up t  ks  p ter α and ight- sing
, 2006)   
6 SUMMARY OF FINDINGS 
The study reported in Chapter 3 aime min vir ecl  the day
is w s 
 viral decline in 
HCV treatment research.  This study contributes to knowledge gaps in HCV treatment research 
.0  E C ION
This dissertation aime to e mine n n s w viral 
in resistan  sam  of p nts infecte with 
Study of Viral Resis  tiv
rs of African Ame n n a auc an Am with 
chronic HCV genotype 1 an no pr ry ent. (Conjeevaram, 2006)  Patients with 
decompensated cirrho  were exclu , 20 ) In  ra eh part ipanic e  re
o 48 wee  with egylated-in feron -2a  we based do  of 
ribavirin.(Conjeevaram
.1 
 
d to deter e if al d ine in  first 28 s of 
treatment was different by host genetic variants of Interferon Stimulated Genes (ISGs).  Th a
the first study that examined the selected 16 ISG SNP associations with 28 day
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by testing for associations between 28 day viral decline and ISG SNPs among two populations 
that traditionally do not respond well to treatment, African Americans and HCV genotype-1 
infected patients.  This study identified statistically significant differences in viral decline by ISG 
SNP genotypes in MX1, MX2, OASL, STAT1 and STAT2.  Statistically significant differences in 
viral decline by the presence or absence of PKR haplotypes were observed in African Americans.  
There were three non-significant differences in viral decline for IFNAR1 rs1041868, OAS3 
rs1981557 and IRF1 ATCCATCC with the same pattern of decline observed in both race groups.     
The study reported in Chapter 3 identified different patterns of 28 day viral decline for 
the ISG variant genotypes MX2 rs443099, rs369908 and OASL rs1169279 between the two race 
groups.  In these genetic variants, a given genotype was associated with greater 28 day viral 
ecline in one race, but a different genotype was associated with greater decline in the other race 
variant related to 28 day viral decline may be in linkage disequilibrium with the associated 
genetic variant observed in this study.  Linkage disequilibrium is a correlation between genetic 
variants along a chromosome and linkage disequilibrium patterns between genetic variants differ 
by racial group.(Costas, 2005)  Since African Americans and Caucasian Americans have 
different allele frequencies and different linkage disequilibrium patterns, it is possible that an 
observed statistically significant association may or may not occur in both races or may not be 
the same in both races.  For example, there was a statistically significant difference in viral 
decline in African Americans for MX2 rs369908 genotypes such that those with the AA 
genotype had greater decline in 28 days compared to those with the AG or GG genotype.  In 
Caucasian Americans, no statistically significant difference in viral decline for this MX2 SNP 
d
and was not necessarily statistically significant.  This could indicate that the causal genetic 
was observed.  Given the lack of consistent significant associations in both race groups, it is 
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difficult to positively conclude whether the associated ISGs are important to HCV treatment 
induced 28 day viral decline. 
Prior examination of ISGs with treatment response has focused exclusively on the 
association between genetic vari ts or the expression of the ISG protein with achieving a 
sustained virologic response (SVR).(Giannelli, 2004; Hijikata, 2001; Hijikata, 2000; 
carrying the OASL rs1169279-GG genotype or the OASL rs3213545-CT or TT genotype showed 
greater decline compared to the other genotypes.  No statistically significant differences were 
observed between the OASL variant genotypes and 28 day viral decline in African Americans.  It 
may be the case that some I cou effectively enhance immune 
response and work with pegIFNα to reduce HCV viral levels.        
he study reported in Chapter 4 aimed to identify associations between selected genetic 
an
MacQuillan, 2002; H Saito, 2002; Su, 2008; Tena-Tomas, 2007; Wietzke-Braun, 2006)  No 
studies found tested the association between the selected ISG genetic variants and 28 day viral 
decline.  A study testing ISG SNP associations with SVR in the Virahep-C cohort found 
associations between OASL rs1169279-A allele, rs3213545-T allele and rs2859398-C allele and 
a SVR in African Americans and Caucasian Americans.(Su, 2008)  The study in Chapter 3 found 
differences in viral level decline in the first 28 days for two of these OASL SNPs but, these 
associations were not consistent across race.  Significant differences in viral decline by OASL 
variant genotypes in the first 28 days were observed among Caucasian Americans such that those 
SGs ld take more than 28 days to 
T
variants for COL1A1, CYP2E1, IL6, IL10, IL1R1, LEPR, MCP1/CCL2, MCP2/CCL8, TNF-α and 
TGF-β1 with steatosis and Insulin Resistance (IR).  Previous work on insulin resistance 
identified genetic variant or gene expression relationships in obese, diabetic or healthy 
populations.(Sartipy, 2003; Scarpelli, 2006; Schattenberg, 2005; Siitonen, 2006; Simeoni, 2004; 
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Stefan, 2005; Testa, 2006; X Yang, 2005)  Few studies have examined genetic variant 
associations with steatosis.(Sanchez-Munoz, 2004; Stefan, 2005)  No studies were found to have 
tested genetic variant associations with the polymorphisms selected for this dissertation with 
either steatosis or IR in HCV infection.  This project contributes to knowledge gaps in the 
literature by testing genetic associations with steatosis and IR in an HCV infected population.  
By examining these relationships, this study helps to develop a greater understanding of the 
mechanisms of steatosis and IR as well as racial differences in their occurrence.  
Statistically significant associations for genetic variants in IL6, IL10, LEPR and TGF-β1 
with steatosis or IR were observed in both race groups.  In African Americans, LEPR rs1137100-
AG or GG genotype was associated with lower odds of steatosis and the LEPR rs1892534-AG 
genotype was associated with higher odds of steatosis in both African Americans and Caucasian 
Americans.  In Caucasian Americans, the IL6 rs2069845-AG or GG genotype was associated 
with higher odds of steatosis compared to having the AA genotype.  In Caucasian Americans, the 
IL6 rs1880242-TT genotype was associated with lower odds of IR compared to having GG or 
GT genotype.  TGFβ rs2278422-GG genotype was associated with statistically significant higher 
odds of steatosis in African Americans and lower odds of IR in both race groups compared to 
possessing the CC or CG genotype. 
Statistically significant interactions between HOMA2-IR scores and IL10, LEPR and 
TGF-β1 genetic variants were observed in the prediction of steatosis.  Statistically significant 
interactions were observed between HOMA2-IR scores and the IL10 rs3024496-CT or -TT, 
LEPR rs1805096-CT or rs1892354-AG such that there were higher odds of steatosis among 
Caucasian Americans with high HOMA2-IR scores and any of these genotypes than would be 
expected by the main effects of HOMA2-IR and genotype alone.  In African Americans, 
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statistically significant interactions were observed for those possessing the IL10 rs3024496-CT 
or TGF-β1 rs2241716-GG indicating higher odds of steatosis than would be expected by the 
main e
selected
ffects or HOMA2-IR and the genotype alone.  The interactions observed between IL10, 
LEPR and TGF-β1 genetic variants may imply that these genetic variants moderate an 
association between steatosis and IR.       
Three previous studies described associations between the IL6 rs1800795-G allele and 
the higher HOMA-IR scores in Caucasian European, healthy or diabetic populations.(Cardellini, 
2005; Testa, 2006; X Yang, 2005)  The study reported in Chapter 4 found no statistically 
significant association with either steatosis or IR and this IL6 SNP.  Reasons for the 
contradictory results may be related to different phenotype measures, statistical methods and 
different populations.  Also the previous studies examined Caucasians who were healthy or 
diabetic compared to the current study that examined both Caucasian Americans and African 
Americans infected with HCV genotype-1.  HCV infection may contribute to the occurrence of 
IR and the mechanisms for the development of IR may be different in those with or without 
HCV.        
The study described in Chapter 5 aimed to identify associations of ADIPOR1 and 
HMGCS2 polymorphisms with steatosis and IR among African Americans and Caucasian 
Americans.  This study utilized tag SNP selection methods to choose genetic variants.  The 
 genetic variants attempted to capture 80% of the common variation in these genes to test 
for associations with steatosis and IR.  Statistically significant associations between two 
ADIPOR1 polymorphisms and steatosis were observed in Caucasian Americans.  In African 
Americans HMGCS2 rs12123085 was associated with steatosis and in Caucasian Americans the 
same SNP was associated with IR.  Statistically significant interactions in Caucasian Americans 
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were observed between the ADIPOR1 rs1539355 or rs6666089 heterozygote genotype and 
HOMA2-IR scores such that individuals who have higher HOMA2-IR scores and possess the 
AG genotype for either of these polymorphisms have significantly higher odds of steatosis 
compared to what would be expected from the main effects of the heterozygote genotype and 
HOMA2-IR scores alone.  These results imply that the heterozygote genotype in the two 
ADIPOR1 genetic variants could moderate the association between steatosis and IR.  Few studies 
have tested ADIPOR1 and HMGCS2 SNP associations with steatosis or with IR.(Crimmins, 
2007; S
 of type 2 diabetes, which measured IR with the 
hyperin
tefan, 2005)  The observed statistically significant associations between ADIPOR1 and 
HMGCS2 genetic variants help to explain the occurrence and mechanism of these conditions in 
HCV infection.  
Previous studies have identified statistically significant associations between ADIPOR1 
rs6666089 or rs1342387 and IR in African American children or healthy Caucasian 
adults.(Crimmins, 2007; Stefan, 2005)  No statistically significant associations were observed 
between IR and those ADIPOR1 polymorphisms in the study reported in Chapter 5.  One 
previous study examined IR in 483 healthy African American children aged 10-19 using 
continuous HOMA-IR scores.(Crimmins, 2007)  The other study included 500 German 
participants from a family study
sulinemic euglycemic clamp and measured liver fat with magnetic resonance 
spectroscopy (MRI) and analyzed continuous values for steatosis and IR.(Stefan, 2005)  The 
study in Chapter 5 examined 138 African American and 152 Caucasian American adults with 
chronic HCV and utilized biopsy to measure liver fat and the HOMA2-IR calculator to quantify 
IR.  The most important difference in these studies was the inclusion of patients infected with 
HCV.  It is possible that HCV could influence the occurrence and severity of these conditions 
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and that the mechanisms for development could be different in those infected with HCV and 
those without.  The different analytical methods and measurement techniques for steatosis and IR 
could also contribute to different findings because the techniques and definitions may not be 
consistent.     
6.2 DISSERTATION STRENGTHS 
The studies completed for this dissertation have several strengths and provide important 
contributions to the HCV literature.  These dissertation studies are the first studies to examine the 
selected genetic variant associations with 28 day viral decline, steatosis and IR in HCV 
genotype-1 infection.  Genetic associations could contribute to understanding mechanisms of 
HCV treatment response and improving treatment outcomes which may also reduce the 
occurrence of steatosis and IR.   
Chapter 3 showed associations with ISG polymorphisms and 28 day viral decline.  
Studies of viral dynamics generally include relatively few participants because these studies 
require frequent viral level measures in the first few hours and days after treatment 
initiation.(Herrmann, 2003; Neumann, 2000; Neumann, 1998)  Virahep-C collected fewer viral 
level measurements during the first week of treatment compared to traditional viral dynamics 
studies, but these measures still allowed for examining 28 day viral decline.(Conjeevaram, 2006; 
Herrmann, 2003; Neumann, 2000; Neumann, 1998)  The fewer measurements in the first 72 
hours of treatment most likely caused the finding of two phases of viral decline in the Virahep-C 
population which differs from previous studies on decline with pegylated interferon α-2a plus 
ribavirin combination therapy.(Hoofnagle, 2008)  However, the inclusion of more patients (401 
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in Virahep-C, 10 in rigorous viral dynamics study with frequent blood draws in the first few 
days) and African Americans in Virahep-C may also have contributed to the difference.  
The Virahep-C study recruited nearly equal numbers of African Americans (n=196) and 
Caucasian Americans (n=205) so the study reported in Chapter 3 utilized a sample of HCV 
genotype-1 infected patients with almost equal numbers of African Americans and Caucasian 
Americans.  Including African Americans in HCV research is important because this group is 
typically under-represented in HCV treatment studies (Strader, 2002) and generally do not 
respond as well to HCV treatment as Caucasian Americans.(Conjeevaram, 2006)  Examining 
both African- and Caucasian-Americans with HCV genotype-1 enables observing genetic 
variants that are associated with viral decline in both race groups or in one race group.     
The studies reported in Chapters 4 and 5 found associations between genetic variants and 
steatosis or IR in HCV infection.  African Americans have not been commonly included in 
studies examining genetic associations with steatosis and IR and genetic associations with these 
conditions have not been studied extensively in HCV infection.(Crimmins, 2007; Sanchez-
Munoz, 2004)  As above with viral decline, including African Americans when examining 
genetic associations with steatosis and IR may contribute to understanding the racial differences 
in the occurrence of these conditions.   These studies also described genetic associations with 
steatosis which has not been examined extensively in the literature because the diagnosis of 
steatosis requires a biopsy, an invasive procedure.(Sanchez-Munoz, 2004; Stefan, 2005)  The 
study of genetic associations with steatosis and IR in HCV infection is important because these 
associations could contribute to understanding whether these conditions are influenced by virus 
infection or associated with the conditions in a more general population experiencing these 
conditions. 
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6.3 DISSERTATION LIMITATIONS 
Limitations for the studies of this dissertation should be addressed so that the results may be 
interpreted in the appropriate contexts.  One limitation was that the Virahep-C cohort was 
relatively small for genetics studies.  In addition, the studies described in Chapters 4 and 5 had 
further reduced sample size because of missing HOMA2-IR scores.  Despite the small sample, 
the studies detected statis y s in the models.  Some 
statistically significant interactions between gene variants and host factors were also identified.   
erence DNA code within a given population.  Genetic variants 
are ofte
ticall significant main effects association
Another possible limitation to these studies was the use of three different methods to 
select and genotype polymorphisms for the genes.  Each of these methods used the best 
technology available at the time they were completed and accounted for different percentages of 
the common genetic variation in the genes.  Common genetic variation is made up of the 
differences in the DNA code that exist within a population at an appreciable frequency (greater 
than 5-10%) compared to the ref
n inherited together creating a pattern of correlation across the genome.  The pattern of 
correlation created by inheritance contributes to describing the common genetic variation.  The 
common genetic variation accounted for in a gene by selected polymorphisms refers to a 
measure of the percent of genetic variation captured with a correlation or r2=0.80 reflecting 
polymorphisms cataloged in the International HapMap Project, Phase II.  This refers to the 
percent of known polymorphisms that are at least 80% correlated with one or more tag selected 
polymorphisms.  In the study reported in Chapter 3, the haplotype-block method accounted for 
39% and 56% of the variation and the two-stage approach accounted for 29% and 54% of the 
variation in the genes for Caucasian Americans and African Americans, respectively.  In the 
study described in Chapter 4, the haplotype-block method accounted for 38% and 47% and the 
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second approach accounted for 19% and 39% of the variation in the genes for Caucasian 
Americans and African Americans, respectively.  The linkage disequilibrium SNP selection 
method
 HCV 
genotyp
re may be participation bias in that individuals who volunteered to participate in 
 utilized in the study reported in Chapter 5 accounted for 71% and 96% of the variation in 
the genes for African Americans and Caucasian Americans, respectively.  The overall 
association for some of the selected genes with respect to 28 day viral decline, steatosis or IR 
cannot be determined because the selected genetic variants for many of these genes captured less 
than 80% of the variability for that gene.    
The limitations with respect to generalizability to the general population of people with 
HCV infection are due to the inclusion criteria for Virahep-C.  The results of the three studies in 
this dissertation can be generalized to African American and Caucasian American
e-1 patients who do not have end stage liver disease because of the exclusion of people 
with decompensated liver disease and the inclusion requirement of no prior treatment, 
eliminating the probability of advanced disease in the Virahep-C cohort.  Further affecting 
generalizability, recruitment occurred in eight US cities and arguably did not capture a 
representative sample of HCV infected individuals.  At the time of screening, Virahep-C 
participants had knowledge of their infection status, may have already been experiencing 
symptoms or disease progression or may have been under the care of a physician.  In the general 
population, some individuals may be unaware that they have HCV infection, may be 
asymptomatic, have mild or minimal disease progression and may not be seeking medical care or 
treatment.  It may be difficult to generalize Virahep-C results to a more general population of 
HCV infection because individuals who seek medical care and volunteer for studies may be 
experiencing infection differently than individuals who do not know their infection status.  
Further, the
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Virahep-C in that they medication and follow 
recommended guidelines compared to individuals who did not volunteer.  The results from this 
 
the vira
may be more likely to consistently take 
dissertation may over estimate true viral decline in HCV genotype-1 patients because enrolled 
study patients may have been more likely to follow treatment guidelines.  The Virahep-C cohort 
also differs from hospital based cohorts of HCV infected patients.  In hospital based cohorts, 
HCV infected patients are generally experiencing more severe complications and illness.  
Virahep-C recruited a relatively healthy cohort of HCV infected individuals.  The results of the 
Virahep-C study are also only generalizable to HCV patients infected with genotype-1 because
l mechanisms of different genotypes of HCV are thought to differ in treatment outcomes 
as well as disease progression.   
Another limitation was the lack of a validation sample to confirm the observed results.  
Validation studies to confirm genetic associations are an important component to genetic 
research to reduce Type I error due to repeated tests.  Validation of the results proved to be 
problematic because no sample was available that included the same measurements among HCV 
patients.  Future studies could be designed to examine these outcomes in a very similar or larger 
sample of African Americans and Caucasian Americans with HCV genotype-1 infection to 
confirm the findings.   
Adjustment for multiple comparisons was not made for any of the three projects that 
make up this dissertation.  The decision to not adjust for multiple comparisons was based on an a 
priori decision that the studies were exploratory and took first looks at associations with 
treatment outcomes and metabolic conditions in an HCV infected population.  The genes 
selected for examination with the 28 day viral decline, steatosis or IR were chosen based on 
possible biological plausibility of associations. This information regarding the selection of genes 
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is found in Chapters 3, 4, and 5.  Although the large number of comparisons increases the 
likelihood of a Type I error, appropriate correction for multiple comparisons is difficult because 
of the unknown correlation structure between polymorphisms within each gene.  Cautious 
interpretation of the findings should be made until additional studies can confirm the results 
through validation studies and lend support to the observed associations.   
6.4 PUBLIC HEALTH SIGNIFICANCE 
infection.(Armstrong, 2006)  However, this estimate does not include incarcerated or homeless 
The cost of HCV therapy is estimated to range from $8,000-$22,000 annually for one 
Recent reports suggest that 3.2 million people in the US have chronic HCV 
individuals and is likely an underestimate of the true number of people with chronic 
infection.(Armstrong, 2006)  Direct and indirect costs associated with HCV infection are 
estimated to be approximately $5.46 billion annually.(Leigh, 2001)  The majority of these costs 
are related to liver complications, morbidity or mortality associated with infection.(Leigh, 2001)  
patient.(Salomon, 2003)  HCV treatment is expensive, can have severe side effects and has only 
been effective in reducing the HCV RNA to undetectable levels in about 54-56% of those 
treated.(MW Fried, 2002; Manns, 2001)  Research that contributes to understanding factors 
associated with HCV treatment response could lead to new therapies, improved treatment 
response and ultimately reduced morbidity and mortality related to HCV infection.         
Steatosis and insulin resistance are common conditions among individuals infected with 
HCV.  African Americans have lower prevalence of steatosis compared to Caucasian 
Americans.(Browning, 2004; Conjeevaram, 2007)  In contrast, African Americans were 
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observed to have higher IR scores compared to Caucasian Americans.(Conjeevaram, 2007; 
Heathcote, 2002; Hui, 2003; Petit, 2001; Romero-Gomez, 2005; Shaheen, 2007)  Research has 
been unable to conclusively identify what factors influence the racial differences in these 
conditions.  Genetic associations with steatosis and insulin resistance in people with HCV may 
help to understand the mechanisms of these conditions and also may explain these racial 
differences.  Further, understanding the biology of these conditions may provide methods for 
prevention, management and treatment. 
The results of the dissertation may help to explain some of the biological mechanisms in 
the occurrence of steatosis, IR and HCV treatment response.  Understanding the biology of a 
condition or disease through genetic epidemiology is helpful in figuring out how to prevent, 
manage
nd 5 identified host genetic variants associated with steatosis and IR in a 
populat
 and treat it.  The results of the study reported in Chapter 3 may be useful for 
understanding mechanisms of viral decline which could be utilized in the development of novel 
therapies.  Ultimately, these novel therapies could improve treatment response and reduce the 
occurrence of co-morbidities.  Results of the Chapter 3 study could also assist in explaining the 
racial differences in treatment response and why African Americans have lower response rates to 
treatment by helping to identify biological mechanisms associated with viral decline.  The 
studies in Chapters 4 a
ion of HCV genotype-1 infected patients.  These associations may help to understand the 
mechanism of the occurrence for these conditions which could lead to methods to prevent or 
treat the conditions. 
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6.5 FUTURE RESEARCH 
The results from the studies that comprise this dissertation provide ideas for possible future 
directions of research on host genetic associations with HCV, including 28 day viral decline, 
steatosis and IR.  Statistically significant associations were observed for genetic variants with 
steatosis or IR in HCV genotype-1 infected patients.  These genetic variants may be specifically 
associated with the occurrence of these conditions in HCV infection or they could be related to 
the conditions in one ra ou sis and IR in a general 
population who experience these conditions.  Future research could help to understand the 
ce gr p or they could be associated with steato
importance of these genetic variants in a more general population of individuals experiencing the 
conditions as well as in HCV infection.   
Results from the three studies could not be validated because a comparable sample of 
African Americans and Caucasian Americans with HCV genotype-1 infection was not available.  
Thus, future research could replicate the current studies in other HCV genotype-1 populations to 
add support to the associated findings.  Additionally, validation could be completed in a slightly 
different population, for example different racial groups, those with more advanced disease or 
individuals experiencing these conditions without HCV could be studied.  Validation in a similar 
or a slightly different sample could provide different biological information, but could extend the 
general understanding of these conditions in all populations that experience these conditions.  
However, it is possible that with a different validation sample the results of the original study 
may not be replicated because of population differences.   
Further, a subsequent research step for associated genetic variants could be to examine 
additional genetic variants on the gene that are close to the associated variant and that may be in 
high linkage disequilibrium with the associated variant.  Several methods exist to further explore 
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the genetic associations such as sequencing or fine mapping techniques.  In the studies reported 
in Chapters 3 and 4, the selected genetic variants did not account for the majority of the common 
variation in most of the genes examined.  Since much of the common variation in the genes was 
not accounted for, the studies cannot conclude on the importance of the gene to the outcome 
examined.  Future studies could select additional genetic variants in the examined genes to 
account for more of the common genetic variation and to possibly identify additional 
associations within these genes.  To account for the more of the common genetic variation, 
availab
6.6 CONCLUSIONS 
Twenty-eight day viral decline may be important to understanding differences in HCV long-term 
treatment outcomes.  Steatosis and IR are common conditions related to HCV infection that also 
le public databases such as HapMap Phase II can be used to identify polymorphisms that 
are not highly correlated with the selected polymorphisms in the current study and cover a larger 
part of the gene region.   This strategy could improve the common genetic variation coverage of 
a gene like MX2 from 25% to at least 80% as was attained for ADIPOR1 (90%).  
This dissertation examined associations between 16 ISGs and 28 day viral decline and 12 
genes with steatosis and IR.  Additional genes have been identified in the literature that may be 
important to HCV treatment response, steatosis, or IR such as microsomal triglyceride transfer 
protein or interleukin 12 and could be examined with these outcomes.(Bernard, 2000; 
Houldsworth, 2005; Mentuccia, 2005; Mirandola, 2006; Namikawa, 2004)  Further, the genes 
examined in this dissertation could be utilized to test for associations with other outcomes such 
as early virologic response at 12 weeks of treatment, fibrosis or cirrhosis.       
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negatively impact the ability to ve i, 2005; Jian Wu, 2006; Patton, 
2004; Romero-Gomez, 2006; Romero-Gomez, 2005; Soresi, 2006; Westin, 2007)  In these 
riants.  Once these results are confirmed and additional 
researc
achie  SVR.(Fabris, 2005; Guid
analyses, we examined genetic variant associations with 28 day viral decline and steatosis and IR 
in both African Americans and Caucasian Americans.  In doing so, we wanted to determine if the 
observed associations were in similar or different directions in the two race groups.  Observing 
different patterns in the associations may help to explain the racial differences in treatment non-
response or in the occurrence of steatosis and IR.  Based on the results from the three studies, 
host genetic factors are associated with 28 day viral decline, steatosis and IR in HCV infection.  
These results indicate that the mechanisms for the occurrence of the outcomes may differ by 
race.  Future research should validate the findings observed in these studies and attempt to 
further understand the functions of the va
h is conducted on genetic variant functions, new therapeutic approaches could be 
developed to improve treatment response and potentially reduce or reverse the occurrence of 
steatosis and IR. 
 
APPENDIX A  
A.1 SUPPLEMENTARY MATERIAL FOR INTERFERON STIMULATED GENETIC 
VARIANTS AND THE EARLY VIRAL DECLINE DURING TREATMENT OF 
CHRONIC HEPATITIS C  
 
 
SUPPLEMENTARY TABLES AND FIGURES 
 FOR CHAPTER 3 
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Table A-1 Baseline Demographic and Viral Characteristics for Virahep-C Study Patients 
 
Characteristic African Americans 
(N=180) 
Caucasian American 
(N=194) 
P-Value 
Participating in the Genetics Ancillary Study by Race (N = 374) 
Gender, n (%) 
Men 
Women
 
118 (65.6) 
62 (34.4) 
 
126 (65.9) 
68 (35.1) 
 
 
0.90 
Age (years), mean (SD) 48.7 (7.1) 47.0 (8.6) 0.03  †
Weight (kg), mean (SD) 91.0 (19.2) 83.9 (17.3) 0.0002† 
HCV Subtype, n(%)    
1 10 (5.6) 16 (8.3)  
1a 86 (48.8) 111 (56.4)  
1a/b 2 (1.1) 12 (6.2)  
1b 81 (59.6) 55 (40.4) 0.002 
Source of Infection    
Blood or Blood Products 37 (23.9) 45 (27.0)  
Sexual Transmission 2 (1.3) 1 (0.6)  
Injection Drug Use 86 (55.5) 101 (54.0)  
Intra-nasal Illicit Drug Use 7 (4.5) 5 (3.0)  
Occupational/Medical 14 (9.0) 7 (4.2)  
Other 9 (5.8) 8 (4.8) 0.47 
Duration of HCV Infection (yrs)‡,  mean    
(SD) 24.4 (9.4) 25.5 (10.0) 0.33† 
Baseline ALT Levels†, mean (SD) 71.3 (45.8) 107.9 (91.9) <0.0001 
Baseline AST Levels , mean (SD) 60.4 (42.1) 73.7 (60.5) 0.02 †
Ishak Fibrosis Score†, mean (SD) 2.2 (1.4) 2.3 (1.6) 0.46 
HCV RNA Level, (log10IU/ml), mean (SD)    
Baseline 6.2 (0.7) 6.3 (0.8) 0.51† 
Day 1 5.8 (0.8) 5.6 (1.2) 0.046 
Day 2 5.6 (1.0) 5.3 (1.2) 0.02 
Day 7 5.7 (1.1) 5.2 (1.4) <0.0001 
Day 14 5.3 (1.3) 4.6 (1.7) <0.0001 
Day 28 4.6 (1.6) 3.5 (2.0) <0.0001 
† Analysis of Variance 
‡  Estimated duration of HCV infection was obtained for 148 Caucasian Americans and 134 African 
Americans 
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Table A-2:  Genotype Frequencies for Single Nucleotide Polymorphisms African Americans and 
Caucasian Americans 
 
Single Nucleotide 
Polymorphism 
Genotypes 
African 
Americans 
N = 180 
Genotype 
Call Rate 
HWE* Caucasian 
Americans 
N = 194 
Genotype 
Call Rate 
HWE* 
       
ISG15 G1P2 rs1921       
AA 28 (0.16)   27 (0.14)   
AG 96 (0.53)   96 (0.50)   
GG 56 (0.31) 1.0 0.21 70 (0.36) 0.99 0.52 
ISG15 G1P2 rs9331223       
CC 15 (0.08)   65 (0.34)   
CT 78 (0.44)   92 (0.48)   
TT 86 (0.48) 0.99 0.65 36 (0.19) 0.99 0.73 
G1P3 rs11247653       
AA 143 (0.79)   61 (0.32)   
AG 36 (0.20)   92 (0.48)   
GG 1 (0.01) 1.00 0.43 40 (0.21) 0.99 0.66 
G1P3 rs1141746   
CC   
CT 0 (0)   0 (0)   
TT 180 (1.0) 1.0 - 193 (1.0) 0.99 - 
G1P3 rs1316896       
CC 0 (0)   0 (0)   
CG 0 (0) 0 (0)   
GG 193 (1.00 193 (1.0) 0.99 - 
IFI35 rs8076790       
CC 17 (0.09)   5 (0.03)   
CT 89 (0.49)   62 (0.32)   
TT 74 (0.81) 1.0 0.18 126 (0.65) 0.99 0.42 
IFI35 rs692692       
 
IFI3  
AA 12 (0.7)   2 (0.01)   
AG 53 (0.29)  (0.15)   
GG 115 (0.64) 1.0 0.10 162 (0.84) 0.99 0.59 
IFI35 rs455055       
GG 89 (0.49)   12 (0.01)   
GT 66 (0.37)   76 (0.40)   
TT 24 (0.13) 0.99 0.04 103 (0.54) 0.99 0.68 
IFNAR1 rs2834190       
AA 142 (0.80)   99 (0.51)   
AT 35 (0.20)   77 (0.40)   
TT 1 (0.006) 0.99 0.69 17 (0.09) 0.99 0.72 
IFNAR1 rs2856968       
AA 68 (0.38)   72 (0.37)   
AG 87 (0.48)   94 (0.49)   
GG 25 (0.14) 1.0 0.74 27 (0.14) 0.99 0.68 
IFNAR1 rs2252930       
CC 143 (0.79)   99 (0.51)   
CG 36 (0.20)   77 (0.40)   
GG 1 (0.01) 1.0 0.70 17 (0.09) 0.99 0.72 
    
0 (0)   0 (0) 
  
0.99 - 
AA 12 (0.07)   5 (0.03)   
AG 74 (0.41)   59 (0.31)   
GG 94 (0.52) 1.0 0.62 129 (0.67) 0.99 0.57
5 rs10840      
   29
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Table A-2 (Continued)       
IFNAR1 rs2243592       
GG 25 (0.14)   27 (0.14)   
 (0.48) 9
 (0.38) 1. 72
      
AA 67 (0.37)  72 (0.3   
AT 90 (0.50)  97 (0.5  
23 (0.13) 1.0 24 (0.1 0.99  
    
8 (0.04)  2 (0.0  
 55 (0.31)   45 (0.23)   
GG 117 (0.65) 1.0 145 (0.7 0.99 73 
IFNAR1 rs2834195      
AA 1 (0.01)  0 (0)   
AG 14 (0.08)  1 (0.0  
G 165 (0.92) 1.0 192 (0. 0.99 
    
 25 (0.1   
GT  99 (0.5   
TT 1.0 69 (0.3 0.99 25 
IFNAR1 rs104186     
AA  4 (0.02)   
AG 65 (0.36)  55 (0.29  
0.99 .62 134 (0.69) 0.99 55 
   
4)  108 (0  
  75 (0  
) 1.0 10 (0. 0.99  
   
 47 (0.24)  
AC 106 (0.5  86 (0.4  
TT 28 (0.16) 1.0 60 (0.3 0.99 
IFNAR2 rs9636866     
CC 12 (0.07)  10 (0.0  
CT 94 (0.52)  62 (0.3  
TT 74 (0.41) 1.0 121 (0.6 0.99 
I     
GG 106 (0.59) 1.0 0.21 95 (0.49) 0.99 0.07 
IFNAR2 rs2248420       
CC 131 (0.73)   105 (0.55)   
CT 45 (0.25)   64 (0.32)   
TT 4 (0.02) 1.0 1.0 25 (0.13) 0.99 0.003 
IFNAR2 rs4986956       
CC 0 (0)   2 (0.01)   
CT 22 (0.12)   62 (0.32)   
TT 158 (0.88) 1.0 1.0 121 (0.63) 0.99 0.16 
IFNAR2 rs2252650       
AA 11 (0.06)   25 (0.13)   
AT 73 (0.41)   72 (0.37)   
TT 96 (0.53) 1.0 0.56 96 (0.50) 0.99 0.06 
       
       
       
GT 87   4 (0.49)   
TT 68 0 0.74 
 
 (0.3 0.99 7) 0.68 
IFNAR1 rs2253923
 
 
7) 
0)  
 
 
0.32TT 
IFNAR1 rs2257167 
0.39 2) 
  
CC  1)  
CG
0.64 6) 0.
 
  
 
.32 
1) 
99) 
 
0.70 G
IFNAR1 rs2243599 
0
 
GG 83 (0.46) 
 
 3) 
77 (0.43)  1
6) 
) 
20 (0.11) 0.74 0.
8   
 8 (0.05)   
 )  
GG 106 (0.59) 
IFNAR1 rs2834202  
0 0.
  
AA 116 (0.6
2)
 .56) 
.3
 
AG 58 (0.3
3
 9) 
05
 
GG 6 (0.0
IFNAR2 rs1476415  
0.70 
 
) 0.51
 
AA 46 (0.26)  
 
 
5) 
 
 9) 
0.01 1) 0.15 
  
 5)  
  2)  
 0.01 
 
3) 0.58 
 FNAR2 rs2300370 
AA 6 (0.03)   25 (0.13)   
AG 68 (0.38)   73 (0.38)   
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Table A-2 (Continued)       
IFNAR2 rs2834165       
AA 39 (0.22)   49 (0.25)   
G 1  
 
IFNA   
AA 6   27    
 59 ( 33) 79 ( 41) 
1  0.  0.  0.  
IFNAR2 rs2250226  
1  0.  0.  0.  
IFNAR2 rs2834167  
AG
1  0.  0.  0.  
IRF1 rs839  
81  
5 ) 0.  0. 0 77 ) 0.  0.  
IRF1 rs2070726  
4 ) 1  0.  28 ) 0.  0.  
IRF1 rs2070723  
1  0.  1  0.  
IRF1 rs2070721  
AG
1  0.  1  0.  
IRF1 rs2549009  
0.  0.  0.  0.  
IRF1 rs2549006  
1  0.  1  0.  
IRF1 rs2549003  
1  0.  0.  0.  
IRF1 rs736801  
0.  0.  1  0.  
IRF7 rs12421158 
0.  0.  0.  0.  
A
GG
R2 rs2834166  
07 (0.59)
34 (0.19) 
 
1.0 
 
 
0.01 
85 (0.44) 
59 (0.31) 
 
0.99 
 
 
0.11 
 
 (0.14)(0.03) 
AC 0.   0.   
TT 115 (0.64) .0 83 87 (0.45) 99 19
     
AA 33 (0.18) 
94 ( 52) 
  95 (0.49) 
73 ( 38) 
  
AG 0.   0.   
GG 53 (0.29) .0 44 25 (0.13) 99 07
     
AA 
 
129 (0.72) 
45 ( 25) 
  109 (0.57) 
77 ( 40) 
  
0.   0.   
GG 6 (0.03) .0 69 7 (0.04) 99 14
     
AA 
AG 
48 (0.27) 
 ( 45)
  24 (0.12) 
92 ( 48) 
  
0.   0.   
GG 0 (0.28 99 2  (0.40 99 67
     
GG 
GT 
50 (0.28) 
82 ( 46) 
  79 (0.41) 
86 ( 45) 
  
0.   0.   
TT 8 (0.27 .0 23  (0.15 99 56
     
CC 
CT 
47 (0.26) 
82 ( 46) 
  24 (0.12) 
91 ( 47) 
  
0.   0.   
TT 48 (0.27) .0 30 79 (0.41) .0 78
     
AA 
 78
34 (0.19) 
 ( 43) 
  55 (0.28) 
101 .52) 
  
0.   (0   
GG 68 (0.38) .0 17 38 (0.20) .0 49
     
AA 
AG 
47 (0.26) 
89 ( 50) 
  27 (0.14) 
97 ( 51) 
  
0.   0.   
GG 43 (0.24) 99 95 68 (0.35) 99 42
     
CC 
CT 
58 (0.32) 
85 ( 47) 
  80 (0.41) 
90 ( 46) 
  
0.   0.   
TT 27 (0.21) .0 57 24 (0.12) .0 87
     
CC 
CT 
54 (0.30) 
82 ( 46) 
  23 (0.41) 
90 ( 47) 
  
0.   0.   
TT 44 (0.24) .0 25 79 (0.41) 99 73
     
CC 
CT 
142 (0.79) 
35 ( 20) 
  76 (0.39) 
93 ( 48) 
  
0.   0.   
TT 2 (0.01) 99 92 25 (0.13) .0 68
      
CC 
CT 
54 (0.30) 
99 ( 55) 
  22 (0.11) 
88 ( 46) 
  
0.   0.   
TT 26 (0.15) 99 07 83 (0.43) 99 86
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Table A-2 (Continued)       
IRF7 rs7932167       
AA 79 (0.44)   118 (0.61)   
AC 73 (0.41)   62 (0.32)   
CC 28 (0.16) 1.0 0.11 13 (0.07) 0.99 0.23 
Mx1 rs462903       
AA 131 (0.73)   65 (0.34)   
AG 46 (0.26)   92 (0.47)   
GG 53 (0.29) 1.0 0.65 37 (0.19) 1.0 0.66 
Mx1 rs17000900       
1  55 ) 
1  
1  
9  1  
AA 10 (0.06)   5 (0.03)   
AC 62 (0.35)   31 (0.16)   
CC 105 (0.59) 0.98 0.83 156 (0.81) 0.99 0.03 
Mx1 rs455816       
AA 23 (0.68)    (0.28   
AG 53 (0.29)   90 (0.46)   
GG 4 (0.02) 1.0 0.79 49 (0.25) 1.0 0.32 
Mx1 rs469390       
AA 40 (0.22)   72 (0.37)   
AG 87 (0.48)   90 (0.46)   
GG 53 (0.29) 1.0 0.71 32 (0.17) 1.0 0.67 
Mx1 rs456298       
AA 67 (0.37)   44 (0.74)   
TA 89 (0.50)   48 (0.25)   
TT 23 (0.13) 0.99 0.43 2 (0.01) 1.0 0.53 
Mx2 rs757368       
CC 57 (0.32)   138 (0.72)   
CG 84 (0.47)   53 (0.28)   
GG 29 (0.22) 1.0 0.59 10 (0.05) 0.99 0.21 
Mx2 rs2838029       
AA 41 (0.23)   2 (0.01)   
AG 82 (0.46)   48 (0.25)   
GG 57 (0.32) 1.0 0.27 143 (0.74) 0.99 0.53 
Mx2 rs443099       
GG 116 (0.64)   28 (0.15)   
GT 57 (0.32)   94 (0.49)   
TT 7 (0.04)  1.0 0.99 71 (0.37) 0.99 0.73 
Mx2 rs116422       
GG 79 (0.44)   127 (0.66)   
GT 79 (0.44)   60 (0.31)   
TT 21 (0.12) 0.99 0.85 7 (0.04) 1.0 0.98 
Mx2 rs9305739       
CC 8 (0.04)   0 (0)   
CT 58 (0.32)   16 (0.08)   
TT 14 (0.63) 1.0 0.85 177 (0.92) 0.99 1.0 
Mx2 rs369908       
AA  (0.05)   28 (0.66)   
AG 68 (0.38)   55 (0.29)   
GG 102 (0.57) 0.99 0.59 10 (0.05) 0.99 0.21 
Mx2 rs11537891       
GG 145 (0.81)   191 (0.99)   
GT 32 (0.18)   3 (0.01)   
TT 2 (0.01) 0.99 0.71 0 (0) 1.0 1.0 
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Table A-2 (Continued)       
Mx2 rs464090        
CC 57 (0.32)   130 (0.67)   
CT 89 (0.49)   54 (0.28)   
TT 34 (0.19) 1.0 0.94 9 (0.05) 0.99 0.55 
Oas1 rs4766662       
AA 23 (0.13)   7 (0.04)   
AC 89 (0.49)   98 (0.51)   
CC 68 (0.38) 1.0 0.46 80 (0.42) 0.99 0.46 
Oas1 rs3741981       
CC 92 (0.51)   29 (0.15)   
CT 81 (0.45)   98 (0.51)   
TT 7 (0.04) 1.0 0.03 65 (0.34) 0.99 0.42 
Oas1 rs2285934       
AA 27 (0.15)   15 (0.08)   
AC 104 (0.58)   98 (0.51)   
CC 49 (0.27) 1.0 0.02 80 (0.42) 0.99 0.04 
Oas1 rs12298890 
 
1  
      
CC 179 (0.99)   0 (0)   
CT 1 (0.01)   0 (0)   
TT 0 (0) 1.0 1.0 193 (1.0) 0.99 - 
Oas1 rs2660       
AA 153 (0.85)   80 (0.42)   
AG 27 (0.15)   100 (0.52)   
GG 0 (0) 1.0 0.60 13 (0.07) 0.99 0.01 
Oas1 rs6489865       
AA 0 (0)   13 (0.07)   
AG 19 (0.11)   98  (0.51)   
GG 161 (0.89) 1.0 1.0 65 (0.34) 0.99 0.02 
Oas2 rs2010604       
CC 1 (0.01)   10 (0.05)   
CG 37 (0.20)   85 (0.44)   
GG 142 (0.79) 1.0 0.69 98 (0.51) 0.99 0.12 
Oas2 rs2072138       
CC 13 (0.07)   13 (0.07)   
CG 60 (0.34)   81 (0.42)   
GG 106 (0.59) 0.99 0.27 97 (0.51) 0.98 0.48 
Oas2 rs1293762       
AA 2 (0.01)   32 (0.17)   
AC 47 (0.26)   108 (0.56)   
CC 131 (0.73) 1.0 0.55 53 (0.28) 0.99 0.07 
Oas2 rs1293739       
AA 11 (0.06)   9 (0.05)   
AG 69 (0.38)   74 (0.38)   
GG 100 (0.56) 1.0 0.84 110 (0.57) 0.99 0.44 
Oas3 rs1981557       
CC 4 (0.02)   15 (0.08)   
CG 17 (0.10)   98 (0.51)   
GG 57 (0.88) 0.99 0.73 80 (0.42) 0.99 0.04 
Oas3 rs6489879       
AA 161 (0.89)   80 (0.42)   
AG 19 (0.11)   99 (0.51)   
GG 0 (0) 1.00 1.0 14 (0.07) 0.99 0.03 
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Oas3 rs2269899       
AA 92 (0.51)   84 (0.44)   
AG 80 (0.44)   95 (0.49)   
GG 8 (0.04) 1.0 0.09 14 (0.07) 0.99 0.06 
Oas3 rs2285933 
      
 
9 
1  
10 
3 
 
10 ) 
0  
1  
45 ) 
      
CC 27 (0.15)   10 (0.05)   
CG 83 (0.86)   85 (0.44)   
GG 70 (0.39) 1.0 0.77 98 (0.51) 0.99 0.12 
Oas3 rs2107418 
GG 39 (0.22)   33 (0.17)   
GT 71 (0.39)   106 (0.55)   
TT 70 (0.39) 1.0 0.01 54 (0.28) 0.99 0.12 
Oas3 rs2240189       
CC 123 (0.68)   99 (0.51)   
CT 51 (0.28)   84 (0.44)   
TT 6 (0.03) 1.0 0.80 10 (0.05) 0.99 0.14 
Oas3 rs757404       
CC 71 (0.39)   98 (0.51)   
CT 82 (0.46)   84 (0.44)   
TT 27 (0.15) 1.0 0.68 11 (0.06) 0.99 0.20 
OASL rs116927       
AA 20 (0.11)   29 (0.15)   
AG 80 (0.44)   82 (0.43)   
GG 80 (0.44) 1.0 1.0 82 (0.83) 0.99 0.26 
OASL rs713414      
AA 4 (0.02)   0 (0)   
AG 45 (0.25)   10 (0.05)   
GG 130 (0.73) 0.99 1.0 184 (0.95) 1.0 1.0 
OASL rs2259697       
CC 23 (0.13)   8 (0.04)   
CT 89 (0.49)   63 (0.33)   
TT 68 (0.38) 1.0 0.99 123 (0.63) 1.0 0.46 
OASL rs128192       
CC 160 (0.89)   124 (0.64)   
CT 20 (0.11)   63 (0.33)   
TT 0 (0) 1.0 1.0 7 (0.04) 1.0 0.77 
OASL rs386179       
CC 0 (0)   0 (0)   
CG 0 (0)   0 (0)   
GG 176 (1.0) 0.98 - 194 (1.0) 1.0 - 
OASL rs11307154       
AA 45 (0.25)    (0.05   
A- 91 (0.51)   65 (0.34)   
-- 43 (0.24) 0.99 0.82 119 (0.61) 1.0 0.77 
OASL rs796918      
AA 0 (0)   0 (0)   
AG 4 (0.02)   0 (0)   
GG 176 (0.98) 1.0 1.0 193 (1.0) 0.99 - 
OASL rs2260399       
CC 71 (0.39)   45 (0.23)   
CT 90 (0.50)   03 (0.53)   
TT 19 (0.11) 1.0 0.22  (0.23 0.99 0.35 
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OASL rs10849829       
AA 19 (0.11)   46 (0.24)   
AG 90 (0.50)   104 (0.54)   
GG 71 (0.39) 1.0 0.22 44 (0.23) 1.0 0.31 
OASL rs3213546       
CC 7 (0.04)   0 (0)   
CG 47 (0.26)   11 (0.06)   
GG 136 (0.70) 1.0 0.33 183 (0.94) 1.0 1.0 
OASL rs3213545       
CC 125 (0.69)   95 (0.50)   
CT 52 (0.29)   74 (0.39)   
TT 3 (0.02) 1.0 0.56 23 (0.12) 0.99 0.15 
OASL rs28360476 
6  
37 ) 
11 ) 0.  
068 
1 ) 
 
1 ) 
1  
1  
3  
      
AA 0 (0)   0 (0)   
AC 0 (0)   0 (0)   
CC 178 (1.0) 0.98 - 194 (1.0) 1.0 - 
OASL rs10849832       
CC 10 (0.06)   (0.03)   
CT 58 (0.29)    (0.19   
TT 2 (0.62 1.0 0.49 150 (0.78) 0.99 06
OASL rs12315       
AA 0 (0)   0 (0)   
AG 0 (0)   0 (0)   
GG 79 (1.0 0.99 - 194 (1.0) 1.0 - 
OASL rs10849833       
AA 0 (0.06   0 (0)   
AG 57 (0.32)   18 (0.09)   
GG 113 (0.63) 1.0 0.43 176 (0.91) 1.0 1.0 
OASL rs2859394       
CC 4 (0.02)   3 (0.02)   
CT 31 (0.17)   54 (0.28)   
TT 112 (0.62) 0.99 0.15 136 (0.71) 0.99 0.61 
OASL rs2859398       
CC 5 (0.03)   29 (0.15)   
CT 57 (0.32)   84 (0.43)   
TT 118 (0.66) 1.0 0.54 81 (0.42) 1.0 0.35 
OASL rs7134069       
AA 16 (0.65)   177 (0.91)   
AC 51 (0.29)   17 (0.09)   
CC 12 (0.07) 0.99 0.06 0 (0) 1.0 1.0 
PKR rs2307478       
CC 0 (0)   0 (0)   
CT 15 (0.08)   0 (0)   
TT 165 (0.92) 1.0 1.0 194 (1.0) 1.0 - 
PKR rs2307479       
AA 42 (0.79)   185 (0.95)   
AC 33 (0.18)   9 (0.05)    
CC 4 (0.02) 0.99 0.26 0 (0) 1.0 1.0 
PKR rs2287350       
AA 129 (0.73)   70 (0.36)   
AG 45 (0.25)   90 (0.47)   
GG  (0.02) 1.0 0.78 33 (0.17) 0.99 0.66 
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PKR rs2254958       
CC 129 (0.73)   64 (0.34)   
CT 45 (0.25)   91 (0.48)   
TT 4 (0.02) 0.99 1.0 34 (0.18) 0.97 0.87 
STAT1  rs2066797  
  
  
  
  
0  
1  16 ) 
  
1 ) 
  
4 ) 
9 ) 31 ) 
0.  0.  
C
G
  
12 ) 19 ) 
1  
1  
  
     
AA 123 (0.68)   168 (0.88)   
AG 51 (0.28)   23 (0.12)   
GG 6 (0.03) 1.0 0.78 1 (0.01) 0.99 0.83 
STAT1  rs3088307      
 CC 12 (0.07)   42 (0.22)   
CG 68 (0.38)   99 (0.51)   
GG 100 (0.56) 1.0 0.92 52 (0.27) 0.99 0.69 
STAT1  rs1400657      
AA 110 (0.61)   156 (0.81)   
AC 61 (0.34)   27 (0.19)   
CC 9 (0.05) 1.0 0.89 0 (0) 0.99 0.23 
STAT1  rs1914408      
AA 7 (0.04)   9 (0.05)   
AG 46 (0.26)   59 (0.31)   
GG 127 (0.71) 1.0 0.28 124 (0.65) 0.99 0.57 
STAT1  rs2280234      
 CC 27 (0.15)   83 (0.43)   
CT 83 (0.46)   84 (0.44)   
TT 70 (0.39) 1.0 0.77 26 (0.14) 0.99 0.52 
STAT1  rs1269359      
 AA 39 (0.77)   7 (0.87   
AC 28 (0.21)   23 (0.12)   
CC 3 (0.02) 1.0 0.71 3 (0.02) 0.99 0.07 
STAT1  rs2066802      
 CC 1 (0.01)   1 (0.01)   
CT 25 (0.14)   23 (0.12)   
TT 154 (0.86) 1.0 1.0 169 (0.88) 0.99 0.55 
STAT1  rs1467199       
CC 84 (0.47)   124 (0.64)   
CG 78 (0.43)   61 (0.32)   
GG 8 (0.10 1.0 0.99 8 (0.04) 0.99 0.89 
STAT2  rs2066808      
 CC 7 (0.26   0 (0)   
CT 6 (0.53    (0.16   
TT 27 (0.21) 1.0 35 162 (0.84) 0.99 36
STAT2  rs2066807       
 CC 0 (0)   0 (0)   
G 2 (0.01)   31 (0.16)   
G 178 (0.99) 1.0 0.94 162 (0.84) 0.99 0.64 
STAT2  rs2066811      
AA 5 (0.69   2 (0.99   
AG 49 (0.27)   (0.01)   
GG 6 (0.03) 1.0 0.66 0 (0) 0.99 .0
STAT2  rs2228259      
CC 0 (0)   0 (0)   
CG 1 (0.01)   0 (0)    
GG 179 (0.99) 1.0 1.0 193 (1.0) 0.99 - 
       
       
       
197 
Table A-2 (Continued)       
STAT2  rs2066816       
GG 0 (0)   0 (0)   
TG 0 (0)    0 (0)    
TT 180 (1.0) 1.0 - 193 (1.0) 0.99 - 
STAT2  rs2066819  
2  
5 ) 
9 ) 2  
0.  1  
     
AA 0 (0)   0 (0)   
AG 2 (0.01)   32 (0.17)   
GG 178 (0.99) 1.0 1.0 161 (0.83) 0.99 0.38 
STAT2  rs1117181      
AA 45 (0.25)   0 (0)   
AG 94 (0.52)   2 (0.01)   
GG 41 (0.23) 1.0 0.55 191 (0.99) 0.99 1.0 
STAT2  rs4301822       
CC 4 (0.30   0 (0)   
CT 0 (0.50   (0.01)   
TT 35 (0.20) 0.99 82 191 (0.99) 0.99 .0
*  Hardy Weinbe  Equilibrium 
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Table A-3:  Haplotype Frequencies for Interferon Stimulating Genes Among African Americans and Caucasian Americans 
 mer  
 180 
aucas Ameri
  
 
SNPs* 
 
African A
N =
icans C ian 
N = 194 
 
cans 
Haplotype 
G1P2 12
0
GT  0.31 0.05 
IFI35 0 s6 , rs108   
0
0
IFNAR1 
rs1921, rs933 23   
AT 
GC 
 
 
0.3
0.26
9 .38
 
 
 0.56
rs8 76790, r 926
 
 
 
92 40 
C
T
AG 
GA 
TGG 
0.2
0.2
0.44
7 
1 
.18 
.09 
 0.73 
rs2834190, rs2856968, rs2252930, rs2243592,  
rs2253923,  rs2257167, rs2243599, rs1041868, 
rs2834202 
  
AACTAGTGA  0.21 0.32 
AGCGTCGAA  0.19 0.13 
A GTGG  
AACTAGGGA  0.27 0.01 
GC GG  0.17 0
TAGTAGTGA  0.25
IFNAR2 
.24 
   0.09
rs9636866, rs2300370, rs4986956, rs2252650, 
rs2834165, rs2834166, rs2250226,  rs2834167 
  
CGT C 0. 0
C 0
C 0
0.03 0.09
TGTTGAAA  0.17 0.25 
TGTTGAAG  0.02 0.07 
TTGC  0
TTGC  0
    
    
 
 
TA
TA
AA
TATAACGG 
AA 
GA 
GA 
 
 
 
 
03 
7 
9 
.15 
.01 
.16 
 
CG
TA
T
T
0.1
0.0
TG
TG
AA 
GA 
 
 
0.17
0.09
.13 
.01 
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IRF1  rs839, rs2070726, rs2070723, rs2070721,    
rs2549009,  rs2549006, rs2549003, rs736801 
ATCCATCC  .38  
ATCCGCCC  .05  
GGTAATCC  .05  
GGTAGCTC  .25  
GGTAGCTT  0
GGTCGCTC  
IRF7 rs12421158, rs7932167   
CA  0
CC  0
TA  0
TC  .20 0.19 
Mx1 rs462903, rs455816, rs469390, rs256928   
AAAA  .26 0.13 
AAGA   0
AAGT   0.03
AGAA  0.04 0.07 
GGAA  0.09 0.31 
OAS1 
0
0
0
0
0
0
 0.35
 0.01
 0.00
 0.17
0.0
0.0
9 
8
.34 
  0.07
0.4
0.1
0.2
2 
6 
2 
.30 
.04 
.47 
0.21
0.29
.32 
 
rs4766662, rs3741981 
AC   
 
0.37
 
0.16 
AT  0.10 0.05 
CC  0.37 0.25 
CT  0.25 0
OAS2 rs2010604, rs2072138, rs1293762, rs1293739 
CGAG  0
GCCG  0.18 0.26 
GGAA  0.03 0.07 
GGAG  0.06 0.11 
GGCA  
GGCG   0.11
    
    
  
.54 
 
.25 
 
0.05 
0.1
0.41
8 0.16 
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Table A-3 (Continued)    
OAS3 rs2269899, rs2285933, rs2240189, rs757404   
ACCT  0.05 0.00 
ACTT  
AGCC  
GCCT   0.01 
GGCC   0.31 
OASL 
0.15 0.26 
0.52 0.42 
0.14
0.09
rs1169279, rs7134141, rs2259697, rs12819210,   
rs7969180,  rs2260399,  rs10849829,  rs3213546,  
rs3213545,  rs10849832 s10849833,  rs2859394,  ,  r
rs2589398,  rs7134069 
AATCGTACCC  ATTC 0.11 0.03 
AGTCGTAGTT  GTCA 0.13 0.27 
GGCCGCGGCT  GTTA 0.27 0.01 
GGCTGCGGCTGCTA   0.16 
GGTCGCGGCCGTTA 0.02 
0.00
 0.07 
GGTCGCGGCTGTTA  0.14 0.20 
GGTC  GTAGCTGTTA 0.04 0.13 
PKR rs2307479, rs2287350, rs2254958 
AAT 0 5  
CAC 0.09 0.02 
STAT1 
  
AAC  0.71 0.53 
AGT  0.08 0.38 
AGC  0.06 0.03 
 
 
.0 0.04
rs2066797, rs3088307 400657,  rs1914408,  , rs1
rs2280234,  rs1269395 rs2066802,  rs1467199 
 
 
 
 
 
 
AGCGTATC 
AGCGTATG  
  
0,  
ACAGCATC 0.11 0.44 
ACAGCATG 0.08 0.02 
AGAATATG 0.09 0.15 
AGAGCATC 0.09 0.10 
AGAGCCTC 0.02 0.07 
AGAGTATC 0.09 
 
0.01 
0. 7  0.08 0
 0.09 0. 2 
GGAGTATC  0.07  
0
0.01
200 
201 
* SNPs are listed i ey appear in the haplotype and along the chromosome 
 
 
n order that th
 
Table A-3 (Continued)    
STAT2 rs , 2066808, rs2068807, rs2066811, rs2228259
rs2066816, rs2066819  
  
CCAAGT  0.00 0.08 
CGAGAC  0.32 0.01 
CGGGAC  0.16 0.01 
TGAGGC  0.05 0.00 
0.42 0.91  TGAGGT 
 
Table A-4:  Multivariable Model Est rferon Stimulating Gene Single Nucleotide Polymorphisms 
During the First 28 Days of Treatmen cans 
 
 African Americans (N = 180) 
hange in Viral Level by Treatment Day* 
 Caucasian Americans (N = 194) 
Estimated Ch n Viral Level by Treatment  
 
 imating Differences in Viral Level by Inte
t Among Caucasian Americans and African Ameri
Estimated C ange i  Day*
Genetic Marker * 1 2 7 14 28 p-value N 0** 2 7 14  p-value N 0 * 1 28
ISG15 G1P2 rs1921                 
AA 05 27 6.37      28 6.        
AG 96 6.26 96 6.36 0.14 0.10 0.21 0.34 0.87  0.03 0.04 -0.01 0.07 0.06  
GG 56 6.22 70 6.24 0.01 -0.07 0.01 0.04 0.28 0.19  0.13 0.13 -0.03 -0.04 0.10 0.77 
ISG15/G1P2 rs9331223                 
CC 15 6.0  65 6.22      6        
CT 78 6.2  0.10 0.30 0.18 -0.001 -0.05  92 6.38 0.16 0.15 0.19 7  0 0.14 0.4
TT 86 6.2  0.04 0.29 0.20 0.12 -0.03 0.81 36 6.33 -0.02 -0.01 -0.02 23 0.19 5 -0.02 -0.
G1P3 rs112                47653  
AA 143 6.2       61 6.30     3   
AG/GG 37 6.16 0.001 0.001 0.18 0.14 0.34 0.29 132 6.32 0.01 -0.11 -0.19 16 0.83 -0.07 -0.
G1P3 rs114                1746§  
G1P3 rs131                6896§  
IF 10840         I35 rs         
AA/AG 65 6.40 32 6.17             
GG 115 11 -0.01 -0.08 -0.09 -0.19 -0.13 0.83 162 6.35 0. 0.15 0.15 -0.14 25 0.49  6. 07 -0.
IFI35 rs455055                 
GG 89 24       12 6.30      6.   
GT 66 26 -0.11 -0.21 -0 0.34 -0.41  76 6.22 -0.14 -0.07 -0.31 4  6. .22 - 0.01 -0.4
TT 24 02 -0.08 -0.08 -0.08 -0.13 0.03 0.59 103 6.39 -0.11 -0.18 -0.49 0 0.29  6. 0.002 -0.9
IF 692         I35 rs692         
AA/AG 86 6.16 62 6.30             
G 2 129 6.33 -0.03 -0.12 -0.02 25 0.44 G 94 6. 6 -0.01 0.05 0.01 0.06 0.01 0.91 -0.03 -0.
IFI35 rs8076790                 
CC/CT 106 6.1       67 6.31     8   
TT 74 6.2 -0.08 0.01 -0.01 0.10 0.10 0.69 126 6.32 -0.02 -0.16 -0.06 32 0.26 6 -0.01 -0.
IFNAR1 rs2834190                 
A 2       99 6.29     A 142 6. 4   
AT/TT 36 6.0  0.06 0.05 0.21 0.32 0.36 0.56 94 6.35 0.02 -0.04 -0.20 12 0.77 9 0.02 -0.
IFNAR1 rs2856968                 
A 27       72 6.39     A 68 6.   
AG/G 18 -0.01 -0.11 -0.08 -0.28 -0.23 0.25 121 6.27 0.06 0.01 0.09 9 0.84 G 112 6. 0.10 0.1
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T                 able A-4 (Continued) 
I         FNAR1 rs2252930         
CC 143 6.24 99 6.29             
CG/GG 37 6.11 0.04 0. 32 0.59 94 6.35 0.02 0.02 -0.04 -0.02 -0.12 0.77 03 0.18 0.30 0.
IFNAR1 rs2243592                 
GG/GT 18       121 6.27     112 6.   
TT 68 6.27 0.01 0.11 0.08 0.28 0.23 0.25 72 6.39 -0.06 -0.01 -0.09 19 0.84 -0.10 -0.
IFNAR1 rs2253923                 
AA 28       72 6.40     67 6.   
AT/TT 18 -0.01 -0.10 -0.07 -0.28 -0.24 0.26 113 6. 121 6.27 0.  0.07 0.04 0.10 20 0.82 11  0.
I         FNAR1 rs2257167         
CC/CG 63 6.20       47 6.19       
GG 117 6.22 0.01 0.03 -0.01 0.14 -0.09 0.15 145 6.36 -0.08 0.01 -0.11 -0.19 -0.34 0.63 
I NAR1 rs2834195                 F
AA/AG 15 6.16       1 †       
GG 165 6.23 -0.12 -0.18 -0.22 -0.34 -0.24 0.88 192        
IFNAR1 rs2243599                 
GG 83 6.29       99 6.22       
GT 77 6.08 0.03 -0.02 -0.08 -0.15 -0.03  26 6.29 -0.23 -0.17 0.12 0.15 0.21  
TT 20 6.40 -0.07 -0.03 0.04 0.27 0.45 0.58 69 6.39 -0.29 -0.16 0.11 0.11 0.03 0.73 
IFNAR1 rs1041868                 
AA/AG 73 6.20       59 6.18       
GG 106 6.23 0.01 0.09 0.06 0.31 0.18 0.07 134 6.37 0.03 0.17 0.17 0.06 -0.14 0.47 
IFNAR1 rs2834202                 
AA 116 6.22       108 6.35       
AG/GG 64 6.20 -0.16 -0.22 -0.20 -0.11 -0.27 0.17 85 6.28 0.13 0.15 0.01 0.06 0.06 0.74 
IFNAR2 rs1476415                 
AA 46 6.34       48 6.20       
AC 106 6.22 0.05 -0.05 -0.01 -0.15 -0.24  86 6.41 0.19 0.09 0.04 -0.02 -0.14  
CC 28 6.02 0.02 -0.09 -0.15 -0.43 -0.43 0.13 60 6.28 0.17 -0.01 -0.21 -0.33 -0.14 0.38 
IFNAR2 rs9636866                 
CC/CT 106 6.22       72 6.34       
TT 74 6.21 0.08 0.10 0.12 0.06 0.10 0.89 121 6.30 -0.09 -0.05 -0.04 0.14 0.06 0.65 
IFNAR2 rs2300370                 
AA/AG 74 6.17       98 6.35       
GG 106 6.24 0.01 0.06 0.06 0.24 0.35 0.26 95 6.28 -0.16 -0.09 -0.05 -0.04 -0.09 0.77 
IFNAR2 rs2248420                 
CC 131 6.23       105 6.27       
CT/TT 49 6.16 -0.05 -0.04 -0.15 -0.27 -0.47 0.16 87 6.36 0.09 -0.01 -0.05 -0.16 -0.14 0.80 
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Table A-4 (Continued)                 
IFNAR2 rs4986956                  
CC/CT 22 6.16       22 6.37       
TT 158 6.22 -0.06 -0.13 0.10 0.17 0.30 0.46 171 6.31 -0.06 -0.11 0.15 0.27 0.38 0.28 
IFNAR2 rs2252650                 
AA/AT 8  94 6.20      7 6.37       
TT  0 3 3 96 6.23 0.02 0.08 0.09 0.15 0.27 .6 96 6.27 -0.17 -0.11 -0.06 -0.05 -0.1 0.68 
IFNAR2 rs2831465                 
AA 39 6.10       80 6.26       
AG 107 6.25 0.05 0.10 0.07 0.20 0.11  85 6.45 0.06 0.17 0.34 0.38 0.002  -
GG 34 6.23 -0 5 .0 -0 2 .0 0.02 0.14 0.26 0 7 0. 7 .7 59 6.17 -0 0 .1 0.03 0.20 0.27 0.07 3
IFNAR2 rs28334166                 
AA 65 6.21       106 6.26       
AC/CC 1 5 6 2 0 4 0 4 0 4 0 5 -0 9 0 6  6 8 0 2 0 2 -0.08 -0.05 -0.001 0. 8 1 .2 .1 .1 .0 .0 .0 .3 87 .3 .0 .0 9
IFNAR2 rs2250226                 
AA 33 6.15       96 6.27       
AG 94 6.30 0.12 0.14 0.06 0.08 -0.22  73 6.35 0.20 0.16 0.20 0.14 0.12  
GG 53 6.10 0.11 0.09 -0.01 0.04 -0.27 0.57 25 6.39 -0.02 -0  -0  -0  -0.17 .56 .64 .46 0.31 
IFNAR2 rs2834167                 
AA 129 6.23       109 6.25       
AG/GG 51 6.18 -0.05 -0.09 -0.16 -0.18 -0.44 0.11 84 6.40 -0.01 -0  -0.01 .03 0.03 -0.14 0.81 
IRF1 rs839                 
AA  6. 1  6. 5 48 3       25 4       
AG 8  6 9 0. 04 -0.18 -0.12 -0.27 -0 1  6 9 -0.01 -0.13 -0.19 -0 3 0 3 1 .1 0 .2  92 .3 .3 .0  
GG 50 6.15 0. 3 00 -0 3 .1 0.10 -0 3 .0 0.01 0.55 77 6.19 -0 9.1  -0 6 .2 -0 0 .2 -0 6 .4 0.14 0.09 
IRF1 rs2070726                 
GG 50 6.15       79 6.20       
GT 82 6.24 0. 3 -0 5 -0 1 -0 3 -0 1 0.  0.  0.  0.  -0 7 00 .0 .2 .2 .2  86 6.39 19 13 03 14 .0  
TT 48 6.24 -0.01 0.13 -0.14 0.002 -0.03 0.55 28 6.45 0.12 0.18 0.14 0.36 -0.25 0.08 
IRF1 rs2070723                 
CC 47 6.31       24 6.45       
CT 83 6.20 -0. 2 0 -0. 9 1 -0. 1 1 -0. 6 2 -0 0 .2  91 6.39 -0. 3 0 -0. 5 1 -0. 1 2 -0 6 .3 -  0. 010  
TT 50 6.15 -0.004 -0.14 0.11 -0.03 -0.01 0.55 79 6.20 -0.18 -0.25 -0.22 -0.46 0.15 0.11 
IRF1 rs2070721                 
AA 34 6.23       55 6.17       
AC 78 6.15 0  0  0.12 .22 -0.01 0.04 .08  101 6.37 -0.003 -0.04 -0.07 -0.08 -0.50  
CC 0 6 0. 6 -0 0 0. 3 -0 6 0. 9 0 0 0. 4 0. 8 0. 3 -0 3 0. 1 68 6.28 .0 2 .1 0 .0 1 38 6.41 .1 1 0 2 .3 1
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Table A-4 (Continued)                 
IRF1 rs2549009                 
AA 47 6. 5  6. 2 3       27 3       
AG 89 6. 7 0. 2 0. 4 0. 5 0. 1 -0 1  6. 3 0. 2 -0 9 -0 2 -0 3 0. 9 1 1 0 0 0 .0  97 4 0 .0 .0 .2 0  
GG 43 6.15 0 4 -0 6 0. 7 0. 0 0. 7 0. 3 -0 9 -0 8 -0 8 -0 8 0. 6 0. 7 .0 .0 0 1 1 9 68 6.18 .0 .1 .0 .3 1 2
IRF1 rs2549006                 
CC 58 6. 8 1       8  0 6. 9 1       
CT 85 6.20 0 4 0 0 0 3 -0.02 -0.23 0 4 0 9 -0.004 0 0 -0.09 .0 .1 .0  90 6.40 .1 .0 .1  
TT 37 6.29 0.03 0.11 0.03 0.02 -0.06 0.82 24 6.45 0.17 0.24 0.21 0.46 -0.12 0.19 
IRF1 rs2549003                 
CC 54 6.30       23 6.44       
CT 82 6.18 0.002 -0.09 -0.04 -0.15 -0.24  90 6.38 -0.06 -0.16 -0.21 -0.37 0.03  
TT 44 6. 7 1 -0 03.  -0  -0  -0  -0.10 0. 0 1 0. 7 0 0. 7 1 0. 1 6 7  9 6. 0 2 -0 21. .27 .23 .48 0. 5 1 0. 1 1
IRF1 rs736801                 
CC 142 6.22       76 6.31       
CT/TT 37 6. 6 1 -0 09 . -0 17 . 0. 60  0.  0.  0.  0.  0.  0.07 06 44 1 8 1 6. 33 08 14 05 -0 04 . 0. 3 0 0. 2 8
IRF7 rs12421158                 
CC 54 6.15       22 6. 14        
CT 99 6. 32  -0  -0 6 2 -0 0 -0 5 -0 6 -0 7 -0 5 .09 -0 06 . 0. 01 .05 0. 0 1  8  8 .2 .1 .1 .3 .5 .5  
TT 26 6.26 0 4 0. 0 0. 0 0. 2 0. 4 0. 3 -0 9 -0 5 -0 2 -0 7 -0 9 0. 0 .0 1 3 1 1 3 83 6.40 .1 .2 .3 .4 .4 9
IRF7 rs7932167                 
AA 79 6.17       118 6.38       
AC 7  3 6. 3 3 -0 5 .0 -0 2 .1 -0 1 .1 -0 7 .0 -0 7 .1  6  2 6. 6 2 -0 8 .0 -0 8 .0 -0 0 .1 -0.007 -0 7 .0  
CC 28 6.03 -0 9 -0 7 -0 7 -0 1 -0 8 0. 9 0. 9 0. 0 -0 6 -0 6 -0 9 0. 2 .1 .2 .0 .0 .0 7 13 6.01 0 2 .1 .1 .4 8
Mx1 rs462903                 
AA 1 1 3 6. 5 2       6  5 6. 6 2       
AG/GG 49 6.13 -0 1 -0 6 0. 5 -0 2 -0 1 0. 2 0 9 0. 5 0. 5 0. 1 0. 3 0. 7 .0 .0 0 .1 .2 4 129 6.36 .1 2 4 4 1 0
Mx1 rs17000900                 
AA/AC 72 6. 6 2       3  6 6. 2 2       
CC 105 6.17 -0 2 -0 9 -0 7 -0 5 -0 1 0. 0 0 5 0. 6 0. 1 0. 5 0. 7 0. 3 .0 .0 .0 .1 .1 9 156 6.35 .0 0 1 2 2 9
Mx1 rs455816                 
AA 123 6.24       55 6.33       
AG 5  3 6. 41  0  0  0  0  0. 3 0 -0 5 .0 0. 7 0 -0 9 .0 -0.001  9  0 6. 32 . 22 . 91 . 33 . 4 1 -0.002  
GG 4 6.53 -0 0 -0 2 -0 4 -0 9 -0 8 0. 7 0 2 0. 3 0. 3 0. 2 0. 4 0. 3 .4 .5 .3 .3 .1 6 49 6.48 .1 2 3 4 2 4
Mx1 rs469390                 
AA 40 6. 7 1       7  2 6. 4 3       
AG 87 6.26 0 9 0. 1 0. 6 0. 3 0. 6 0 1 0. 2 0. 3 -0 3 0. 4 .1 2 2 4 4  90 6.30 .1 0 1 .1 0  
GG 53 6.16 0.19 0.22 0.29 0.36 0.48 0.58 32 6.34 0.13 0.22 0.32 0.11 0.23 0.57 
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Table A-4 (Continued)                 
Mx1 rs456298                 
AA 67 6. 1 1  6. 9 2       44 2       
AT/TT 1 2 6. 1 0. 4 0. 4 -0 5 0. 2 0. 7 0. 9  6. 9 -0 8 0. 5 0. 3 0. 5 -0 9 0. 6 1 2 0 0 .0 0 1 4 50 3 .0 0 0 0 .2 1
Mx2 rs757368                 
CC 57 6.20       138 6.30       
CG/GG 1 3 2 6. 2 2 0.0 030 0. 4 0 0. 3 0 0. 9 0 -0 8 .0 0. 4 6 5  5 6. 6 3 -0 3.1  -0  -0  -0  -0.13 .08 .11 .14 0. 3 9
Mx2 rs2838029                 
AA 41 6.33       2 5.60       
AG 8  2 6. 3 1 -0 1 .0 -0 5 .0 -0 9 .1 -0 6 .1 -0 7 .1  4  8 6. 04  0.  0.44 46 -0 6 .2 -0 9 .0 -0 35 .  
GG 57 6.24 -0.10 -0.14 -0.21 -0 9 -0 6 0 7 0 8 0. 0 -0 9 -0 5 -0 5 0. 3 .1 .2 .9 143 6.30 .5 6 .1 .0 .3 9
Mx2 rs443099                 
GG 116 6.24       28 6.33       
GT 57 6.18 0.10 -0.01 -0.04 -0.07 0.04  94 6.35 0.30 0.45 -0.03 -0.10 -0.29  
TT 7 6. 2 0 -0 76.  -0  -0  -0  -0  -0.83 .62 .91 .99 0. 4 0 7  1 6. 7 2 0. 7 1 0. 8 3 -0 10. .10 0. 4 0 0. 3 0
Mx2 rs116422                 
GG 79 6.17       127 6.33       
GT/TT 100 6.24 0.  0.  0.  0.  0.  0.  0.  0.  0.  0.13 13 21 13 29 21 67 6.30 17 22 12 30 0.19 0.34 
Mx2 rs9305739                 
CC/CT 66 6.24       16 6.43       
TT 114 6.20 -0.04 -0.07 0.02 0.11 0.26 0 9 0. 2 .3 177 6.31 0.35 0.46 0.39 0.68 1.00 1
Mx2 rs369908                 
AA 9 6. 8 1       1 8 2 6. 5 3       
AG 68 6.19 0 7 0. 8 0. 4 0. 1 0. 5 -0 0 -0 4 -0 0 -0 1 -0 7 .7 8 6 6 5  55 6.25 .3 .4 .5 .6 .9  
GG 102 6.23 0.69 0.83 0.56 0.54 0.36 0.06 10 6.32 0.18 0.10 -0.11 -0.40 0.10 0.003 
Mx2 rs11537891†                 
GG/GT 145 .22 19 6        2         
TT 34 6.16 -0.01 -0.004 0.02 0.04 0.14 0 7 .9 2 †       
Mx2 rs464090                 
CC 57 6. 5 2       1 0 3 6. 8 3       
CT/TT 123 6.20 0 6 0. 3 0. 3 0. 7 0. 9 0. 5 -0 0 -0 1 -0 3 -0 9 -0 3 0. 4 .1 2 0 1 2 04 63 6.18 .2 .3 .4 .5 .6 1
OAS1 rs4766662                 
AA/AC 112 6.24       75 6.34       
CC 68 6. 7 1 -0 03 . -0 10 . 0. 30  0.  0.  0.  0.  0.  0.05 15 53 1 8 1 6. 03 02 -0 03 . 0. 80 06 16 0. 9 8
OAS1 rs3741981                 
CC 92 6.20       29 6.52       
CT 81 6.26 0.  0.  0.  0.  0.  0.  0.  0.  0.06 05 01 20 03  98 6.17 03 16 12 20 0.39  
TT 7 5.88 -0 6 .3 -0.66 -0.32 -0.003 0.12 0.08 65 6.43 0.24 0.26 0.48 0.62 0.67 0.35 
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Table A-4 (Continued)                 
OAS1 rs2285934                 
AA/AC 131 6.20       113 6.27       
CC 49 6.24 -0.02 -0.002 0.05 0.11 0.12 0.98 80 6.39 0.20 0.16 0.39 0.48 0.44 0.13 
OAS1 rs12298890§                 
OAS1 rs2660                 
AA 1 2 6. 8  6. 0  5 1       80 4       
AG/GG 27 6. 8 0. 7 0. 0 0. 8 0. 8 0. 8 0. 3 1  6. 6 -0 0 -0 4 -0 7 -0 8 -0 2 0. 1 3 0 1 1 2 1 8 13 2 .2 .1 .3 .4 .4 1
OAS1 rs6489865                 
AA/AG 19 6.34       111 6.26       
GG 161 6.20 -0.11 -0.07 -0.07 -0.19 -0.07 0. 5 0. 4 8 82 6.40 0.22 0.17 0.37 0.47 0.41 1
OAS2 rs2010604                 
CC/CG 38 6. 6 3       9  5 6. 3 2       
GG 142 6.17 0 1 0. 0 -0 1 0. 7 0. 0 0. 4 0 2 0. 3 0. 2 0. 1 0. 2 0. 5 .0 1 .0 1 1 5 98 6.40 .1 1 2 3 1 4
OAS2 rs2072138                 
CC/CG 73 6.18       94 6.36       
GG 106 6.25 -0.15 -0.15 -0.21 -0.20 -0.20 0.64 97 6.26 -0.22 -0.34 -0.43 -0.44 -0.33 0.25 
OAS2 rs1293762                 
AA/AC 49 6.34       140 6.29       
CC 131 6.17 -0.12 -0.20 -0.22 -0.39 -0.33 0. 4 0. 0 3 53 6.38 0.12 0.15 0.27 0.26 0.17 8
OAS2 rs1293739                 
AA/AG 80 6. 8 1       8  3 6. 1 3       
GG 100 6.24 -0 7 0. 1 0. 1 0. 9 0. 3 0. 5 0 3 0. 5 0. 1 0. 1 0. 5 0. 2 .0 0 1 1 2 5 110 6.32 .2 2 2 2 2 5
OAS3 rs1981557                 
CC/CG 21 6. 0 2       1 3 1 6. 5 2       
GG 157 6.22 -0.04 -0.001 0 1 -0.01 0 7 0 7 0 2 0 6 0 9 0 1 0 6 0. 9 .1 .1 .6 80 6.41 .2 .1 .3 .5 .4 0
OAS3 rs6489879                 
AA 161 6.20       80 6.41       
AG  0.  0.  0.  0.  0.  0./GG 19 6. 43 11 07 07 19 07 85 1 3 1 6. 5 2 -0 2 .2 -0 6 .1 -0 9 .3 -0 51 . -0 46 . 0. 9 0
OAS3 rs2269899                 
AA 92 6.15       84 6.36       
AG 0 2 0. 2 /GG 88 6.28 -0.14 -0.14 -0.22 -0.23 -0.42 .1 109 6.28 -0.10 -0.13 -0.32 -0.41 -0.34 4
OAS3 rs2285933                 
CC/CG 1 0 1 6. 8 1       9  5 6. 8 3       
GG 70 6.27 -0 4 -0 7 -0 3 -0 3 0. 8 0. 8 -0.15 -0.16 -0.22 -0 4 -0 5 0. 9 .0 .0 .0 .0 0 8 98 6.26 .2 .0 4
OAS3 rs2107418                 
GG 39 6. 7 2       3  3 6. 7 3       
GT 71 6.14 -0 5 0. 0 -0 8 -0 7 -0 8 0 0 0. 8 0. 3 0. 7 0. 7 .0 1 .0 .0 .1  106 6.24 .1 2 2 6 7  
TT 70 6.26 -0.09 -0.08 0.05 0.07 -0.02 0.97 54 6.45 0.20 0.32 0.35 0.49 0.36 0.06 
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OAS3 rs2240189                 
CC 123      6.27       99 6.27  
CT/TT 57 6.10 0.20 0.19 0.09 0.21 0.06 0.11 94 6.36 0.11 0.10 0.17 0.17 -0.02 0.57 
OAS3 rs757404                 
CC 71 6.29       98 6.26       
CT/TT 109 6.16 -0.01 0.03 -0.03 -0.01 -0.12 0. 1 0. 3 8 95 6.37 0.13 0.12 0.18 0.20 0.02 6
OASL rs1169279                 
AA   /AG 1 00 6. 0 2       1 11 6. 4 3       
GG  6. 3 0. 7 0. 6 0. 2 0. 5 0. 5 0. 8  6. 8 -0 8 -0 1 -0 6 -0 9 0. 4 0. 1  80 2 0 1 1 0 1 5 82 2 .0 .1 .2 .1 2 0
OASL rs7134141                 
AA/AG 49 6. 4  6. 4 2       10 6       
GG 130 6.21 0 9 0. 2 0. 8 0. 5 0. 1 0. 6 0 4 0. 1 -0 2 0. 5 0. 3 0. 7 .0 1 0 1 1 8 184 6.30 .0 1 .0 0 2 9
OASL rs2259697                 
CC/CT 1 2 1 6. 2 2       7  1 6. 3 4       
TT 68 6.20 -0 3 0. 4 -0 5 0. 2 0. 3 0. 5 -0 3 -0 0 -0 1 -0 4 -0 5 0. 6 .1 0 .0 1 1 2 123 6.26 .1 .1 .1 .1 .3 4
OASL rs12819210                 
CC 160 6.20       124 6.26       
CT/TT  6. 9 0.  0. 8 0. 9 0. 9 0. 7 0. 1  6. 4 0. 3 0. 0 0. 2 0. 6 0. 2 0. 4 20 2 17 2 2 3 3 7 70 4 1 1 1 1 4 2
OASL rs3861793§                 
OASL rs11307154                 
AA/A- 136 6.20       75 6.13       
-- 43 6. 4 2 -0 8.0  -0  -0.16 .11 0. 1 0 -0 09 . 0. 2 7 1 9 1 6. 4 4 -0 6 .0 -0 4 .0 -0 1 .0 -0 6 .0 0. 3 1 0. 0 7
OASL rs7969180§                 
OASL rs2260399                 
CC 71 6.27       45 6.29       
CT 90 6. 71  -0  -0.03 -0 07 . 0. 2 0 0. 61 .02  1 3 0 6. 5 2 -0 0 .1 -0 8 .1 -0 5 .0 -0 9 .1 -0 5 .5  
TT 19 6.19 0 5 -0 4 0. 1 0. 8 0. 7 0. 7 -0 9 -0 8 -0 3 -0 4 -0 6 0. 5 .0 .0 1 1 1 6 45 6.50 .1 .0 .0 .2 .6 2
OASL rs10849829                 
AA 19 6. 9 1       4  6 6. 1 5       
AG 90 6.17 -0 8 -0 4 -0 8 -0 2 -0 8 0. 7 0. 8 -0 1 0. 4 0. 7 .0 .0 .0 .0 .1  104 6.26 0 0 .0 0 0  
GG 71 6.27 -0.05 0.03 -0.11 -0.18 -0.17 0.67 44 6.27 0.18 0.16 0.01 0.24 0.62 0.30 
OASL rs3213546                 
CC/CG 54 6.20       11 6.58       
GG 126 6.22 0.05 0.06 0.12 0.20 0.15 0 8 0. 5 .8 183 6.30 0.03 0.09 -0.09 -0.04 0.02 9
OASL rs3213545                 
CC 1 5 2 6. 0 2       9  5 6. 8 2       
CT/TT 55 6.24 -0 5 -0 0 -0 2 0. 5 0. 1 0. 3 6. 5 -0 1 0. 8 0. 8 0. 5 -0 3 0. 2 .0 .1 .1 0 0 6 97 3 .0 0 1 0 .3 0
OASL rs28360476§                 
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OASL rs10849832                 
CC/CT 68 6.18       43 6.23       
TT 1 2 1 6. 32  0.  0.  0.  0.  0.  0.  0.08 08 -0 01 . -0 08 . -0 04 . 0. 3 8 1 0 5 6. 43 05 11 10 03 09 0. 8 9
OASL rs12315068§                 
OASL rs10849833                 
AA/AG 67 6. 6 1       1  8 6. 8 4       
GG 113 6.24 0 0 0. 8 0. 7 0. 6 0. 1 0. 1 -0 9 -0 8 -0 7 -0 1 -0 3 0. 4 .1 0 0 0 1 9 176 6.30 .0 .0 .2 .2 .2 9
OASL rs2859394                 
CC/CT 35 6.28       57 6.45       
TT 144 .09 - 36 .16 - .05 - .09 - .16 -6.20 0.01 -0 0.13 -0.09 -0.15 0.92 1 6.27 -0 0 0 0 0.35 0.40 
OASL rs2859398                 
CC/CT 62 6. 6 1  6. 8 2       13 3       
TT 1 8 6. 9 0. 1 0. 3 0. 1 -0 5 -0 4 0. 7  6. 3 -0 2 -0 0 -0 7 -0 1 0. 9 0. 0 1 1 0 0 0 .1 .1 6 81 2 .0 .1 .1 .1 1 2
OASL rs7134069                 
AA 116 6.24       177 6.30       
AC/CC 63 6.18 -0.11 -0 0 -.1 -0.05 0.001 -0.08 0.74 17 6.47 0.05 0.10 0.22 0.15 0.17 0.99 
PKR  rs2307478                 
CC/CT 15 6.24 0 §              
TT 1 5 6. 1 0. 0 0. 2 0. 7 0. 9 -0 5 0. 8 1  6 2 2 3 0 0 .1 2 94        
PKR rs2307479                 
AA 142 6.20       185 6.30       
AC/CC 37 6. 5 2 -0 2.2  -0  -0  -0  -0  -0.34 .32 .57 .57 0. 5 04 9 6. 4 6 0. 0 1 0. 6 0 -0 16. .20 0. 6 0 0. 0 9
PKR rs2287350                 
AA 129 6.23       70 6.34       
AG 45 6. 8 1 -0 7.0  -0  -0  -0  -0  -0.15 .13 .20 .04  9  0 6. 7 2 0. 4 1 0. 6 2 0. 7 1 -0 05. .22  
GG 4 5.99 0 2 0. 5 0. 8 0. 3 -0 0 0. 8 0 6 0. 9 0. 3 0. 9 -0 3 0. 4 .1 1 2 0 .5 6 33 6.42 .0 0 2 0 .0 5
PKR rs2254958                 
CC 1 9 2 6. 1 2       6  4 6. 8 2       
CT 48 6.18 -0 1 -0 3 -0 4 -0 3 -0 6 0. 8 0. 2 0. 7 -0 8 -0 5 .2 .3 .2 .4 .2  91 6.29 1 3 1 .0 .2  
TT 3 6.60 -0.02 0.35 0.14 0.01 0.12 0.14 34 6.42 0.07 0.15 0.28 0.10 -0.08 0.31 
STAT1 rs2066797                 
AA 123 6.25       168 6.31       
AG/GG 57 6.14 -0.08 -0.12 -0.10 -0.10 0.02 0.78 24 6.32 0.22 0.20 0.44 0.42 -0.11 0.04 
STAT1 rs3088307                 
CC/CG 80 6.27       141 6.37       
GG 100 6.17 0.19 0.22 0.09 0.16 0.23 0.15 52 6.18 0.17 -0.07 0.02 0.04 -0.15 0.18 
STAT1 rs1400657                 
AA 110 6.27       156 6.33       
AC/CC 70 6.12 -0.03 0. 2 0 -0.12 -0.15 -0.23 0.59 37 6.27 -0.05 -0.10 -0.06 -0.02 -0.15 0.95 
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STAT1 rs1914408                 
AA/AG 53 6.15       68 6.25       
GG 127 6.24 0.14 0.17 0.20 0.30 0.19 0.50 124 6.35 -0.02 0.19 0.01 0.05 -0.02 0.39 
STAT1 rs2280234                 
CC 27 6.05       83 6.35       
CT 83 6.29 -0.21 -0.09 -0.06 0.07 -0.16  84 6.33 -0.05 -0.15 -0.04 -0.16 -0.27  
TT 70 6. 9 1 -0 1.1  -0  -0  -0  -0.04 .13 .09 .31 0. 0 5 2  6 6. 4 1 0. 1 0 -0 17 . 0. 7 2 0. 3 2 -0 20 . 0. 0 2
STAT1 rs12693590                 
AA 139 6.25       167 6.33       
AC  -0  -0  -0  -0  -0  -0/CC 41 6. 0 1 0. 2 0 0. 8 0 -0 4.0 .10 .15 0. 1 8 2  6 6. 6 2 -0 07. .23 .42 .44 .66 0. 0 4
STAT1 rs2066802                 
CC/CT 26 6.13       24 6.26       
TT 154 6.23 0.24 0.21 0.20 0.24 0.09 0.41 169 6.32 -0.25 -0.21 -0.49 -0.60 -0.32 0.19 
STAT1 rs1467199                 
CC 84 6. 8 1  6. 7 1       24 3       
CG/GG 96 6. 4 -0 7 -0 2 0. 9 0. 3 -0 5 0. 2  6. 1 -0 2 -0 6 -0 7 -0 5 -0 0 0. 3 2 .1 .1 0 0 .1 0 69 2 .1 .2 .1 .2 .1 4
STAT2 rs2066808                 
CC/CT 143 6.21       34 6.37       
TT 3  7 6. 3 2 -0 6 .1 -0 5 .1 0. 21  0  0  0 60  0  0  0  0. 70 . 02 . 0 1 1 6. 13 . 02 . 12 . 90 . 7 0 -0.003 0. 0 8
STAT2 rs2066807†                 
CC/CG 2 31 .47         6        
GG 1 8 7 †       1 2 6 6. 9 3 0. 3 1 0. 3 0 -0 4 .0 -0 08 . -0 22 . 0. 3 8
STAT2 rs2066811                 
AA 1  25 .21 96        1  2        
AG  0.  0.  0.  0.  0.  0./GG 55 6. 32 21 21 01 01 23 02 1 †       
STAT2 rs2228259§                 
STAT2 rs2066816§                 
STAT2 rs2066819                 
AA/AG 2 5.53       32 6.39       
GG 178 6.22 -0.90 -0.83 -0.75 0.09 0.18 0.18 161 6.30 0.14 0.06 -0.004 -0.02 -0.18 0.82 
STAT2 rs11171812†                 
AA/AG 1  39 .21 26                
GG 41 6.21 -0.10 -0.1 0.15 0.10 0.19 0.17 191 †       
STAT2 rs4201822†                 
 144 6.24 2              
 35 6.14 0 1 0. 4 0. 3 0. 8 0. 0 0. 4 .1 1 2 0 0 6 191 †       
*   Model ad etic nt, m he cti we e a  g  v
ean HCV RN  
SNP, †  allele freque y less t an 5% 
justed for the n ge  varia  age, ti e, and t  intera on bet en tim nd the enetic ariant 
**  Reflects the m
 
A levels 
§ Monomorphic  Minor nc h
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Table A-5:  Multivariable Model Esti ating iffe s in Viral Level for nter n ulat  Gene Haplotypes During the First 28 
Days of Treatm A g C si e  a
 
ericans (N = 180) 
stim hang  in Viral Level b Treatm nt Day*
 aucasia Ameri ns (N = 194) 
E at ange i  Viral L vel by Treatme Day* 
 
m D rence  I fero Stim ed  
ent mon auca an Am ricans nd African Americans 
 African Am
E ated C e  y e  
C n ca
stim ed Ch n e nt 
Genetic Marker - val e 0 1  14 28  valueN 0 1 2 7 14 28 p u N   2 7 p-  
ISG15 G1P2                 
AT 9 6.2  -0.1 -0.0 0.06 0.11 -0.0 0.35 120 6.36 0.11 14 15 21 32 0.79 11 2 0 7   4    0.  0.  0.  0.
GC  0.06 -0.0 0.00 -0.0 0.08 0.52 15 6.3 .07 0.09 0.14 0.16 0.55 0.15 88 6.20  2 2 7   6 2 0
GT 95 6.28 0. 0. 0. 0. 0. 0. 1 6.2 .0 .2 .2 .2 .2 0.9807 18 007 03 001 40 8 7 -0 7 -0 1 -0 2 -0 3 -0 2  
IFI35                  
CAG 0.02 -0.0 -0.0 -0.0 -0.0 0.85 64 6.3 .03 03 12 02 25 0.44  85 6.16  6 2 8 2   0 0  0.  0.  0.  0.
TGA  0. 0 0 0. 0. 0. 31 6.1 .0 .1 .1 .18 .29 0.4765 6.40 01 .08 .09 19 13 83  5 -0 2 -0 1 -0 2 0  0   
TGG 23 6.1  0.0 -0 0 0 0 0.8 1 6.32 -0.11 -0.27 -0.26 -0.55 -0.92 0.26 1 7 1 .08 - .09 - .17 - .17 7 79 
IFNAR1                 
AACTAGGGA 8 6.2  0.11 0.18 0.15 0.15 0.04 0.61 3 †       7 5       
AACTAGTGA 4 6.1  -0 0 0 0 0 0.5 1 6.38 -0.20 -0.16 -0.11 -0.10 -0.20 0.56 6 9 .03 - .06 - .17 - .21 - .07 6 04 
AGCGTCGAA  -0.0  -0.0  -0.0  -0.1 0.08 0.13 47 6.1 .08 -0.02 0.10 0.18 0.33 0.66 62 6.21 1 6 1 6    9 0
AGCGTGGGG -0 -0 -0 0. -0 0. 8 6.2 .11 .13 .0 .03 00 0.7854 6.16 .08 .12 .05 002 .17 48 4 8 0  0  -0 2 0  0. 8  
TAGTAGTGA 2 6.1  0.05 0.02 0.20 0.39 0.50 0.20 81 6.30 0.007 0.08 09 -0.13 -0.15 0.61 3 3        0.
IFNAR2                 
CGTTACAA 9 6.39 0.01 0.16 0.12 0.18 0.49 0.65 54 6.3 .12 11 20 08 07 0.86        6 0  0.  0.  0.  0.
CGTT A 0. 0. -0 -0 -0 0. †  ACG  59 6.14 05 04 .06 .06 .15 75 1       
TATA  9 6.1  -0.0  -0.0  -0.0  -0.0  -0.2 0.74 46 6.32 0.15 0.10 0.14 0.17 0.43 0.41 ACGA 2 7 3 7 7 9 7  
TA G  -0.0  -0.2  -0.1  -0.5  -0.8 0.12 23 6.3 .01 -0.07 .19 .10 0.01 0.95 TAACG 11 6.25 2 1 8 0 2   8 0  -0  -0
TGT A -0 -0 -0 -0 0. 0. 7 6.1 .0 .0 .03 .0 .24 0.46TGAA  54 6.25 .18 .16 .06 .08 13 10 2 9 -0 2 -0 5 0  -0 2 0   
TGTTGAAG  †       23 6.59 -0.20 -0.08 0.06 0.12 -0.32 0.17 4  
TGTTGCGA  0.11 0.10 0.15 0.28 0.30 0.73 †       29 6.21       3  
IRF1                 
ATCCA C 13 6.2  0.0 0.1 -0 0.0 -0 0.8 1 6.41 0.16 .16 .07 .22 -0.09 0.07 TC 1 4 2 0 .001 2 .04 4 13  0  0  0
ATCCGCCC 0.09 -0.0 -0.1 0.09 0.04 0.75 †  15 6.32  1 1    1        
GGTAATCC  0. -0 0. 0.05 0 0. 58 6.1 .1 .1 .01 .05 .36 0.1279 6.15 02 .04 09  .16 50  4 -0 3 -0 6 0  0  0   
GGTAGCTT 30 6.23 -0.08 -0.17 0.05 0. 0.10 0.46 108 6.32 0.07 0.10 0.04 -0.07 0.02 0.87 12 
GGTCGCTC 9 6.1  0.0 0.1 0.0 -0 -0 0.5 27 6.25 -0.003 0.04 -0.02 -0.11 -0.04 0.99 2 0 3 3 2 .07 .23 6 
IRF7                 
CA  0. 0. -0 -0 -0 0. 10 6.26 0.08 09 05 07 10 0.99  131 6.23 09 10 .09 .08 .10 54 7  0.  0.  0.  0.
CC 9 6.2  -0.2 -0.2 -0.2 -0.0 0.0 0.2 9  3 1 0 7 2 7 4 2 †      
TA -0.0 0.03 0.10 -0.0 0.20 0.20 1 6.3 .09 .25 .08 .11 0.02 0.43  60 6.25 2   2   30 5 -0  -0  -0  -0
TC  -0 -0 0. -0 -0 69 6.2 .0 .0 .2 .1 .2 0.7278 6.24 .06 .10 03 .04 .12 0.53  5 -0 7 -0 5 -0 0 -0 3 -0 2  
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Mx1                 
AAAA  0. 0. -0 -0 -0 0. 3 6.1 .1 .2 .4 .1 .1 0.3581 6.24 001 01 .08 .01 .11 78 7 9 -0 5 -0 7 -0 4 -0 7 -0 5  
AAGA 1 0. 0. 0. 0. 0 0. 95 6. 04 .0 04 .1 04 0.476 6.1  6 05 01 20 16 .14 53  27 0.  -0 4 0.  -0 5 0.   
AAGT 90 6.21 0.10 0.15 0.06 0.16 0.31 0.29 5 †               
AGAA  23 6.1 .13 .10 .0 .03 .09 0.97   8 †       5 0  0  -0 1 0  0  
GGAA  0. 0. 0. -0 -0 0. 95 6.3 .12 .14 .25 .13 .0 0.5032 6.09 03 02 07 .15 .06 60  3 0  0  0  0  -0 5  
OAS1                 
AC  -0 -0 -0 0 0 0.9 1 .3 .001 -0.05 0.04 -0.06 -0.23 0.63 141 6.19 .01 .001 .05 - .16 - .14 4 29 6 6 -0
AT  2 †       15 6.3 .23 .11 .24 .45 .41 0.724 0  0  0  0  0   
CC 110 6 0. 0. 0. 0. 0. 0. 78 6.3 0 0 0 0 0.37.2  0 02 04 07 02 10 82  0 - .09 - .09 - .20 - .19 -0.002  
CT  -0.0 -0.0 -0.0 0.14 0.12 0.24 15 6.3 .10 11 24 27 26 0.51 86 6.21 1 9 4    9 1 0  0.  0.  0.  0.
OAS2                 
CGAG 19 6.3  7 0. 0. 0. 0. -0 0. 8 6.2 0.4305 08 03 13 .003 92 8 1 -0.08 -0.11 -0.23 -0.30 -0.08  
GCCG 61 6.21 0.18 0.19 0.25 0.35 0.32 0.37 9 6.3 .26 34 44 49 38 0.20       1 4 0  0.  0.  0.  0.
GGAA 6.5 .1 .1 .01 .06 .4 0.095 †       24 0 -0 0 -0 5 0  0  -0 6  
GGAG  6. -0 0. 0. 0. 0. 0. 33 6.22 0.07 16 .0 .0 0.24 0.3115 3  7 .01 18 20 28 18 83    0.  -0 5 -0 9   
GGCA 6 6.1  -0 0 0 0 0 0.2 54 6.23 -0.23 -0.23 -0.28 -0.27 -0.14 0.53 5 6 .06 - .15 - .27 - .34 - .48 7 
GGCG  -0 0 0 0 0 0.8 3 6.4 .06 -0.14 -0.12 -0.04 -0.03 0.98 108 6.23 .13 - .09 - .06 - .07 - .05 4 7 2 -0
OAS3                 
ACTT 5 4 6.0  7 0. 0. 0. 0. 0. 0. 6. 12 13 20 22 06 0.6621 19 12 19 13 35 92 36 0.  0.  0.  0.  0.   
ACCT  -0.0 0.14 0.17 0.38 0.36 0.61  15 6.34 4      0 †      
AGCC  0. 0. 0. 0. -0 0.97 13 6.2 .2 .1 .1 .1 .0 0.68 133 6.22 05 02 06 02 .05  4 8 -0 1 -0 9 -0 6 -0 7 -0 9 
GCCT  -0 -0 -0 -0 -0 0. 2 †       50 6.22 .21 .19 .24 .30 .40 20   
GGCC 22 6 -0 0 0 0 0 0. 1 6.2 0 0 0 0 0 0.36.3  1 .10 - .15 - .18 - .37 - .38 65 06 7 - .13 - .16 - .33 - .44 - .33  
OASL                 
AATCGTACCCATTC  -0 -0 0. 0 0 0. 10 6.6 .0 .1 .03 .0 .2 0.9736 6.18 .09 .07 06 .06 .07 86  4 -0 3 -0 1 0  -0 5 -0 2  
AGTCGTAGTTGTCA  -0 -0 -0 0. 0 0. 85 6. 01 06 17 12 .2 0.0543 6.2  0 .01 .11 .05 13 .03 47  33 0.  0.  0.  0.  -0 4 7 
GGCCGCGGCTGTTA  -0 0 0 0 0 0.64 1 †       82 6.19 .11 - .08 - .09 - .20 - .23    
GGCTGCGG 0. 0. 0. 0. 0. 0. 5 6.4 .16 .05 .08 .16 .35 0.38CTGCTA 14 6.31 17 35 28 36 34 72 7 5 0  0  0  0  0   
GGTCGCGGCCG A 5 † 6. 2 6.0 0 0 0 0 0 0.75TT 24      8 4 - .09 - .21 - .33 - .18 - .27  
GGTCGCGGCT A  0.0 0.0 -0 0.003 -0 0.9 7 .1 .04 .08 .04 .14 .27 0.78 GTT 47 6.22 5 2 .005 .02 9 3 6 5 0  0  0  0  0
GGTCGTA A  0. 0. 0. 0. -0 0. 47 6.2 .1 .2 .4 .5 .3 0.40GCTGTT 12 5.92 10 04 07 15 .21 45  4 -0 7 -0 8 -0 4 -0 1 -0 9  
PKR                 
ACC  0.02 -0.0 -0.2 0.01 0.20 0.62 15 6.2 .03 04 -0.11 -0.05 0.11 0.79  153 6.19  9 4    2 8 0  0.
AGT  25 6.09 -0 -0 -0 -0 0. 0. 1 6.3 .15 .23 .15 .0 .19 0.26.09 .11 .10 .08 08 83 19 3 0  0  0  -0 4 -0  
AGC  6 -0.04 -0.12 0. -0.04 -0.14 0.  15 .21 09 72 8 †      
AAT 3 6.2  -0.3  -0.2  -0.2  -0.7  -0.7 0.02 14 6.29 0.03 0.21 0.33 0.28 0.28 0.96 1 9 1 7 0 2 6   
CAC 1 6.1  -0 0 0 0 0 0.0 8 †       2 5 .31 - .42 - .41 - .65 - .95 08   
                 
Table A-5 (Continued)                 
STAT1                 
ACAGCATC 33 -0 -0 -0 -0 -0 0. 13 6.37 -0.18 0.12 0.01 0.005 0.09 0.14 6.28 .11 .14 .09 .11 .20 87 5  
ACAGCATG  -0 0 0 0 0 0. †       25 6.2  3 .21 - .24 - .13 - .27 - .32 41 5 
AGAATATG 9 6.3  -0.1 0.10 0.16 0.24 0.23 0.53 53 6.21 -0.17 -0.41 -0.21 -0.32 -0.32 0.14 2 4 1      
AGAGCATC 6 6.2  0.25 0.24 0.29 0.44 0.65 0.15 36 6.35 0.28 31 08 23 48 0.08 2 2        0.  0.  0.  0.
AGAGCCTC        2 6.2 -0 -0 -0 -0 0.14 8 † 3 7 -0.09 .32 .59 .65 .90 
AGA C 0 -0 0 0. 0. 0.  GTAT  29 6.32 .06 .004 .07 20 32 66 2 †      
AGCGTATC 27 6 -0 0 0 0 0 0. 2 6.2 0 0 0.0 0 0.28.13 .06 - .06 - .31 - .38 - .48 32 8 7 - .13 - .16 - 2 -0.07 - .42  
AGCGTATG 8 6.1  0.02 0.02 0.16 0.20 -0.0 0.25 7 †  2 4     9       
GGAGTATC 0.04 -0.0 0.05 -0.2 -0.2 0.53 2 †   22 6.08  1  1 2        
STAT2                 
CCAAGT        31 6.39 -0.13 -0.03 0.04 0.08 0.22 0.83 2 †  
CGAGAC  0.05 0.09 -0.0 0.09 -0.0 0.44 1 †  103 6.26   2  3        
CGGGAC  0. 0. 0. 0. 0. 0.   1 †52 6.27 15 17 03 02 24 10      
TGAGGC 15 6.05 -0.11 -0.17 -0.04 -0.04 0.22 0.56 0 †       
0.17 -0.19 0.05 -0.07 -0.15 0.048 193 ‡ TGAGGT 122 6.23 -       
                 
* Model adjusted for age, time, genetic variant and interaction between time and genetic variant 
** Reflects the mean HCV RNA levels  
† Haplotype frequency less than 5%  
‡ No variation in the haplotype  
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African Americans Caucasian Americans
Figures A3-2a and 2b: ed Viral Level for OASL rs1169279 Genotypes Ove the First 28 Days of Treatment among African 
cans (N=180) and Cauc sian mericans (N=193) 
Depictions of v er the first 28 day rea  w mp ted b hi he edi ira ls h t oi
representative individuals at e  level of the genetic variant 
 
 
 
 
 
 
 
 
 Predict r 
Ameri  a A
iral level ov s of t tment ere co le y grap ng t  pr cted v l leve at eac ime p nt for 
ach
215 
  
African merA icans Caucasian Americans
Figur
Amer
es A3-3a and 3b: iral vel fo 45 Genotypes over the First 28 Days of Treatment among African 
icans (N=1 a ia
Depictions of viral level e first 28 day mp ph
representative ind a  e le th ti nt
 
 
 
 
 
 
OASL rs32135  Predicted V Le r 
80) and C ucas
over th
n Americans (N=192) 
s of treatment were co leted by gra ing the predicted viral levels at each time point for 
ividu ls at ach vel of e gene c varia  
 
216 
 African Americans Caucasian Americans
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 African Americans Caucasian Americans
Figures A3-5a and 5b:  Predicted Viral Level for STAT1 rs2966797 Genotypes Over the First 28 Days of Treatment among African 
Americans (N=180) and Caucasian Americans (N=193) 
Depictions of viral level over the first 28 days of treatment were completed by graphing the predicted viral levels at each time point for 
representative individuals at each level of the genetic variant 
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 African Americans Caucasian Americans
Figures A3-6a and 6b – Predicted Viral Level for PKR AAT Over the First 28 Days of Treatment among African Americans (N=193) and 
Caucasian Americans (N=163) 
Depictions of viral level over the first 28 days of treatment were completed by graphing the predicted viral levels at each time point for 
representative individuals at each level of the genetic variant 
 
 
 
 
 
 
 
 
 
219 
 African Americans Caucasian Americans
Figures A3-7a and 7b:  Predicted Viral Level for PKR CAC Over the First 28 Days of Treatment among African Americans (N=193) and 
Caucasian Americans (N=163) 
Depictions of viral level over the first 28 days of treatment were completed by graphing the predicted viral levels at each time point for 
representative individuals at each level of the genetic variant 
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Table A-6:  Common Variation in Genes Accounted for with Selected Single Nucleotide Polymorphisms 
 
SNP Selection Method:  Haplotype Block Method           
Minor Allele Frequency:  10%             
        
African 
Americans     
Caucasian 
Americans   
Gene 
Virahep-C 
SNPs 
Virahep-C 
SNPs in 
High LD 
# SNPs for    
R2 = 0.8 
# SNPs 
Covered 
% of Variation 
Covered 
# SNPs for    
R2 = 0.8 
# SNPs 
Covered 
% of 
Variation 
Covered 
                  
IRF1 8 4 19 18 94% 25 22 88% 
Mx1 5 0 61 17 27% 79 39 49% 
PKR 4 0 4 20% 12  20 4 33%
AVERAGE     100 39 39% 116 65 56% 
           
SNP Selection Method:  Two Stage Tagging        
Minor Allele Frequency:  5%             
        
African 
Americans     
Caucasian 
Americans   
Gene 
Virahep-C 
SNPs 
Virahep-C 
SNPs in 
High LD 
# SNPs for 
R2 = 0.8 
# SNPs 
Covered 
% of Variation 
Covered 
# SNPs for 
R2 = 0.8 
# SNPs 
Covered 
% of 
Variation 
Covered 
              
G1P2 2 0 1 1 100% 1 1 100% 
G1P3 3 0 10 0 0% 2 1 50% 
IFI35 4 0 7 4 57% 8 7 87% 
IFNAR1 10 4 41 23 56% 36 27 75% 
IFNAR2 10 1 43 20 46% 50 24 48% 
IRF7 2 0 6 3 50% 6 2 33% 
Mx2 8 2 60 9 15% 50 17 34% 
OAS1 6 0 13 3 23% 35 35 100% 
OAS2 4 0 36 4 11% 55 13 23% 
OAS3 7 3 49 10 20% 59 39 66% 
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Table A-6 Continued        
OASL 18 5 25 10 40% 21 11 52% 
STAT1 8 0 59 11 18% 39 14 35% 
STAT2* 8 2 8 5 62% 6 6 100% 
AVERAGE     358 103 29% 368 197 54% 
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Table B-1:  Demographic Characteristics of VIRAHEP-C Study Population by Race 
 
Characteristics 
African American 
N = 167 
Caucasian American 
N = 184 
 
value p-
    
 N (%) N (%)  
Gender    
Ma 107 (64.1) 118 (64.1)  le 
9‡ Fema 60 (35.9) 66 (35.9) .9le 0
HCV Subtype    
1 10 (6.0) 15 (8.2)  
1a 77 (46.1) 104 (56.5)  
1a/b 2 (1.2) 12 (6.5)  
1b  77 (46.1) 53 (28.8)  
Indete 1 (0.6) 0 (0) 002‡ 0.
Portal Inflammation Score (HAI)    
Mild 27 (16.2) 30 (16.3)  
Moderate 108 (64.7) 101 (54.9)  
Severe 32 (19.2) 53 (28.8) .09‡ 0
Steatosis    
No Steatosis 64 (38.3) 63 (34.2)  
Steatosis Present 103 (61.7) 121 (65.8) .43‡ 0
Insulin Resistance    
HOMA2-IR < 2 83 (58.5) 104 (66.7)  
HOMA2-IR ≥ 2 59 (41.6) 52 (33.3) .14‡ 0
    
 Mean (SD) Mean (SD)  
Homeostasis Model Assessment 2   
(ln HOMA2-IR) 
 
0.6 (0.7) 
 
0.4 (0.7)  0
 
06† 0.
Alanine Aminotransferase (ALT) 70.6 (45.8) 108.0 (91.5) 0  001†<0.
Aspartate Aminotransferase (AST) 60.0 (43.2) 73.0 (58.7) .06† 0
Age (years) 48.7 (6.9) 47.3 (8.4) .13† 0
Body Mass Index (BMI) 30.8 (6.4) 28.2 (5.2) 0001† <0.
8† Baseline Viral Level (log10 IU/mL) 6.2 (0.6) 6.3 (0.8) .00
Total Inflammation (HAI) 10.0 (3.2) 10.4 (3.5) .21† 0
Triglycerides (mg/dL) 132.4 (100.0) 114.9 (68.4) .14† 0
Cholesterol (mg/dL) 177.7 (36.7) 179.2 (35.5) .67† 0
3† Ishak Fibrosis Score 2.1 (1.4) 2.3 (1.5) .30
9† Alcohol Consumption (Week) 3.6 (10.8) 2.3 (6.2) .90
    
‡  Chi-square Test 
†  Wilcoxon Two Sample Test 
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Table B-2:  Frequencies of Genotypes for Single Nucleotide Polymorphisms among African 
Americans and Caucasian Americans 
 
 African Am
N = 167 
Caucasian A
N = 184 
ericans mericans 
Single Nucleotide 
Polymorphism 
Genotype 
Frequency 
 
Call Rate 
 
HWE* 
Genot
Frequency 
 
Call Rate 
 
HWE* 
ype 
       
COL1A1 rs2586485       
CC 21 (0.13) .04)   8 (0   
CT 75 (0.45)  60 (0.33)    
TT 71 (0.43) 1.0 0.94 115 (0. 0.99 0.96 63) 
COL1A1 rs2586494       
AA .03)   4 (0.02)   5 (0
AC .32)  0.22)  52 (0  41 (  
CC 110 (0.66) 1.0 0.70 .76) 0.99 0.53  138 (0
COL1A1 rs7406586       
AA .28)   12 (0.07)   47 (0  
AG .50)   56 (0.30)   83 (0
GG 37 (0.222) 1.0 0.98 115 (0.63) 0.99 0.16 
COL1A1 rs2269336       
CC .56)  0.75)  94 (0  137 (  
CG .39)   44 (0.24)   65 (0
GG .05) 1.0 0.44 2 (0.0 0.99 0.73 8 (0 1) 
CYP2E1 rs10857735       
AA .17)  1 (0.01)  27 (0   
AC .46)  17 (0.09)  73 (0   
CC .3   6 59 (0 7) 0.94 0.59 169 (0.90) 0.9 0.39 
CYP2E1 rs2070673       
AA .45)  6 (0.03)  76 (0   
AT .40)   46 (0.25)   66 (0
TT .15) 1.0 0.10 131 (0.72) 0.99 0.44 25 (0
CYP2E1 rs915908       
AA .0  .01)  1 (0 1)  3 (0  
AG .0   37 (0.   9 (0 5) 21) 
GG 156 (0. 0.99 0.17 140 (0 0.98 0.76 94) .78) 
CYP2E1 rs2070676       
CC .1   144 (0   22 (0 4) .81) 
CG .477 (0 8)   33 (0.18)   
GG .3 0.96 0.81 2 (0.0 0.9 1.0 62 (0 9)  1) 7 
IL6 rs1880242       
GG .0   34 (0.   4 (0 2) 19) 
GT .2   106 (0   48 (0 9) .58) 
TT 115 (0. 9 69) 1.0 1.0 43 (0.24) 0.9 0.03 
IL6 rs2056576       
CC .3   69 (0.   54 (0 2) 38) 
CT .4   0.   79 (0 8) 94 ( 51) 
TT .2 0.99 0. 0. 0.99 033 (0 0) 67 20 ( 11) .15 
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Table B-2 (Continued)       
IL6 rs2069827       
GG 15   152 (0.83)   8 (0.96) 
GT 7   30 (0.16)    (0.04) 
TT 0 (0) 0.99 1.0 1 (0.01) 0.99 1.0 
IL6 rs1800797       
AA 0 (0)   23 (0.12)   
AG 22 (0.13)   92 (0.50)   
GG 14 0.99 1.0 69 (0.38) 1.0 0.37 4 (0.87) 
IL      6 rs1800795  
CC 0 (0)   27 (0.15)   
CG 23 (0.14)   91 (0.49)   
GG 143 (0.86) 0.99 1.0 66 (0.36) 1.0 0.63 
IL6 rs2069830       
CC 13   182 (0.99)   3 (0.81) 
CT 30 (0.    1 (0.01)   18)
TT 2 (0.01) 0.99 0.69 0 (0) 0.99 1.0 
IL6 rs2069837       
AA 132 (0.80)   159 (0.86)   
AG 34 (0.20)   25 (0.14)   
GG 0 (0) 0.99 0.20 0 (0) 1.0 1.0 
I      L6 rs1554606  
GG 79 (0.48)   60 (0.33)   
GT 71 (0.43)   95 (0.52)   
TT 16 (0.10) 0.99 0.99 29 (0.15) 1.0 0.40 
IL6 rs2069845       
AA 75 (0.    60 (0.33)   45)
AG 75 (0.45)   95 (0.52)   
GG 17 (0.10) 1.0 0.78 28 (0.15) 0.99 0.34 
IL10 rs11119474       
AA 0 (0)   0 (0)   
AG 2 (0.01)   27 (0.15)   
GG 17 1.0 1.0 156 (0.85) 0.99 0.61 5 (0.99) 
I      L10 rs3024505  
CC 148 (0.89)   138 (0.76)   
CT 19 (0.11)   40 (0.22)   
TT 0 (0) 1.0 1.0 4 (0.02) 0.99 0.54 
IL10 rs3024498       
AA 128 (0.77)   96 (0.53)   
AG 39 (0.23)   67 (0.37)   
GG 0 (0) 1.0 0.13 20 (0.11) 0.99 0.12 
IL10 rs3024496       
CC  (0.17)   50 (0.27)   28
CT 82 (0.49)   86 (0.47)   
TT  (0.34) 1.0 0.87 48 (0.26) 1.0 0.38 57
IL10 rs1554286       
CC  (0.37)   132 (0.72)   61
CT 79 (0.47)   50 (0.27)   
TT 27 (0.16) 1.0  0.87 3 (0.02) 1.0 0.76 
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Table B-2 (Continued)       
IL10 rs2222202       
CC 84 (0.50)   48 (0.26)   
CT 68 (0.41)   86 (0.47)   
TT 15 (0.09) 1.0 0.82 50 (0.27) 1.0 0.38 
IL10 rs1800890       
AA 10 (0.06) 29 (0.16)     
AT 60 (0.36)   87 (0.47)   
TT 97 (0.59) 1.0 0.86 67 (0.37) 0.99 0.93 
IL1R1 rs3917257       
CC 0 (0)   0 (0)   
CG   0 (0)   0 (0) 
GG 0.99 - 167 (1.0) 1.0 - 183 (1.0) 
IL1R1 rs3917275       
AA 153 (0.92)   182 (0.99)   
AG 13 (0.07)   1 (0.01)   
GG 1 (0.01) 1.0 0.23 0 (0) 0.99 1.0 
IL1R1 rs2110726       
CC 136 (0.81) 70 (0.38)     
CT 30 (0.18)   94 (0.52)   
TT 1 (0.01) 1.0 1.0 19 (0.10) 0.99 0.12 
IL1R1 rs3917332       
AA 4 (0.02)   7 (0.04)   
AT 40 (0.24)   60 (0.33)   
TT 123 (0.74) 1.0 0.73 116 (0.63) 0.99 0.83 
IL1R1 rs871656       
AA 11 (0.06)   10 (0.05)   
AT 61 (0.37)   54 (0.30)   
TT 95 (0.57) 1.0 0.78 118 (0.65) 0.99 0.26 
LEPR 33  rs667 24      
AA 42 (0.25)   51 (0.28)   
AG 87 (0.52)   90 (0.50)   
GG 37 (0.22) 0.99 0.53 41 (0.22) 0.99 0.91 
LEPR rs1137100       
AA 112    (0.67)   100 (0.55)
AG 49 (0.29)   69 (0.68)   
GG 6 (0.04) 1.0 0.82 14 (0.08) 0.99 0.66 
LEPR rs1343982       
AA 16 (0.10)   16 (0.09)   
AG 75 (0.45)   69 (0.38)   
GG 76 (0.45) 1.0 0.69 99 (0.54) 0.99 0.45 
LEPR rs1137101       
AA 42 (0.25)   53 (0.29)   
AG 73 (0.44)   91 (0.50)   
GG 52 (0.31) 1.0 0.11 39 (0.21) 0.99 0.99 
LEPR rs2376018       
AA 115 (0.69)   124 (0.68)   
AG 49 (0.29)   54 (0.29)   
GG 3 (0.02) 1.0 0.58 5 (0.03) 0.99 0.76 
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T  able B-2 (Continued)      
LEPR rs1805096       
CC 52 (0.31)     74 (0.41) 
CT 83 (0.50)  70    (0.38)  
TT 32 (0.19) 1.0 0.91 38 (0.21) 0.99 0.01  
LEPR rs1892534       
AA 33 (0.20)   40 (0.22)   
AG 83 (0  69   .50)   (0.38) 
GG 51 1 0.94 74 0.99 003 (0.31) .0  (0.40) 0.
M 917879       CP1/CCL2 rs3
GG 0 (0)   0    (0) 
GT 0 (0)     0 (0) 
TT 167 (1 1.0 - 183 0.99 - .0)   (1.0) 
MCP1/CCL2 rs1024611       
CC 9 (0   16 (0   .05) .09) 
CT 51 (0.31)   72 (0.40)   
TT 106 (0 0. 0.39 96 1.0 0.64 .64) 99  (0.52) 
MCP1/CCL2 rs3760396       
CC 148  96    (0.89)   (0.52) 
CG 17 (0.10)   77 (0.42)   
GG 0. 0.42 11 1.0 0.39 1 (0.01) 99  (0.06) 
MCP1/CCL2 rs285765    7    
CC 144 (0.86)   124 (0.68)   
C  54   G 23 (0.14)   (0.29) 
G 1 1.0 5 0.99 .76 G 0 (0) .0  (0.03) 0
MCP1/CCL2 rs4586       
CC 66 (0.40)  2    6 (0.14) 
CT 82 (0.49)   86 (0.47)   
TT 18 (0.11) 0.9 0.31 72 1.0 97 9  (0.39) 0.
M    CP1/CCL2 rs13900    
CC 115 (0.63)  9    6 (0.52) 
CT 51 (0.31)  72     (0.39) 
TT 10 (0.06) 0. 0.27 16 1.0 4 99  (0.09) 0.6
M   CP1/CCL2 rs991804     
AA 26 (0.15)  16     (0.09) 
AG 75 (0.45)  7    0 (0.39) 
GG 66 (0.40)  9 0.99 .53 1.0 0.54 6 (0.53) 0
M 6    CP2/CCL8 rs313803    
AA 150 (0.90)  134     (0.73) 
AG 15 (0.09)   47 (0.25)   
GG 1 (0.01) 0.99 0.44 3 (0.02) 1.0 0.80 
M       CP2/CCL8 rs3138038 
AA 156 (0.89)   135 (0.73)   
AC 19 (0.11)   45 (0.25)   
CC 1 (0.01) 0.99 0.46 2 (0.02) 1.0 1.0 
M P2/CCL8 rs11575057       C
CC 1 (0.01)   5 (0.03)   
CT 19 (0.11)   53 (0.29)   
TT 146 (0.88) 0.99 0.66 126 (0.68) 1.0 0.84 
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TGF-Β1 rs2278422       
CC 14 (0.08)   29 (0.16)   
CG 71 (0.43  101 (0  )  .55)  
GG 82 (0.49) 0.80 54 (0.29) 0.11 1.0 1.0 
TGF-Β1 rs2241716       
AA 0 (0)   0 (0)   
AG 16 (0.10)   0 (0)   
GG .90) 1.0 1.0 183 (1.0) 0.99 - 151 (0
TGF-Β1 rs1800471       
CC 0 (0)   1 (0.01)   
CG 23 (0.14)   17 (0.09)   
GG 144 ( .86) 1.0 1.0 165 (0.90) 0.99 0.38 0
TNFα rs2229094       
CC 6 (0.04)   13 (0.07)   
CT 78 (0.47)   57 (0.31)   
TT 83 (0.50) 1.0 0.02 113 (0.62) 0.99 0.13 
TNFα rs3093662       
AA 138 (0.83)   156 (0.85)   
AG 28 (0.17)   25 (0.14)   
GG 1 (0.01) 1.0 1.0 3 (0.01) 1.0 0.11 
TNFα rs3093665       
AA 153 (0.92)   178 (0.97)   
AC 14 (0.08)   6 (0.03)   
CC 0 (0) 1.0 1.0 0 (0) 1.0 1.0 
       
* P-value from test of Hardy  Equilibrium (HWE) 
 
Weingberg
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Table B-3:  Frequencies of Genotypes for Single Nucleotide Polymorphisms and Association with 
ricans and Caucasian Americans 
 
 ican Am icans 
N = 
ian Ame cans 
N = 18
Steatosis among African Ame
Afr er Caucas ri
167 4 
Single Nucleotide 
Polymorphism 
 No 
Steatosis 
Steatosis 
≥ 5% 
p-
value*
 No 
Ste
Steatosis 
≥ 5% 
p-
value*atosis  
COL1A1 rs2586485       
CC 0.10 0.15  0 0.06  .02  
CT 0.52 0.42  0.33 0.32  
TT 0.38 0.43 0.42 0 0.62 0.33  .65 
COL1A1 rs2586494       
AA 0.02 0.04  0 0.02  .03  
AC 0.29 0.33  0.24 0.22  
CC 0.69 0.63 0.59 0 0.77 0.44  .73 
COL1A1 rs7406586       
AA 0.22 0.30  0.1 0.0  1 4 
AG 0.46 0.51  0.29 0.31  
GG 0.32 0.18 0.08 0 0.65 0.09  .60 
COL1A1 rs2269336       
CC 0.56 0.57  0.7 0.75  5  
CG 0.41 0.38  0.24 0.24  
GG 0.03 0.06 0.9 0 0.01 0.99 1 .02 
CYP2E1 rs10857735       
AA 0.20 0.15  0.0 0.01   
AC 0.46 0.49  0.08 0.10  
CC 0.35 0.37 0.7 0 0.89 0.64 3 .92 
CYP2E1 rs2070673       
AA 0.46 0.45  0 0.0  .03 3 
AT 0.37 0.43  0.19 0.29  
TT 0.18 0.12 0.59 0.7 0.68 0.37  8 
CYP2E1 rs915908       
AA 0.0 0.01  0 0.0  .03 1 
AG 0.09 0.04  0.21 0.20  
GG 0.91 0.95 0.29 0 0.79 0.44  .76 
CYP2E1 rs2070676       
CC 0.26 0.07  0 0.7  .84 8 
CG 0.41 0.51  0.15 0.21  
GG 0.33 0.42 0.00  0 0.01 0.50 3 .02 
IL6 rs1880242       
GG 0.02 0.03  0 0.2  .16 0 
GT 0.31 0.28  0.56 0.59  
TT 0.68 0.70 0.7 0 0.22 0.33 4 .29 
IL6 rs2056576       
CC 0.26 0.28  0 0.42  .32  
CT 0.45 0.50  0.54 0.50  
TT 0.19 0.22 0.5 0 0.09 0.21 5 .14 
IL6 rs2069827       
GG 0.93 0.98  0 0.84  .83  
GT 0.08 0.02  0.18 0.16  
TT 0.0 0.0 0.07 0.0 0.01 0.74  
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IL6 rs1800797       
AA 0.0 0.0  0 0.12  .13 
AG 0.15 0.12  0 0.54  .41 
GG 0.85 0.88 0 0 0.34 0.2.48 .46  0 
IL6 rs1800795       
CC 0.0 0.0  0 0.13  .18 
CG 0.15 0.13  0 0.55  .38 
GG 0.85 0.87 0 0 0.3 0.0.44 .44 2 9 
IL6 rs2069830       
CC 0.79 0.80  1.0 0.99   
CT 0.21 0.18  0.0 0.01   
TT 0.0 0.02 0.4 0.0 0.47 9 0.0  
IL6 rs2069837       
AA 0.77 0.79  0 0.85  .87 
AG 0.24 0.21  0 0.15  .13 
GG 0.0 0.0 0 0.0 0.0 0.51.64    
IL6 rs1554606       
GG 0.52 0.45  0 0.29  .41 
GT 0.40 0.44  0 0.57  .40 
TT 0.09 0.10 0. 0 0.1 0.073 .19 4 8 
IL6 rs2069845       
AA 0.49 0.43  0 0.28  .43 
AG 0.41 0.47  0 0.58  .40 
GG 0.10 0.10 0 0 0.1 0.0.76 .18 4 7 
IL10 rs11119474       
AA 0.0 0.0  0.0  0.0 
AG 0.02 0.01  0 0.12  .19 
GG 0.99 0.99 0 0 0.8 0.3.75 .81 8 8 
IL10 rs3024505       
CC 0.82 0.93  0 0.79  .69 
CT 0.18 0.07  0 0.18  .29 
TT 0.0 0.0 0 0 0.0 0.3.04 .02 3 1 
IL10 rs3024498       
AA 0.74 0.80  0 0.53  .52 
AG 0.27 0.20  0 0.38  .33 
GG 0.0 0.0 0 0 0.0 0.5.30 .14 9 6 
IL10 rs3024496       
CC 0.27 0.10  0 0.21  .38 
CT 0.46 0.50  0 0.51  .40 
TT 0.28 0.40 0. 0 0.2 0.0096 .22 8 7 
IL10 rs1554286       
CC 0.37 0.35  0 0.71  .73 
CT 0.46 0.49  0 0.29  .24 
TT 0.18 0.17 0 0 0.0 0.6.93 .03 1 0 
IL10 rs2222202       
CC 0.43 0.57  0 0.28  .22 
CT 0.43 0.38  0 0.51  .40 
TT 0.15 0.06 0 0 0.2 0.0.04 .38 1 7 
       
       
Table B-3 (Continued)       
IL10 rs1800890       
AA 0.07 0.05  0 0.12  .22 
AT 0.38 0.34  0 0.47  .49 
TT 0.54 0.62 0 0 0.4 0.0.45 .29 1 9 
IL1R1 rs3917257§       
IL1R1 rs3917275       
AA 0.94 0.91  0 1.0  .98 
AG 0.06 0.08  0 0.0  .02  
GG 0  0.01 0.5 0.0 0.0 0.16 .0 8 
IL1R1 rs2110726       
CC 0.74 0.87  0.4 0.35  6 
CT 0.25 0.13  0 0.5  .44 5 
TT 0.  0.0 0.02 0.10 0.11 0.21 02  
IL1R1 rs3917332       
AA 0.02 0.03  0 0.02  .08 
AT 0.22 0.25  0 0.33  .33  
TT 0.  0.73 0.80 0.59 0.65 0.10 77  
IL1R1 rs871656       
AA 0.06 0.06  0 0.07  .03 
AT 0.34 0.40  0 0.32  .24  
TT 0.  0.54 0.74 0.73 0.61 0.21 60  
LEPR rs6673324       
AA 0.37 0.22  0 0.29  .25 
AG 0.40 0.57  0 0.4  .51 9 
GG 0.22 0.21 0.09 0.24 0.22 0.91  
LEPR rs1137100       
AA 0.53 0.73  0 0.55  .56 
AG 0.40 0.26  0 0.37  .38  
GG 0.  0.01 0.00  0.06 0.08 0.80 07 8
LEPR rs1343982       
AA 0.16 0.07  0 0.10  .06 
AG 0.49 0.44  0 0.36  .40  
GG 0.  0.49 0.10 0.54 0.54 0.57 35  
LEPR rs1137101       
AA 0.22 0.26  0 0.30  .27 
AG 0.41 0.42  0 0.5  .49 0 
GG 0.  0.32 0.86 0.24 0.20 0.76 37  
LEPR rs2376018       
AA 0.75 0.67  0 0.65  .75 
AG 0.24 0.31  0 0.31  .25  
GG 0.  0.02 0.46 0.0 0.04 0.11 02  
LEPR rs1805096       
CC 0.29 0.29  0 0.37  .49 
CT 0.46 0.51  0 0.39  .37  
TT 0.  0.19 0.6 0.14 0.24 0.12 25 0 
LEPR rs1892534       
AA 0.25 0.20  0 0.25  .16 
AG 0.47 0.51  0 0.39  .35  
GG 0.28 0.29 0.77 0.49 0.36 0.14  
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MCP1/CCL2 rs3917879       §  
MCP1/CCL2 rs10246    11    
CC 0.06 0.05  0 0.07  .13 
CT 0.41 0.25  0 0.43  .33  
TT 0.53 0.70 0.0 0.54 0.51 0.15 9 
MCP1/CCL2 rs37603     96   
CC 0.94 0.86  0.5 0.52  4 
CG 0.06 0.13  0 0.4  .40 3 
GG 0.0 0.01 0.2 0.06 0.06 0.93 2 
MCP1/CCL2 rs28576    57    
CC 0.88 0.84  0 0.64  .76 
CG 0.12 0.16  0 0.3  .19 5 
GG 0.0 0.0 0.43 0.05 0.02 0.07  
MCP1/CCL2 rs4586       
CC 0.43 0.35  0 0.12  .19 
CT 0.47 0.55  0 0.4  .41 9 
TT 0.10 0.10 0.62 0.40 0.39 0.26  
MCP1/CCL2 rs13900        
CC 0.53 0.69  0 0.51  .54 
CT 0.41 0.25  0 0.43  .33  
TT 0.06 0.06 0.10 0.13 0.07 0.15  
MCP1/CCL2 rs99180    4    
AA 0.13 0.16  0 0.07  .13 
AG 0.54 0.40  0.3 0.43  2  
GG 0.32 0.45 0.15 0.56 0.51 0.20  
MCP2/CCL8 rs3138036       
AA 0.88 0.92  0.71 0.73  
AG 0.12 0.07  0.29 0.24  
GG 0.0 0.01 0.36 0.0 0.03 0.82 
M P2/CCL8 rs3138038       C
AA 0.85 0.91  0.71 0.74  
AC 0.15 0.08  0.29 0.22  
CC 0.0 0.01 0.23 0.0 0.04 0.64 
MCP2/CCL8 rs11575057       
CC 0.0 0.01  0.02 0.04  
CT 0.16 0.08  0.33 0.26  
TT 0.84 0.91 0.15 0.65 0.70 0.74 
TGF-Β1 rs2278422       
CC 0.12 0.06  0.16 0.16  
CG 0.52 0.39  0.52 0.56  
GG 0.37 0.55 0.06 0.32 0.28 0.92 
TGF-Β1 rs2241716       
AA 0.0 0.0  0.0 0.0  
AG 0.12 0.07  0.0 0.0  
GG 0.88 0.93 0.35 1.0 1.0  
TGF-Β1 rs1800471       
CC 0.0 0.0  0.0 0.01  
CG 0.12 0.16  0.10 0.09  
GG 0.88 0.84 0.43 0.91 0.90 0.77 
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Table B-3 (Continued)       
TNFα rs2229094       
CC 0.03 0.04  0.03 0.09  
CT 0.47  0.4   0.47 0 0.27 
TT 0.50  0.96 0.57 0.10 0.50 0.65 
TNFα rs3093662       
AA 0.82 0.82  0.84 0.85  
AG 0.16 0.18 0.14 0.13   
GG 0.02 0.0  0.02 0.02 0.99 0.42
TNFα rs3093665       
AA 0.90 0.93  0.94 0.98  
AC 0.10 0.07  0.06 0.02  
CC 0.0 0.0 0.53 0.0 0.0 0.19 
       
* P-value based on genotype association chi square test 
† Chi Square could n  estimated because r allel uency  for the S
P 
 
  
NP ot be  mino e freq  < 5%
§ Monomorphic SN
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Table B-4:   Unadjusted Odd Ratios for Steatosis for Single Nucleotide Polymorphisms among 
aucasi n Americans
 Afric ericans
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Cau  America  
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COL1A1 rs2586485         
CC 1.00   8 1.0   96  6 0 
TT 1.23 . 0.52 5 0.8 0.46-1 0.68 71  0.66-2 27  11 8 .65 
COL1A1 rs2586494         
A C 1.00   5 1.0   A/A 57  4 0 
CC .40-1. 0.43 8 1.2 0.61-2 0.56 110 0.77 0 47 13 3 .47 
COL1A1 rs7406586         
AA 1.00   2 1.0   47  1 0 
AG 0.82 .39-1.74 0.61 6 2.9 0.82-10.6  0.10 83  0   5 6 0
GG 0.41 . 0.04 5 2.8 0.86-9 0.09 37  0.18-0 98  11 7 .65 
COL1A1 rs2269336         
CC 1.00  7 1.0   94   13 0 
C G 0.96 .52-1.77 0.90 6 0.9 0.48-1.9 0.93 G/G 73  0   4 7 5 
CYP2E1 rs10857735          
AA/AC 1.00  8 1.0   100   1 0 
CC 1.09 .08 0.79 9 0.7 0.24-2.1 0.54 59  0.57-2   15 1 1 
CYP2E1 rs2070673         
AA 1.00   1.0   76   6 0 
AT 1.19 .61-2. 0.61 6 1.4 0.24-9 0.69 66  0 31  4 6 .00 
TT 0.70 0.28-1.69 0.41 1 0.8 0.15-4.7 0.84 25  13 4 4 
CYP2E1 rs915908         
A G 1.00   0 1.0   A/A 10  4 0 
GG .58-6. 0.27 0 1.2 0.58-2 0.62 156 1.99 0 81  14 0 .49 
CYP2E1 rs2070676         
CC 1.00  4 1.0   22   14 0 
CG 4.77 76-12 0.002 3 1.5 0.66-3 0.32 77  .1 .89  3 2 .51 
GG 4.86 .76-13 0.002 †   62 1 .45  2  
IL6 rs1880242         
GG/GT 52 1.00  0 1.0     14 0 
TT 1.10 . 0.77 3 0.6 0.34-1 0.29 115  0.57-2 11  4 8 .38 
IL6 rs2056576         
CC 1.00   9 1.0   54  6 0 
CT 1.39 .70-2.79 0.35 4 0.7 0.36-1.3 0.31 79  0   9 1 8 
TT 1.43 .61-3 0.42 0 0.4 0.18-1 0.17 33  0 .38  2 9 .36 
IL6 rs2069827         
GG   2 1.0   158 1.00 15 0 
GT/TT †   1 0.9 0.42-2.1 0.87 7 3 4 0 
IL6 rs1800797         
AA/AG 1.00  5 1.0   22   11 0 
GG 1.26 .06 0.61 9 0.5 0.32-1.1 0.10 144  0.52-2   6 9 1 
IL6 rs1800795         
CC/CG 1.00  8 1.0   23   11 0 
GG 1.16 . 0.74 6 0.5 0.31-1 0.10 143  0.48-2 78  6 9 .10 
Table B-4 (Continued)         
IL6 rs2069830         
CC 133 1.00   182 1.00    
CT/TT 0.94 .44-2.01 0.88 †   32  0   1  
IL6 rs2069837         
AA   9 1.0   132 1.00 15 0 
AG/GG  0.88 0.43-1.82 0.73 25 1.19 0.49-2.9 0.70 34   1 
IL6 rs1554606         
GG 1.00   0 1.0   79  6 0 
GT/TT 1.28 .35 0.43 4 1.7 0.92-3.3 0.09 87  0.70-2   12 5 0 
IL6 rs2069845         
AA  1.00   60 1.00   75  
A G 1.24 .29 0.48 3 1.9 1.02-3.6 0.045 G/G 92  0.68-2   12 2 3 
IL10 rs11119474         
AA/AG 1.00   7 1.0   2 2 0 
GG 165 †   156 1.66 0.73-3.8 0.23  1 
IL10 rs3024505         
CC   8 1.0   148 1.00 13 0 
CT/TT 0.37 .14-0. 0.04 4 0.6 0.30-1 0.15 19  0 96  4 0 .20 
IL10 rs3024498         
AA 1.00  6 1.0   128   9 0 
A G 0.70 .34-1.43 0.33 7 0.9 0.53-1.8 0.95 G/G 39  0   8 8 0 
IL10 rs3024496         
CC  1.00   50 1.00   28  
CT 2.85 .19-6.81 0.02 6 2.2 1.11-4.7 0.03 82  1   8 9 2 
TT 3.80 .51-9.54 0.01 8 2.2 0.97-5.1 0.06 57  1   4 4 6 
IL10 rs1554286         
CC  1.00   131 1.00  61   
CT/TT 1.09 .04 0.80 2 1.1 0.58-2.2 0.69 106  0.58-2   5 5 6 
IL10 rs2222202         
CC 1.00   8 1.0   84  4 0 
CT  0.66 0.35-1.27 0.21 86 1.02 0.47-2.2 0.96 68   2 
TT 0.28 .09-0.85 0.02 0  0.4 0.19-1.0  15  0   5 5 3 0.06
IL10 rs1800890         
AA/AT 70 1.00  6 1.0     11 0 
TT  1.34 0.72-2.47 0.35 67 1.70 0.88-3.2 0.11 97   8 
IL1R1 rs3917275         
AA   2 1.0   153 1.00 18 0 
A G 1.62 .49-5. 0.43 †   G/G 14  0 37  1  
IL1R1 rs2110726         
CC 1.00  0 1.0   136   7 0 
CT/TT 0.41 .89 0.02 3 1.6 0.86-1.9 0.14 31  0.19-0   11 0 9 
IL1R1 rs3917332         
AA/AT  1.00   67 1.00   44  
TT .40-1.63 0.56 6 1.3 0.71-2.4 0.38 123 0.81 0   11 2 7 
IL1R1 rs871656         
A T 1.00   4 1.0   A/A 72  6 0 
TT  0.78 0.42-1.44 0.42 118 0.60 .1 0.13 
      
95   0.31-1 6 
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Table B-4 (Continued)         
LEPR rs6673324         
AA  1.00   51 1.00   42  
AG  2.39 1.17-4.91 0.02 90 0.84 0.41-1.7 0.65 87   5 
GG 1.60 .68-3.77 0.29 1 0.7 0.33-1.8 0.60 37  0   4 9 9 
LEPR rs1137100         
AA   0 1.0   112 1.00 10 0 
AG/GG  0.41 0.22-0.77 0.006 83 1.04 0.57-1.9 0.90 55   2 
LEPR rs1343982         
A G 1.00   5 1.0   A/A 91  8 0 
GG 1.74 .93-3. 0.08 8 0.9 0.54-1 0.97 76  0 24  9 9 .82 
LEPR rs1137101         
AA 1.00   3 1.0   42  5 0 
AG 0.88 .40-1.93 0.75 1 0.9 0.45-1.9 0.84 73  0   9 3 1 
GG 0.75 . 0.49 9 0.7 0.32-1 0.53 52 0.33-1 69  3 6 .80 
LEPR rs2376018         
AA   4 1.0   115 1.00 12 0 
A G 1.48 .75-2.92 0.26 9 1.6 0.82-3.1 0.16 G/G 52  0   5 2 9 
LEPR rs1805096         
CC  1.00   74 1.00   52  
CT 1.13 .56-2.30 0.74 0 1.4 0.73-2.8 0.29 83  0   7 4 4 
TT 0.77 .33-1.81 0.55 8 2.2 0.94-5.4 0.07 32  0   3 7 6 
LEPR rs1892534         
AA  1.00   40 1.00   33  
AG 1.33 .62-2.86 0.47 9 0.7 0.30-1.7 0.45 83  0   6 1 1 
GG 1.30 .56-3.05 0.54 4 0.4 0.20-1.1 0.09 51  0   7 7 1 
MCP1/CCL2 rs3917879‡         
MCP1/CCL2 rs1024611         
CC/CT 1.00   8 1.0   60  8 0 
TT 2.11 .97 0.02 6 0.8 0.48-1.6 0.69 106  1.12-3   9 8 2 
MCP1/CCL2 rs3760        396  
CC 148 1.00   96 1.00    
C G 2.58 .82-8.13 0.11 8 1.1 0.60-2.0 0.76 G/G 18  0   8 0 2 
MCP1/CCL2 rs2857      657    
CC   4 1.0   144 1.00 12 0 
CG/GG  1.39 0.56-3.41 0.48 59 1.83 0.92-3.6 0.09 23   4 
MCP1/CCL2 rs4586         
CC 1.00   6 1.0   66  2 0 
CT 1.41 .74-2. 0.30 6 1.8 0.76-4 0.18 82  0 69  8 5 .49 
TT  1.20 0.41-3.47 0.74 72 1.50 0.61-3.7 0.38 18   0 
MCP1/CCL2 rs13900          
CC 1.00  6 1.0   105   9 0 
CT/TT 0.50 .26-0. 0.03 8 1.1 0.62-2 0.69 61  0 93  8 4 .09 
MCP1/CCL2 rs991804         
AA/AG 1.00   6 1.0   101 8 0 
GG 1.71 .91-3.22 0.10 6 0.8 0.45-1.5 0.54 66  0  9 3 3 
MCP2/CCL8 rs3138        036  
AA 150 1.00   134 1.00    
A G 0.68 .86 0.46 0 0.9 0.47-1.8 0.83 G/G 16 0.25-1  5 3 2 
         
         
Table B-4 (Continued)         
MCP2/CCL8 rs3138038         
AA 147 1.00   135 1.00    
A C 0.59 .23-1.51 0.27 9 0.8 0.45-1.7 0.74 C/C 19  0   4 9 5 
MCP2/CCL8 rs11575      057    
C T 1.00   8 1.0   C/C 20  5 0 
TT 146 1.89 0.76-4.73 0.17 126 1.23 0.65-2.3 0.53   5 
TGF-β1 rs2278422         
CC/CG 85 1.00  0 1.0     13 0 
GG 2.11 . 0.02 4 0.8 0.43-1 0.58 82 1.13-3 92  5 3 .61 
TGF-β1 rs2241716         
AA/AG 1.00   1.0   16   0 0 
GG 1.68 .60-4.72 0.32 3 †   151  0   18  
TGF-β1 rs1800471         
CC G  1.00   18 1.00   /C 23  
GG 144 0.72 0.29-1.78 0.48 165 0.96 0.34-2.68 0.93 
T   NFα rs2229094       
CC/CT 84 1.00   70 1.00   
TT 83 0.98 0.54-1.80 0.95 113 1.36 0.73-2.54 0.33 
TNFα rs3093662         
AA 138 1.00   156 1.00   
AG/GG 29 1.05 0.48-2.31 0.91 28 0.92 0.40-2.13 0.84 
TNFα rs3093665         
AA 153 1.00   178 1.00   
AC/CC 14 0.69 0.24-2.00 0.49 6 †   
         
‡ Monomorphic SNP 
† Minor allele frequency less then 5% in one population 
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Table B-5:  Adjusted Odds Ratios for Steatosis for Single Nucleotide Polymorphisms among African 
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C     OL1A1 rs2586485     
CC  1.00 6 1.96    8 00   
TT 71 .65 0.3 1 1. 01.41 0 -3.05 8 15 04 .43-2 50 . 0. 3 9
C     OL1A1 rs2586494     
AA/AC  1.00 4 1.57    5 00   
CC 110 .75 .33 0.5 1 0. 00  0 -1.72 0 38 60 .23-1 59 . 0. 0 3
C     OL1A1 rs7406586     
AA  1.00 1 1.47    2 00   
AG  0.59 .23 0.2 5 1. 083  0 -1.52 7 6 93 .32-11.73 0.47 
GG  .15 0.1 1 2. 0. 37 0.46 0 -1.39 7 15 25 40-12.72 0.36 
C     OL1A1 rs2269336     
CC 94 1 1.1.00   37 00   
CG/GG 73 .3 0.5 4 1. 00.80 0 7-1.70 6 6 55 .59-4 04 . 0. 7 3
C     YP2E1 rs10857735      
AA 0 .00 1 1./AC 10 1    8 00   
CC 59 .52 0.7 1 0. 01.14 0 -2.53 4 59 99 .19-5 06 . 0. 9 9
C      YP2E1 rs2070673    
AA  6 1. 76 1.00    00   
AT  .48 0.8 4 0. 066 1.11 0 -2.53 1 6 48 .03-7.71 0.60 
TT  .20 0.3 1 0. 025 0.60 0 -1.87 7 31 46 .03-6 55 . 0. 7 5
C     YP2E1 rs915908     
AA/AG  1.00 4 1.10    0 00   
GG 6 2.32 .34 0.3 1 0. 0 15  0 -16.0  4 9 40 91 .34-2 47 . 0.85 
C    YP2E1 rs2070676      
CC  1 1. 22 1.00   44 00   
CG  3.37 .90 . 3 0. 077  0 -12.66 0 07 3 93 .30-2 86 . 0.90 
GG  .76 . 2 1.5 0.08-3 4 0.77 62 2.85 0 -10.70 0 12 8 1.6
IL     6 rs1880242     
GG  .00 1 1./GT 52 1    40 00   
TT 5 .28 .57 0.5 4 0. 011 1  0 -2.89 5 3 78 .29-2.06 0.61 
IL     6 rs2056576     
CC  1.00 6 1.54    9 00   
CT  .47 0.8 9 0. 079 1.08 0 -2.52 5 4 57 .23-1.42 0.23 
TT  .38 0.8 2 0. 033 1.10 0 -3.14 7 0 91 .23-3 65 . 0. 0 9
IL     6 rs2069827     
GG 158 1.00   1 1. 52 00   
GT/TT  †   3 1. 07 1 47 .50-4 30 . 0.49 
IL    6 rs1800797      
AA  .00 1 1./AG 22 1    15 00   
GG 4 .06 .61 0.2 6 0. 014 2  0 -6.98 5 9 45 .19-1 05 . 0. 7 0
IL    6 rs1800795      
CC  .00 1 1./CG 23 1    18 00   
GG 3 .78 .55 0.3 6 0. 014 1  0 -5.73 4 6 47 .20-1.20 0.08 
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T         able B-5 (Continued) 
IL         6 rs2069830 
CC 3 1.00   1 1.   13  82 00  
CT/TT  .33 0.7 1 †  32 0.87 0 -2.27 8  
IL         6 rs2069837 
AA 2 1.00   1 1.   13  59 00  
AG/GG  .32 0.6 2 0. 034 0.81 0 -2.04 5 5 82 .23-2.91 0.76 
IL         6 rs1554606 
GG  1.00   6 1.  79  0 00  
GT/TT  .41 0.7 1 2. 087 0.88 0 -1.90 5 24 24 .94-5.30 0.07 
IL         6 rs2069845 
AA  1.00   6 1.  75  0 00  
AG/GG  .40 0.7 1 2. 192 0.86 0 -1.86 0 23 52 .06-6.00 0.04 
IL         10 rs11119474 
AA  1.00  2 1.  /AG 2   7 00  
GG 5 1.59 0.09-27.0 0.75 1 1. 0 16 9  56 46 .48-4.48 0.51 
IL         10 rs3024505 
CC 8 1.00   1 1.   14  38 00  
CT/TT  .11 0.1 4 0. 019 0.36 0 -1.23 0 4 50 .21-1.22 0.13 
IL         10 rs3024498 
AA 8 .00  9 1.   12 1   6 00  
AG/GG  .23 0.2 8 1. 039 0.56 0 -1.37 0 7 31 .58-2.96 0.52 
IL         10 rs3024496 
CC  1.00   5 1.  28  0 00  
CT  .93 0.0 8 2. 082 2.98 0 -9.58 7 6 22 .81-6.09 0.12 
TT  6.06 .73 .0 4 1. 057  1 -21.28 0 05 8 35 .43-4.22 0.61 
IL         10 rs1554286 
CC   1 1.   61 1.00  31 00  
CT/TT 6 .41 .64 0.4 5 1. 010 1  0 -3.14 0 2 39 .57-3.42 0.47 
IL         10 rs2222202 
CC  1.00   4 1.  84  8 00  
CT  .22 0.1 8 1. 068 0.50 0 -1.15 0 6 65 .56-4.88 0.37 
TT  .03 0.0 5 0. 015 0.12 0 -0.57 1 0 74 .24-2.33 0.61 
IL         10 rs1800890 
AA   1 1.  /AT 70 1.00  16 00  
TT  .73 0.2 6 1. 097 1.60 0 -3.48 4 7 00 .41-2.43 0.99 
IL         1R1 rs3917275 
AA 3 1.00   1 1.   15  82 00  
AG/GG  .23 0.9 1 †  14 1.05 0 -4.83 5  
IL         1R1 rs2110726 
CC 6 .00  7 1.   13 1   0 00  
CT/TT  .12 0.0 1 2. 031 0.32 0 -0.86 2 13 21 .92-5.31 0.08 
IL         1R1 rs3917332 
AA/AT  1.00   6 1.  44  7 00  
TT 3 .86 .35 0.7 1 1. 012 0  0 -2.11 4 16 38 .60-3.17 0.45 
IL         1R1 rs871656 
AA/AT  1.00   6 1.  72  4 00  
TT  .39 0.6 1 0. 095 0.83 0 -1.76 2 18 87 .37-2.08 0.77 
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T         able B-5 (Continued) 
L         EPR rs6673324 
AA  1.00   5 1.  42  1 00  
AG  .97 0.0 9 1. 087 2.43 0 -6.05 6 0 64 .58-4.62 0.35 
GG  .57 0.3 4 1. 037 1.82 0 -5.79 1 1 18 .34-4.06 0.79 
L         EPR rs1137100 
AA 2 1.00   1 1.   11  00 00  
AG/GG  .11 .0 8 0. 055 0.25 0 -0.58 0 01 3 90 .40-2.05 0.81 
L         EPR rs1343982 
AA/AG  1.00   8 1.  91  5 00  
GG  .77 0.1 9 1. 076 1.66 0 -3.58 9 8 11 .49-2.53 0.80 
L         EPR rs1137101 
AA  1.00   5 1.  42  3 00  
AG  .35 0.8 9 1. 073 0.92 0 -2.42 6 1 58 .58-4.30 0.37 
GG  .24 0.4 3 0. 052 0.67 0 -1.86 4 9 31 .09-1.10 0.07 
L         EPR rs2376018 
AA 5 1.00   1 1.   11  24 00  
AG/GG  .61 0.4 5 2. 052 1.38 0 -3.12 5 9 09 .84-5.22 0.11 
L         EPR rs1805096 
CC  1.00   7 1.  52  4 00  
CT  .87 0.1 7 1. 083 2.11 0 -5.13 0 0 55 .62-3.90 0.35 
TT  .21 0.4 3 2. 032 0.63 0 -1.90 2 8 35 .73-7.53 0.15 
L         EPR rs1892534 
AA  1.00   4 1.  33  0 00  
AG  .07 0.0 6 0. 083 2.98 1 -8.33 4 9 69 .22-2.20 0.54 
GG  .52 0.4 7 0. 051 1.55 0 -4.62 3 4 44 .14-2.37 0.16 
MCP1/CCL2 rs3917879‡         
M         CP1/CCL2 rs1024611 
CC/CT  1.00   8 1.  60  8 00  
TT 6 .09 .94 0.0 9 1. 010 2  0 -4.63 7 6 10 .49-2.47 0.82 
M         CP1/CCL2 rs3760396 
CC 8 .00  9 1.   14 1   6 00  
CG/GG  .59 0.2 8 1. 018 2.36 0 -9.48 3 8 91 .82-4.42 0.13 
M         CP1/CCL2 rs2857657 
CC 4 1.00   1 1.   14  24 00  
CG/GG  .49 0.4 5 1. 023 1.54 0 -4.88 6 9 55 .60-3.97 0.37 
M         CP1/CCL2 rs4586 
CC  1.00   2 1.  66  6 00  
CT  1.59 .71 0.2 8 3. 0.82  0 -3.56 6 6 21 94-10.95 0.06 
TT  .31 0.7 7 3. 018 1.21 0 -4.70 9 2 16 .89-1.28 0.08 
M         CP1/CCL2 rs13900 
CC 5 .00  9 1.   10 1   6 00  
CT/TT  .24 0.1 8 0. 061 0.52 0 -1.15 1 8 91 .41-2.05 0.82 
M         CP1/CCL2 rs991804 
AA 1 .00  8 1.  /AG 10 1   6 00  
GG  .67 0.3 9 1. 066 1.46 0 -3.18 4 6 08 .48-2.44 0.85 
M         CP2/CCL8 rs3138036 
AA 0 1.00   1 1.   15  34 00  
AG/GG  .12 0.2 5 1. 016 0.44 0 -1.58 1 0 29 .49-3.32 0.63 
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T         able B-5 (Continued) 
M         CP2/CCL8 rs3138038 
AA 7 1.00   1 1.   14  35 00  
AC/CC  .11 0.1 4 1. 019 0.36 0 -1.23 1 9 27 .49-3.32 0.63 
M         CP2/CCL8 rs11575057 
CC/CT  1.00   5 1.  20  8 00  
TT 6 3.16 .95 0.0 1 1. 014  0 -10.47 6 26 03 .42-2.57 0.94 
T         GF-β1 rs2278422 
CC   1 1.  /CG 85 1.00  30 00  
GG  4.42 .84 .0 5 1. 082  1 -10.65 0 01 4 50 .62-3.60 0.37 
T         GF-β1 rs2241716 
AA   0 1.  /AG 16 1.00  00  
GG 1 .69 .51 0.3 1 †  15 1  0 -5.65 9 83  
T         GF-β1 rs1800471 
CC/CG  1.00   1 1.  23  8 00  
GG 4 .57 .18 0.3 1 1. 014 0  0 -1.76 3 65 61 .37-6.95 0.52 
T         NFα rs2229094 
CC/CT  1.00   7 1.  84  0 00  
TT  .37 0.5 1 1. 083 0.78 0 -1.67 3 13 36 .58-3.19 0.48 
T         NFα rs3093662 
AA 8 1.00   1 1.   13  56 00  
AG/GG  .37 0.9 2 1. 029 0.98 0 -3.66 7 8 24 .41-3.82 0.70 
T         NFα rs3093665 
AA 3 1.00   1 1.   15  78 00  
AC/CC  .29 0.9 6 0.3 0.06-2  0.32 14 1.06 0 -3.85 3 9 .53
         
* M  genetic variant, Ishak fibrosis score, log10 baseline viral level, ln HOMA2-IR, 
wee xcluded individuals taking exogenous insulin 
‡ Monomorphic SNP 
† Minor allele frequency less then 5% in one population 
Abbreviations:  95% Confidence Interval (Confidence Interval) 
odel adjusted for the
kly alcohol consumption and body mass index and e
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Likelihood Square 
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g Chi 
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COL1A 6 3 6  9 0 0 0.060 1 rs258 485 1 160.8 9 1 0.552 0.287 0.5 2 1 142.61  142.55 0.806 
COL1A1 rs2586494 1 1.155 16 50 0.005 44 1 141.537 136.630 4.907 16 1.1 0.9 0.027 
COL1A1 rs7406586 2 159.551  2  10.889  158.614 0.937 0.626 141.721 130.832 0.004 
COL1A1 rs2269336 1 161.270 160.069 1.201 1 141.803 140.708 1.095 0.273 0.295 
CYP2E1 5773 8 5  5 7 6 9 rs108 5  1 158.1 6 1 8.182 0.004 0.9 0 1 139.87  139.48 0.3 1 0.532 
CYP2E1 rs2070673 2 160.522   159.087 1.435 0.488 2 142.266 139.443 2.823 0.244 
CYP2E1 rs915908 1 159.798 155.249 4.549 0.033 1 140.544 140.474 0. 0.070 791 
CYP2E1 070676 0.99 14 7 3 0.14 2 744 966 0. rs2 2 15 0 7.10  3.88 4 140.  138. 1.778 411 
IL6 rs18 42 0.802 1 161.262 160.132 1.130 0.288 1 142.358 142.158 0.200 655 
IL6 rs20 76 1.57 16 2 0 0.55 2 013 112 0.565 2 16 2 0.38  1.19 2 141.  140.  0.901 637 
IL6 rs2069827 1 147.450 147.450 0.000 1.000 1 142.125 142.010 0.11 0.5 735 
IL6 rs1800797 1 159.221 159.220 0.001 0.975 1 140.203 139.579 4 0. 0.62 430 
IL6 rs1800795 1 159.652 159.652 0.000 1.000 1 140.597 139.824 0.773 0.379 
IL6 rs2069830 1 159.811 159.659 0.152 0.697 1 143.577 143.577 0 1. 0.00 000 
IL6 2069  86 5 489 8 7 2 1.085 0. rs 837 1 160.3 1 9.897 0. 0.4 4 1 143.57  142.49 298 
IL6 rs1554606 1 160.483 9 8 0.160.394 0.08 0.766 1 140.294 138.616 1.67 195 
IL6 rs2069845 1 161.470 161.154 0.316 0.574 1 138.162 135.869 2.293 0.130 
IL10 rs1 74 0.11194  1 161.514 158.237 3.277 0.070 1 142.174 141.730 0.444 505 
IL10 rs3024505 843 155. 1 1  0.1 158.  772 3.07 0.080 139.318 139.205 0.113 737 
IL10 rs3024498 1 159.974 159.817 0.157 0.692 1 142.206 137.026 0.5.180 023 
IL10 rs3 496 2.91 14 9 2 0.02 2 097 272 0.024 2 15 1 5.23  7.67 2 141.  135. 5.825 054 
IL10 rs1554286 1 160.896 160.686 0.210 0.647 1 142.098 136.241 5.857 0.016 
IL10 rs2 202 2.97 14 2 424 0.00 2 097 272 2 0.222 2 15 6 0.55 12. 2 141.  135. 5.8 5 054 
IL10 rs1800890 1 160.228 159.789 0.439 0.508 1 142.617 140.556 2.06 0.1 151 
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Table B-6 (C nue    onti d)        
IL1R1 rs3917 1 13 160. 084 98 .963 963 0.275 1 61.6 529 1. 0.2 1 141  141. 000 1.000 
IL1R1 rs2110 1 01 154. 675 96 .451 431 0.726 1 56.3 626 1. 0.1 1 139  139. 020 0.888 
IL1R1 rs3917 1 06 161. 331 65 .057 806 0.332 1 61.5 175 0. 0.5 1 142  141. 251 0.616 
IL1R1 rs8716 73 161.307 0.066 0.797 1 140.503 138.850 1.653 0.56 1 161.3  199 
LEPR rs6673324 157.93 156.344 1.593 0 139.5 13 1 0.2 7  .451 2 85 8.48  1.104 576 
LEPR r 0 0 4 0 0 4 4 1s11371 0 1 15 .364 150.13  .230 .632 1 1 2.556 1 0.039 2.5 7 0.113 
LEPR rs1343982 1 159.908 159.707 0.201 0.654 1 142.551 140.393 2.158 0.142 
LEPR rs1137101 2 160.868 160.668 0.200 0.905 2 134.871 134.759 0.112 0.946 
LEPR rs2376018 1 161.030 160.124 0.906 0.341 1 140.012 139.526 0.486 0.486 
LEPR rs 96 5 6 4 0 2 4 2 7 0.002 18050  2 15 .409 151.39  .013 .134  1 0.230 1 7.957 12.2 3 
LEPR rs1892534 2 156 7 4 0 2 4 2 2 0.005 .513 151.99  .516 .105  1 0.373 1 9.746 10.6 7 
MCP1/CCL2 rs1024611 1 157.269 157.175 0.094 0.759 1 143.622 143.510 0.112 0.738 
MCP1/CCL2 rs3760396 158. .972 0 0 14 6 14 5 0.442 1 978 158  .006 .938 1 1.33 0.74  0.591 
MCP1/CCL2 rs2857657 1 161 .115 4 0 1 14 5 14 5 0.24 0.624 .059 156  .944 .026  1.78 1.54 0 
MCP1/ 2 rs4 159. .750 3 0 13 6 13 7 0.861 CCL 586 2 279 155  .529 .171 2 9.73 9.43  0.299 
MCP1/CCL2 rs13900 157.  901 0.09  143.  143. 2 0.734 1 994 157. 3 0.760 1 622 510 0.11  
MCP1/CCL2 rs991804 1 160.683 160.675 0.008 0.929 1 142.581 142.293 0.288 0.592 
MCP2/ 8 rs3 036 158. .659 2 0 14 14 5 0.093 CCL 138 1 963 156  .304 .129 1 3.436 0.61  2.821 
MCP2/CCL8 rs3138038 157. 248 2.55 143.  140. 0.093 1 807 155. 9 0.110 1 436 615 2.821 
MCP2/CCL8 rs11575057 1 156.828 154.079 2.749 0.097 1 143.667 141.727 1.940 0.164 
TGF-β1 rs2278422 1 149.478 147.202 2.276 0.131 1 142.853 141.564 1.289 0.256 
TGF-β1 rs2241716 1 160.878 154.731 6.147 0.013 1 143.672 143.672 0.000 1.000 
TGF-β1 4 0 9 0 0 1 4 4 20 .517  rs1800 71 1 16 .878 160.19  .679 .410  1 2.617 1 2.197 0.4 0
TNFα 1 142. 141. 6 0.524  rs2229094 161.210 158.233 2.977 0.084 1 125 719 0.40
TNFα rs3093662 1 161.615 158.342 3.273 0.070 1 143.524 143.001 0.523 0.470 
TNFα 1 161. .065 1 0 14 9 14 9 0 0.290  rs3093665 609 160  .544 .214 1 2.65 1.53  1.12
    Abbr ion: rees reedom (df) eviat
 
Deg of F
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COL1A1 rs2586485           
C 00  1  C 96 1.    68 .00   
TT 71 1.41 (0.65- ‡ 0  3.05) 0.38  115 1.04 ( .43-2.50) 0.93 ‡ 
COL1A1 rs2586494           
AA/A 0  1 . ) 0.01 C 57 1.0    45 .00   19.54(2 32-164.49
CC 110 0.75 (0.33-1.72) 0.50 ‡  138 0.22 (0.05-1.02) 0.05 2.29 (1.05-4.98) 0.04 
COL1A1 rs7406586           
AA 47 1.00    12 1.00  1.00  
A 83 0.23 2) 7 ‡ 56 5 (0. 95) 6 2.80 0.01 G 0.59 ( -1.5 0.2  7.7 94-63. 0.0 4  (3.
.40
63-
) 504
G 37 0.15 9) 7 ‡ 15 6 (0. 34) 8 6 (0 3) 0.10 G 0.46 ( -1.3 0.1  1 3.3 58-19. 0.1 1.9 .88-4.3
COL1A1 rs2269336           
CC 94 1.00    137 1.00    
CG/G 73 0.37 0) 6 ‡ 46 55 (0 4) 7  G 0.80 ( -1.7 0.5  1. .59-4.0 0.3 ‡ 
CYP2E1 rs10857735            
AA/AC 100 1.00    18 1.00    
CC 59 1.14 (0.52-2. 0.74 ‡  159 0. (0.18-5.06) 0.99 ‡  53 99 
CYP2E1 rs2070673           
AA 76 1.00    6 1.00    
A 48  (0  T 66 1.11 (0. -2.53) 0.81  46 0.48 .03-7.71) 0.54 ‡ 
TT 25 0.59 (0.19-1.87) 0.37   131 0.46 (0.03-6.55) 0.57 ‡  
CYP2E1 rs915908            
AA/AG 10 1.00    40 1.00    
G 56 .34- 4) 9 ‡ 40 1 (0 7) 5  G 1 2.32 (0 16.0 0.3  1 0.9 .34-2.4 0.8 ‡ 
CYP2E 2070       1 rs 676      
C 22 1.00  44 1    C    1 .00 
CG 77 .90- .66)  ‡ 33 0.93 (0 86)   3.37 (0 12 0.07  .30-2. 0.90 ‡ 
GG 62 2.85 (0.76-10.70) 0.12 ‡  2 †  ‡  
Table B-7 (Continued)           
IL6 rs1880242           
GG/GT 52 1.00   1.0      140 0 
TT 115 1.28 (0.57-2.89) 0.5 0.2 06) 61 5 ‡  43 0.76 ( 9-2. 0. ‡  
IL6 rs2056576           
CC 54 1.00  1.0      69 0 
CT 79 1.08 (0.47-2.52) 0.8 94 57 ( 42 0.235 ‡  0. 0.23-1. )  ‡  
TT 33 1.10 (0.38-1.34) 0.8 2 9 3. 06 ‡  0 0. 1 (0.23- 65) .90 ‡  
IL6 rs2069827           
GG 158 1.00   52 00     1 1.
GT/TT 7 †  †  31 1.47 .50-(0 4.30) 0.49 ‡  
IL6 rs1800797           
AA/AG 22 1.00  1    1 5 1.00   
GG 144 2.06 (0.61-6.98) 0.25 ‡  69 0.45 (0.19-1.05) 0.07 ‡  
IL6 rs1800795           
CC/CG 23 1.00   118 1.00     
GG 143 1.78 (0.55-5.73) 0.3 6 0.4 .20-1. 0 ‡  4 ‡  6 7 (0 10) .08 
IL6 rs2069830           
CC 133 1.00  18 00     2 1.  
CT/TT 32 0.87 (0.33-2.27) 0.7 1  ‡  7 ‡  † 
IL6 rs2069837           
AA 132 1.00  15 00     9 1.  
AG/GG 34 0.81 (0.32-2.04) 0.65 ‡  25 0.82 (0.23-2.91) 0.76 ‡  
IL6 rs1554606           
GG 79 1.00   60 .00      1
GT/TT 87 0.88 (0.41-1.91) 0.75 ‡  124 2.24 (0.94-5.30) 0.07 ‡  
IL6 rs2069845           
AA 75 1.00  60       1.00  
AG/GG 92 0.86 (0.40-1.86) 0.70 ‡  123 2.52 (1.06-6.00) 0.04 ‡  
IL10 rs11119474           
AA/AG 2 1.00  27 1.00      
GG 165 †  15 1.46 .48-4.48) 0 ‡  ‡  6 (0 .51 
IL10 rs3024505           
CC 148 1.00  13 00     8 1.  
CT/TT 19 0.36 (0.11-1.23) 0.10 44 0.50 ( .21-1.22) ‡  ‡   0 0.13 
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Table B-7 (Continued)           
IL10 rs3024498           
AA 128 1.00    96 1.00  7.53 (2.34-24.26) 0.001 
AG/GG 39 0.56 (0.23-1.37)  8  0.85 (0.34-2. 8-3.87) 0.28 0.20 ‡ 7 16) 0.74 1.62 (0.6
IL10 rs3024496            
CC 28 (0.05- 1) 0.  .46 (0 4.15) 0.47 1.00  0.27 1.3 10 50 1.00  1 .52-
CT 82 2.02 (0 36) 0.23 .39 (1.31  0.01 86 3.27 ( 10.09) 7.66 ( 25.42) 0.001 .64-6.  3 -8.78) 1.06- 0.04 2.31-
TT 57 98 (0. .92) .30 .5 2 3.  (1.15-13.77) 0.03 2.24 80-6.28) 0.13 48 1.69 (0.48-5  0.41 9  (1.45-59 3) 0.0
I   L10 rs1554286         
CC 61  1  2.15 .60) 5 1.00   31 1.00  (1.00-4  0.0
CT/TT 106 1.41 ( ) 0. ‡ 3 10.40) 15.30 8.51 02 0.64-3.14 40  52 .01 (0.87- 0.08  (2.64-8 ) 0.0
I   L10 rs2222202         
CC 84 2 (1.1  9.30 ( 9.53) 2 1.00  3.0 8-7.73) 0.02 48 1.00  1.45-5  0.0
CT 68 0.55 ( ) 0. 1 (1.1  1 7.56) 7.66 ( 5.42) 01 0.23-1.29 17 3.2 6-8.85) 0.03 86 .94 (0.50- 0.34 2.31-2  0.0
TT 15 .85 ( 0) 0. 2 (0.0  0 2.07) 1.46 .15) 7 0 0.07-10.0 90 0.0 1-3.14) 0.12 50 .59 (0.17- 0.41 (0.52-4  0.4
I   L10 rs1800890         
AA/AT 70  1  1.00   16 1.00    
TT 97 1.60 ( ) 0. ‡ 1 2.43) 0.73-3.48 24  67 .00 (0.41- 0.99 ‡  
I   L1R1 rs3917275         
AA 153  1  1.00   82 1.00    
AG/GG 14 ( ) 0. ‡1.05 0.23-4.83 95   1 †    
I   L1R1 rs2110726         
CC 136  1.00   70 1.00    
CT/TT 31 0.32 ( ) 0. ‡ 1  2 5.31) 0.11-0.86 02  13 .21 (0.92- 0.08 ‡  
I   L1R1 rs3917332         
AA/AT 44  1.00   67 1.00    
TT 123 0.86 ( ) 0. ‡ 1  1 3.17) 0.35-2.11 74  16 .38 (0.60- 0.45 ‡  
I   L1R1 rs871656         
AA/AT 72  1.00   64 1.00    
TT 95 0.83 ( ) 0. ‡ 1  0 2.08) 0.29-1.76 62  18 .88 (0.37- 0.77 ‡  
L   EPR rs6673324         
AA 42  1.00   51 1.00    
AG 87 2.43 ( ) 0. ‡ 1 4.62) 0.97-6.05 057  90 .64 (0.58- 0.35 ‡  
GG 37 1.82 ( ) 0. ‡ 1 4.06) 0.57-5.79 31  41 .18 (0.34- 0.79 ‡  
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T        able B-7 (Continued)    
L       EPR rs1137100     
AA 112  1  1.00   00 1.00    
AG/GG 55 0.25 ( ) 0. ‡ 0 2.05) 0.11-0.58 001  83 .90 (0.40- 0.81 ‡  
L   EPR rs1343982         
AA/AG 91  1.00   85 1.00    
GG 76 1.66 ( ) 0. ‡ 1 2.53) 0.77-3.58 19  98 .11 (0.49- 0.75 ‡  
L   EPR rs1137101         
AA 42  1.00   53 1.00    
AG 73 0.92 ( ) 0. ‡ 1 4.30) 0.35-2.42 86  91 .58 (0.58- 0.37 ‡  
GG 52 0.67 ( ) 0. ‡ 0 1.10) 0.24-1.86 44  39 .31 (0.09- 0.07 ‡  
L   EPR rs2376018         
AA 115  1  1.00   24 1.00    
AG/GG 52 1.38 ( ) 0. ‡ 2 5.22) 0.61-3.12 45  59 .09 (0.84- 0.11 ‡  
L   EPR rs1805096         
CC 52  2.01 .40) 7 1.00   74 1.00  (0.75-5  0.1
CT 83 2.11 ( ) 0. ‡ 4. 15.73) 29.60 05.2 01 0.87-5.13 10  70 36 (1.21- 0.03 (4.27-2 ) 0.0
TT 32 0.63 ( ) 0. ‡ 2 7.33) 1.01 .32) 8 0.21-1.90 42  38 .36 (0.76- 0.14 (0.31-3  0.9
L   EPR rs1892534         
AA 33  1.20 .90) 6 1.00   40 1.00  (0.37-3  0.7
AG 83 2.98 ( ) 0. ‡ 1 7.16) 26.22 80.4 01 1.07-8.33 04  69 .79 (0.45- 0.41 (3.81-1 ) 0.0
GG 51 1.55 ( ) 0. ‡ 0 1.34) 1.97 .25) 8 0.52-4.62 43  74 .44 (0.15- 0.15 (0.74-5  0.1
MCP1/CCL2 rs3917879‡           
M   CP1/CCL2 rs1024611         
CC/CT 60  1.00   88 1.00    
TT 106 2.09 ( ) 0. ‡ 1 2.47) 0.94-4.63 07  96 .10 (0.49- 0.82 ‡  
M 6   CP1/CCL2 rs376039         
CC 148  1.00   96 1.00    
CG/GG 18 2.36 ( ) 0. ‡ 1 4.42) 0.59-9.48 23  88 .91 (0.82- 0.13 ‡  
M 657   CP1/CCL2 rs2857         
CC 144 3 (0.9   1  1.00  1.7 5-3.16) 0.07 24 1.00    
CG/GG 23 .33 ( 9) 0. 0 (1.2 ) 1 3.97) 2 0.42-12.8 33 24.8 3-500.2 0.04 59 .55 (0.60- 0.37 ‡  
M     CP1/CCL2 rs4586       
CC 66 1.00    26 1.00    
CT 82 1.59 (0.71-3.56) 0.26 ‡  86 3.21 (0.94-10.95) 0.06 ‡  
TT 18 1.21 (0.31-4.70) 0.79 ‡  72 3.16 (0.89-11.28) 0.08 ‡  
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MCP1/CCL2 rs13900           
CC 105 1.00   96 1.00      
CT/TT 61 0.52 (0.24- ‡  88 0.91 (0.41- ‡  1.15) 0.11 2.05) 0.82 
MCP1/CCL2 rs991804           
AA/AG   101 1.00    86 1.00    
GG  1   1  66 .46 (0.67-3.18) 0.34 ‡  96 .08 (0.48-2.44) 0.85 ‡  
MC 6 P2/CCL8 rs313803           
AA  150 1.00    134 1.00    
AG/GG  58)   32)  16 0.44 (0.12-1. 0.21 ‡  50 1.27 (0.49-3. 0.63 ‡  
MCP2/CCL8 rs3138038           
AA 147 1.00    135 1.00    
AC/CC 19 0.36 (0.11-1.23) 0.10 ‡  49 1.27 (0.49-3.32) 0.63 ‡  
MCP2/CCL8 rs11575057           
CC/CT 20 1.00    58 1.00    
TT 146 3.16 (0.95-10.47) 0.06 ‡  126 1.03 (0.42-2.57) 0.94 ‡  
TGF-β1 rs2278422           
CC/CG    85 1.00    130 1.00    
GG 82 4.42 ( 0.65) 1 1.50 ( 3.60)  1.84-1 0.00 ‡  54 0.62- 0.37 ‡  
TGF-β1 rs2241716           
AA/AG 16 1.00  0.65 .22-(0 1.94)     0.44 0 1.00 
GG 151 1.48 (0.47-4.62) 0.50 3.34 (1 -6.91) 0.001.61 183 †  †  
TGF-β1 rs1800471           
CC/CG 23 1.00    18 1.00    
GG 144 0.57 (0.18-1.76) 0.33 ‡  165 1.61 (0.37-6.95) 0.52 ‡  
TNFα rs2229094           
CC/CT 84 1.00    70 1.00    
TT 83 0.78 ( 1.67)   1.36 ( 3.19)  0.37- 0.53 ‡  113 0.58- 0.48 ‡  
TNFα rs3093662           
AA  138 1.00    156 1.00    
AG 0.98 ( 2.66)  1.24 ( 3.82)  /GG 29 0.37- 0.98 ‡  28 0.41- 0.70 ‡  
TNFα rs3093665           
AA 153 1.00    178 1.00    
AC/CC 14 1.06 (0.29-3.85) 0.93 ‡  6 0.39 (0.06-2.53) 0.32 ‡  
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Table B-8:  Chi Square Association between Insulin  gle e Polymorphisms 
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p-value* 
A2-
 2 
 
lue*
HOM
IR
2-
 
HO
IRIR p-va  
COL1A1 rs2586485       
CC 0.11 0.17  0.04 0.08  
CT 0 0.48   0.37  .47  0.29  
TT 0 0.35 .67 0.56 0.37 .42  0.44 0  
COL1A1 rs2586494       
AA 0 0.02   0.0  .02  0.03
C 0 0.33   0.15  A .28  0.25  
CC 0 5 .7 .11  .70 0.6  0.77 0 2 0.85 0
CO 6     L1A1 rs740 586   
AA 0 0.26   0.06  .29  0.07  
AG 0 0.55  0.37  .43   0.29  
GG 0.28 0.19 0.21 0.64 0.58   0.51
CO   L1A1 rs2269336     
CC 0.54 0.58  0.72 0.83  
CG 0.41 0.39  0.26 0.17  
GG 0.05 0.03 0.02 0.0 0.25 0.66 
CYP2E1 rs10857735       
AA 0.20 0.14 0.0 0.02   
AC 0.40 0.56 0.07 0.12   
CC 0.41 0.30 .93 0.86 0.11   0.17 0
CYP2E1 rs2070673       
AA 0.46 0.49 0.03 0.04   
AT 0.40 0.39  0.20 0.37  
TT 0.15 0.12 0.89 0.77 0.60 0.04 
CY 1 rs 908      P2E 915  
AA 0 0.0   0.02  .0  0.02  
AG 0.05 0.04  0.21 0.17  
GG 0 0.96 .78 0.81 0.80 .95  0.79 0  
CYP2E1 rs2070676       
CC 0 9  0.   .19 0.0  0.83 72 
CG 0 9  0.  .39 0.4   0.16 28 
GG 0 0.42 .02 0.0 0.07 .43  0.33 0
IL 880      6 rs1 242  
GG 0.0 0.03  0.14 0.23  
 GT 0.31 0.29 0.56 0.65  
TT 0 8 .30 0. .03 .69 0.6  0.29 0 12 0
IL 0     6 rs2 56576   
CC 0 0.35   0.  .29  0.38 39 
CT 0.48 0.44  0.48 0.   58 
TT 0.23 0.22 0.81 0. 4 0.15  14 0.0
IL6 rs206982     7   
GG 0.98 0.94  0. 9  82 0.8
GT 0.02 0.06  0. 2  18 0.1
TT 0.0 0.0 0.28 0  0.26  .0 0.0
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IL6 rs1800797       
AA 0.0 0.0  0.11 0.17  
AG 0.11 0.16  0.47 0.56  
GG 0 84 0.45  0.27 0.24 .89 0.  0.42
IL6 rs1800795       
CC 0.0 0.0  0.11 0.17  
CG 0.11 0.18  0.47 0.56  
GG 0.89 0.82 0.33 0.42 0.27 0.24 
IL6 rs2069830       
CC 0 84   1.0  .77 0. 1.0
CT 0.23 0.13  0.0 0.0  
TT 0 03 0.15  0.0  .0 0.  0.0
IL6 rs206983      7  
AA 0.83 0.71  0.83 0.92  
AG 0.17 0.29  0. 0.17 08  
GG 0 .0 0.095  0.0 0.15 .0 0  0.0
IL6 rs155460      6  
GG 0.51 0.43  0.39 0.23   
GT 0.41 0.43  0.49 0.60  
TT 0.08 0.15 0.41 0.13 0.17 0.16 
IL6 rs2069845       
AA 0.49 0.39  0.39 0.23  
AG 0.42 0.46  0.49 0.60  
GG 0.08 0.15 0.34 0.12 0.17 0.14 
IL10 rs11119474       
AA 0 .0   0.0  .0 0 0.0
AG 0.0 0.03  0.16 0.12  
GG 1.0 0.97 0.12 0.84 0.89 0.61 
IL10 rs3024505       
CC 0.88 0.90  0.72 0.77  
CT 0 10   0.17  .12 0. 0.28
TT 0 .0 0.73  0.06 0.13 .0 0  0.01
IL10 rs3024498       
AA 0 78   0.42  .81 0. 0.56
AG 0 22   0.48  .19 0. 0.35
GG 0.0 0.0 2  0.  0.6  0.10 10 0.43
IL10 rs30244    96    
CC 0 17   0.33  .11 0. 0.26
CT 0 36   0.42  .58 0. 0.51
TT 0.31 0.46 0.057 0.23 0.25 0.37 
IL10 rs1554286       
CC 0.33 0.35  0.66 0.79  
CT 0.54 0.41  0. 0.31 21  
TT 0.13 0.25 0.13 .03 0.0 0.23  0
IL10 rs2222202       
CC 0.49 0.58  0. 5   23 0.2
CT 0.47 0.29  0. 2   51 0.4
TT 0.04 0.13 0.05 0. 3 0.37  26 0.3
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IL10 rs1800890       
AA 0.02 0.07  0.12 0.23  
AT 0.31 0.36  0.55 0.42  
TT 0 0  0.34 5 0.13 .66 .57 0.42 0.3
IL1R1 rs3917       257§  
IL1R1 rs3917       275 
AA 0.94 0.90  0.99 1.0  
AG 0.06 0.09  0.01 0.0  
GG 0.0 0 3  .02 0.4  0.0 0.0 0.47
IL1R1 rs2110726       
CC 0.80 0.87   0.35  0.40
CT 0 0 9 4  .19 .13  0.4 0.5
TT 0 4 0.11 2 0.61 .01 0.0 0.3 0.1
IL1R1 rs3917332       
AA 0.01 0 3 6  .03  0.0 0.0  
AT 0 0 7 3  .19 .23  0.3 0.3
TT 0 0  0.61 2 0.69 .80 .74 0.67 0.6
IL1R1 rs871656       
AA 0.06 0.07  0.04 0.06  
AT 0.39 0.39  0.30 0.29  
TT 0.55 0.54 0.95 0.66 0.65 0.85 
LEPR rs6673324       
AA 0.24 0.29  0.20 0.39  
AG 0.54 0.55  0.57 0.35  
GG 0.22 0.16 0.61  0.27 0.04  0.22
LEPR rs1137100       
AA 0.66 0.61  0.60 0.52  
AG 0.30 0.35  0.34 0.37  
GG 0.04 0.04 0.77 0.07 0.12 0.57 
LEPR rs1343982       
AA 0 0 8 2  .10 .13  0.0 0.1
AG 0 0 5 7  .48 .45  0.3 0.3
GG 0.42 0.42 0.79 0.58 0.52 0.74 
LE rs 7101PR 113        
AA 0 0 3 9  .29 .19  0.3 0.2
AG 0.41 0 1 0  .42  0.5 0.4  
GG 0.30 0  0.16 1 .24 .39 0.24 0.3  0
LE rs 6018PR 237        
AA 0 0 5 1  .71 .70  0.6 0.7
AG 0.28 0.29  0.33 0.23  
GG 0.01 0.02 0.97   0.02 0.06 0.36
LE rs 5PR 180 096       
CC 0.29 0.29  0.39 0.43  
CT 4 0 0.0.5 .39  41 0.29  
TT 0.17 0 5 0. 0.  .32 0.0  19 28 0.27
LEPR rs1892534       
AA 0.18 0.3  0. 0.2 21 27  
AG 0.54 0.3  0. 0.9 39 31  
GG 0.28 0.2 0.07 0. 0.  9  39 42 0.49
       
Table B-8 (Continued)       
MCP1/CCL2 rs3917879§       
MCP1/CCL2 rs1024611       
CC 0.06 0.04  0.06 0.14  
CT 0.33 0 .43 0.46  .28  0
TT 0.62 0.68 0.83 0.51 0.40 0.23 
MCP1/CCL2 rs3760396       
CC 0.92 0.88  0.48 0.60  
CG 0.08 0.10  0.45 0.39  
GG 0.0  0.08  0.18  0.02 0.50  0.02
MCP1/C  rs285        CL2 7657
CC 0.87 0.87  0.70 0.71  
CG 0.13 0.13 .26 0.27   0
GG 0.0 0.0 9 0.04 0.02 0.80 0.9
M /C 8  CP1 CL2 rs45 6      
CC 0.45 4 .1 5    0.3  0 4 0.1
CT 0.46 0.56 .49 0.52   0
TT 0.10 0.10 0.39 0.37 0.33 0.76 
MC   P1/CCL2 rs13900      
CC 0 0  .60 0.68  0.51 0.4
CT 0.33 0.28  0.43 0.46  
TT 0.07  0.06 0.14 0.23 0.04 0.69
MCP1/CCL2 rs991804       
AA 0.17 0.15  0.06 0.14  
AG 0.46 0.41 0.45  0.39  
GG 0.37  0.53 0.41 0.21 0.46 0.60
MCP2/C  rs313      CL8 8036   
AA 0.89 0.70 0.79  0.93  
AG 0.11 0.30 0.17  0.06  
GG 0.0  0.01 0.04 0.19 0.02 0.25
MCP2/CCL8 rs3138038       
AA 0.87 0 .70 0.81  .93  0
AC 0.13 0 .29 0.16  .06  0
CC 0.0 0.02 0.14 0.02 0.04 0.17 
MCP2/C  rs115      CL8 75057   
CC 0.0 0 .03 0.04  .02  0
CT 0.15 .3 9    0.06  0 2 0.1
TT 0.86  .6 7 0.17  0.93 0.10 0 5 0.7
TGF-β1 rs2278422        
CC 0.04 0 .13 0.21  .12  0
CG 0.45 0.51  0.52 0.64  
GG 0.52 0.38 0.06 0.35 0.15 0.04 
TG 1 rs2241716       F-β  
AA 0.0 .    0.0  0 0 0.0
AG 0 7  0.0 0.0 .13 0.0  
GG 0  0.24 1.0 .87 0.93  1.0  
TGF-β1 rs 471       1800
CC 0 0.0   0.0  .0 0.01
CG 0 0.12     .17 0.08 0.14
GG 0.83 0.88 0.37   0.43   0.91 0.87
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TN 229094       Fα rs2
CC 0.01 0.06  0.06 0.08  
CT 0.46 0.45  0.30 0.33  
TT 0.53 0.49 0.16 0.64 0.60 0.63 
TN 093662       Fα rs3
AA 0.83 0.83  0.83 0.87  
AG 0.17 0.16  0.16 0.10  
GG 0.0 0.02 0.29 0.01 0.04 0.36 
TN 093665       Fα rs3
AA 0.90 0.93  0.95 1.0  
AC 0.10 0.07  0.05 0.0  
CC 0.0 0.0 0.86 0.0 0.0 0.37 
       
* P-value based on genotype association chi square test 
† C re could not be estimated because minor allele frequency < 5% for the SNP 
§ M rphic SNP 
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COL1A1 rs2586485         
CC/CT  1.0 1.00    85 0   57 
TT  0.7 0.38-1 0.35 0.61 0.31-1.21 0.16  57 3 .42 98 
COL1A1 rs2586494         
AA/AC  1.0 1.00    45 0   37 
CC  0.8 0.41-1.60 0.54  2.13 0.89-5.06 0.09  97 1 118
COL1A1 rs7406586          
AA  1.0   1.00   41 0 10 
AG  1.4 0.66-3.02  1.48 0.34-6.24 0.60  70 1  0.38 49 
GG  0.7 0.30-1.88  1.05 0.25-4.32 0.95  31 5  0.54 96 
COL1A1 rs2269336          
CC  1.0    1.00   79 0 117
CG/GG  0.8 0.45-1.64  0.54 0.23-1.25 0.15  63 6  0.64 38 
CYP2E1 rs10857735           
AA/AC  1.0   1.00    86 0 14 
CC  0.9 0.58-1 0.71  0.44 0.16-1.22 0.12  51 2 .46 136
CYP2E1 rs2070673         
AA  1.0 1.00   68 0   5 
AT  0.9 0.46-1 0.80 1.36 0.20-9.02 0.75  54 1 .82 39 
TT  0.7 0.27-2 0.57  0.58 0.09-3.65 0.56  20 5 .04 111
CYP2E1 rs915908         
AA/AG  1.0 1.00    6 0   33 
GG 5 1.1 0.24-5 0.88  1.22 0.53-2.81 0.64  13 3 .22 120
CYP2E1 rs2070676         
CC  1.0  1.00   19 0   121
CG  2.6 0.92-7.73 0.07 2.07 0.91-4.67 0.22  61 6 29 
GG 58 2.0 0.71-6 0.19 †   6 .01 2 
IL6 rs1880242         
GG/GT  1.0  1.00    45 0   119
TT  0.9 0.49-1.94  0.31 0.12-0.79 0.02  97 7  0.94 36 
IL6 rs2056576         
CC  1.0   1.00   47 0 58 
CT 5 0.7 0.36-1.57  1.17 0.58-2.37 0.66 6 5  0.45 80 
TT  0.7 0.33-1.91 0.60 0.26 0.05-1.25 0.09  30 9 17 
IL6 rs2069827         
GG 4 1.0    1.00   13 0 130
GT/TT  2.5 0.44-14.0   0.58 0.22-1.56 0.28  6 0 9 25 
IL6 rs1800797         
AA/AG  1.0   1.00    19 0 99 
GG 2 0.6 0.25-1 0.34 0.51 0.25-1.06 0.07  12 3 .62 57 
IL6 rs1800795         
CC/CG  1.0   1.00    20 0 99 
GG 1 0.5 0.22-1 0.23 0.51 0.25-1.06 0.07  12 7 .44 57 
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IL6 rs2069830         
CC 3 1.0    1.00   11 0 155
CT/TT  0.6 0.29-1.51 0.33 †    27 6  0 
IL6 rs2069837         
AA  1.00    1.00   112 135
AG/GG 9 2.0 0.95-4.4  0.40 0.13-1.26 0.12 2 5 6 0.07 21 
IL6 rs1554606         
GG  1.0   1.00   66 0 52 
GT/TT 75 1.38 0.95-0.33   2.14 1.00-4.54 0.05  0.33 104
IL6 rs2069845         
AA  1.0    1.00   63 0 52
AG/GG 9 1.5 0.80-2 0.21  2.17 1.02-4.62 0.04 7 2 .90 103
IL10 rs11119474         
AA/AG  1.0   1.00    2 0 23 
GG 0 †    1.50 0.55-4.06 0.43  14  132
IL10 rs3024505         
CC  1.00    1.00   126 113
CT/TT  0.8 0.30-2.29  0.76 0.35-1.64 0.48  16 2  0.71 41 
IL10 rs3024498         
AA 2 1.0   1.00   11 0 79 
AG/GG 30 1.16 0.53-2.56  6 1.72 0.88-3.37 0.11  0.71 7
IL10 rs3024496         
CC  1.0   1.00   20 0 44 
CT  0.3 0.15-1 0.06 0.65 0.30-1.42 0.28  70 9 .05 75 
TT 52 0.92 0.34-2.53  7 0.86 0.35-2.13 0.75  0.88 3
IL10 rs1554286         
CC  1.0    1.00   49 0 109
CT/TT 3 0.9 0.46-1 0.77 0.51 0.23-1.10 0.09 9 0 .78 46 
IL10 rs2222202         
CC  1.0   1.00   74 0 37 
CT  0.5 0.26-1.05  0.75 0.33-1.74 0.51  57 3  0.07 75 
TT 1 3.0 0.78-12 0.11  7-2.88 5 1 8 .19 44 1.16 0.4 0.7
IL10 rs1800890         
AA/AT  1.0    1.00    55 0 102
TT  0.6 0.34-1.28  1.04 0.52-2.11 0.91  87 6  0.22 53 
IL1R1 rs3917275         
AA  1.00    1.00   130 154
AG/GG  1.7 0.53-5.8 0.35 †    12 6 2 1 
IL1R1 rs2110726         
CC 7 1.0   1.00   11 0 59 
CT/TT 25 0.58 0.24-1.41  6 1.28 0.64-2.56 0.49  0.23 9
IL1R1 rs3917332         
AA/AT  1.0   1.00    33 0 60 
TT 9 0.7 0.34-1 0.42 1.04 0.53-2.06 0.91  10 3 .56 95 
IL1R1 rs871656         
AA/AT  1.0   1.00    64 0 53 
TT  0.9 0.49-1.77   0.93 0.46-1.88 0.84  78 3  0.83 101
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LEPR rs6673324         
AA  1.0   1.00   33 0 41 
AG  0.8 0.40-1.80 0.66  4-0.72 6  81 4  76 0.32 0.1 0.00
GG  0.6 0.23-1 0.32 0.64 0.26-1.58 0.33  28 1 .62 37 
LEPR rs1137100         
AA 93 1.00   8 1.00   8
AG/GG  1.2 0.65-2.45  1.37 0.70-2.67 0.36  49 6  0.49 67 
LEPR rs1343982         
AA/AG 9 1.0    1.00   7 0 69
GG 63 0.99 0.52-1.90  6 0.79 0.41-1.55 0.49  0.99 8
LEPR rs1137101         
AA  1.0   1.00   36 0 49 
AG  1.5 0.68-3 0.29 0.90 0.41-1.98 0.79  62 8 .64 73 
GG 44 1.99 0.84-4.74  3 2.13 0.86-5.32 0.10  0.12 3
LEPR rs2376018         
AA  1.0    1.00   98 0 104
AG/GG  1.0 0.54-2 0.84 0.77 0.37-1.58 0.47  44 8 .16 51 
LEPR rs1805096         
CC  1.0   1.00   44 0 62 
CT  0.7 0.34-1.54  0.65 0.30-1.42 0.28  68 2  0.40 58 
TT  1.8 0.77-4 0.17 1.31 0.55-3.07 0.54  30 9 .62 34 
LEPR rs1892534         
AA  1.0   1.00   31 0 36 
AG  0.4 0.18-0.92  0.61 0.25-1.49 0.28  68 1  0.03 57 
GG  0.5 0.24-1 0.25 0.84 0.36-1.97 0.69  43 9 .44 62 
MCP1/CCL2 rs3917879‡         
MCP1/CCL2 rs1024       611   
CC/CT  1.0   1.00    50 0 81 
TT  1.3 0.67-2 0.43 0.64 0.33-1.25 0.19  91 1 .57 75 
MCP1/CCL2 rs3760396         
CC 7 1.0   1.00   12 0 80 
CG/GG  1.4 0.50-4.22  0.62 0.31-1.21 0.16  14 5  0.50 76 
MCP1/CCL2 rs2857       657   
CC  1.00    1.00   124 109
CG/GG  0.9 0.38-2.53  0.96 0.46-1.99 0.90  18 8  0.97 46 
MCP1/CCL2 rs4586          
CC  1.0   1.00   59 0 22 
CT 67 1.61 0.81-3.20  8 0.99 0.37-2.64 0.99  0.18 7
TT  1.4 0.45-4.40  0.82 0.29-2.29 0.70  15 1  0.56 56 
MCP1/CCL2 rs1390       0   
CC  1.0   1.00   90 0 75 
CT/TT 51 0.73 0.37-1.42  1 1.56 0.80-3.06 0.19  0.35 8
MCP1/CCL2 rs9918       04   
AA/AG  1.0   1.00    84 0 78 
GG  1.4 0.76-2 0.26 0.62 0.32-1.23 0.17  58 5 .78 76 
MCP2/CCL8 rs3138036         
AA 8 1.0    1.00   12 0 114
AG/GG  0.6 0.21-2.05  0.61 0.28-1.34 0.22  13 5  0.46 42 
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MCP2/CCL8 rs3138038         
AA  1.00    1.00   126 115
AC/CC  0.5 0.17-1.5  0.54 0.24-1.22 0.14  15 2 8 0.25 41 
MCP2/CCL8 rs1157        5057   
CC/CT  1.0   1.00    16 0 48 
TT  2.13 0.71-6.38   1.81 0.85-3.87 0.13 125  0.18 108
TGF-β1 rs2278422         
CC/CG  1.0    1.00    76 0 111
GG 6 0.5 0.29-1 0.08 0.33 0.14-0.78 0.01 6 6 .08 45 
        TGF-β1 rs2241716 
AA/AG  1.0   1.00    16 0 0 
GG 126 1.9 0.65-5.93 0.24  †   6  155
TGF-β1 rs1800471         
CC/CG 16 1.00   6 1.00   1
GG 6 1.5 0.61-3.9   0.61 0.21-1.74 0.35  12 5 4 0.36 139
TNFα rs2229094         
CC/CT  1.0   1.00    69 0 58 
TT 73 0.86 0.45-1.63  7 0.82 0.41-1.62 0.56  0.65 9
TNFα rs3093662         
AA 9 1.0    1.00   11 0 131
AG/GG  1.0 0.45-2 0.93 0.75 0.29-1.93 0.55  23 4 .42 25 
TNFα rs3093665         
AA 0 1.0    1.00   13 0 151
AC/CC  0.7 0.23-2.35 0.60 †    12 3  5 
         
‡ Monomorphic SNP 
† Minor allele freque ss the  one pop
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COL1A1 rs2586485         
CC 85 .00  57     1  1.00
TT 57 0.89 0.41-1.91 0.76 98 0.72 0.34-1.52 0.39 
COL1A1 rs2586494         
AA/AC 45 00   37    1.  1.00
CC 97 .00 0.45-2.22 0.99 118 2.07 -5.17 0.12 1  0.82
COL1A1 rs7406586          
AA 41 1.00   10 1.00   
AG 70 1.88 0.75-4.70 0.18 49 0.87 0.18-4.20 0.86 
GG 31 0.87 0.27-2.78 0.82 96 0.69 0.15-3.12 0.63 
COL1A1 rs2269336         
CC 79 1.00   117 1.00   
CG/GG 63 0.77 0.36-1.66 0.51 38 0.46 0.19-1.14 0.09 
CYP2E1 rs10857735          
AA/CC 86 1.00   14 1.00   
CC 51 0.86 0.50-1.47 0.57 136 0.52 0.14-1.57 0.25 
CYP2E1 rs2070673         
AA 68 1.00   5 1.00   
AT 54 0.87 0.39-1.97 0.74 39 1.56 0.21-11.86 0.67 
TT 20 0.68 0.21-1.28 0.51 111 0.80 0.11-5.68 0.83 
CYP2E1 rs915908         
AA/AG 6 1.00   33 1.00   
GG 135 4.49 0.42-47.89 0.21 120 1.37 0.55-3.42 0.50 
CYP2E1 rs2070676         
CC 19 1.00   121 1.00   
CG 61 2.33 0.57-9.79 0.25 29 2.01 0.81-4.98 0.13 
GG 58 1.96 0.47-8.25 0.36 2 †   
IL6 rs1880242         
GG/GT 45 1.00   119 1.00   
TT 97 1.06 0.47-2.39 0.89 36 0.29 0.10-0.80 0.02 
IL6 rs2056576         
CC 47 1.00   58 1.00   
CT 65 0.48 0.20-1.14 0.10 80 1.22 0.57-2.61 0.62 
TT 30 0.51 0.17-1.47 0.21 17 0.35 0.07-1.81 0.21 
IL6 rs2069827         
GG 134 1.00   130 1.00   
GT/TT 6 5.19 0.65-41.52 0.12 25 0.62 0.20-1.91 0.41 
IL6 rs1800797         
AA/AG 19 1.00   99 1.00   
GG 122 0.55 0.18-1.69 0.30 57 0.60 0.28-1.32 0.20 
IL6 rs1800795         
CC/CG 20 1.00   99 1.00   
GG 121 0.62 0.29-1.36 0.23 57 0.48 0.16-1.44 0.19 
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IL       6 rs2069830   
CC 113 1.00   155 1.00   
CT/TT 27 0.61 33 0 †  0.23-1.65 0.   
IL6 rs20698       37   
AA/AG 112 1.00  1.00  135    
GG  29 7 -5 3  0.2 02.0 0.81 .28 0.1  21 4 .06-0.88 0.03 
IL6      rs1554606     
GG   52 1.00  66 1.00    
GT/TT  9-3 5 4 075 1.45 0.6 .15 0.3 10 1.71 .76-3.85 0.20 
IL6    rs2069845       
AA 63 1.00  52 1.00     
AG/GG  3-3 4 3 .70 0 79 1.59 0.7 .48 0.2 10 1  .75-3.85 0.20 
IL1   0 rs11119474       
AA/AG    23   2 1.00 1.00 
GG 1  2 040 †  13 1.00 .33-2.94 0.98 
IL10 rs3024505         
CC 1  3 1.0026 1 00.   11    
CT/TT  5-2.97 0.81 41 .16 0.49-2  0.73 16 0.86 0.2 1  .73
IL10 rs3024498         
AA 112 1 00.   1.00  79    
AG/GG 30 1.71 8-4 33 0.26 76 0.85-3  0.13 0.6 . 1.77 .70
IL10 rs3024496         
CC     .0020 1 00. 44 1    
CT  8-0.82 0.03 75 0.52 0.22-1  0.14 70 0.26 0.0  .23
TT  2-1 6  052 0.41 0.1 .41 0.1 37 0.47 .17-1.33 0.16 
IL10 rs1554286         
CC 4  9 1.009 1 00.   10    
CT/TT  6-1.31 0.19 46 0.20-1  0.09  93 0.59 0.2 0.48 .11
IL10 rs2222202         
CC     .0074 1 00. 37 1    
CT  0-1.57 0.38 75 .10 0.43-2  0.85 57 0.69 0.3 1  .84
TT  -23 4  .11 011 5.07 1.10 .45 0.0 44 2  .75-5.94 0.16 
IL10 rs1800890         
AA/AT  2 1.00  55 1 00.   10  
TT  8-0.88 0.02 53 .65 0.29-1  0.28  87 0.39 0.1 0  .43
IL1R1 rs3917275         
AA 1  4 1.0030 1 00.   15    
AG/GG  7-8.60 0.35 1 †  12 2.00 0.4  
IL1R1 rs2110726         
CC 1   1.0017 1.00   59    
CT/TT 2  3-1 2  05 0 65. 0.2 .86 0.4 96 1.18 .55-2 56 . 0. 7 6
IL1       R1 rs3917332   
AA/AT  60 1.0033 1 0.0      
TT  5-1 5 95 0109 0.60 0.2 .43 0.2 0.94 .44-2 00 . 0. 7 8
IL1       R1 rs871656   
AA/AT      64 1.00 53 1.00   
TT  9-2 3 1 078 1 03. 0.4 .18 0.9 10 1.03 .48-2 22 . 0. 4 9
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LEP         R rs6673324 
AA    41 .00   33 1.00 1  
AG  9-2 4  0.33 0.14-0  0.01 81 0.97 0.3 .37 0.9 76 .79
GG 28 0.66 .20-2.12 0.48 37 0.75 0.28-2  0.56 0 .00
LEPR rs1137100          
AA   1.00 93 1.00   88    
AG/GG 49 1.77 .78-4.03 0.17 67 1.44 0.69-2  0.33 0 .98
LEPR rs1343982          
AA/AG   1.0079 1.00   69    
GG 63 0.95 .44-2.05 0.90 86 0.75 0.36-1  0.44 0 .55
LEPR rs1137101         
AA     .00 36 1.00 49 1    
AG 62 1.60 .60-4.22 0.35 73 0.86 0.36-2  0.74 0 .06
GG  3-4.95 0.28 33 0.80-6  0.12  44 1.77 0.6 2.25 .32
LEPR rs2376018          
AA 98 1.00    1.00  104  
AG/GG  2-2.61 0.72 51 .57 0.25-1  0.18 44 1.16 0.5 0  .30
LEPR rs1805096         
CC 44 1.00   62 1.00   
CT  7-1.60 0.35 58 0.23-1  0.16 68 0.65 0.2 0.54 .28
TT  5-5 4  0 30 1.88 0.6 .44 0.2 34 1.05 .41-2.74 0.91 
LEP         R rs1892534 
AA    36   31 1.00 1.00 
AG 6  4-1 6  08 0.38 0.1 .02 0.0 57 0.57 .22-1.50 0.25 
GG 4  2-1 8  03 0.62 0.2 .78 0.3 62 1.00 .39-2.57 0.99 
MC 11         P1/CCL2 rs10246
CC/CT    81 .00   50 1.00 1  
TT  7-2 3  091 1.04 0.4 .29 0.9 75 0.83 .40-1.75 0.63 
MC 96         P1/CCL2 rs37603
CC 1    80   27 1.00 1.00 
CG/GG 1  1-4 0  04 1.40 0.4 .83 0.6 76 0.61 .29-1.27 0.18 
MCP1/CCL2 rs2857657         
CC 124 1.00    1.00   109
CG/GG  5-2.47 0.68 46 .85 0.38-1  0.68  18 0.79 0.2 0  .88
MCP1/CCL2 rs4586         
CC 59 1.00   22 1.00   
CT  8-2.98 0.51 78 .73 0.25-2  0.56 67 1.32 0.5 0  .13
TT  7-5 4  0.79 0.26-2  0.68  15 1.66 0.4 .88 0.4 56 .43
MC         P1/CCL2 rs13900 
CC    75   90 1.00 1.00 
CT/TT  1-1 9  051 0.90 0.4 .97 0.7 81 0.90 .41-1.97 0.79 
MC          P1/CCL2 rs991804
AA/AG    78    84 1.00 1.00 
GG 5  3-2 3  08 1.15 0.5 .47 0.7 76 0.79 .37-1.67 0.53 
MC 36         P2/CCL8 rs31380
AA    1.00   128 1.00  114   
AG/GG 1  8-2 9  .59 03 0.69 0.1 .65 0.5 42 0  .24-1.45 0.25 
MCP2/CCL8 rs3138038         
AA 126 1.00    1.00  115  
AC/CC 15 0.59 .16-2.19 0.43 41 0.59 0.24-1  0.25 0 .45
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MC 57         P2/CCL8 rs115750
CC/CT   48 1.00  16 1.00    
TT 1  3-6 3 8 025 2.07 0.6 .83 0.2 10 1.78 .75-4.25 0.19 
TGF-β1 rs2278422         
CC/CG 76 1.00    1.00  111  
GG  7-0.89 0.03 45 0.14-0  0.02 66 0.38 0.1 0.35 .87
TGF-β1 rs2241716          
AA/AG 16 1.00   0 1.00   
GG  1-4.29 0.64  †   126 1.32 0.4 155  
TGF-β1 rs1800471         
CC/CG 16 1.00   16 1.00   
GG 1  6-5.00 0.35  0.25-2  0.65 26 1.68 0.5 139 0.77 .39
TNFα rs2229094         
CC/CT   1.0069 1.00   58    
TT 73 0.75 .35-1.61 0.45 97 0.80 0.37-1  0.58 0 .75
TNFα rs3093662         
AA  1 1.00 119 1.00   13    
AG/GG 23 0.91 .34-2.46 0.85 25 0.79 0.26-2  0.68 0 .41
TNFα rs3092665         
AA 1  1 1.0030 1.00   15    
AC/CC 1  7-2 9  † 2 0.63 0.1 .38 0.4 5   
         
* Model adjusted for the genetic nt ak f  score, ste as dex nd
levels and excluded individuals taking e nou lin 
† Model coul  se or a requ  fo NP
§ Mo
Abbre  Interval onfide e Interval)
 
 
 varia , Ish ibrosis atosis, body m s in , age a  trig ceride ly
xoge s insu
d not be estimated
nomorphic SNP 
becau  min llele f ency < 5% r the S  
viations: 95% Confidence (C nc  
 
Table B-11:  Log Likelihood Ratio Test of the Significance  Intera n T Bet n Steatosis and the tic ant 
Prediction of Insulin Resistance 
 
  African Amer  an rica
of t
ica
he
ns 
ctio erm wee Gene
Ame
Vari
ns 
in the 
Caucasi
    Main Effects Interaction       n Ef  actioMai fects Inter n     
  df 
Log 
Likelihood 
Log 
Likelihood 
hi 
are p-value df 
Log 
Likelihoo
og 
Likelihoo
C
Squ
L Chi 
d d Square p-value 
COL1A1 rs2586485 1 162.940 162.760 0 1 173  172.   0.180 .67 1 .080 397 0.683 0.409
COL1A1 rs2586494 1 163.036 159.543 0 1 1  17 0.609  3.493 .062  71.264 1.003 0.261 
COL1A1 rs7406586 2 159.791 159.690  0.069  0.101 0.951 2 173.342 168.009 5.333 
COL1A1 rs2269336 1 162.596 162.131 5 0.49 1 1 795 170.406 0.389 0.533  0.46 5 70.
CYP2E1 rs10857735  1 156.161 154.397  1.764 0.184 1 168.180 168.559 -0.379 0.538
CYP2E1 rs2070673 2 162.579 162.518 0.061 0.805 2 171.416 168.349 3.067 0.080 
CYP2E1 rs915908 1 160.563 159.405 0  17 00 0.938  1.158 .282 1 172.238 2.232 0. 6 
CYP2E1 rs2070676 2 158.144 156.441  0.535  1.703 0.427 2 166.876 165.625 1.251 
IL6 rs1880242 1 163.018 162.804 0.214 0.644 1 167.222 167.114 0.108 0.742 
IL6 rs2056576 2 159.945 159.738 0.20 0 2 030 16 1 0.541 7 .90 2 171. 9.80  1.229 
IL6 rs2069827 
1 158.137 153.791 4.34  104 1 9 0.00 0.944 6 
<0.05, 
n=7 1 173. 73.09 5 
IL6 rs1800797 1 161.348 161.347 0.00 5 1 967 172.966 0.975 1 0.97 172.  0.001 
IL6 rs1800795 1 160.711 160.681 0.03 0 3 182 17 4 0.929 0 .86 1 173. 3.17  0.008 
IL6 rs2069830 1 159.840 159.840 0.00 1 0 036 17 6 1.000 0 .00 1 173. 3.03  0.000 
IL6 rs2069837 1 160.123 159.372 0.751 0.386 1 169.083 168.575 0.508 0.476 
IL6 rs1554606 1 161.553 161.469 0.08  4 0.772 1 172.914 172.498 0.416 0.519
IL6 rs2069845 1 161.159 161.151 0.008 0.929 1 172.140 171.528 0.612 0.434 
IL10 rs11119474 1 159.642 159.642 0.000 1  17 09 0.759 .000 1 173.823 3.729 0. 4 
IL10 rs3024505 1 162.979 162.010 0.969  0.842 0.325 1 173.360 173.320 0.040 
IL10 rs3024498 1 161.757 161.736 0.02 0.885 1 171.474 171.440 0.034 0.854 1 
IL10 rs3024496 2 157.403 155.933 1.470 0 0 825 16 8 0.397 .48 2 171. 9.97  1.847 
IL10 rs1554286 1 161.317 161.314 0.00  3 0.956 1 170.698 170.687 0.011 0.917
IL10 rs2222202 2 155.915 152.955 2.960 8 2 825 0.397 0.22 171. 169.978 1.847 
IL10 rs1800890 1 157.670 157.664 0.006 0.938 1 172.649 172.387 0.262 0.609 
264 
265 
Table B-11 (Continued)           
IL1R1 rs391727  145 15 5 0 0.09 173.45 .458 000 5 1 162. 9.35  2.79 5 1 8 173  0. 1.000 
IL1R1 rs211072  381 16 5 6 0.19 173.64 .590 054 6 1 162. 0.70  1.67 5 1 4 173  0. 0.816 
IL1R1 rs3917332 1 699 16 2 7 0.87 173.79 .768 027  161. 1.67  0.02 0 1 5 173  0. 0.870 
IL1R1 rs8716 1 163.0 163. 2 0 171.28 .732 557 56 29 027 0.00 .964 1 9 170  0. 0.456 
LE 6 62 8  16 0.865 PR rs6 73324 2 1 .397 160. 77 1.520 0.468 2 166.341 5.476 0.649 
LEPR rs1137100 1 161.  0.51  1   0.581 142 160.630 2 0.474 172.880 172.299 0.446 
LEPR rs1343982 1 163.021 162.4 0.607 0.436 1 173.21 172.731 0.482 14 3  0.488 
LEPR rs1137101 2 161.  1.55  2  5 715 160.163 2 0.213 169.790 168.795 0.99 0.319 
LEPR rs2376018 1 162.908 161.849 1.059 0.303 1 171.971 171.344 0.627 0.429 
LE 8 5 1   17 54PR rs1 05096 2 1 8.557 157. 06 1.451 0.484 2 172.087 1.545 0. 2 0.462 
LEPR rs1892534 2 159.  1.63  2  145 157.511 4 0.442 173.415 171.385 2.030 0.152 
MCP1/CCL2 rs3917879‡       0.000     0    .000   
M /CC s102 1 16 6 62.1 573 1 89 17 59 0CP1 L2 r 461 1 2.43 1 18 0.318 0. 174.3 4.2 0.130 .718 
MCP1/C s3 6 2 86 1 16 0CL2 r 76039 1 162.16 162.131 0.031 0. 0 172.836 172.5  0.320 .572 
M /CC s285 7 16 4 60.3 116 1 56 17 57 0CP1 L2 r 765 1 2.86 1 95 2.469 0. 173.6 3.4  0.199 .656 
MCP1/CCL2 rs4586 2 161.673 161.165 0.508 0.776 2 174.293 174.178 0  0.115 .944 
MCP CL2 900 1 162.3 161.883 0.490 0  174.389 174. 0 01/C rs13 73 .484 1 259 0.13 .718 
MCP1/ s9 5 79 1 53 3 0CCL2 r 91804 1 162.91 162.846 0.069 0. 3 173.436 173.3  0.08 .773 
MCP2/CCL8 rs3138036 1 162.138 161.572 0.566 0.452 1 173.244 172.788 6 0 0.45 .500 
M C 3 6 8   17 0.456 0CP2/C L8 rs31 8038 1 1 1.796 160. 63 0.933 0.344 1 173.244 2.788 .500 
M 1 161.600 160.482 1.118 0.290 1 172.868 172.861 0.007 0CP2/CCL8 rs11575057 .933 
TGF-β1 rs2278422 1 157.728 157.727 0.001 0.975 1 168.910 168.453 45 00. 7 .499 
TGF-β1 rs2241716 1 162.817 161.394 1.423 0.233 1 174.626 174.626 0.00 10 .000 
TGF-β1 rs18 1 1 162.138 162.062 0.076 0.783 1 173.616 173.543 00047  0.073 .787 
TNFα rs2229094 1 162.474 161.383 1.091 0.296 1 173.521 172. 0405 1.116 .291 
TN  16 1 62.7 590 1 57 17 29 0Fα rs3093662 1 3.00 1 11 0.290 0. 174.4 4.4 0.028 .876 
TNFα rs3093665 1 162.552 162.542 0.010 0.920 1 172.118 172.118 1 0.000 .000 
Abbreviation:  Degrees of F  (df)
 
reedom  
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Table B-12:   Haplotype F es and Trait Test for Steatosis by Race 
  
 
H type
 
Single Nucleotide Polymorphisms 
rica mer  
  
requenci
aplo  
Af n A
N = 167 
  
icans Caucasian Ameri
N = 184 
cans
COL1A1 rs2586485, rs25864 s7406586, rs22 36  
C 0. .0
CCAG  0.07 0.01 
CCGG  0.00 0.01 
TAGG  0.03 0.10 
 0.19
0.07  
GC 0. 0.4
GG 0. 0.0
CYP2E
94, r
 
 
693  
05 
0.07
CAA
CCAC
 
 
0 0 
  0.02
CCGC  0.16 0.17 
TAA
TCAC
C  
 
0.06 0.02 
  0.18
TCAG   0.00
TC
TC
 
 
 
 
22 
05 
8 
1 
1 rs108577 070   rs9 rs20 76  
AAGC  0.04
AAGG  0.22 0.01 
GG 0. 0.1
TA
CTGC  0.16 0.73 
G 0. .00 
IL6 
35, rs2 673,
 
15908, 706  
0.18  
CA
C
  
 
25 
03 
0 
1 C 0. 0.1
CTG  15 0
rs2056576, rs2069827, rs1800797, rs1800795, 
rs2069830, rs2069830, rs2069837, rs1554606, rs2069845 
  
A G 0. .27 
CGGGCATG  0.13 0.02 
CGGGCGGA  0.10 0.06 
G 0. 0.08 
GG GA 
TGG ATG 0. 0.01 
GA  0.10 0.00 
    
CG
CG
CC
GC
AT
AG
 
 
03 
24 
0
0G A 0. .18 
CTACCAT
GCA
GC
TGGGTA
 
 
 
02 
23 
11 
 
T 0. 0.34 
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IL10 rs11119474, rs302 498,  r 4496,  4505, rs3024 s302
rs1554286, 800 rs2222  
  
  rs1 890, 202 
ACA
GCA
C
C
CC  0.01  
CC  0.09  
C 0.07  
GCGCCTA  0.09 0.26 
IL1R1 
TT 
CT 
TT 
T 
 0.07
 0.00
G
G
AC
AT
GCATTCT
 
 
 0.01
 0.15
CC 0.1
0.40
8 0.34 
   
GTACCTA  0.06 0.14 
rs3917257, rs3917275, rs2110726,  
rs3917332, rs871656 
  
 
CTT  0.56 0.25 
TTT 9 
PR 
CA
CTA
T  
 
0.1
0.20
0 0.20 
  0.19
 0.0 0.35 
LE rs6673 , rsS 7100 398324 113 , rs134 2,  
rs11371 s23
AAGAA  0.02 0.06 
GGA 8 
AGAGA  0.18 0.26 
A 
G
GAGGA  0.06 0.02 
1
01, r
 
76018  
 
0.12
 
AAAGA  0.00 
AA
A
 
 
0.0
0.1
0.18
.00
 
 A GGG 0 0
GA
GAGA
GA  
 
0.3
0.05
5 0.29 
   0.16
MCP /CCL2 rs102 3 ,4611, rs 760396, rs2857657, rs4586   rs13900, 
rs991804 
  
CCCCTA  0.21 0.28 
TCCCCA  0.16 0.00 
7 
T CG 4 
7 
    
TCCCCG 
CCT
TCGTCG 
TGCTCG 
 
 
 
 
0.2
0.2
0.0
0.06
0.10
0.18
0.17
 
 
 
 
 
 0.27
Table B-12 (Continued)    
MCP2/CCL8 rs11575057,  rs3 038 138036, rs3138   
CGC 5  
TAA 4  
TGF-β1 
 
 
0.0
0.9
 0.15
 0.82
rs2278422, rs22 71 
CGG 0.28 3 
GGC 0 .0
GGG 
TNFα 
417
 
 
 
16, rs18004   
0.4 
.05 
0.60
0 4 
  0.52
rs3093662 0  
AA 
GA 0.05 0.07 
   
, rs3
 
 
93665   
91 0. 0.92 
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Table B-13:  Haplotype Frequencies by Presence of Steatosis and Trait Association Test by Race 
  African Americans Caucasian Americans 
 
Single Nucleo * 
 No Steatosis Steatosi
≥ 5%
Steatosis 
≥ 5% 
 
 
tide Polymorphisms
s 
 
 No Steatosis 
Haplotype 
     
COL1A1 rs2 5864 86, r 36   
AAC 0.  
CAC 0.0 09  
CAG 0.0 08  
CGC 0.2 13  
CGG 0.0 00  
GG 0.0 03  
AC 0.0 09  
TCAC 0.1 20  
CAG 0.0 08  
TCGC 0.2 19  
TCGG 0.0 05  
     
  
586485, rs2 94, rs74065
 
s22693  
0.04
 
0.00 C
C
03  0.00
 3 0.  0.01 0.03 
C  7 0.  0.01 0.01 
C  4 0.  0.15 0.18 
C  0 0.  0.02 0.01 
TA
A
 5 0.  0.10 0.10 
T  
 
4 
7 
0.
0.
 0.02
 0.25
0.01 
0.15 
T  7 0.  0.00 0.00 
 3 0.  0.45 0.49 
 4 0.  0.00 0.01 
Trait Test  0.61 0.77 
 
    
CYP2E1 rs10 s20706 908, r 76  
AAGC 0.2 17  
AAGG 0.2 23  
CAGG 0.2 29  
CTAC 0.0 01  
CTGC 0.2 13  
CTGG 0.1 17  
  
  
  
  
  
  
857735, r 73,  rs915 s20706    
 0 0.  0.00 0.05 
 2 0.  0.02 0.01 
 
 
2 
4 
0.
0.
 0.08
 0.13
0.12 
0.10 
 1 0.  0.76 0.71 
 1 0.  0.00 0.00 
Trait Test  0.95 0.79 
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IL6 rs20565 , rs2069827, rs 800797, rs18 0795, 76 1 0
rs20 2069830 37, rs 6, 69830, rs , rs20698 155460
rs2
    
069845 
CGACCATG 0.0 04  
GCAGA 0.2 25  
GCATG 0.1 13  
CGGA 0.1 09  
CCATG 0.0 01  
CAGA 0.2 23  
GCATG 0.0 13  
GTAGA 0.0 10  
  
 4 0.  0.20 0.30 
CGG  4 0.  0.19 0.17 
CGG  3 0.  0.02 0.01 
CGGG  
 
2 
3 
0.
0.
 0.05
 0.09
0.07 
0.07 CTA
TGGG  3 0.  0.38 0.33 
TGG  9 0.  0.00 0.01 
TGG  9 0.  0.00 0.00 
Trait Test  1.00 1.00 
    
IL10 rs111194 , rs302450 498,  r 96,  74 5, rs3024 s30244
rs1 5425 86,  rs1 s2222
 
 0.0 01  
 0.1 07  
0.1 04  
CT 0.1 24  
CT 0.4 44  
A 0.0 07  
 0.0 04  
 
   
800 0, r
 
89 202  
ACACCTT 0 0.  0.11 0.06 
GCACCCT  0 0.  0.00 0.00 
GCACCTT  1 0.  0.00 0.01 
GCATC  1 0.  0.28 0.34 
GCATT  1 0.  0.15 0.16 
GCGCCT  9 0.  0.24 0.27 
GTACCTA  
 
9 0.
0.99 
 0.21 0.13 
Trait Test 1.00 
 
IL1R1 
    
rs3917257, rs39 211017275, rs 726,  
rs391733 56 
 
CAT 0.0 12  
CTA 0.1 22  
CTT 0.5 57  
TTT 0.1 06  
 
     
      
   
2, rs8716
 7 0.  0.25 0.18 
 8 0.  0.13 0.22 
 
 
6 
4 
0.
0.
 0.31
 0.29
0.22 
0.35 
Trait Test  0.38 0.10 
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LEPR rs6673324, rsS1137100, rs1343982,  
rs1137101, rs237601  
    
8 
AAAG
AAGA
A 0.09  
A 0.05  0.02  
AAGGA .06 0.08 0.23 0.16 
AAGGG 0.06 0.00  
AGAGA  0.27 0.24  
GAGAA  0.31 0.35  
GAGAG  0.04 0.13  
GAGGA  0.06 0.01  
Trait Test  0.23 
     
MCP1/CCL2 
 
 
0.14 
0.01
0.00 0.00
 0.08
 0
 0.12  0.00
0.12  0.26
0.38  0.25
0.05  0.18
0.07  0.03
0.99 
 
rs1024611, rs3760396, rs2857657, rs4586,  
rs13900, rs991804 
   
CCCCTA  0.25 0.29  
TCCCCA  0.15 0.00  
TCCCCG 28  0.11  
TCCTCG 0.22 0.17  
TCGTCG  0.06 0.16  
TGCTCG  0.03 0.27  
Trait Test  1.00 
     
MCP2/CCL8 
 
0.17  0.31
0.17 
0.27
 0.00
 0.09 0.
 0.24  0.18
0.07  0.17
0.07  0.27
1.00 
 
rs11575057,  rs3138036, 038    
CGC 07  0.14  
TAA  0.82 0.83 
Trait Test 0.87 
    
TGF-β1 
rs3138  
0.04 0.
 0.91 
 
 0.14
0.96
0.91 
  
rs2278422, rs2241716, rs1800471    
 0.33 0.43  
 0.00 0.05  
 0.56 0.52  
Trait Test  0.03 
    
    
 
CGG 0.23  0.42
GGC 0.06  0.04
GGG 0.65  0.53
0.89 
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TNFα rs3093662, rs3093665      
AA  0.91 0.91 0.91 
0.04 0.06  
Trait Test  0.89 
    
 0.91
 GA 0.05  0.08
0.38 
  
* SNPs are listed in or  appear in the haplotype and al ng the chromosome 
 
 
 
 
 
der that they o
Table B-14:   Unadjusted Odds Ratios for Steatosis for Gene Haplotypes 
 African Americans 
N = 167 
Caucasian Americans 
N = 184 
 
Haplotype  
N Ratio 
95% 
Confidence 
Interval 
 
 
p-value 
 
 
N 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
 
p-value 
  
Odds 
COL1A1         
CAAC 11 2.01 0.52-7.73 0.31 0 †   
CCAC 13 3.45 0.73-16.33 0.12 3 †   
CCAG 18 0.96 0.35-2.65 0.94 0 †   
CCGC 28 0.53 0.23-1.18 0.12 60 1.08 0.56-2.07 0.83 
T 4  0.59-8.52 0.24 6 †   AAC 1  2.24
T 7  0.11-1.66 0.22 37 0.83 0.39-1.76 0.63 AGG 0.42
TCAC 38 0.86 0.45-1.65 0.65 57 1.41 0.63-3.18 0.41 
TCAG 14 1.47 0.43-5.00 0.54 0 †   
TCGC 45 0.71 0.34-1.50 0.37 132 1.81 0.92-3.59 0.09 
TCGG 11 1.56 0.39-6.22 0.53 2 †   
CYP2E1         
AAGC 43 0.59 0.29-1.20 0.14 12 1.64 0.43-6.30 0.47 
AAGG 52 1.45 0.72-2.90 0.30 3 †   
CAGG 64 2.07 1.05-4.09 0.04 33 1.61 0.70-3.70 0.27 
CTAC 10 0.53 0.15-1.82 0.31 36 0.70 0.32-1.45 0.32 
CTGC 0.57 0.27-1.21 0.15 163 1.38 0.42-4.54 0.60 36 
CTGG 1.63 0.75-3.58 0.17 0 †   37 
IL        6  
CGACCATG 12 0.99 0.31-3.19 0.99 86 1.79 0.96-3.37 0.07 
CGGGCAGA 0.99 0.51-1.91 0.97 57 0.84 0.44-1.62 0.60 64 
CGGGCATG 0.94 0.43-2.08 0.89 5 †   32 
CGG GA 0.76 0.36-1.62 0.48 22 1.50 0.56-4.02 0.42 GCG 33 
CTACCATG †   28 0.74 0.32-1.70 0.48 6 
TGG  55 1.26 0.64-2.47 0.50 108 0.83 0.44-1.56 0.57 GCAGA
TGGGCATG 24 1.98 0.78-5.02 0.15 1 †   
TGGGTAGA 31 1.00 0.46-2.20 0.99 0 †   
IL10         
ACACCTT 2 †   27 0.60 0.26-1.38 0.23 
GCACCCT 31 0.84 0.38-1.84 0.66 0 †   
GCAC 2  0.16-0.94 0.04 2 †   CTT 2  0.39
GCAT 3.41 1.64-7.07 0.001 78 1.78 0.96-3.30 0.07 CCT 48 
GCATTCT 105 1.04 0.56-1.96 0.89 51 1.24 0.63-2.48 0.53 
GCGCCTA 32 0.81 0.38-1.76 0.60 79 0.91 0.49-1.68 0.78 
GTACCTA 19 0.37 0.14-0.96 0.04 45 0.59 0.30-1.17 0.13 
IL1R1         
CAT 24 1.50 0.60-3.70 0.38 66 0.79 0.42-1.49 0.46 
CTA 55 1.19 0.62-2.29 0.61 64 1.68 0.86-3.28 0.13 
CTT  0.91 0.40-2.07 0.81 75 0.65 0.35-1.22 0.18 125
TTT 0.44 0.20-0.95 0.04 110 1.70 0.91-3.18 0.09 31 
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Tab ontile B-14 (C nued) 
LEP    R      
AAAGA 33 1.97 0.89-4.39 0.096 0 †   
AAGAA 7 †   22 3.76 1.07-13.25 0.04 
AAGGA 22 1.36 0.55-3.36 0.50 63 0.81 0.43-1.53 0.52  
AAGGG 34 1.92 0.83-4.42 0.13 0 †   
AGAGA 51 0.32 0.16-0.62 0.001 81 1.09 0.59-2.02 0.78 
GAGAA 0.07 0.29-0.99 0.047  101 85 1.81 0.96-3.39 0.54 
GAGAG 12 0.98 0.31-3.13 0.97 55 1.41 0.71-2.80 0.32 
GAGGA 18 1.50 0.55-4.11 0.43 8 1.61 0.31-8.19 0.57 
MCP1/CCL2         
CCCCTA  .23 0.54  60 87 0.47 0.25-0.89 0.02 1.21 0.66-2
TCCCCA 49 0 1.32 0.67-2.62 0.43 †   
TCCCCG 49 0.93 0.51-1.72 0.83 32 0.98 0.44-2.19 0.97 
TCCTCG 68 1.06 0.57-1.96 0.85 62 0.91 0.48-1.73 0.77  
TCGTCG 21 1.52 0.59-3.90 0.39 58 1.74 0.88-3.47 0.11  
TGCTCG 18 2.58 0.82-8.13 0.11 88 1.10 0.60-2.02 0.76 
MC 8    P2/CCL      
CGC 0.46 0.45-1.75 0.73  16 49 0.68 0.25-1.86 0.89 
TAA 165 §   178 0.31 0.04-2.65 0.29 
TGF-β1         
CGG 75 0.43 0.23-0.83 0.01 129 1.16 0.60-2.24 0.67 
G 137 2.61 0.99-6.91 0.0 143 0.96 0.46-1.99 0.91 GG 5 
G 11 6.45 0.81-51.70 0.0 18 1.04 0.37-2.91 0.95 GC 8 
TNFα         
AA 166 §   181 0.99 0.09-10.88 0.98 
GA 16 1.29 0.46-3.58 0.6 22 1.43 0.53-3.86 0.48 4 
         
† H
§ N
 
 
aplotyp t c on enough in population to estimate the odds ratio 
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Table B-15: s for Ste s among ericans and 
Caucasian A
 
 African  
N = 167 N = 184 
  A
me
dj
ric
ust
ans
ed 
 
Odds Ratio atosis for Haplotype African Am
Americans* Caucasian Americans* 
 
Haplotype 
 Odds Confidence 
Interval 
  Odds 
Ratio 
Confidence 
l 
 
p-value N Ratio p-value N Interva
COL1A1         
CAAC 11 0.87 0.14-5.42 0.88 0 †   
CCAC 13 2.66 0.52-13.67 0.24 3 †   
CCAG 18 0.77 0.22-2.65 0.68 0 †   
CCGC 0.17-1.24 1.02 0.97  28 0.45 0.12 60 0.41-2.55 
TAAC . 5 3   14 2.22 0 41-12.0  0.36 6 0.55 0.06-5.1 0.60
TAGG 7 0.17 0.02-1.30 0.09 37 1.88 0.66-5.36 0.24 
TCAC 38 2.01 7-6.03 0.21 57 0.86 0.36-2.04 0.74 0.6
TCAG 14 1.98 6-8.53 0.36 0 †   0.4
TCGC 45 0.92 0.35-2.40 0.86 132 1.97 0.76-5.10 0.16 
TCGG 0.31-6.53 †   11 1.42  0.66 2  
CYP2E1         
AAGC 43 0.95 0.39-2.34 0.91 12 1.27 0.13-12.03 0.84 
AAGG 52 0.92 0.40-2.13 0.84 3 †   
CAGG 64 2.10 0.91-4.88 0.08 33 1.24 0.41-3.76 0.71 
CTAC 10 0.39 0.06-2.73 0.34 36 0.96 0.35-2.64 0.94 
CTGC 36 0.79 0.31-2.01 0.62 163 1.28 0.23-6.97 0.78 
CTGG 37 1.33 0.50-3.50 0.57 0   † 
IL6         
CG G 12 1.10 0.25-4.89 0.90 86 1.58 0.69-3.65 0.28 ACCAT
CGGGCAGA 64 1.51 0.66-3.45 0.33 57 0.78 0.33-1.84 0.57 
CGGGCATG 32 1.09 0.43-2.78 0.85 5   † 
CGG  GCGGA 33 0.75 0.29-1.93 0.55 22 0.85 0.20-3.58 0.83
CT 6 †  28 1.31 0.44-3.87 0.63 ACCATG  
TGG A 55 1.20 0.52-2.79 0.67 108 0.69 0.29-1.63 0.40 GCAG
TGG G 24 1.35 0.44-4.14 0.60 1   GCAT † 
TGG A 31 0.87 0.33-2.30 0.77 0   GTAG † 
IL10         
ACACCTT 2 †  27 0.68 0.22-2.09 0.51  
G T 31 0.74 0.27-2.01 0.55 0 †   CACCC
GCACCTT 22 0.31 0.10-0.98 0.046 2 †   
GCATCCT 0.83-5.01 0.14  48 2.03 0.12 78 1.95 0.78-4.79 
GCATTCT 0.64-3.14 1.39 2 0.47  105 1.41  0.40 51 0.57-3.4
GCGCCTA 0.22-1.49 1.48 0.36  32 0.57  0.25 79 0.65-3.38 
GTACCTA 0.11-1.23 0.48 0.20-1.16 0.11  19 0.36  0.10 45 
IL1R1         
CAT 24 2.40 7-8.61 0.18 66 0.77 0.33-1.79 0.55 0.6
CTA 55 1.13 0-2.55 0.78 64 1.14 0.48-2.70 0.77 0.5
CTT 125 1.30 7 8 0.61 75 0.78 0.33-1.83 0.57 0.4 -3.5
TTT 31 0.34 2 3 0.04 110 2.30 0.96-5.  0.1 -0.9 52 0.06
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Table B-15 (Continued) 
LEPR         
AAAGA 33 5.30 1.57-17.84 0.01 0 †   
AAGAA 7 †    6.88 0.83-57.34 0.08 22
AAGGA 22 0.88 0.29-2.65 0.82  0.81 0.34-1.95 0.63 63
AAGGG 34 1.80 0.67-4.84 0.25 0 †   
AGA 0. 8GA 51 0.20 0.09- 47 0.001 1 1.01 0.44-2.32 0.98 
GAG 0.95-4.67 85 0.34-1.96 0.66 AA 101 2.10 0.07 0.82 
GAGAG 12 0.73 0.23-4.25 0.99 55 1.61 0.64-4.08 0.31 
GAGGA 18 1.81 0.49-6.63 0.37 8 †   
MCP1/CCL2         
CCCCTA 0.22-1. 87 0.43-2.15 0.91  60 0.48 06 0.07 0.96 
TCCC 2. 0CA 49 1.29 0.56- 98 0.57  †   
TCCCCG 49 1.06 0.52-2.19 0.87 32 0.89 0.31-2.58 0.83 
TCCTCG 68 1.32 0.60-2.91 0.49  0.69 0.29-1.65 0.40 62
TCGTCG 21 1.39 0.43-4.51 0.58  1.51 0.59-3.87 0.39 58
TGCTCG 18 2.36 0.59-9.48 0.23 88 1.91 0.82-4.42 0.13 
MCP2/CCL8         
C 0.12-1. 49 0.49-3.32 0.63 GC 16 0.44 58 0.21 1.27 
TAA 165 §   178 0.12 0.01-2.01 0.14 
TGF-β1         
CGG 75 0.18 0.07-0.46 0.0003 129 0.67 0.28-1.60 0.36 
GGG 137 8.89 2.10-37.70 0.003 143 1.19 0.45-3.19 0.72 
GGC 11 †  18 0.61 0.48  0.16-2.42 
TNFα          
AA 166 §  181 1.47 0.10-21.995 0.78  
GA 16 0.75 0.20-2.76 0.66 22 2.21 -8.63 0.26 0.56
* Mod aplotype, Ishak fibrosis score, weekly alcohol consumption, ln HOMA2-IR scores, 
log10 baseline viral level and body mass in
† Hapl
§ No v haplotype in the popu
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Table B-16:  Haplotype Frequencies by Insulin Resistance Category and Trait Association Test by Race 
 
  eostasis sment ulin ResistaH mo  Model Asses of nsI n  ce
  an Americ casian Ame s Afric ans Cau rican
 
Haplotype 
 
Single Nucleotide Polymorphisms* 
HOM  
< 2
HO A2-IR 
≥ 2 
2-I
 2 
A2-IR 
 2 
A2-IR M HOMA R HOM
 < ≥
COL1A1 rs2586485, rs2586494, rs7406586, rs2269336     
CAAC  0.02 0.07 0.00 0.00 
CCAC  0.05 0.10 0.01 0.00 
CCAG  0.07 0.08 0.01 0.03 
CCGC  0.18 0.17 0.15 0.00 
TAAC  0.08 0.06 0.02 0.20 
TAGG  0.03 0.05 0.12 0.04 
TCAC  0.19 0.17 0.17 0.19 
TCAG  0.09 0.05 0.00 0.00 
TCGC  0.21 0.20 0.49 0.47 
TCGG  0.05 0.05 0.01 0.00 
Trait Test  0.89 0.45 
CYP2E1 rs10857735, rs2070673,  rs915908, rs2070676     
AAGC  0.17 0.19 0.06 0.02 
AAGG  0.22 0.22 0.01 0.01 
CAGG  0.26 0.27 0.09 0.14 
CTAC  0.03 0.02 0.12 0.10 
CTGC  0.18 0.13 0.75 0.68 
CTGG  0.13 0.16 0.00 0.00 
Trait Test  0.99 0.88 
IL6 rs2056576, rs2069827, rs1800797, rs1800795, 
rs2069830, rs2069830, rs2069837, rs1554606, 
rs2069845 
    
CGACCATG  0.04 0.03 0.23 0.37 
CGGGCAGA  0.28 0.19 0.19 0.17 
CGGGCATG  0.11 0.16 0.01 0.05 
CGGGCGGA  0.08 0.13 0.07 0.04 
CTACCATG  0.01 0.03 0.09 0.05 
TGGGCAGA  0.23 0.21 0.37 0.31 
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Table B-16 (Continued)      
IL6 (Continue   d)    
TGGGCATG  0. 0.11 1
TGG 0. 0.08 0
Trait Test 1.00 1.00 
IL10 
13 
11 
0.0
0.0
 
 
0.00 
0.00 GTAGA  
 
rs11119474, 30rs3024505, rs3024498,  rs 24496,  
rs1554 02
 
0.08 
GCACCC  0. 0.02 0.00 
GCATCCT  0.20 0.18 0.31 
GC  0 0.
GTACCTA  0.06 0.05 0.16
Trait Test  1.00 0
IL
 
0.00
  
0.06 
0.00 
0.01 
0.35 
0.11 
0.29 
0.14 
286,  rs1800
 
890, rs22222   
ACACCTT  0.02 
T 
T 
11 
GCACCT  0.08 0.05 0.00 
AT
C
TC
CT
T 
A 
0.4
0.0
0.4
0.1
5 
1 
18 
4 
 
GCG  6 0.2
.99 
1R1 rs3917 7 6257, rs391 275, rs211072 ,   
0.0
0.22
 
0.0
 
21 
 
 
0.22 
0.18 
0.21 
0.36 
rs3917332, rs871656 
CA
CTA
T 
 
 8 0.
 0.18
CTT  0.57 0.58 0.26 
 0 0.
  
LEPR 
9 
  0.21
TTT 0.1 0.07 34 
Trait Test 0.59 0.91
rs6673324, rsS1137100, rs1343982,  
rs1137 , rs2376018  
  
1
AAGAA  0.01 0.02 0.07 
AAGGA  0.07 0.10 0. 0.19 
0.00 
 0.20 0.28 
GAGAA  0.40 0.30 0.32 0.24 
4 0.06 0. 0.16 
0.04 
Tr 9 0.99
      
     
  
0.00 
0.06 
101
AAAGA  0.1  0.13 0.00 
17 
0 
0.23 
AAG
AGAGA
GG 
 
 
 
0.0
0.18
9 0.09 0.0
GAG
AG
A
G
G 
A 
 
 
 
0.0
0.0
17 
2 G 4 0.07 0.0
ait Test 0.9  
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Table B-16 (Continued)      
MCP1/CCL2 rs1024611, rs376039 57657, 86,  6, rs28 rs45
rs13900, 04 
   
 rs9918
 
CCCCTA 0.2 0.18 0.27 
TCCCCA 0.1
TCCCCG 
TCCTCG  
TCGTCG 
TGCTCG .04 0.07 .30 
Trait Test 
MCP2/CCL8 
 
 
 
 
 
 
 
2 
6 
8 
0.37 
0.00 
0.05 
0.22 
0.15 
0.21 
0.1
0.2
0.2
6 
7 
6 
 
0.0
0.1
0.1
0.17
0 
1 
5 
 
0.2
0.22
0.07 0.07
0 0
1.00 1.00 
rs11575057,  rs3 , rs3138038     
CGC 5 0.12 
TAA 0.89 
Trait Test 0.80 0.54 
TGF-β1 
1380
 
 
 
36
0.0
0.9
0.0
0.9
4 
6 
0.1
0.8
6 
1 3 
rs2278422, rs22 800471     
CGG  0.53 
GGC 0.07 
GGG   0.40 
Trait Test  
TNFα 
417
 
 
16, rs1
0.26
0.0
0.59
0.3
0.0
0.6
0 
1 
1 
0.3
0.0
0.5
7 
3 
8 
8 
0.008 0.03 
rs309366       
AA   0.91 
GA  0.09 
Trait Test  0.79 0.04 
2, rs3093665
0.92
0.04
0.91 
 
0.9
0.0
1 
7  0.06
* SNPs are listed in order that they appear in the haplot n th o
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Table B-17:   Unadjusted Odds of Insulin Resistance for Gene Haplotypes among Virahep-C Study 
Patients 
 
 ricans 
N = 142 
ns 
 156 
African Ame Caucasian America
N =
Single Nucleotide 
m 
R
 
f
nte
 
p-va  
O
Rat
 
n
rva
 
lue 
Polymorphis
 
 
N 
 
Odds 
atio 
95%
Con
I
idence 
rval 
 
lue
 
 
N 
 
dds 
io 
95%
Confide
Inte
ce 
l 
 
p-va
         
COL1    A1      
CAAC 8-12 0.1 0 †   7 2.87 0.6 .18 5 
CCAC 71-7 0.1 3 †   13 2.34 0. .70 6 
CCAG 42-3 0. †   16 1.20 0. .41 73 0  
CCGC -2 0. 1.2 2.63 49 26 1.03 0.44 .38 95 49 9 0.63-  0.
T AA C -3 0. †   11 1. .3211 0 .88 88 5  
TAGG 32-5 0. 0.3 1.01 05 6 1.34 0. .68 69 29 6 0.13-  0.
TCAC 38-2 0. 1.2 2.63 49 33 0.88 0. .02 76 49 9 0.63-  0.
TCAG 10-1 0.   12 0.40 0. .56 19 0 † 
TCGC 34-1 0 1 1.0 2.32 85 37 0.75 0. .67 .48 10 8 0.50-  0.
TCGG 27-4 0.9 2 †   9 1.05 0. .17 4 
CYP2E1         
AAGC 49-2 0. 2. 1.13 .13 37 1.04 0. .22 93 9 85 0.73-1  0
AAGG 60-2 0.5 3 †   47 1.23 0. .51 8 
CAGG 76-3 0. 1.8 4.23 14 58 1.54 0. .11 23 29 6 0.82-  0.
CTAC 21-4 0. 0.7 1.78 49 6 1.00 0. .64 99 30 3 0.30-  0.
CTGC 25-1 0 1 0.6 0.58 58 31 0.58 0. .33 .20 29 9 0.31-  0.
CTGG 52-2 0 †   32 1.15 0. .54 .11 0  
IL6         
CGAC G 0. 19-2 0. 2.81 -5.63 004 CAT 10 67 0. .42 55 75  1.40 0.
CGGG A 28-1 0. 0.8 1.67 58 CAG 53 0.57 0. .16 12 51 2 0.40-  0.
CGGG G 62-3 0. †   CAT 28 1.41 0. .21 42 4  
CGGG A 81-4 0.1 18 0.48 0.15-1.54 0.22 CGG 28 1.81 0. .03 5  
CTAC G  0.4 1.33 15 CAT 5 †  24 7 0.16-  0.
TGGG GA  0.82 0.40-1.66 0. 0.9 1.88 89 CA 45  58 93 5 0.48-  0.
TGGG G 59-3 0 †   CAT 22 1.41 0. .36 .44 1  
TGGG A 28-1 0.2 0 †   TAG 27 0.64 0. .47 9 
IL10         
ACACCTT  23 0.67 0.25-1.81 0.43 2 †   
GCA CT  0.41 0.16-1.04 0. †   CC 25  06 0  
GCA T 23-1 0. †   CCT 18 0.61 0. .62 32 2  
GCA T .4-1. 0.8 65 1.08 0.55-2.11 0.82 TCC 42 0.93 0 83 4  
GCA T 46- 0. 46 0.51 -1.10 09 TTC 93 0.90 0. 1.78 77   0.23 0.
GCG A 77-4 0. 1.4 2.77 31 CCT 25 1.82 0. .27 17 69 2 0.73-  0.
GT A 30-2 0. 0.7 1.53 38 ACCT 16 0.82 0. .29 71 42 1 0.33-  0.
IL1R1         
CAT 39-2 0. 0.9 1.82 80 17 1.06 0. .86 91 59 1 0.46-  0.
CTA  0.91 0.46-1.80 0.7 53 1.08 0.53-2.17 0.84 51  8  
CTT 54-3 0. 0.7 1.43 34 108 1.33 0. .29 53 62 2 0.36-  0.
TTT 26-1 0. 1.1 2.36 63 25 0.64 0. .56 33 93 9 0.60-  0.
         
         
Table B-17 (Continued) 
LEPR         
AAAGA -2 0.5 0 †   27 1.28 0.58 .79 4 
AAGAA †  0. .53 85 5  19 90 0.32-2  0.
AAGGA 57-3 0. 1. 2.35 66 20 1.39 0. .39 47 52 17 0.58-  0.
AAGGG 56-2 0.   28 0 †1.26 0. .88 58  
AGAGA 61- 0. 1.3 2.54 45 46 1.19 0. 2.34 61 65 0 0.66-  0.
GAGAA 36- 0. 0.4 0.82 01 88 0.69 0. 1.33 27 75 1 0.21-  0.
GAGAG 47-4 0. 0.7 1.56 44 12 1.46 0. .57 13 48 5 0.36-  0.
GAGGA 67-5 0. 2.7 2.90 .19 15 7 1.86 0. .17 14 8 0.60-1  0
MCP1/CCL2         
CCCCTA  0.76 0.39-1.50 0.4 80 1.62 0.83-3.18 0.16 50   3 
TCCCCA 44-1 0. †   43 0 0.90 0. .83 77  
TCCCCG 51-1 0.9 26 0.42 0.16-1.12 0.09 43  0.98 0. .61 3 
TCCTCG 87-3 0. 1.9 3.86 08 57 1.67 0. .20 13 51 2 0.96-  0.
TCGTCG 33-2 0. 0.9 2.01 93 17 0.87 0. .31 78 46 9 0.47-  0.
TGCTCG 50-4 0. 0.6 1.21 16 14 1.45 0. .22 50 76 2 0.31-  0.
MCP2/CCL8         
CGC 21-2 0. 0.5 1.22 14 13 0.65 0. .05 47 41 4 0.24-  0.
TAA 1. 61-4 0. 1 1.53 -2.93 20 140 51 65 0. .44 32  0.80 0.
TGF-   β1       
CGG  1.67 0.85-3.27 0 1 3.1 7.31 .009 66 10  .14 2 1.33-  0
GGG 0.26 0.08-0.87 0.0 122 0.50 0.23-1.07 0.08 116   3 
GGC 02- 0 1.6 4.74 34 8 0.16 0. 1.33 .09 16 6 0.58-  0.
TNFα          
AA  †  1 0.2 2.71 25 141  53 4 0.02-  0.
GA  1.68 0.55-5.11 0.3 20 1.10 0.41-2.95 0.85 12   6 
         
† Haplot on enough in o es  the o ratioype not comm  population t timate dds  
§ No variation in the haplotype in the population 
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African Americans* 
N = 142 
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Hapl
 Odds Confidence 
l 
  Odds 
Ratio 
Confidence  
p-value otype N Ratio Interva p-value N Interval 
         
COL1A1         
CAAC 7 4.83 0.82-28.29 0.08 0 †   
CCAC 13 2.63 0.70-9.91 0.15 3 †   
CCAG 16 1.05 0.29-3.76 0.95 0 †   
CCGC 0 1.05 0.90 26 0.61 0.20-1.9 0.39 49 0.48-2.31 
TAAC 11 0.99 0.25-3.88 †  0.98 5  
TAGG 6 †   29 0.34 0.12-1.02 0.05 
TCAC 33 0.66 0.22-1.93  49 1.19 0.54-2.62 0.68  0.44
TCAG 12 0.26 0.06-1. 0.09 0 †   22 
TCGC 37 0.98 0.36-2.66  110 1.06 0.45-2.49 0.89  0.97
TCGG 9 1.46 0.31-6.79 0.63 2 †   
CYP2   E1       
AAGC 37 1.31 0.53-3.22 2.11 0.34 0.56 9 0.46-9.61 
AAGG 47 0.99 0.42-2.31 0.98 3 †   
CAGG 58 1.46 0.64-3.35 0.37 29 1.66 0.67-4.13 0.28 
CTAC 6 0.25 0.02-3.63 0.25 30 0.65 0.24-1.72 0.38 
CTGC 31 0.52 0.19-1.38 0.19 129  0.15-2.60 0.51  0.62
CTGG 32 1.32 0.53-3.28 0.55 0    † 
IL6         
CGACCA 10 0.49 0.09-2.79 0.42 75  1.13-5.19 0.02 TG 2.42
CGGGCA 53 0.65 0.28-1.50 0.31 51  0.47-2.18 0.99 GA 1.01
CGGGCA 28 1.91 0.75-4.91 0.18 4   TG † 
CGGGCG 28 2.07 0.77-5.56 0.15 18 0.07-1.03 0.06 GA 0.27 
CTACCA 5 †   24 0.14-1.54 0.21 TG 0.46 
TGGG 0.80 CAGA 45 0.65 0.27-1.53 0.32 93 1.10 0.52-2.32 
TGGGCA 22 0.82 0.28-2.39 0.72 1   TG † 
TGGGTA 27 0.59 0.21-1.62 0.30 0   GA † 
IL10         
ACACC 2 †   23  0.34-3.02 0.98 TT 1.01
GCACC 25 0.60 0.21-1.70 0.34 0   CT † 
GCACC 18 0.59 0.17-2.02 0.40 2   TT † 
GCATCCT 42 0.79 0.34-1.82 0.58 65  0.28-1.42 0.27  0.64
GCATTCT 93 0.59 0.26-1.31 0.19 46  0.20-1.11 0.09  0.48
GCGCCTA 25 3.00 1.09-8.26 0.03 69 1.56 0.75-3.22 0.24 
GTACCTA 7 1.14 0.76 16 0.86 0.25-2.9 0.81 42 0.49-2.68 
IL1R1         
CAT 4 1.01 0.98 17 0.99 0.30-3.2 0.99 59 0.47-2.17 
C 51 0.74 0.32-1.68 0.47 53 0.99 0.94 TA 0.45-2.09 
CTT 108 1.23 0.43-3.48 0.70 62 0.74 0.44 0.35-1.58 
TTT 25 0.70 0.24-2.04  93 1.02 0.47-2.21 0.95  0.52
         
         
         
Comparison of  one or more copies of otype compar  copies of the haplotype 
* Model adjusted for the haplotype, Ishak fib core, body ma x, steatosis, age and triglyceride 
levels 
† Haplotype not common enough in populat stimate the od  
Abbreviation: onfidence Interval (Confidence Interval) 
  
C nTable B-18 ( onti ued) 
LEPR         
AAAGA 27 0.71 0.27-1.87 0.49 0 †   
AAGAA 5 1.25 0.17-9.00 0. 19 0.74 0.2 23 0.59 83 5-2.
AAGGA 20 1.00 3-3.05 0. 52 1.01 0.4 22 0.97 0.3 99 6-2.
AAGGG 28 1.35 0.53-3.45 0.53 0 †   
AGAG 0.71-3.  -2 0.43 A 46 1.67 95 0.24 65 1.35 0.65 .81 
GAGAA 0.33-1.  -1.09 0.08 88 0.72 59 0.42 75 0.51 0.22
GAGAG 12 1.29 0.34-4.85 0.71 48 0.56 0.24-1.30 0.18 
GAGGA 15 1.54 0.43-5.54 0.51 7 3.29 0.63-17.24 0.16 
MCP1/CCL2         
CCCCTA 50 0.97 0.44-2.13 0.93 80 1.23 0.59-2.60 0.58 
TCCCCA 0.43-2.    43 0.99 27 0.98 0 † 
TCCCCG 0.47-1.  -1.02 0.05 43 0.95 91 0.88 26 0.31 0.10
TCCTCG 57 1.62 0.75-3.51 0.22 51 2.15 0.99-4.67 0.053 
TCGTCG 17 0.72 2-2.34 0. 46 0.86 0.3 91 0.71 0.2 58 9-1.
TGCTCG 14 1.40 1-4.83 0. 76 0.61 0.2 27 0.18 0.4 60 9-1.
MCP2/CCL8         
CGC 13 0.69 0.18-2.65 0.59 41 0.59 0.24-1.45 0.25 
TAA 1 14 0.85 140 §   51 1.27 0.11- .89 
TGF-         β1 
CGG 66 2.43 1.01-5.84 0.047 110 3.09 1.24-7.71 0.02 
GGG 116 0.13 0.03-0.52 0.004 122 0.50 0.21-1.16 0.10 
G 8 0.16 0.02-1.48 0.11 16 1.32 0.42-4.12 0.63 GC 
TNFα         
AA 141 §   153 0.18 0.01-2.32 0.17 
GA 12 1.94 0.52-7.29 0.33 20 1.12 0.35-3.62 0.84 
 having
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 Table B  C n al osis and Insulin Resistance for IL10 
rs22222 auca eri
 
 Stea   
-19
02 G
a:
en
 De
ot
sc
yp
rip
es i
tive
n C
ompa
sia
riso
n Am
 of In
can
div
s 
idu s by Steat
tosis
 No  Steatosis % Row Total Steatosis ≥ 5
 
AHOM 2-IR  
< 2 
 
 
C
CT:  21 
TT:  12 
16 
CT:  32 
TT:  15 
 
CC:  24  
CT:  53 
TT:  27 
 
C:  C :   8 C
In
su
lin
 R
es
is
ta
nc
e 
 
HOMA2-IR 
 
CC:  2 
CT: 
TT: 
 
CC:  11 
20 
11 
 
CC:  13 
CT:  22 
TT:  17 
≥ 
 
2  2  
 6 
C
T
T:  
T:  
 
Column Tota
 
 
 
:  10 
:  23 
TT:  18 
 
CC:  27  
CT:  52 
TT:  26 
TOTAL 
CC:  37 
CT:  75 
TT:  44 
l CC
CT
 
Table B-19b:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for IL10 
rs2222202 Genotypes in African Americans 
 
 Steatosis  
 
 No Steatosis Steatosis ≥  Row Total  5%
 
HOMA2-IR  
< 2 
 
CC:  17 
CT: 22 
TT: 1 
 
CC:  24
CT: 17
TT: 2 
 
CC: 41 
CT: 39 
TT: 3 
 
 
 
In
su
n 
R
es
is
ta
nc
e 
 
HOMA2-IR 
≥ 2 
 
CC:  5 
CT: 4 
TT: 6  
 
CC:  28
CT: 14
TT: 2 
 
CC: 33 
CT: 18 
TT: 8 
 
 
 
li
 
Column Total 
 
 
CC: 22 
CT: 26 
TT: 7 
 
CC: 52
CT: 31
TT: 4 
TOTAL 
CC: 74 
CT: 57 
TT: 11 
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Table B-20a:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for IL10 
rs1800890 Genotypes in Caucasian Americans 
  
 
Steatosis  
 No Ste Steatosis ≥ 5% Row atosis Total 
 
  
< 2 
 
 
:   
AT:  23 
 
 
AT:  33 
TT:  23 
 
  1
AT:  56 
T:  35 
HOMA2-IR AA 6 
TT:  12 
AA:   6 AA: 2  
T
In
su
lin
 R
es
is
ta
nc
e 
 
HOMA2-IR 
 
A:  3
T:  4
T:  3
AT:  18 
 
:  12 
T:  22 
:  18
 
A  AA:   9 
≥ 2 
 
A  
T  TT:  15 
AA
A
TT  
 
uCol ta
 
 
:  1
:  27
:  15
AA:  27  
AT:  51 
TAL
:  24
:  78
:  53
 TO  
mn To l AA 0 AA
T
 
  AT  A
TT  TT:  38 TT  
 
Table B-20b:  Descriptive Compa  of I s by osis a  Insu esi L1
rs1800890 Genotypes in African A
 
is  
 
stance for I 0 rison ndividual Steat nd lin R
mericans 
 Steatos
 teato Stea  ≥ 5  TotNo S sis tosis % Row al 
 
R 
 
:   2
:  14
:  24
AT:  12 
 
:   2
:  26
:  55
 
HOMA2-I  
< 2 
 
AA  
AT  
TT  
AA:   0 
TT:  31 
AA  
AT  
 TT
In
su
lin
 R
es
is
ta
nc
e 
 
R 
 
T:  6
T:  7
AA:   3 
AT:  16 
 
:   5
:  22
:  32 
 
HOMA2-I AA:  2 
≥ 2 
 
A  
T  TT:  25 
AA  
AT  
TT
 
Column Total 
 
 
T:  20
:  31
AA:   3  
AT:  28 
TAL 
A:   7 
:  48
:  87 
 TO
AA:   4 A
 A  
 
AT  
TT TT:  56 TT
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Table B-21a:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for LEPR 
24 Genotypes in Caucasian Americans  
 
 Steatosis  
rs66733
 teato Stea  ≥ 5%  TotNo S sis tosis  Row al 
 
HOMA2-IR 
 
:   9
:  2
:  1
AA:  12 
AG:  37 
GG:  12 
 
:  21
:  58
:  2
 
 
< 2 
 
AA  
AG 1 
GG 1 
AA   
AG  
GG 3 
In
su
lin
 R
es
is
ta
nc
e 
 
R 
 
A:  4
G:  4
G:  2
AA:  16 
AG:  14 
GG:  12 
 
:  20
:  18 
:  14
 
HOMA2-I A  
≥ 2 
 
A  
G  
AA  
AG
GG  
 
C ta
 
:  1
:  2
AA:  28  
AG:  51 
GG:  24 
TAL
:  41
:  76
 TO  
olumn To l AA 3 AA  
 AG 5 AG  
 GG:  13 GG:  37 
 
1b:   D iv mpa  of I  by sis nsu sist EP
rs6673324 Genotypes in African A
 
is  
 
Table B-2 ance for L R escript e Co rison ndividuals Steato and I lin Re
mericans 
 S atoste
 No Steatosis Steato is ≥ 5  Tots % Row al 
 
HOMA2 R
 
AA:  11 AA:   9 
GG:   8 
 
AA:  20 
AG:  45 
GG:  18 
 
-I   
< 2 AG:  19 AG:  26 
 GG:  10 
In
su
lin
 R
es
is
ta
nc
e 
 
HOMA2-IR 
≥ 2 
 
 
AA:  6 
AG:  8 
GG:  1 
 
AA:   7 
AG:  28 
GG:   9 
 
AA:  13 
AG:  36 
GG:  10 
 
Column Total 
 
 
 
AA:  17 
AG:  27 
GG:  11 
 
AA:  16 
AG:  54 
GG:  17 
TOTAL 
AA:  33 
AG:  81 
GG:  28 
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Table B-22a:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for LEPR 
rs1137100 Genotypes in Caucasian Americans  
 
 Steatosis  
 No s Steatosis ≥ 5% Row Steatosi Total 
 
HOMA2-IR  
< 2 
A
AG:  13 
G
3  
AG:  22 
:   
 
:  6
AG:  35 
G:    
 
:  25 
 
AA:  
 
A
G:   3 
6
GG 4 
AA 1  
G 7
In
su
lin
 R
es
is
ta
nc
e 
 
A  
 2
 
AA
AG
GG
 
:  23 
:  14
:   5 
 
A:  27 
:  19
G:   6 
 
HOM 2-IR :  4 AA
≥  :  5 
:  1 
AG  
GG
A
AG  
G
 
n al 
 
 
 
AA
AG
GG
 
:  59
:  36 
:   9
TAL
:  88
G:  54 
:  13
TO  
Colum  Tot :  29 AA   AA  
:  18 AG A
:   4 GG  GG  
 
 
Table B-2 e Comparison o als b tosis d Insu esista PR 
rs1137100 pe  Afri meric
 
 Steatosis  
nce for LE2b:  Descriptiv
Genoty
f Individu y Stea  an lin R
s in can A ans 
 
 No St Steatosis ≥ 5  Totaeatosis % Row l 
 
A   
 2
 
 
AA
AG
GG
 
:  34
: 9 
: 0 
 
: 55
: 25
HOM 2-IR
<  
:  21 
: 16 
: 3 
AA  
AG
GG
AA  
AG  
GG: 3 
In
su
lin
 R
es
is
ta
nc
e 
 
A R 
 2
 
AA:  6 
AG
GG
 
: 11
: 1 
 
: 38
: 18
 
HOM 2-I AA:  32 
≥  : 7 
: 2 
AG  
GG
AA  
AG  
GG: 3 
 
n Total 
 
AA: 27 
AG
GG
 
A: 66
: 20 
: 1 
: 93
G: 43 
 TOTAL 
Colum A  AA  
: 23 AG A
 : 5 GG GG: 6 
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Table B-23a:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for LEPR 
34 Genotypes in Caucasian Americans 
 
 Steatosis  
rs18925
 No St St is ≥ 5  Totaeatosis eatos % Row l 
 
A   
 2
 
AA
AG
GG
 
  17 
  23 
  22 
 
:  22
:  41
:  40
 
HOM 2-IR
<  
:   5 
:  18  
:  18 
AA:
AG:
GG:
AA  
AG  
GG  
In
su
lin
 R
es
is
ta
nc
e 
 
A  
 2
 
AA
AG
GG
 
  11 
  16 
  15 
 
:  14
:  16 
:  22
 
HOM 2-IR :  3 AA:
≥  :  0 
:  7 
AG:
GG:
AA
G
 
A
GG  
 
n Total 
 
AA
AG
GG
 
  28 
  39 
TAL
:  36
:  57
:  62 
 TO  
Colum :   8 AA: AA  
:  18 AG: AG  
 :  25 GG:  37 GG
 
3b e Comparison o als b osis Insu esista PR 
rs1892534 G pe fric eric
 
 Steatosis  
 
Table B-2 nce for LE:  Descriptiv f Individu y Steat  and lin R
enoty s in A an Am ans 
 No Steatosis Steatosis ≥  Tota5% Row l 
 
HOMA2-IR  AA
  
:  15 
< 2 AG:  19 AG:  26 AG:  45 
 
:  10
 GG:  11 GG:  12 GG:  23 
 AA:   5 AA
In
su
lin
 R
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is
ta
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e 
   
AG:  19 
:  13 
 
AA:  16 
AG:  23 
GG:  20 
HOMA2-IR AA:  4 AA:  12 
≥ 2 AG:  4 
 GG:  7 GG
 
Column Total 
 
 
 
AA:  14 
AG:  23 
GG:  18 
 
AA:  17 
AG:  45 
GG:  25 
TOTAL 
AA:  31 
AG:  68 
GG:  43 
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Table B-24a:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for TGF-
β1 rs2278422 Genotypes in Caucasian Americans 
 
 Steatosis  
 No Steatosis Steatos  ≥ 5% Row Total is
 
HOMA2-IR  
< 2 
GG: 14 GG: 23 GG:  37 
   
 
CC:   6 
CG:  21 
CC:   6 
CG: 34 
CC:  12  
CG:  55 
 
HOMA2-IR 
≥  
GG:  1 GG:   7 
 2
 
 
CC:  2 
CG:  7 
 
CC:   9 
CG:  26 
 
CC:  11 
CG:  33 
GG:   8 
In
su
lin
 R
es
is
ta
nc
e 
 
Colum  Total 
 
 GG:  15 GG:  30 GG:  45 
  TOTAL 
n CC:   8 CC:  15  CC:  28 
CG:  28 CG:  60 CG:  88 
 
 
Table B-24b:   Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for TGF-
β1 rs2278422 Genotypes in African Americans 
 
 Steatosis  
 No Steatosis Steatos  ≥ 5% Row Total is
 
HOMA2-IR  
< 2 CG:  23 
GG:  14 
CG:  14 
GG:  29 
CG:  37 
GG:  43 
   
 
CC:   3 CC:   0 CC:   3 
 
HOMA2-IR 
≥  
GG:  3 
CG:  20 
GG:  20 
CG:  29  2
 
 
CC:  3 
CG:  9 
 
CC:   4 
 
CC:   7 
GG:  23 In
su
lin
 R
es
is
ta
nc
e 
 
Colum  Total 
 
 
CG:  32 
GG:  17 
CG:  34 
GG:  49 GG:  66 
  TOTAL 
n CC:   6 CC:   4 CC:  10 
CG:  66 
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ividuals by Steatosis and Insulin Resistance for IL6 
rs2069845 Genotypes in Caucasian Americans 
 
 Steatos
 
Table B-25a:   Descriptive Comparison of Ind
is  
 No Steatosis Steatos  ≥ 5% Row Total is
 
HOMA2-IR  
< 2 
GG:   5 GG:   7 GG:  12 
   
 
AA:  22 
AG:  14 
AA:  18  
AG:  37 
AA:  40 
AG:  51 
 
HOMA2-IR 
≥  
GG:  2 GG:   7 
 2
 
 
AA:  3 
AG:  5 
 
AA:   9 
AG:  36 
 
AA:  12 
AG:  51 
GG:   9 In
su
lin
 R
es
is
ta
nc
e 
 
Colum  Total 
 
 GG:   7 GG:  14 GG:  21 
  TOTAL 
n AA:  25 AA:  27 AA:  52 
AG:  19 AG:  63 AG:  82 
 
 
Table B-25b:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for IL6 
rs20698 5 Genotypes in African Americans 
 
 Steatos
4
is  
 No Steatosis Steatos  ≥ 5% Row Total is
 
HOMA2-IR  
< 2 
GG:   4 GG:  3 GG:   7 
   
 
AA:  19 
AG:  17 
AA:  22 
AG:  18 
AA:  41 
AG:  35 
ns
ul
in
 R
es
is
ta
nc
e 
 
HOMA2-IR 
≥  
GG:  2 GG:   7 
   
AA:  6 AA:  16 
 2
 
AG:  7 AG:  21 
AA:  22 
AG:  28 I
GG:   9 
 
Colum  Total 
 
 GG:   6 GG:  10 GG:  16 
  TOTAL 
n AA:  25 AA:  38 AA:  63 
AG:  24 AG:  39 AG:  63 
 
 
 
 
 
Table B-26:  Amount of CommonVariation in Each Gene Accounted for  Single Nucleotide Polymorphisms Using Dif
Methods  
 
SNP Selection Method:  Haplotype Block Method          
 by Selected ferent 
  
Minor Allele Frequency:  10%              
      
African 
America     Am ans
Caucasian 
eric  ns    
Gene 
Virahep-C 
SNPs LD 
# SNPs for 
R2 = 0.8 
Covered w
Genotyp
SNPs 
% of 
Variation
Covered 
# SNPs for 
R2 = 0.8 
h 
SNPs  
# SNP
Covered wit
Genotyped 
s # SNPs 
% of 
Variation 
Covered
ith 
ed 
Virahep-C 
SNPs in High  
                  
IL6 9 2 15 26% 13 10 4 76% 
IL10 7 1 14 12 85% 16 13 81% 
TGF-β1 3 11 9 1 1% 13 1 7% 
TNF-a 3 20 18 4 2% 15 3 20% 
AVERAGE 22 21   56 38% 57 27 47% 
           
SNP Selection Method:  Two Stage Tagging         
Minor Allele Frequency:  5%               
    
ican 
ricans 
Caucasia
an
Afr
Ame
n 
s         Americ   
Gene 
Virahep-C 
SNPs 
-
SNPs in High 
LD 
# SNPs for 
R2 = 0.8 
NPs 
Covered with
Genotyped 
SNPs 
% of 
Variation 
# SNPs for 
R2 = 0.8 
w
Genotype
SNPs 
%
 
# S # S
ver
NP
ed 
s 
Virahep C  Co ith 
d 
 of 
Variation 
Covered
COL1A1 4 0 21 5 23% 20 14 70% 
CYP2E1 4 1 44 7 15% 32 29 8% 
IL1R1 5 4 2 10 8 4% 48 8 6% 
LEPR 7 2 40% 2 234 51 1% 220 89 
MCP1 7 1 4 4 82 0 0% 6 5 3% 
MCP2 3 3 6 0 0% 18 48 4% 
AVERAGE 30   363 69 19% 344 133 39% 
Abbreviations:  Linkage Disequilibrium (LD)
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APPENDIX C
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T
A nd Caucasian Americans 
 
 African Ame Caucasian Americans 
able C-1:  Genotype Frequencies for ADIPOR1 and HMGCS2 Single Nucleotide Polymorphisms and 
ssociation with Steatosis in African Americans a
ricans 
N = 163 N = 179 
Single Nucleotide 
Polymorphism 
No 
teatosis 
Steatosis 
 
 
p-va
No 
teatosis 
Steatosis  
p-value* S ≥ 5% lue* S ≥ 5% 
ADIPOR1 rs1075   39  29    
CC 0.66 0.79  0.61  0.85 
CT 0.29   0.21  0.37 0.15 
TT 0.05  0.41 0.0 0.31 0.02  0.0 
ADIP  rs109    OR1 20531    
AA 0.22 4  0.44  0.2 0.31 
AC 0.45 1  0.46  0.5 0.58 
CC 0.34 0.26 0.51 0.10 0.20 0.12 
ADIPOR1 rs12    045862    
CC 0.86   0.53  0.78 0.53 
CT 0.14   0.42  0.22 0.41 
TT 0.0  0.32   0.01  0.05 0.07 0.90
ADIPOR1 rs12733285       
CC 0.64 0.70  0.55 0.44  
CT 0.28 0.25  0.36 0.43  
TT 0.08 0.05 0.67 0.09 0.13 0.38 
ADIPOR1 rs1342387       
AA 0.28 7  0.22  0.1 0.22 
AG 0.42 4  0.52  0.4 0.47 
GG 0.30 0.26 0.49 0.39 .31 0.50 0
ADIP  rs153    OR1 9355    
AA 0.29   0.43  0.28 0.48 
AG 0.45   0.41  0.52 0.45 
GG 0.26 0.20 0.66 0.16 .07 0.20 0
ADIP  rs168    OR1 50799    
AA 0.89 6  0.59  0.8 0.55 
AG 0.11 4  0.37  0.1 0.40 
GG 0.0  0. 0.03 0.80 0.0 51 0.05 
ADIPOR1 rs22    75736    
AA 0.08  0.0  0.07  0.0 
AT 0.28   0.02  0.29 0.04 
TT 0.65  0. 0.98 0.38 0.64 96 0.96 
ADIPOR1 rs4336908       
AA 0.89 0.86  0.63 0.59  
AG 0.11 0.13  0.33 0.39  
GG 0.0 0.01 0.63 0.03 0.03 0.75 
ADIPOR1 rs6666089       
AA 0.76 0.77  0.44 0.50  
AG 0.21 0.20  0.39 0.43  
GG 0.03 0.03 0.98 0.17 0.07 0.11 
ADIPOR1 rs7514221       
CC 0.37 0.31  0.40 0.33  
CT 0.43 0.55  0.43 0.48  
TT 0.19 0.14 0.33 0.17 0.19 0.68 
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Table C-1 (Continued)       
ADIPOR1 rs7539542       
CC 0.19 0.16  0.51 0.39  
CG 0.42 0.49  0.42 0.54  
GG 0.40 0.36 67 0.07 .08 0.30  0. 0
HMGCS2 rs12123085       
AA 0.80  0.75  0.80 0.77  
AG 0.18   0.20  0.23 0.22 
GG 0.02  0.7 0.0 0.57 0.02 4 0.02 
HMGCS2 rs1256343    3    
CC 0.72   0.48  0.73 0.36 
CT 0.27   0.44 0.26 0.50  
TT 0.02 1 0.9 0.09 0.31 0.0 4 0.14 
HMGCS2 rs1441008        
CC 0.0 1  0.14  0.0 0.09 
CT 0.23 0.14  0.41  0.45 
TT 0.77  0.2 0.46 0.56 0.85 2 0.47 
HMGCS2 rs14410    10    
AA 0.18   0.27  0.23 0.42 
AG 0.50   0.54  0.49 0.42 
GG 0.32 0.28 0.71 0.19 0.16 0.17 
HMGCS2 rs2241868       
CC 0.89 0.83  0.83 0.85  
CT 0.11 0.16  0.17 0.15  
TT 0.0 0.01  0.0 0.0 0.81  0.46
HMGCS2 rs3790693       
AA 0.06 2  0.06  0.1 0.15 
AT 0.36 0.36  0.51 .42  0
TT 0.58  0.9 0.37  0.58 9 0.42 0.55
HMGCS2 rs4659233        
AA 0.03   0.0  0.04 0.02 
AT 0.25   0.24 0.28 0.22  
TT 0.72 8 0.8 0.76  0.6 4 0.77 0.58
HMG  rs536    CS2 662    
AA 0.42 5  0.27  0.4 0.22 
AG 0.46 2  0.54  0.4 0.47 
GG 0.12 0.14 0.84 0.19 0.20 0.31 
HMGCS2 rs61     9167   
AA 0.48   0.27  0.51 0.22 
AG 0.42   0.55  0.43 0.45 
GG 0.11 0.07 0.66 0.18 0.33 0.12 
HM 3       GCS2 rs64973
AA 0.57 0.59  0.42 0.59  
AG 0.37 0.37  0.48 0.34  
GG 0.06 0.04 0.79 0.10 0.07 0.10 
HM 6       GCS2 rs66722
CC 0.83 0.85  0.68 0.67  
CT 0.15 0.15  0.30 0.32  
TT 0.02 0.0 0.45 0.02 0.02 0.98 
* P-value based on genotype association chi square test 
† Chi Square could not be estimated  
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Table C-2:  Unadjusted Odd Ratios for Steatosis for Single Nucleotide Polymorphisms  
 ans 
N = 163 
Caucasian Americans 
N = 179 
 
African Americ
Single Nucleotide 
Polymorphis  
 
 
N 
 
Od
Ra
95
l 
   
Od
Ra
95% 
ence 
 
 
 
p-value 
m ds 
tio 
Confiden
Interva
% 
ce  
p-value 
 
N 
ds 
tio 
Confid
Interval
ADIPOR1 rs1075    3929       
CC 106 1.00   1.00    145  
CT/TT 62 1.24 2.37 0.  0.66 1.49 0.32 51 290.65-  0.29-
ADIPOR1 rs10920531          
AA 1.00   62 1.00    38 
AC 81 1.05 -2.33 0. 5 1.82 3.57 0.08 91 90.47  0.93-
C 48 0.69 -1.65 0.  1.69 4.97 0.34 C 40 200.29  0.57-
ADIPOR1 rs1204586         2 
CC 135 1.00   1.00    93  
CT/TT 32 1.81 4.21 0.  1.00 1.87 0.99 17 840.78-  0.54-
ADIPOR1 rs12        733285   
CC 110 1.00   1.00    84  
CT 43 0.83 1.69 0.  1.47 2.87 0.27 60 710.40-  0.75-
TT 10 0.59 0.16-2.18 0.43 20 1.85 0.61-5.57 0.28 
ADIPOR1 rs1342387         
AA 41 1.00   36 1.00   
AG 80 1.54 0.71-3.23 0.28 81 0.81 0.34-1.93 0.64 
GG 46 1.11 0.48-2.61 0.81 59 0.60 0.25-1.48 0.27 
ADIPOR1 rs1539355         
AA 47 1.0 1.0   80 0  0  
AG 1.18 0.56-2.48 0.67 76 0.99 0.50-1.94 0.97  81 
GG 37 0.82 1.96 0.  0.40 1.17 0.10 65 170.34-  0.14-
ADIPOR1 rs1685        07  99 
AA 148 1.00  0 1.00    10  
AG/GG 1.38 3.59 0.  1.19 -2.24 0.59  22 51 770.53-  0.63
ADIPOR1 rs2275        736  
AA/AT 60 1.00  1.00    6  
TT 108 0.98 -1.87 0. 1 0.39 3.41 0.40 94 170.51  0.04-
ADIPOR1 rs4336908         
AA 149 1.00   107 1.00    
AG/GG 22 1.41 3.62 0.  1.23 2.33 0.53 49 710.54-  0.65-
ADIPOR1 rs6666089         
AA 131 1.00   1.00    85  
AG or AG/GG 35 0.93 0. -1.99 0.  0.98 -1.92 0.95 84 7443  0.50
GG 5 0.93 0.15-5.74 0.93 18 0.35 0.13-1.00 0.049 
ADIPOR1 rs7514221         
CC 57 1.00   64 1.00   
CT 86 1.54 0.77-3.06 0.22 83 1.32 0.66-2.61 0.43 
TT 28 0.90 0.36-2.24 0.82 33 1.38 0.56-3.39 0.48 
ADIPOR1 rs7539542         
CC 28 1.00   76 1.00   
CG 77 1.39 0.57-3.36 0.47 89 1.67 0.87-3.21 0.12 
GG 63 1.07 0.43-2.63 0.89 13 1.47 0.41-5.20 0.55 
         
295 
296 
Table C-2 (Continued) 
H S2 rs12123085   MGC       
AA 1 1.00   14 1.00   32 0 
AG/GG 39 1.34 0.63-2.84 44 40 1.22 0.57-2.61 0.61 0.
H S2 rs12563433       MGC   
CC 122 1.00  1.00    75 
CT 44 0.96 0.47-1.95 0.25 0.91 85 1.49 0.76-2.87 
TT 2 0. 04 91  0.69-6.3 0.20 61 0. -9. 0.73 21 2.08 3 
H S2 rs1441      MGC 008    
CC  1.00   1.00   1 18 
CT 29    77 1.77 0.62-5.04 0.29  
TT 1 1.76 0.79-3.90 0.16 82 1.63 0.58-4.60 0.36 38  
H S2 01   MGC  rs1441 0       
AA 3 1.00   65 1.00   6  
AG 83 0.76 0.33-1.72 51 82 0.51 0.25-1.05 0.07 0.  
GG 50 0.69 0.28-1.69 0.42 30 0.56 0.22-1.43 0.23 
H S2 rs2241868        MGC  
CC 1.  15  142 00  0 1.00  
CT/TT 1. 0 0.28 28 0.81 24 68 0.65-4.3  0.90 0.39-2.09 
H S2 rs3790693        MGC  
AA 10 1.00   25 1.00   
AT 61 1.03 0.26-4.03 0.97 0.65 0.24-1.73 0.39 80 
TT 98 1.05 0.28-3.98 0. 0.88 0.32-2.42 0.81 94 72 
H S2 rs4659     MGC 233     
AA/AT 50 1.00   41 1.00   
TT 113 0.82 0.41-1.63 1.01 0.48-2.12 0.97 0.57 133 
H S2 rs536662       MGC   
AA 74 1.00   42 1.00   
AG 74 0.84 0.44-1.63 0.62 87 1.06 0.50-2.27 0.89  
GG 2 1.07 0.40-2.86 0.90 48 2.07 -5.1 0.12 2  0.83 8 
H S2 rs 67   MGC 6191        
AA 8 1.00   42 1.00   3  
AG 71 0.97 0.51-1.87 93 86 0.99 0.46-2.11 0.98 0.
GG 14 0.60 0.19-1.86 0.37 50 2.18 0.88-5.44 0.09  
H S2 9733       MGC  rs64   
AA 1.00   1.00   98 95 
AG/G  71 0.77 0.03 G 70 0.91 0.49-1.   82 0.50 0.27-0.95 
H S2 7226       MGC  rs66   
CC 1 1.00   11 1.00   41 9 
CT/TT 26 0.85 0.36-1.98 0.70 58 1.08 0.55-2.10 0.82  
† M alle ency less the  in one population 
 
 
 
inor le frequ n 5%
Table C-3: Log Likelihood Ratio Test of the Significance of the Interaction m Between Natural Log Transformed HOMA2-IR Scores and 
the Genetic Variant in the Prediction of Steato
  ic ans  Caucasian Americans 
Ter
sis 
Afr an Americ
    Main Effects e on       Main Effects Interaction     Int racti
  df 
Log 
Likelihood 
Chi 
Square p-value df 
Log 
Likelihood 
Log 
Likelihood 
Chi 
Square p-value 
Log 
Likelihood 
ADIPOR1 rs10753929 1 154.505 154. 2 0.003 0.960 1 128.176 126.176 2.000 0.157 50
ADIPOR1 rs10920531 2 153.166 151. 6 1.660 0.436 2 132.502 129.117 3.385 0.184 50
ADIPOR1 rs12045862 1 151.201 150. 1 0.360 0.549 1 135.408 5.250 0.158 0.691 84 13
ADIPOR1 rs12733285 2 150.598 148. 3 1.905 0.386 2 130.503 6.264 4.239 0.120 69 12
ADIPOR1 rs1342387 2 150.762 148. 0 2.402 0.301 2 132.659 0.286 2.373 0.305 36 13
ADIPOR1 rs1539355 2 150.215 149. 9 0.666 0.305 2 126.322 9.720 6.602 0.037 54 11
ADIPOR1 rs16850799 1 155.855 155. 0 0.065 0.799 1 135.156 5.139 0.017 0.896 79 13
ADIPOR1 rs2275736 1 155.173 5 1 1.312 0.252 35.122 1.201 3.921 n=6 1 3.86 1 1 13
ADIPOR1 rs4336908 1 156.12 156. 7 0.072 0.788 1 35.920 5.727 93 0.660 9 05 1 13 0.1
ADIPOR1 rs6666089 1 155.94 7 -0.116 0.733 26.314 3.276 38 0.001 1 156.05 2 1 11 13.0
ADIPOR1 rs7514221 2 153.83 153. 4 0.529 0.768 2 35.142 1.197 45 0.139 3 30 1 13 3.9
ADIPOR1 rs7539542 2 155.14 152. 9 2.966 0.227 2 31.121 0.716 05 0.817 5 17 1 13 0.4
HMGCS2 rs12123085 1 149.614 149. 5 0.029 0.865 1 36.133 5.854 79 0.597  58 1 13 0.2
HMGCS2 rs12563433 1 154.467 153. 9 1.158 0.282 2 135.023 4.665 0.358 0.836 30 13
HMGCS2 rs1441008 1 153.845 153. 8 0.667 0.414 1 133.736 3.556 0.180 0.109 17 13
HMGCS2 rs1441010 2 151.615 151. 1 0.244 0.855 2 132.729 2.227 0.502 0.778 37 13
HMGCS2 rs2241868 1 152.597 5 7 0.960 0.327 1 135.273 9.412 5.861 no est 1 1.63 12
HMGCS2 rs3790693 1 152.192 148. 1 3.241 0.072 2 134.582 1.131 3.451 0.178 95 13
HMGCS2 rs4659233 1 149.165 147. 6 1.279 0.258 1 132.198 131.949 0.249 0.618 88
HMGCS2 rs536662 2 152.107 152. 5 0.072 0.965 2 130.627 129.622 1.005 0.605 03
HMGCS2 rs619167 2 151.699 150. 7 1.622 0.444 2 131.244 130.355 0.889 0.641 07
HMGCS2 rs649733 1 155.288 155. 2 0.196 0.658 1 133.915 133.509 0.406 0.524 09
HMGCS2 rs667226 1 150.238 148. 8 1.400 0.237 1 134.688 132.912 1.776 0.183 83
HMGCS2 rs667246 2 148.282 146. 7 1.295 0.523 2 134.988 134.387 0.601 0.740 98
Abbreviations:  Degrees of Freedom (df)
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Table C-4:  Genotype Frequencies for ADIPOR1 and HMGCS2 Single Nucleotide Polymorphisms 
and Association with Insulin Resistance among African Americans and Caucasian Americans 
 
 African Americans 
N = 138 
Caucasian Americans 
N = 152 
Single Nucleotide 
Polymorphism 
HO 2- HO 2-MA
IR < 2 
HOMA2-
IR ≥ 2 
 
p-value* 
MA
IR < 2 
HOMA2-
IR ≥ 2 
 
p-value* 
ADIPOR1 rs10753929       
CC 0.62 0.65  0.81 0.84  
CT 0.37 0.29  0.19 0.16  
TT 0.01 0.06 0.17 0.0 0.0 0.67 
ADIPOR1 rs10920531       
AA 0.19 0.26  0.37 0.35  
AC 0.49 0.52  0.55 0.55  
CC 0.32 0.23 0.36 0.09 0.10 0.95 
ADIPOR1 rs12045862       
CC 0.78 0.82  0.55 0.52  
CT 0.21 0.18  0.38 0.44  
TT 0.01 0.0 0.59 0.08 0.04 0.56 
ADIPOR1 rs12733285       
CC 0.70 0.67  0.50 0.48  
CT 0.25 0.26  0.40 0.40  
TT 0.05 0.07 0.86 0.10 0.13 0.90 
ADIPOR1 rs1342387       
AA 0.22 0.25  0.21 0.21  
AG 0.48 0.48  0.46 0.46  
GG 0.30 0.27 0.83 0.34 0.33 0.99  
ADIPOR1 rs1539355       
AA 0.29 0.31  0.46 0.46  
AG 0.49 0.43  0.46 0.42  
GG 0.23 0.26 0.76 0.09 0.13 0.79 
ADIPOR1 rs16850799       
AA 0.83 0.91  0.57 0.59  
AG 0.17 0.09  0.37 0.39  
GG 0.0 0.0 0.16 0.06 0.02 0.57 
ADIPOR1 rs2275736       
AA 0.09 0.06  0.0 0.0  
AT 0.30 0.24  0.01 0.10  
TT 0.62 0.70 0.59 0.99 0.90 0.007  
ADIPOR1 rs4336908       
AA 0.87 0.86  0.62 0.61  
AG 0.12 0.14  0.35 0.37  
GG 0.01 0.0 0.65 0.03 0.02 0.94 
ADIPOR1 rs6666089       
AA 0.76 0.74  0.45 0.52  
AG 0.23 0.20  0.45 0.35  
GG 0.01 0.06 0.25 0.10 0.13 0.53 
ADIPOR1 rs7514221       
CC 0.35 0.33  0.36 0.36  
CT 0.51 0.47  0.45 0.48  
TT 0.13 0.20 0.54 0.19 0.16 0.86 
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ADIPOR1 rs7539542       
CC 0.14 0.19  0.45 0.45  
CG 0.44 0.49  0.49 0.47  
GG 0.42 0.32 0.40 0.06 0.08 0.87 
HMGCS2 rs12123085       
AA 0.78 0.77  0.75 0.88  
AG 0.20 0.22  0.24 0.12  
GG 0.03 0.02 0.90 0.01 0.0 0.16 
HMGCS2 rs12563433       
CC 0.75 0.75  0.38 0.35  
CT 0.25 0.22  0.53 0.45  
TT 0.0 0.03 0.27 0.10 0.20 0.20 
HMGCS2 rs1441008       
CC 0.0 0.02  0.09 0.04  
CT 0.21 0.14  0.43 0.51  
TT 0.79 0.84 0.32 0.49 0.45 0.44 
HMGCS2 rs1441010       
AA 0.26 0.19  0.36 0.47  
AG 0.44 0.52  0.51 0.37  
GG 0.30 0.30 0.55 0.14 0.16 0.28 
HMGCS2 rs2241868       
CC 0.81 0.87  0.85 0.84  
CT 0.19 0.11  0.15 0.16  
TT 0.0 0.02 0.26 0.0 0.0 0.80 
HMGCS2 rs3790693       
AA 0.03 0.09  0.11 0.12  
AT 0.39 0.33  0.52 0.37  
TT 0.59 0.58 0.19 0.38 0.51 0.22 
HMGCS2 rs4659233       
AA 0.04 0.05  0.01 0.0  
AT 0.23 0.28  0.25 0.17  
TT 0.73 0.67 0.75 0.74 0.83 0.40 
HMGCS2 rs536662       
AA 0.44 0.47  0.23 0.18  
AG 0.42 0.39  0.48 0.51  
GG 0.14 0.14 0.94 0.30 0.31 0.82 
HMGCS2 rs619167       
AA 0.49 0.54  0.23 0.18  
AG 0.42 0.38  0.47 0.49  
GG 0.09 0.08 0.86 0.30 0.33 0.84 
HMGCS2 rs649733       
AA 0.61 0.59  0.56 0.53  
AG 0.33 0.37  0.36 0.45  
GG 0.06 0.05 0.88 0.08 0.02 0.26 
HMGCS2 rs667226       
CC 0.83 0.91  0.66 0.69  
CT 0.16 0.09  0.33 0.29  
TT 0.01 0.0 0.31 0.01 0.02 0.77 
* P-value based on genotype association chi square test 
† Chi Square could not be estimated 
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T hisms  able C-5: Unadjusted Odds Ratios for Insulin Resistance for Single Nucleotide Polymorp
 
 African Americans 
N = 138 
Caucasian Americans 
N = 152 
Single Nucleotide 
Polymorphism 
 
 
N 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
 
p-value 
 
 
N 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
 
p-value 
ADIPOR1 rs10753929         
CC 91 1.00   121 1.00   
CT/TT 53 0.87 0.44-1.72 0.68 27 0.82 0.33-2.04 0.67 
ADIPOR1 rs10920531         
AA 31 1.00   54 1.00   
AC 72 0.50 0.32-1.74 0.50 82 1.07 0.51-2.23 0.86 
CC 40 0.16 0.19-1.32 0.16 14 1.21 0.35-4.16 0.76 
ADIPOR1 rs12045862         
CC 114 1.00   81 1.00   
CT/TT 29 0.76 0.33-1.74 0.51 70 1.10 0.56-2.18 0.78 
ADIPOR1 rs12733285         
CC 96 1.00   73 1.00   
CT 35 1.10 0.50-2.40 0.82 59 1.03 0.50-2.16 0.93 
TT 8 1.46 0.35-6.20 0.61 16 1.30 0.42-4.02 0.64 
ADIPOR1 rs1342387         
AA 33 1.00   31 1.00   
AG 69 0.87 0.38-1.99 0.74 68 1.00 0.41-2.49 0.99 
GG 41 0.75 0.30-1.89 0.55 50 0.99 0.38-2.58 0.98 
ADIPOR1 rs1539355         
AA 42 1.00   67 1.00   
AG 65 0.81 0.37-1.77 0.59 65 0.91 0.44-1.89 0.80 
GG 34 1.08 0.43-2.67 0.87 15 1.36 0.43-4.32 0.60 
ADIPOR1 rs16850799         
AA 126 1.00   87 1.00   
AG/GG 20 0.49 0.18-1.35 0.17 63 0.93 0.47-1.86 0.84 
ADIPOR1 rs2275736         
AA/AT 50 1.00   6 1.00   
TT 94 1.44 0.71-2.89 0.31 144 0.09 0.01-0.78 0.03 
ADIPOR1 rs4336908         
AA 126 1.00   93 1.00   
AG/GG 20 1.06 0.41-2.73 0.91 58 1.02 0.51-2.06 0.95 
ADIPOR1 rs6666089         
AA 110 1.00   71 1.00   
AG or AG/GG 37 1.10 0.52-2.32 0.81 63 0.68 0.33-1.42 0.31 
GG     16 1.10 0.36-3.39 0.86 
ADIPOR1 rs7514221         
CC 50 1.00   55 1.00   
CT 72 0.99 0.48-2.05 0.97 70 1.07 0.51-2.27 0.86 
TT 24 1.63 0.61-4.35 0.33 28 0.82 0.30-2.22 0.70 
ADIPOR1 rs7539542         
CC 23 1.00   68 1.00   
CG 67 0.79 0.31-2.04 0.63 73 0.96 0.47-1.95 0.91 
GG 54 0.54 0.20-1.45 0.22 10 1.39 0.36-5.45 0.63 
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HMGCS2 rs12123085         
AA 113 1.00   121 1.00   
AG/GG 33 1.05 0.48-2.29 0.90 32 0.40 0.15-1.06 0.07 
HMGCS2 rs12563433         
CC 108 1.00   55 1.00   
CT     75 0.93 0.44-1.98 0.85 
TT 36 1.00 0.47-2.14 0.99 20 2.24 0.79-6.37 0.13 
HMGCS2 rs1441008         
CC  27 1.00   11 1.00   
CT     68 2.62 0.52-13.08 0.24 
TT 117 1.41 0.60-3.33 0.44 71 2.02 0.40-10.13 0.39 
HMGCS2 rs1441010         
AA 33 1.00   59 1.00   
AG 69 1.60 0.68-3.76 0.28 69 0.55 0.26-1.17 0.12 
GG 43 1.39 0.55-3.51 0.49 22 0.89 0.32-2.47 0.83 
HMGCS2 rs2241868         
CC 119 1.00   128 1.00   
CT/TT 23 0.64 0.25-1.63 0.35 23 1.13 0.44-2.88 0.80 
HMGCS2 rs3790693         
AA 8 1.00   17 1.00   
AT 52 0.23 0.04-1.23 0.09 70 0.64 0.21-1.97 0.43 
TT 84 0.26 0.05-1.38 0.11 63 1.21 0.40-3.68 0.74 
HMGCS2 rs4659233         
AA/AT 41 1.00   34 1.00   
TT 98 0.76 0.36-1.57  114 1.76 0.73-4.24 0.21 
HMGCS2 rs536662         
AA 66 1.00   32 1.00   
AG 59 0.88 0.44-1.79 0.73 73 1.33 0.54-3.31 0.54 
GG 20 0.98 0.36-2.68 0.97 45 1.29 0.48-3.44 0.63 
HMGCS2 rs619167         
AA 74 1.00   32 1.00   
AG 58 0.83 0.42-1.66 0.60 72 1.28 0.51-3.19 0.60 
GG 12 0.84 0.24-2.89 0.78 47 1.32 0.50-3.51 0.58 
HMGCS2 rs649733         
AA 86 1.00   83 1.00   
AG/GG 58 1.08 0.55-2.11 0.83 67 1.15 0.58-2.27 0.70 
HMGCS2 rs667226         
CC 124 1.00   100 1.00   
CT/TT 20 0.49 0.18-1.35 0.17 50 0.87 0.42-1.81 0.71 
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Table C-6: Log Likelihood Ratio Test of the Significance of the Interaction Term Between Natural Log Transformed HOMA2-IR Scores 
and the Genetic Variant in the Prediction of Steatosis 
  African Americans C aucasian Americans 
  Ef         Main fects Interaction   Main Effects In   teraction 
  
Log 
elih iho
Chi 
ua
p-
e  L
C
S p-df Lik ood Likel
Log 
od Sq re valu df
Log 
Likelihood 
Log 
ikelihood 
hi 
quare value
ADIPOR1 rs10753929 153.784 .621 1.163 1 41  215   80.2 1 165.221 160.767 .454 est ns 
ADIPOR1 rs10920531 148.918 6.682 2.236 27 1 1 0.2  14   0.3 2 165.744 64.253 .491 474 
ADIPOR1 rs12045862 153.457 9.361 4.096 est 1 0 0.1  14   no 1 166.498 65.508 .990 320 
ADIPOR1 rs12733285 148.124 4.846 3.278 94 1 2 0.2  14   0.1 2 163.807 60.941 .866 239 
ADIPOR1 rs1342387 155.286 3.642 1.644 40  16 2. 0.22 15 0.4 2 165.837 3.087 750 53 
ADIPOR1 rs1539355 147.642 6.733 0.909 35 1 2 0.2  14   0.6 2 162.973 60.343 .630 269 
ADIPOR1 rs16850799 154.651 2.533 2.118 46 1 0 0.1  15   0.1 1 165.743 65.708 .035 852 
ADIPOR1 rs2275736 151.920 0.755 1.165 80 1 2 0.1  15   0.2 1 161.347 58.858 .489 115 
ADIPOR1 rs4336908 158.239 7.729 0.510 75 1 0 0.71  15   0.4 1 167.160 67.022 .138 10 
ADIPOR1 rs6666089 157.621 7.621 .000 00 1 5 0.1  15  0  1.0 2 162.784 56.882 .902 052 
ADIPOR1 rs7514221 155.250 3.815 1.435 88 1 2 0.2  15   0.4 2 168.476 65.989 .487 288 
ADIPOR1 rs7539542 152.062 0.686 1.376 03 1 1 0.2  15   0.5 2 165.689 64.547 .142 565 
HMGCS2 rs12123085 157.727 6.796 0.931 35 1 0 0.1  15   0.3 1 163.553 63.526 .027 870 
HMGCS2 rs12563433 156.126 5.713 0.413 20 1 1 0.1  15   0.5 2 162.764 61.704 .060 589 
HMGCS2 rs1441008 154.684 1.170 3.514 61 1 2 0.1  15   0.0 1 164.524 62.381 .143 343 
HMGCS2 rs1441010 154.274 3.980 0.294 63 1 3 0.2  15   0.8 2 165.445 61.672 .773 152 
HMGCS2 rs2241868 152.136 1.979 0.157 92 1 4 no1  15   0.6 1 165.870 61.313 .557  est 
HMGCS2 rs3790693 153.829 1.776 2.053 52 1 3 0.1  15   0.1 2 164.947 61.513 .434 180 
HMGCS2 rs4659233 146.110 4.641 1.469 26 1 2 0.1  14   0.2 1 161.866 59.845 .021 155 
HMGCS2 rs536662 153.888 3.882 0.006 97 1 0 0.2  15   0.9 2 165.576 64.746 .830 660 
HMGCS2 rs619167 152.993 1.981 1.012 03 1 0 0.2  15   0.6 2 166.141 65.395 .746 689 
HMGCS2 rs649733 154.749 2.317 2.432 19 1 1 0.1  15   0.1 1 164.885 63.458 .427 232 
HMGCS2 rs667226 152.517 2.464 0.053 18 1 0 0.1  15   0.8 1 161.515 61.351 .164 686 
HMGCS2 rs667246 51.257 9.949 1.308 20 1 3 0.2 1  14   0.5 2 165.109 61.728 .381 184 
Abbreviations:  Degrees of Freedom (df)
Table C Haplot Frequ es a t for Steatosis by Race 
ican A icans c
179 
 
plotyp
Steatos
≥ 5% 
No Stea
≥ 
ADIPO  
-7:  
Ha
R1 
ype 
e 
enci
  
nd Trait Tes
Afr
No Steatosis 
 
mer
N = 163 
Caucasian Ameri
N = 
tosis 
ans 
tosis 
5% 
 
 
Single Nucleotide Polymorphisms 
 
is Stea
 
CACCAGATAACC rs10753 2929, rs10920531, rs1 045862, 
rs12744285, rs1342387, rs1539355, 
rs16850799, rs2275736, rs4336908, rs6666089, 
rs7514221, rs7539542 
 0.
 0.07 0.00 0.
CACCGGATAGCC 0.10 0.11  0.
A 0. 1 0.
0 0.
CCCCGGAAAACG 0.16 0.13 0.01 0.
CCCTAAATAATG 0.09 0.06 0.07 0.
CCTCGAGTGACG 0.02 0.04 0.16 0.
AT 0. 1 0.
T  0.16 0 0.
Trait Test  1.00 1.00
     
HMGCS2     
0.08 
0.02
0.06 
 
0.00 00 
02 
25 
19 
02 
00 
10 
18 
08 
00 
 
 
CACCGGAAAACC 
0.33
CAC
AC
TA
TA
A
A
TAA
AA
TC
TG
 
 
05 
05 
0.0
0.0
6 
5 
0.
0.
7 
0 
 
C AT 0.
TAC
CC
CA
CA
A
AA
A
TAA
ATC
TG
 
 
04 
0.13
0.04 
 
0.
0.
0 
0 
 
ACCATTTAAAC rs12123085, rs12563433, rs1441008, 
rs144101 8680, rs2241 ,  
rs3790693, rs4659233, rs536662, rs619167, 
rs649733,  
rs66
0 0.
ACCGCATA GC 0.07 0.05 0.2 0.
ACTACTTGGAC 0.07 0.08 0.01 0.
ACTACTTGGAT 0.09 0.07 0.14 0.
0. 0 0.
 0.12 0 0.
ACTGCTTAAGC 0.17 0.16 0.08 0.
ATTACTTGGAC 0.14 0.12  0.
ATTATTTAAAC 0.01 0.01 0.0 0.
0. 1 0.
0.03 0.03 0. 7 
5 
07 
22 
01 
15 
01 
01 
01 
36 
01 
13 
A
7226 ACTGCA
ACTGCTTA
AAAAC
AAC
 
 
05 
0.15
0.05 
 
0.
0.
3 
0 
0.29
0 
0 GCTGCAAAAAC 09 0.13 0.
Trait Test  1.00 1.00 
* SNPs are listed in order that they appear in the haplotype and along the chromosome 
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Table C-8:  Unadjusted Odds Ratio Estimates of Steatosis for Gene Haplotypes  
 African A ans 
N = 
cans 
N = 179 
meric Caucasian Ameri
163 
  
 
N 
 
tio 
 
Confidence 
al p-value 
 
 
N 
 
Odds 
Ratio 
% 
rval p-value 
95%  95
Confidence 
 
 Odds  Haplotype 
Ra Interv Inte
ADIPOR1         
CACCAGATAACC 21 4 0 69 0 †   1.0 .41-2. 0.93   
CACCGGAAAACC 10  0.38-6.16 0.55 4 †  1.53  
CACCGGATAGCC 31 1.01 0 27 0.97 83 0.86 1.61 .63 .45-2.  0.45- 0
CACTAAATAATC 18 1.00 0 75 0.99 56 1.37 2.73 .38  .37-2.  0.68- 0
CACTAAATAATG 18 00 0 75 3 †   1. .37-2. 0.99   
CCCCGGAAAACG 42  0.39-1.65 0.54 1 †  0.80  
CCCTAAATAATG 21 0.66 0 67 0.38 30 1.45 3.49 .41 .26-1.  0.60- 0
CCTCGAGTGACG 11 1.77 0 94 0.42 60 1.25 2.45 .52  .45-6.  0.64- 0
TACCAAATAATC 11 0.75 0 58 0.63 1.39   .22-2. 0.65 31 0.28- 0.25
TCCCAAATAATG 44  0.57-2.40 0.68 0 †  1.17  
         
HMGCS2         
ACCATTTAAAC 8 2 0 58 24 1.01 2.51   0.6 .15-2. 0.51  0.41- 0.98
ACCGCATAAGC 20 0.75 0.29-1.93  72  .55 5 0.55  0.82 0.44-1 0.5
ACTACTTGGAC 23 9 0 44 0.98 2 †    0.9 .40-2.  
ACTACTTGGAT 23 0.80 0 96 0.63 51 1.01 2.01 .97  .33-1.  0.51- 0
ACTGCAAAAAC 14 16 0 63 4 †   1. .37-2. 0.80  
ACTGCTTAAAC 39  0.37-1.61 0.49 1 †  0.77  
ACTGCTTAAGC 49 0.89 0 77 0.74 11 0.10 0.46 0.004  .45-1.  0.02-
ATTACTTGGAC 41 9 0 05 0.98 10 1.59 2.97 .15  0.9 .48-2. 3 0.85- 0
CGTGCAAAAAC 34 0 0 84 40 1.23 2.64 0.59  1.7 .75-3. 0.21  0.58-
         
† Haplotype not common enoug pulation t ate oddsh in po o estim
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T s and 
Caucasian Americans 
 
 African s* 
 = 
Caucasian Americans* 
N
able C-9:  Adjusted Odds Ratios for Steatosis for Gene Haplotype among African American
American
163 N  = 179 
 
Ha
 
N 
Od
Ratio 
on
Interval p-value N
O
Ratio 
Confidence 
Interval p-value 
ds C fidence   dds  
plotype  
ADIPOR1         
CACCAGATAA 0.37-4.56 0.77 CC 20 1.31 0   †
CACCGGAAAACC 10 2.47 0.37-16.32 0.23 4 †   
CACCGGATAGC 0.21-1.48 0.36 83 0.67 0.28-1.62 C 30 0.56 0.37 
CACTAAATAATC 0.39-7.42 0.48 56 2.81 1.00-7.92 5  17 1.71 0.0
CACTAAATAATG 17 1.39 0.38-5.11 0.62 3   †
CCCCGGAAAACG 40 0.76 0.31-1.83 0.54  1  †
CCCTAAATAA 0.24-2.28 0.72 30 2.30 0.69-7.71 8 TG 21 0.74 0.1
CCTCGAGTGACG 10 1.90 0.33-10.90 0.47 60 1.47 0.59-3.67 0.41 
TACCAAATAATC 11 0.52 0.11-2.37 0.44 31 0.47 0.17-1.28 0.14 
TCCCAAATAATG 0.21-1.32 0.23  41 0.53 0   †
         
HM        GCS2  
ACCATTTAAA 8 0.45 0.09-2.30 0.36 23 1.26 0.36-4.43 C 0.72 
ACCGCATAAG 0.25-2.96 0.82 72 1.13 0.47-2.76 9 C 18 0.86 0.7
ACTACTTGGAC 21 0.91 0.31-2.64 0.86 2   †
ACTACTTGGAT 21 0.39 0.12-1.32 0.13 51 1.53 0.59-3.94 0.38 
ACTGCAAAAA 0.25-4.54 0.94 C 13 1.06 4   †
ACTGCTTAAA 0.25-1.51 0.29 C 38 0.61 1   †
ACTGCTTAAGC 47 1.21 0.52-2.78 0.66 11 0.05 0.01-0.50 0.01 
ATTACTTGGAC 40 0.65 0.26-1.63 0.36 103 1.26 0.54-2.95 0.59 
ATTATTTA 1 † 2 AAC     †
CGTGCAAAAAC 34 3.59 1.24-10.36 0.02 39 0.72 0.25-2.03 0.53 
         
* Model adjusted for Ishak fibrosis score, weekly nsum , ba  vira l, ho  model of 
ins dy mass index
† Haplotype not comm o r too mon to es mate the odds ratio
Abbreviations:  95 en terv nfid al) 
 
 alcohol co ption seline l leve meostasis
ulin resistance 2, and bo   
on en ugh o  com ti  
% Confid ce In al (Co ence Interv
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Table C-10:   Haplotype Frequenci nd T  Test f sulin  Race 
  African Americ
 138 
Caucasi mer
 
 
Haplotype 
2- MA2-I O R  
ADIPOR1    
es a rait or In
 
NP
 Resistance by
ans 
HOMA2-IR  
≥ 2
an A
N = 152
R  
ican
MA
≥ 2
 
s 
2-I
 
N =
IR  HOMA
< 2
HO
S s   < 2 
 
H
CACCAGATAACC rs10753929, rs10920531, rs12045862, 
rs12744285, rs1342387, rs1539355, 
rs16850799, rs2275736, rs4336908, rs6666089, 
rs7514221, rs7539542 
0.06 0.05 0.00 0.00 
CACCGGAAAAC  
CACCGGATAGCC 0.10 0.12 0.29 0.28 
CACTAAATAATC 0.05 0.06 0.18 0.18 
CACTAAATAATG  
CCCCGGAAAACG 0.17 0.12 0.01 0.00 
CCCTAAATAATG 0.07 0.05 0.08 0.02 
CCTCGAGTGACG  0.0 17 0.15 
TACCAAATAATC  
TCCCAAATAATG  0.1 00 0.00 
Trait Test  1.00 1.00 
HMGCS2      
ACCATTTAAAC
C 0.05 0.05 0.00 0.04
 0.04 0.08 0.01 0.01
 
 
 
0.00
0.03
0.17
4 
 
3 
0.
0.
0.
 0.07 10 0.08
 rs12123 1256 rs1441008, 085, rs 3433, 0.04
0.05rs1441010, rs2241868,  
rs3790693, rs4659233, rs536662, rs619167, 
rs649733,  
rs667226 
 0.0 06 0.06 
ACCGCATAAGC  0.21 
ACTACTTGGAC 0.09 0.09 0.01 0.00 
ACTACTTGGA .0 .16 
ACTGCAAAAAC 0.02 
ACTGCTTAAAC 0.12 0.14 0.00 0.01 
ACTGCTTAAGC .1 .02 
ATTACTTGGAC 0.40 
ATTATTTAAAC 0.01 0.00 0.00 0.01 
GCTGCAAAAAC  0.1 0.06 
Trait Test  1.
2 
 
0.
0.22  0.07
T 
 
0.0
0.03
8 0 4 
 
0.15
0.01
 
 
0
 0.07
 0.1
0.12
7 0 6 
 
0.03
0.34
 
 
0
 0.13
 0.12 1 0.13 
1.00 00 
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ableT  C-11:   Un
 
N = 138 N = 152 
adjusted Odds Rat
A
ios 
fri
for 
can
Ins
 Am
ulin
eric
 R
ans
esis
 
tance for Gene Haplot
Ca
ype
uca
s  
sian Americans 
Single Nucleotide 
Po r
 
 
p-value 
lymo phism 
 
 
 N
 
Od
Ratio
ds 
 
95%
fid
ter
 
enc
val 
Con
In
e 
 
 
valup- e 
 
 
N 
 
ds 
tio 
Od
Ra
95%
fid
ter
 
enc
val 
Con
In
e 
AD R         IPO 1 
CAC AACC 15 0.97 0.34-2.79 0.96 0 †   CAGAT
CACC A  GGAA ACC 8 1.27 0.31-5.32 0.74 4 †  
CACC 0.77 GGATAGCC 28 1.22 0.54-2.79 0.63 72 0.90 0.45-1.80 
CAC 0.93 TAAATAATC 12 0.76 0.24-2.47 0.65 46 0.97 0.46-2.04 
CAC AATG 15 2 † TAAAT 1.72 0.60-4.94 0.31   
CCCC AAAACG 34 0.74 0.34-1.60 0.44 1 †   GG
CCCTA AATG 0.77 AAT 17 0.65 0.23-1.87 0.42 23 0.86 0.33-2.27 
CCTCGA 0.74 GTGACG 9 1.28 0.35-4.64 0.71 48 0.88 0.42-1.85 
TACCA 0.48 AATAATC 11 3.71 0.94-14.68 0.06 29 0.72 0.29-1.78 
TCCCA A  AAT ATG 34 0.81 0.37-1.74 0.58 0 †  
         
H S  MGC 2        
ACCATTTA C 8 0.17 0.02-1.39 0.10 18 0.97 0.34-2.72 0.95 AA
ACCG 0.82 CATAAGC 15 1.14 0.41-3.14 0.81 60 1.09 0.54-2.17 
ACTACTTG  GAC 20 0.85 0.34-2.14 0.73 2 †  
ACTACTTG  16 0.59 0.21-1.67 0.32 45 0.93 0.44-1.97 0.85 GAT
ACTGCA  AAAAC 11 1.29 0.39-4.20 0.68 4 †  
AC T  TGC TAAAC 32 1.25 0.57-2.73 0.58 1 †  
AC TTA  39 0.85 0.41-1.78 0.67 8 0.69 0.13-3.54 0.66 TGC AGC
AT GGAC 32 1.06 0.49-2.33 0.88 93 1.30 0.64-2.63 0.47 TACTT
GC A 0.07 TGCAA AAC 28 0.93 0.40-2.15 0.87 31 0.41 0.16-1.08 
† U
 
 
 
 
 
 
 
 
 
nable to estimate odds because haplotype not common enough in population 
Table C 2: djusted Odds Ratios for Insulin Resistance for ADIPOR1 and HMGCS2 Haplotypes 
among ic er ns 
* Model adjusted for Ishak fibrosis score, body mass index, age, steatosis and triglyceride levels
† Haplotype not commo too common to estimate the
African Americans* 
N = 138 
Caucasian Americans* 
N = 152 
-1
 Afr
 
   A
an Am icans and Caucasian America
Haploty
 Odds Confidence   Odds Confidence 
terval 
 
p-value pe N Ratio Interval p-value N Ratio In
ADIPO   R1       
CACCAGA CC 15 0.75 0.21-2.74 0.67 0 †   TAA
CACCGGAAAACC 8 0.86 0.14-5.31 0.87 4 †   
CACCGGAT  28 1.55 0.60-4.03 0.37 72 0.82 0.38-1.78 0.62 AGCC
CACTAAA   0-2.04 0.81 TAATC 12 0.68 0.17-2.75 0.59 46 0.90 0.4
CACT A    AA TAATG 15 1.79 0.50-6.35 0.38 2 † 
CCCC  34 0.74 0.29-1.90 0.53 1 †   GGAAAACG
CCCT AATG 17 0.79 0.24-2.66 0.71 23 1.05 0.37-2.97 0.93 AAAT  
CCTC GACG 9 1.22 0.28-5.3 0.80 48 0.87 0.38-1.97 0.74 GAGT 3 
TACC TC 11 5.94 1.23-18.6 0.03 29 0.72 0.26-2.00 0.53 AAATAA 5 
TCCC A TG    AA TAA 34 0.78 0.31-1.94 0.59 0 † 
         
HMGCS2         
ACCATTTAAAC 8 0.22 0.03-1.97 0.18 18 0.91 0.28  0.87 -2.99
ACCGCATAAGC 15 1.96 0.55-6.92 0.48 60 1.26 0.58  0.57 -2.73
ACTACTTGGAC 20 0.86 0.29-2.54 0.79 2 †    
ACTACTTGGAT 6 0.36 0.09-1.48 0.16 45 0.81 0.36  0.61 1  -1.83
ACTGCAAA  1.92 0.52-7.11 4 †  AAC 11 0.33  
ACTGCTTA  1.32 0.54-3.25 1 †  AAC 32 0.54  
ACTGCTTA  .75 0.32-1.77 8 1.45 0.24  0.68 AGC 39 0 0.51 -8.76
ATTACTTG  .13 0.43-2.96 93 1.23 0.57  0.60 GAC 32 1 0.80 -2.67
GCTGCAAA  .94 0.37-2.42 0.32 0.11  0.04 AAC 28 0 0.90 31 -0.96
 
         
n enough or  odds ratio 
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 Table C-13a:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for 
ADIPOR1 rs666089 Genotypes Among Caucasian Americans 
 
 Steatosis  
 No Steat Steatosis ≥ 5  ow Toosis % R tal 
 
HOMA2-I
 
AA:  14 
AG
GG
  32
:   27
:   4
AG:  45 
GG:  10 
  
A:
 
R  
< 2
 
:  18 
:   6 
A  
AG  
GG  
AA:  46 
In
su
lin
 R
es
is
ta
nc
e 
 
HOMA2-
 
AA
AG
GG
 
:  20
:  16
:   3
A:
AG:  17 
GG:   6 
  
IR :  5 AA  
≥ 2
 
:  1 
:  3 
AG  
GG  
A   25 
  
AA
AG
GG
 
:  52
:  43
:  
OT
A:
G:
GG:  16 
T AL 
Column Total :  19 AA  A   71 
 
 
:  19 
:   9 
AG
G
 A   62 
G  7 
 
 
T ri e C ison iduals by Ste is a sul ce 
A e pes g C mericans 
osis  
able C-13b:  Desc ptiv ompar  of Indiv atos nd In in Resistan for 
DIPOR1 rs666089 G noty  Amon aucasian A
 
 Steat  
 No Ste Steatosis ≥  ow Totaatosis 5% R l 
 
HOMA2-
 
AA
AG
GG:   1 
 
:  3
:  19
GG:   0 
A:
G:
GG:   1 
  
IR  
< 2
 
:  29 
:  10 
AA 3 
AG  
A   62 
A   29 
In
su
lin
 R
es
is
ta
nc
e 
  
HOMA2-IR 
≥ 2 
 
AA: 10 
AG:  4 
GG:  0 
 
AA:  31 
AG:   8 
GG:   3 
 
AA:  41 
AG: 12 
GG:   3 
 
Column Total 
 
 
 
AA:  39 
AG:  14 
GG:   1 
 
AA:  64 
AG:  17 
GG:   3 
TOTAL 
AA: 103 
AG:  31 
GG:   4 
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5 Genotypes Among Caucasian Americans 
 
 Steatosis 
 Table C-14a:  Descriptive Comparison of Individuals by Steatosis and Insulin Resistance for 
HMGCS2 rs1212308
 
 No is Steatosis ≥ 5% RowSteatos  Total 
 
HOMA2-IR  
< 2 
 
A
G
 
:  4
AG:  15 
G:    
A:
AG:  24 
GG:    1 
 
A:  30 
 
  77 
AG:   9 
G:   0 
AA 7 
G 1 
A
In
su
lin
 R
es
is
ta
nc
e 
 
A  
 
 
 
A:  3
G:  
G:   
 
AA
AG
GG:   0 
 
HOM 2-IR AA:  8 A 6 :  44 
≥ 2 AG:  1 A  5 :   6 
GG:  0 G 0 
 
n tal 
 
A
G
 
A:  8
G:  2
G:  
TOTAL 
A:
AG
GG
 
Colum  To A:  38 A 3 A  121 
AG:  10 A 0 :  30 
 G:   0 G  1 :   1  
 
 
e C-14b:  Descriptive Comparison of Individuals b Steatosi nd Ins in Resistan  for 
08 eno Amo an A
 
 Steatos  
Tabl y s a ul ce
HMGCS2 rs12123 5 G types ng Caucasi mericans 
 
is 
 No osis  ow  Steatosis Steat ≥ 5% R Total 
 
A   
 
 
A
A
G
 
A:  3
G:  1
G: 
 
AA:  63 
AG
GG
 
HOM 2-IR
< 2 
A:  32 
G:   6 
G:   1 
A 1 
A 0 
G   1 
:  16 
:   2 
In
su
lin
 R
es
is
ta
nc
e 
 
A  
 2 
 
AG:  1 
 
A:  3
AG:  11
 
AA
AG:  12 
HOM 2-IR AA:  13 A 0 :  43 
≥
 GG:   0 GG:   1 GG:   1 
 
 
Column Total AA:  45 AA:  61 
 AG:   7 
 
 
GG:   1 
 
AG:  21 
GG:   2 
TOTAL 
AA:  106 
AG:   28 
GG:    3 
 
 
 
Table C-15:   Amount of Common Variation in Each Gene Accounted for by Selected Single Nucleotide Polymorphisms (SNPs) 
     SNP Selection Method:  Linkage Disequilibrium Tagging   
Minor Allele Frequency:  10%              
      
African 
Americans 
Caucasian 
      Americans   
Gene
ADIPOR1 & 
SN
# SNPs 
Covered with 
ed 
Covered with 
S
% f 
 
# SNPs 
 o
 SNPs 
HMGCS2 Ps in High 
LD 
# SNPs for 
R2 = 0.8 
Genotyp
SNPs 
% of # SNPs for Genotyped Variation 
Variation R2 = 0.8 NPs Covered
              
ADIPOR 14 1 12 0 17 82% 21 21 100% 
HMGCS 0 28 18 2 12 64% 31 29 93% 
AVERA   45 32 GE   71% 52 50 96% 
Abbreviati uilibrium (LD)ons:  Linkage Diseq
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